0001564590-20-007399.txt : 20200227 0001564590-20-007399.hdr.sgml : 20200227 20200227162715 ACCESSION NUMBER: 0001564590-20-007399 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200227 DATE AS OF CHANGE: 20200227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 20662524 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 10-K 1 arna-10k_20191231.htm 2019 10-K arna-10k_20191231.htm
0001080709 --12-31 Large Accelerated Filer 2019 FY false Through the remaining terms of the leases in fiscal year 2027 us-gaap:OtherAssetsNoncurrent us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent P5D P10D P3Y P3Y 2017-06-30 P3Y P3Y us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent P1Y P1Y P1Y P1Y P5Y P5Y P5Y P5Y P5Y29D P5Y29D P4Y2M4D P4Y5M19D P4Y6M29D P4Y6M29D P2Y7M13D P2M15D P6M25D 0001080709 2019-01-01 2019-12-31 xbrli:shares 0001080709 2020-02-21 iso4217:USD 0001080709 2019-06-28 0001080709 2019-12-31 0001080709 2018-12-31 iso4217:USD xbrli:shares 0001080709 us-gaap:LicenseMember arna:UnitedTherapeuticsMember 2019-01-01 2019-12-31 0001080709 arna:CollaborationAndOtherRevenueMember 2019-01-01 2019-12-31 0001080709 arna:CollaborationAndOtherRevenueMember 2018-01-01 2018-12-31 0001080709 arna:CollaborationAndOtherRevenueMember 2017-01-01 2017-12-31 0001080709 us-gaap:RoyaltyMember 2019-01-01 2019-12-31 0001080709 us-gaap:RoyaltyMember 2018-01-01 2018-12-31 0001080709 us-gaap:RoyaltyMember 2017-01-01 2017-12-31 0001080709 2018-01-01 2018-12-31 0001080709 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember 2016-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001080709 us-gaap:RetainedEarningsMember 2016-12-31 0001080709 us-gaap:ParentMember 2016-12-31 0001080709 us-gaap:NoncontrollingInterestMember 2016-12-31 0001080709 2016-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember us-gaap:AccountingStandardsUpdate201609Member 2017-01-01 2017-12-31 0001080709 us-gaap:RetainedEarningsMember us-gaap:AccountingStandardsUpdate201609Member 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:ParentMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember arna:AtMarketOfferingMember 2017-01-01 2017-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember arna:AtMarketOfferingMember 2017-01-01 2017-12-31 0001080709 us-gaap:ParentMember arna:AtMarketOfferingMember 2017-01-01 2017-12-31 0001080709 arna:AtMarketOfferingMember 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001080709 us-gaap:ParentMember 2017-01-01 2017-12-31 0001080709 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001080709 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember 2017-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001080709 us-gaap:RetainedEarningsMember 2017-12-31 0001080709 us-gaap:ParentMember 2017-12-31 0001080709 2017-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-12-31 0001080709 us-gaap:RetainedEarningsMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-12-31 0001080709 us-gaap:ParentMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-12-31 0001080709 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:ParentMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001080709 us-gaap:ParentMember 2018-01-01 2018-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001080709 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001080709 us-gaap:CommonStockMember 2018-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001080709 us-gaap:RetainedEarningsMember 2018-12-31 0001080709 us-gaap:ParentMember 2018-12-31 0001080709 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001080709 us-gaap:ParentMember 2019-01-01 2019-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001080709 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001080709 us-gaap:CommonStockMember 2019-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001080709 us-gaap:RetainedEarningsMember 2019-12-31 0001080709 us-gaap:ParentMember 2019-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001080709 arna:SubleaseAgreementMember 2019-01-01 2019-12-31 arna:Segment 0001080709 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 xbrli:pure 0001080709 us-gaap:SalesRevenueNetMember arna:EisaiMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:BoehringerIngelheimMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:BoehringerIngelheimMember 2017-01-01 2017-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:OutpostMedicineMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:EverestMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:EverestMember 2017-01-01 2017-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:AxovantMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:AxovantMember 2017-01-01 2017-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:UnitedTherapeuticsMember srt:MinimumMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember 2019-01-01 2019-12-31 0001080709 srt:MaximumMember 2019-01-01 2019-12-31 0001080709 us-gaap:BuildingMember 2019-01-01 2019-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0001080709 us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-12-31 0001080709 arna:CollaborationAndOtherRevenueMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001080709 arna:CollaborationAndOtherRevenueMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:RoyaltyMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:RoyaltyMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001080709 arna:RestrictedStockUnitsAndRestrictedStockMember 2018-01-01 2018-12-31 0001080709 arna:RestrictedStockUnitsAndRestrictedStockMember 2017-01-01 2017-12-31 0001080709 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001080709 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001080709 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001080709 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001080709 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001080709 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember srt:MinimumMember 2019-01-01 2019-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember srt:MinimumMember 2019-01-01 2019-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember srt:MaximumMember 2019-01-01 2019-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember srt:MaximumMember 2019-01-01 2019-12-31 0001080709 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001080709 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001080709 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001080709 arna:LongTermInvestmentsMember 2019-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember srt:MinimumMember 2018-01-01 2018-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember srt:MinimumMember 2018-01-01 2018-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember srt:MaximumMember 2018-01-01 2018-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember srt:MaximumMember 2018-01-01 2018-12-31 0001080709 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001080709 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001080709 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001080709 arna:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001080709 arna:LongTermInvestmentsMember 2018-12-31 0001080709 us-gaap:LandMember 2019-12-31 0001080709 us-gaap:LandMember 2018-12-31 0001080709 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0001080709 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001080709 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001080709 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001080709 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001080709 us-gaap:MachineryAndEquipmentMember 2018-12-31 0001080709 arna:ComputersAndSoftwareMember 2019-12-31 0001080709 arna:ComputersAndSoftwareMember 2018-12-31 0001080709 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001080709 us-gaap:FurnitureAndFixturesMember 2018-12-31 arna:employee 0001080709 arna:SiegfriedPharmaAGAndSiegfriedAGMember 2019-12-31 iso4217:CHF 0001080709 arna:ArenaGmbHMember 2018-03-31 0001080709 arna:ArenaGmbHMember 2018-03-01 2018-03-31 arna:Property 0001080709 arna:PropertiesUnderSaleAndLeasebackAgreementsMember 2019-01-01 2019-12-31 0001080709 arna:PropertiesUnderOperatingLeasesMember arna:SanDiegoCaliforniaMember 2019-01-01 2019-12-31 0001080709 arna:PropertiesUnderOperatingLeasesMember arna:MassachusettsBostonMember 2019-07-01 2019-09-30 utr:sqft 0001080709 arna:PropertiesUnderOperatingLeasesMember arna:MassachusettsBostonMember 2019-09-30 0001080709 arna:PropertiesUnderOperatingLeasesMember arna:SwitzerlandZugMember 2019-06-30 0001080709 arna:PropertiesUnderOperatingLeasesMember arna:SwitzerlandZugMember 2019-09-30 0001080709 arna:PropertiesUnderOperatingLeasesMember arna:SwitzerlandZugMember 2019-04-01 2019-06-30 0001080709 arna:PropertiesUnderOperatingLeasesMember arna:SwitzerlandZugMember 2019-07-01 2019-09-30 0001080709 arna:PropertiesUnderOperatingLeasesMember 2019-12-31 0001080709 2016-01-01 2016-12-31 0001080709 arna:SubleaseAgreementMember 2019-12-31 0001080709 arna:UnderwrittenPublicOfferingMember us-gaap:CommonStockMember 2018-03-01 2018-03-31 0001080709 arna:UnderwrittenPublicOfferingMember us-gaap:CommonStockMember 2017-07-01 2017-07-31 0001080709 arna:UnderwrittenPublicOfferingMember us-gaap:CommonStockMember 2017-04-01 2017-04-30 0001080709 us-gaap:CommonStockMember arna:EquityDistributionAgreementMember arna:CitigroupGlobalMarketsIncMember arna:AtMarketOfferingMember 2017-02-01 2017-04-30 0001080709 srt:WeightedAverageMember us-gaap:CommonStockMember arna:EquityDistributionAgreementMember arna:CitigroupGlobalMarketsIncMember arna:AtMarketOfferingMember 2017-04-30 0001080709 arna:EquityDistributionAgreementMember arna:CitigroupGlobalMarketsIncMember arna:AtMarketOfferingMember 2017-02-01 2017-04-30 0001080709 arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-12-31 0001080709 arna:AmendedLongTermIncentivePlanTwentySeventeenMember arna:OtherThanStockOptionsAndStockAppreciationRightsMember 2019-12-31 0001080709 arna:EquityCompensationPlansMember 2019-12-31 0001080709 us-gaap:EmployeeStockOptionMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 us-gaap:RestrictedStockUnitsRSUMember srt:MinimumMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 us-gaap:RestrictedStockUnitsRSUMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember srt:MaximumMember 2019-01-01 2019-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember srt:MinimumMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 us-gaap:StockAppreciationRightsSARSMember srt:MinimumMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2018-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2019-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember srt:MaximumMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-07-01 2019-09-30 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-01-01 2019-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2018-01-01 2018-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2014-03-01 2014-03-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2018-03-01 2018-03-31 0001080709 arna:TwoZeroZeroNineEmployeeStockPurchasePlanMember 2019-12-31 0001080709 arna:TwoZeroZeroNineEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember arna:TwoZeroZeroNineEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001080709 arna:TwoZeroOneNineEmployeeStockPurchasePlanMember 2019-12-31 0001080709 arna:TwoZeroOneNineEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember arna:TwoZeroOneNineEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001080709 arna:TwoZeroZeroNineEmployeeStockPurchasePlanMember 2017-01-01 2017-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001080709 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001080709 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001080709 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001080709 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001080709 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001080709 us-gaap:SegmentDiscontinuedOperationsMember 2018-01-01 2018-12-31 0001080709 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-12-31 0001080709 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001080709 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001080709 arna:UnitedTherapeuticsMember 2019-01-01 2019-12-31 0001080709 arna:EverestMember 2019-01-01 2019-12-31 0001080709 arna:EverestMember 2018-01-01 2018-12-31 0001080709 arna:EisaiIncorporationAndEisaiCorporationLimitedMember 2019-01-01 2019-12-31 0001080709 arna:EisaiIncorporationAndEisaiCorporationLimitedMember 2018-01-01 2018-12-31 0001080709 us-gaap:OtherCustomerMember 2019-01-01 2019-12-31 0001080709 us-gaap:OtherCustomerMember 2018-01-01 2018-12-31 0001080709 us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0001080709 us-gaap:TransferredAtPointInTimeMember 2018-01-01 2018-12-31 0001080709 us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0001080709 us-gaap:TransferredOverTimeMember 2018-01-01 2018-12-31 0001080709 arna:UnitedTherapeuticsMember 2019-01-01 2019-12-31 0001080709 arna:UnitedTherapeuticsMember 2019-01-01 2019-01-31 0001080709 arna:UnitedTherapeuticsMember 2018-01-01 2018-12-31 0001080709 arna:UnitedTherapeuticsMember 2019-01-01 2019-03-31 0001080709 srt:MaximumMember arna:UnitedTherapeuticsMember 2019-03-31 0001080709 arna:NonUsMarketMember arna:UnitedTherapeuticsMember 2019-03-31 0001080709 arna:USMarketMember arna:UnitedTherapeuticsMember 2019-03-31 0001080709 arna:EverestMember 2017-12-01 2017-12-31 0001080709 arna:EverestMember srt:MaximumMember 2017-12-31 0001080709 arna:EverestMember arna:ChineseNationalMedicalProductsAdministrationMember 2018-10-01 2018-12-31 0001080709 arna:EverestMember 2019-12-31 0001080709 arna:EisaiFirstAmendedAgreementMember 2019-01-01 2019-12-31 0001080709 arna:EisaiSecondAmendedAgreementMember 2019-01-01 2019-12-31 0001080709 arna:EisaiAgreementMember 2016-12-01 2018-03-31 0001080709 arna:EisaiIncorporationAndEisaiCorporationLimitedMember arna:LorcaserinProductMember 2019-01-01 2019-12-31 0001080709 arna:PriorToTransactionAgreementMember 2019-01-01 2019-12-31 0001080709 arna:PriorToCommercialDistributionAgreementMember 2019-01-01 2019-12-31 0001080709 arna:IldongMember arna:PriorToTransactionAgreementMember 2019-12-31 0001080709 arna:EisaiAgreementMember 2019-01-01 2019-12-31 0001080709 arna:EisaiAgreementMember 2019-12-31 0001080709 arna:EisaiAgreementMember us-gaap:RoyaltyMember 2018-12-31 0001080709 us-gaap:RoyaltyMember 2019-12-31 0001080709 arna:EisaiAgreementMember us-gaap:RoyaltyMember 2019-01-01 2019-12-31 0001080709 arna:EisaiAgreementMember us-gaap:RoyaltyMember 2018-01-01 2018-12-31 0001080709 arna:EisaiAgreementMember us-gaap:RoyaltyMember 2017-01-01 2017-12-31 0001080709 arna:SupplyAgreementMember us-gaap:ProductMember 2018-01-01 2018-12-31 0001080709 arna:SupplyAgreementMember us-gaap:ProductMember 2017-01-01 2017-12-31 0001080709 2016-12-28 0001080709 arna:InventoryDeliverableMember 2017-01-01 2017-12-31 0001080709 arna:ManufacturingAndSupplyCommitmentDeliverableMember 2017-01-01 2017-12-31 0001080709 arna:BoehringerIngelheimMember 2018-12-01 2018-12-31 0001080709 arna:BoehringerIngelheimMember 2019-10-01 2019-10-31 0001080709 arna:BoehringerIngelheimMember 2019-12-31 0001080709 arna:BoehringerIngelheimMember arna:BeaconDiscoveryIncMember 2019-12-31 0001080709 arna:BoehringerIngelheimMember 2019-01-01 2019-12-31 0001080709 arna:BoehringerIngelheimMember 2018-01-01 2018-12-31 0001080709 arna:BoehringerIngelheimMember 2017-01-01 2017-12-31 0001080709 arna:OutpostMedicineMember 2018-04-01 2018-04-30 0001080709 arna:OutpostMedicineMember 2019-09-30 0001080709 arna:OutpostMedicineMember 2019-01-01 2019-12-31 0001080709 arna:OutpostMedicineMember 2018-01-01 2018-12-31 0001080709 arna:OutpostMedicineMember 2017-01-01 2017-12-31 0001080709 arna:AxovantMember 2019-01-01 2019-12-31 0001080709 arna:AxovantMember 2018-01-01 2018-12-31 0001080709 arna:AxovantMember 2017-01-01 2017-12-31 0001080709 us-gaap:InternalRevenueServiceIRSMember 2019-12-31 0001080709 us-gaap:InternalRevenueServiceIRSMember srt:MinimumMember 2019-01-01 2019-12-31 0001080709 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001080709 us-gaap:StateAndLocalJurisdictionMember srt:MinimumMember 2019-01-01 2019-12-31 0001080709 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2019-12-31 0001080709 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0001080709 us-gaap:InternalRevenueServiceIRSMember srt:MinimumMember arna:OrphanDrugMember 2019-12-31 0001080709 arna:LitigationAmountSettlementByInsurerMember 2017-11-30 0001080709 arna:LitigationAmountSettlementByParentMember 2017-11-30 0001080709 2019-10-01 2019-12-31 0001080709 2019-07-01 2019-09-30 0001080709 2019-04-01 2019-06-30 0001080709 2019-01-01 2019-03-31 0001080709 2018-10-01 2018-12-31 0001080709 2018-07-01 2018-09-30 0001080709 2018-04-01 2018-06-30 0001080709 2018-01-01 2018-03-31 0001080709 arna:BeaconDiscoveryIncMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember arna:SubleaseAgreementMember 2019-12-31 0001080709 arna:BeaconDiscoveryIncMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember arna:SubleaseAgreementMember 2019-08-01 2019-12-31 0001080709 arna:BeaconDiscoveryIncMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-01-01 2017-12-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2019

or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from          to           

COMMISSION FILE NUMBER 000-31161

 

ARENA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

23-2908305

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

6154 Nancy Ridge Drive, San Diego, CA

 

92121

(Address of principal executive offices)

 

(Zip Code)

858.453.7200

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

 

 

Common Stock, par value $0.0001 per share

 

ARNA

 

The Nasdaq Global Select Market

 

 

 

Securities registered pursuant to 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒    No  ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   ☒     No   ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes   ☒     No   ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  

☒

 

 

Accelerated filer  

☐

Non-accelerated filer   

☐

 

 

Smaller reporting company  

☐

 

 

 

 

Emerging growth company  

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐     No  ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $2.9 billion as of June 28, 2019, based on the last sale price of the registrant’s common stock as reported on the Nasdaq Global Select Market on such date. For purposes of this calculation, shares of the registrant’s common stock held by directors and executive officers have been excluded. This number is provided only for purposes of this Annual Report on Form 10-K and does not represent an admission that any particular person or entity is an affiliate of the registrant.

As of February 21, 2020, there were 50,249,149 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Certain information required by Part III of this Annual Report on Form 10-K is incorporated by reference from the Registrant’s Definitive Proxy Statement for the Annual Meeting of Stockholders to be held in June 2020, which will be filed with the Securities and Exchange Commission on or before April 29, 2020.

 

 

 

 

 

ARENA PHARMACEUTICALS, INC.

FORM 10-K – ANNUAL REPORT

For the Fiscal Year Ended December 31, 2019

Table of Contents

 

 

Page

PART I

Item 1.

Business

2

Item 1A.

Risk Factors

19

Item 1B.

Unresolved Staff Comments

42

Item 2.

Properties

43

Item 3.

Legal Proceedings

43

Item 4.

Mine Safety Disclosures

43

 

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

44

Item 6.

Selected Financial Data

46

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

48

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

56

Item 8.

Financial Statements and Supplementary Data

57

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

89

Item 9A.

Controls and Procedures

89

Item 9B.

Other Information

92

 

PART III

Item 10.

Directors, Executive Officers and Corporate Governance

93

Item 11.

Executive Compensation

93

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

93

Item 13.

Certain Relationships and Related Transactions, and Director Independence

93

Item 14.

Principal Accounting Fees and Services

93

 

PART IV

Item 15.

Exhibits, Financial Statement Schedules

93

Item 16.

Form 10-K Summary

97

 

 

 

i

 

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K, or Annual Report, includes forward-looking statements, which involve a number of risks and uncertainties. These forward-looking statements can generally be identified as such because the context of the statement will include words such as “may,” “could,” “will,” “intend,” “plan,” “believe,” “anticipate,” “expect,” “estimate,” “predict,” “potential,” “prospect,” “continue,” “likely,” “opportunity,” “focused on,” “evaluating for,” “in development for,” the negative of these words or other similar words. Similarly, statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects and other statements that are not historical facts are also forward-looking statements. Discussions containing these forward-looking statements may be found, among other places, in “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Annual Report. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Readers of this Annual Report are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the time this Annual Report was filed with the Securities and Exchange Commission, or SEC. These forward-looking statements are based largely on our expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, without limitation, those discussed in “Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Annual Report. In addition, past financial or operating performance is not necessarily a reliable indicator of future performance, and you should not use our historical performance to anticipate results or future period trends. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update publicly or revise our forward-looking statements to reflect events or circumstances that arise after the filing of this Annual Report or documents incorporated by reference herein that include forward-looking statements.

TRADEMARKS AND CERTAIN TERMS

In this Annual Report, “Arena Pharmaceuticals,” “Arena,” “we,” “us” and “our” refer to Arena Pharmaceuticals, Inc., and our wholly owned subsidiaries on a consolidated basis, unless the context otherwise provides. “APD” is an abbreviation for Arena Pharmaceuticals Development.

Arena Pharmaceuticals ® and Arena ® are registered service marks of Arena. Any other brand names or trademarks appearing in this Annual Report are the property of their respective holders.

 

 

 

1

 

PART I

Item 1.    Business.

Overview

We are a biopharmaceutical company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Our internally-developed pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility.

Our most advanced investigational clinical programs include: etrasimod (APD334), being evaluated in a Phase 3 program for ulcerative colitis, or UC, a Phase 2b/3 program for Crohn’s disease, or CD, and a Phase 2b program in atopic dermatitis, or AD. We also plan to evaluate etrasimod in a Phase 2b program for eosinophilic esophagitis, or EOE, and a Phase 2 program in alopecia areata, or AA. Olorinab (APD371) is being evaluated for a broad range of visceral pain conditions associated with gastrointestinal diseases and is currently in a Phase 2b trial for treatment of abdominal pain associated with irritable bowel syndrome, or IBS. APD418 is being evaluated in a Phase 1 trial for acute heart failure, or AHF.

We continue to leverage our two decades of world-class G-protein-coupled receptor, or GPCR, target discovery research to develop breakthrough drugs and ultimately deliver these to patients with large unmet needs. Our long-term pipeline prospects include an enhanced collaboration with Beacon Discovery across a broad range of immune-mediated inflammatory targets and compounds (which we refer to as Project Cabrillo) and the buildout of Arena Neuroscience to focus on treating neurological conditions with microglial neuroinflammation.

We have license agreements or collaborations with various companies, including United Therapeutics (ralinepag in a Phase 3 program for pulmonary arterial hypertension), Everest Medicines Limited (etrasimod in development in Greater China and select countries in Asia), Beacon Discovery (early research platform for GPCR targets), Boehringer Ingelheim International GmbH (undisclosed orphan GPCR program for central nervous system – preclinical), and Eisai Co., Ltd. and Eisai Inc., collectively, Eisai (BELVIQ®/BELVIQ XR®).

Our Strategy

The primary elements of our focus are to:

 

•

Develop etrasimod – a modulator of the sphingosine 1-phosphate, or S1P, receptor intended for the treatment of a broad range of immune-mediated inflammatory diseases including gastrointestinal and dermatologic diseases;

 

•

Develop olorinab – an agonist of the cannabinoid receptor 2, or CB2, intended for the treatment of a range of visceral pain associated with gastrointestinal conditions;

 

•

Develop APD418 – a β3-AdrR antagonist and cardiac myotrope for AHF;

 

•

Progress a broad earlier stage pipeline build via Project Cabrillo and the Arena Neuroscience effort;

 

•

Develop our pipeline by efficiently managing our cash and development timelines, which may include entering strategic agreements for certain clinical and preclinical programs;

 

•

Progress additional pipeline programs over time in select therapeutic areas; and

 

•

Prudently build a vibrant, sustainable, high-performing organization.

Arena Pharmaceuticals, Inc. was incorporated in the state of Delaware in April 1997 and is headquartered in San Diego, California. We also have operations in Boston, Massachusetts and Zug, Switzerland.

2

 

Pipeline of Development Programs and Commercial Products

Below is a summary of our internally developed, proprietary portfolio:

 

We also own and have rights to other clinical and preclinical stage compounds that were internally discovered by us and have additional licensed or partnered programs that are not included in the above pipeline summary.

Etrasimod Program

Etrasimod is a next-generation, oral, highly selective sphingosine 1-phosphate, or S1P, receptor modulator, discovered by Arena, designed to provide systemic and local cell modulation by selectively targeting S1P receptor subtypes 1, 4 and 5. S1P receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. By isolating subpopulations of lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage. Etrasimod has therapeutic potential in immune-mediated inflammatory disease areas including gastroenterology and dermatology. We are currently evaluating etrasimod in ulcerative colitis, Crohn’s disease, eosinophilic esophagitis, atopic dermatitis, and alopecia areata.

Gastrointestinal Diseases

Inflammatory bowel diseases

Inflammatory bowel diseases, or IBD, like UC and CD are chronic life-long immune-mediated inflammatory conditions of the gastrointestinal tract that affect approximately 1.8 million patients in the United States, or US, alone. The prevalence of UC and CD in the US are currently estimated at approximately 0.9 million and 0.8 million patients, respectively. The prevalence of IBD in United Kingdom, France, Germany, Italy and Spain collectively, or EU5, is estimated at 1.3 million with approximately 0.7 million patients with UC and 0.6 million patients with CD. Both conditions represent a significant burden to patients, including hospitalization, surgery, and a longer-term risk of colon cancer, as well as impaired quality of life, economic productivity and social functioning. Additionally, Japan has an estimated prevalence of approximately 0.2 million IBD patients. In aggregate, there are approximately 3.3 million patients across the US, EU5 and Japan that are currently living with IBD.

UC is characterized by contiguous mucosal inflammation limited to the colon which involves the rectum in approximately 95% of cases and may extend to involve parts or all of the large intestine. In contrast, CD is characterized by full thickness inflammation that can occur anywhere in the gastrointestinal, or GI, tract but most typically involves the terminal ileum and colon; and causes fistulation and scarring. Symptoms for UC and CD can vary, depending on the location and severity of inflammation, but some of the most common are diarrhea, abdominal cramps, and rectal bleeding.

Important goals of therapy for IBD are durable remission while improving the patient’s quality of life. Although a number of therapies are approved for the treatment of IBD, they are often associated with an inability to induce or maintain remission, serious side effects, and complicated administration regimens. There is therefore an unmet medical need for novel oral agents with an enhanced risk-benefit profile and more convenient administration for the treatment of moderately to severely active IBD.

3

 

Eosinophilic Esophagitis

Eosinophilic Esophagitis, or EOE, is a chronic, relapsing and remitting, immune mediated disease of the esophagus driven by an allergic Th2 T cell inflammatory profile. Histologically, EOE is characterized by the accumulation of eosinophils in the lining of the esophagus, a tissue that under normal conditions lacks these cells. In addition to eosinophils, CD4 and CD8 T cells, dendritic cells and mast cells increase in the tissue. The presence of these unwelcome inflammatory cells has been shown to have a direct effect on immune function and tissue damage. Both pediatric and adult populations can develop EOE, however, the disorder is most common in individuals between the ages of 20 and 40 years old. EOE also exhibits a strong hereditability pattern and predominance for males and for Caucasians, and principally in socioeconomically developed countries. There are no approved therapies in the US for the treatment of EOE. We believe that etrasimod may represent a significant opportunity to provide an effective treatment to EOE due to its potential to modulate the trafficking of multiple immune subsets.

Dermatologic Conditions

Atopic Dermatitis

Atopic Dermatitis, or AD, is a chronic, inflammatory skin disorder characterized by dry skin, pruritus, and relapsing lesions. AD has a severe impact on quality of life, including potential occupational, social, and psychological impairments. The adult diagnosed prevalence is approximately 8.5 million patients in the US, and 6.5 million patients in the EU5. According to a recent survey with dermatologists in the US, 62% of dermatologists reported a high unmet need in Atopic Dermatitis.

Long-term efficacy of these therapies also remains relatively unknown. Therefore, we believe a significant unmet need remains for differentiated, safe, oral agents that are effective and have a favorable side effect profile. AD pathology is driven by a combination of impaired skin epithelial barriers, altered microbiota, and aberrant inflammation driven by activated immune cells, including skin-infiltrating T cells and dendritic cells, or DCs. Etrasimod may have the potential to reduce DC migration/activation (S1P receptor subtypes 1 and 4 mediated) and T cell infiltration (S1P receptor subtype 1 mediated) in the skin. These effects could reduce the T cell-mediated inflammation in the skin that underlies atopic dermatitis pathogenesis.

Alopecia Areata

Alopecia areata, or AA, is a T-cell-mediated autoimmune skin disorder with unmet medical need that causes non-scarring patchy hair loss, most often on the scalp. The prevalence is approximately 2.9 million patients in the US and 2.2 million in the EU.

The disease may be limited to 1 or more discrete, round or oval patches of hair loss the size of a coin on the scalp, or it may progress to full hair loss of the scalp (alopecia totalis) or the entire body (alopecia universalis). The course of disease is unpredictable, with spontaneous regrowth of hair occurring in 80% of patients within the first year, and sudden relapse at any given time. Patients with extensive disease (at least 50% total scalp hair loss) rarely have spontaneous hair regrowth. Patients with persistent moderate-to-severe AA also often suffer tremendous emotional and psychosocial distress and reduced quality of life as a result of their hair loss. Thus, psychosocial support and therapy is an important part of disease management, as this often-disfiguring disease can be psychosocially burdensome. The estimated lifetime risk of AA is 1.7% among the general population and represents the second most common form of human hair loss, second only to androgenetic alopecia. The current standard of care is injected corticosteroids which have limitations in terms of efficacy. Etrasimod may have the potential to reduce circulating CD4+ and CD8+ lymphocytes available to infiltrate the hair follicle which may decrease inflammation and restore hair growth.

Etrasimod Development

Inflammatory Bowel Disease

We are currently in a Phase 3 program in UC and a Phase 2b/3 program in CD.

In 2019, we announced positive results from a 34-week open-label extension, or OLE, of the Phase 2 OASIS trial of etrasimod for the treatment of ulcerative colitis. The trial enrolled 118 patients (84% of OASIS study completers), of which 22 completers also received 2 mg in OASIS, for a total of 46 weeks of treatment with etrasimod. Overall, etrasimod demonstrated durable, long-term clinical remission and was generally well tolerated in this trial. Adverse events in the OLE study were generally mild to moderate in severity and no new safety findings were noted. Impact on heart rate and atrioventricular, or AV, conduction was minimal throughout the study with no discontinuations from study related to bradycardia or AV block.

In 2018, we announced topline results from OASIS, a dose finding 12-week randomized, double-blind, placebo-controlled multinational Phase 2 clinical trial of etrasimod in moderate to severe UC. The aim of the trial was to investigate dose response and compare the active arm(s) to placebo. The trial evaluated the effects of etrasimod at 1mg and 2mg versus placebo on multiple efficacy

4

 

measures including a three-component partial Mayo Clinic Score, clinical remission, clinical response, and endoscopic improvement in 156 patients. Etrasimod demonstrated a clear dose response and statistically significant improvements versus placebo in the primary, all secondary, and clinical remission endpoints at the 2 mg dose. There were fewer patients with serious adverse events, or SAEs, compared to placebo (0% in 2 mg, 5.8% in 1 mg and 11.1% in placebo). Impact on heart rate and atrioventricular, or AV, conduction was low throughout the study with no discontinuations from study related to bradycardia or AV block. There were no increases in liver function tests compared to placebo and no reports of macular edema or pulmonary function test abnormalities. In this trial, etrasimod was well tolerated.

 

 

Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists.

       2 Δ = LS mean change from baseline. The 6-point MCS is based on stool frequency and rectal bleeding. Least-squares mean and standard error were estimated using a mixed-effects model with current oral corticosteroid use, prior exposure to anti-TNFα, treatment, week, and treatment-by-week interaction as factors and baseline value as covariate.

Eosinophilic Esophagitis

We are preparing for a Phase 2b program in Eosinophilic Esophagitis.

Atopic Dermatitis

We are currently in a Phase 2b program in atopic dermatitis.

Alopecia Areata

We are preparing for a Phase 2 program in Alopecia Areata.

Prior Development

In January 2015, we announced top-line results from a Phase 1b multiple-ascending dose clinical trial for etrasimod. In this trial, etrasimod demonstrated a dose-dependent effect on lymphocyte count lowering in blood, with mean decreases from baseline of up to 69%. Lymphocyte counts, on average, recovered to baseline within one week of conclusion of dosing. There was a modest impact on heart rate, but none of the changes were classified by the investigator as clinically significant. There were also no findings with respect to pulmonary function or liver enzyme tests that were classified by the investigator as clinically significant. The most common treatment-emergent adverse events were mild or moderate contact dermatitis, headache, constipation and diarrhea, with none being clearly drug related. There were no discontinuations for adverse events, and no serious adverse events were observed.

5

 

The randomized, double-blind, placebo-controlled Phase 1b clinical trial evaluated the safety, tolerability, pharmacodynamics and pharmacokinetics of multiple-ascending doses of etrasimod. In five different dosing cohorts, 50 healthy volunteers received etrasimod and 10 healthy volunteers received placebo for 21 days.

Prior to commencing the Phase 1b multiple-ascending dose clinical trial for etrasimod, we completed a Phase 1 single-ascending dose clinical trial of the compound. This randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of single-ascending doses of etrasimod in 40 healthy adult volunteers. In the trial, etrasimod demonstrated favorable pharmacokinetic and pharmacodynamic effects, a dose-responsive reduction in blood lymphocyte count and a slowing of heart rate that appears comparable to other S1P receptor modulators. The terminal half-life was approximately 35 hours.

Etrasimod Intellectual Property

As of February 14, 2020, we owned issued patents that cover compositions of matter for etrasimod and related compounds, methods of treatment utilizing etrasimod and related compounds, and various salts of etrasimod and crystalline forms thereof in 61 jurisdictions, including the United States, China, Japan, Germany, France, Italy, the United Kingdom, Spain, Canada, India, Russia, South Korea and Australia, and had an application pending in one other jurisdiction (Brazil). The earliest priority date for the patents on etrasimod is 2008. The terms of these patents are capable of continuing into 2029 in most jurisdictions without taking into account any patent term adjustment or extension regimes of any country or any additional term of exclusivity we might obtain by virtue of the later filed patent applications.

Olorinab Program

Olorinab, a potentially first-in-class, orally available, potent, peripherally restricted, highly selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate we are exploring for the treatment of visceral pain, specifically pain associated with the gastrointestinal system, such as IBD and irritable bowel syndrome, or IBS.

Visceral pain is defined as pain that originates within muscle, pleura, connective tissue, nervous system or solid organs within the abdomen or peritoneum. It is distinct from somatic or neuropathic pain, and is perceived as stretching, pulling and distention, rather than by cutting, crushing, or burning more commonly associated with neuropathic pain. Visceral pain is one of the most common types of pain. For example, abdominal pain affects approximately 20% of the general population. Visceral pain may be caused by a diverse set of organic causes, such as inflammation (e.g., IBD, including CD and UC, pancreatitis, prostatitis, and vaginitis), obstruction (e.g., bowel obstruction, and nephrolithiasis), ischemia, and malignancy, among others. Visceral pain may also be caused by functional disorders such as interstitial cystitis, dyspepsia, IBS, and vulvodynia.

There are approximately 1.8 million patients in the US diagnosed with IBD, with most patients experiencing abdominal pain or cramps. There are approximately 27 million patients in the US with IBS, with 78% reporting frequently recurring or continuous abdominal pain. Common treatments for visceral pain range from non-invasive, conservative approaches (e.g., physical therapy or acupuncture), to pharmacologic (e.g., tricyclic antidepressants acting as neurotransmitter reuptake inhibitors), and invasive interventions (e.g., bowel resection). Potent analgesics, such as opioids, can adversely affect GI function. Other commonly prescribed analgesics are often not potent enough and may lead to other GI side effects such as bleeding. Except for linaclotide and lubiprostone, prescribed for IBS, no visceral-specific analgesics are currently available. Approximately one in eight CD patients is chronically treated with opioids.

The CB2 receptor is expressed in the GI nervous system, and in many tissues and organs of the abdomen. CB2 receptors are found peripherally on immune cells but also on microglia, terminal neurons, dorsal root ganglia, and on visceral sensory neurons. We believe selectively targeting the CB2 receptor may provide therapeutic benefit for visceral pain without the potential for dependence, abuse, and GI and cardiovascular side effects associated with opiates or nonsteroidal anti-inflammatory drugs, or NSAIDs, which are among the most common pain relievers. In addition to analgesic effects, olorinab may have anti-inflammatory properties.

Olorinab is designed to be a peripherally restricted and selective CB2 receptor agonist and is intended to provide pain relief without the unwanted side effects associated with CB1 receptor activation.

Olorinab Development

In 2018, we announced positive topline results from our Phase 2a trial of olorinab in development for the treatment of pain associated with CD. This exploratory study was an open‑label investigation to evaluate safety and tolerability of olorinab in this patient population and to gain initial insights into its efficacy via a pain visual analog scale, or VAS. Fourteen patients were enrolled into two cohorts at 25 mg and 100 mg administered three times daily for up to eight weeks. Reductions in pain were seen within the first week of treatment and statistically significant improvement from baseline in Average Abdominal Pain Score, or AAPS, at weeks

6

 

four and eight. In this trial, olorinab appeared generally well tolerated with no clinically significant changes in heart rate or blood pressure, no psychotropic effects, and no discontinuations due to adverse events.

 

In April 2016, we announced favorable results from a Phase 1b multiple-ascending dose clinical trial of olorinab. This randomized, double-blind, placebo-controlled Phase 1b clinical trial enrolled 36 healthy adults to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of olorinab. Cohorts of 12 subjects (nine active, three placebo) were administered doses of 50 mg, 100 mg, or 200 mg of olorinab or placebo three times daily for 10 days and, in connection with the pharmacokinetic evaluation, one time on the 11th day. The most common adverse events were headache and nausea. All adverse events were classified as mild, and there were no serious adverse events reported. There was one discontinuation in the high-dose group due to an adverse event of mild thirst and somnolence. Reductions in blood pressure and heart rate were observed, but none were symptomatic or resulted in an adverse event. Drug levels at all doses tested in the trial, including the lowest dose, were well above those believed to be needed to stimulate the CB2 receptor.

In April 2015, we announced favorable top-line results from a Phase 1 single-ascending dose clinical trial of olorinab. The randomized, double-blind and placebo-controlled trial enrolled 56 healthy adults to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of olorinab. Dose-responsive exposure was observed over the explored dose range of 10-400 mg with good tolerability at all doses administered.

Olorinab Intellectual Property

As of February 14, 2020, we owned issued patents covering compositions of matter for olorinab and related compounds, and methods of treatment utilizing olorinab and related compounds, in 21 jurisdictions, including the United States, China, Japan, Canada, Russia, South Korea and Australia, and we had applications pending in 11 other jurisdictions, of which the ones with the largest pharmaceutical markets were Europe, Venezuela, Brazil and India. The earliest priority date for the patents on olorinab is 2009. The terms of these patents are capable of continuing into 2030 in most jurisdictions without taking into account any patent term adjustment or extension regimes of any country or any additional term of exclusivity we might obtain by virtue of the later filed patent applications.

APD418 Program

APD418 is a first-in-class β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the serious adverse events associated with currently available inotropes. APD418 is in early-stage clinical development for patients with acute heart failure, or AHF.

In January 2020, we announced acceptance of our investigational new drug, or IND, and were granted Fast Track designation for APD418. We have initiated a Phase 1 trial.

 

AHF is broadly defined as a rapid onset of new or worsening signs and symptoms of HF. It is a potentially life-threatening condition, requiring hospitalization, and emergency treatment is aimed predominantly at managing fluid overload and achieving hemodynamic stability. In most cases, hospitalization for AHF results when the neurohormonal compensatory mechanism, which acts to maintain hemodynamic stability in chronic heart failure, are inadequate.

 

7

 

Management of AHF is focused on treating clinical conditions and precipitating factors, immediate stabilization, and symptom relief. Most patients presenting to the emergency department with AHF are congested and have normal to high blood pressures. Diuretics are first line therapy to treat volume overload including congestion; vasodilators are also used as first line therapy for symptom relief in normotensive and hypertensive patients who fail to respond adequately to diuretics. Unfortunately, neither diuretics nor vasodilators have been associated with improved survival.

 

For patients presenting as hypotensive, who are at the highest risk of mortality, and patients who fail to adequately respond to initial therapy, treatment options are particularly limited and may require the use of inotropic agents. These agents aim increase cardiac contractility and restore hemodynamic status via stimulation of the myocardial β1-AdrR, but they are associated with significant risk of unwanted hemodynamic effects, arrhythmias, and pathway dependent cardiotoxicity, leading to adverse outcomes and increased mortality.

 

Arena is developing APD418, an internally discovered and developed this investigational drug candidate, to address the significant unmet need in AHF.

APD418 Intellectual Property

As of February 14, 2020, we owned an issued patent covering compositions of matter for APD418 and related compounds, and methods of treatment utilizing APD418 and related compounds, in the United States, and we had applications pending in 42 other jurisdictions, of which the ones with the largest pharmaceutical markets were Europe, China, and Japan. The earliest priority date for the patent on APD418 is 2016. The term of this patent is capable of continuing into 2037 without taking into account any patent term extension.

Additional Internal Preclinical and Clinical Programs

We have initiated Project Cabrillo for the development of multiple novel, early stage, oral autoimmune programs. The multiple G-protein-coupled receptors, or GPCRs, targets in this collaboration with Beacon Discovery and their associated chemistry, represent the next generation of oral compounds which, if successfully developed and approved, may transform the way autoimmune diseases are approached and treated. Project Cabrillo includes both novel and validated targets and compounds.

We are progressing early-stage neuroscience assets in an underlying platform focused on microglial neuroinflammation. These programs have applications in multiple diseases and will be placed into a new subsidiary, Arena Neuroscience.

We have additional assets, including temanogrel and other 5-HT2A modulators, which are either in or being evaluated for future clinical and preclinical development. We are also evaluating additional delivery forms of the products in our pipeline to extend clinical utility or improve the product profile.

Collaborations and License Agreements

In addition to our primary focus on developing our proprietary, unencumbered clinical pipeline, we have strategic collaborations and licenses with pharmaceutical companies, including United Therapeutics, Everest Medicines Limited, or Everest, Boehringer Ingelheim International GmbH, or Boehringer Ingelheim, Beacon Discovery, Inc., or Beacon, and Eisai.

United Therapeutics License Agreement

In November 2018, we entered into a collaboration and license agreement with United Therapeutics. Under the United Therapeutics Agreement, we granted United Therapeutics an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize ralinepag. This transaction was completed in January 2019. At the closing of the transaction, we transferred to United Therapeutics certain other assets relating to ralinepag, including, among others, related domain names and trademarks, permits, certain contracts, inventory, regulatory documentation, IND, and non-clinical, pre-clinical and clinical trial data. United Therapeutics has agreed to assume certain limited liabilities, including, among others, all post-closing obligations under assumed contracts and the IND. United Therapeutics is responsible for all development, manufacture and commercialization of the licensed products globally.

Upon the closing of this transaction, in January 2019, we received an upfront payment of $800.0 million. We are eligible to receive a payment of $150.0 million upon first marketing approval of ralinepag in a major non-US market, and a payment of $250.0 million upon US marketing approval of an inhaled formulation of ralinepag. In addition, we are entitled to receive low double-digit, tiered royalties on net sales of ralinepag products, subject to certain adjustments for third party license payments.

The United Therapeutics Agreement contains various representations and warranties of Arena and United Therapeutics, and various covenants of the parties, including covenants to cooperate in seeking regulatory approvals, as well as our agreement not to

8

 

compete, during the period in which royalties are payable (or during the five-year period following the closing if we are subject to a change of control transaction) in the development of a prostacyclin to treat pulmonary arterial hypertension, or PAH.

Ralinepag Program

Ralinepag is in a Phase 3 program for PAH. Ralinepag is a next-generation potent, highly selective oral IP receptor agonist intended for the treatment of PAH. Ralinepag was designed by us to deliver intravenous prostacyclin-like potency and pharmacokinetics in an oral tablet. In non-clinical experiments, ralinepag demonstrated potentially best-in-class activation of the IP receptor resulting in vasodilation, inhibition of smooth muscle cell proliferation and inhibition of platelet aggregation. Additionally, early stage studies of ralinepag pharmacokinetics in humans revealed an approximately 24-hour half-life and a low peak-to-trough ratio supporting therapeutic blood levels with once daily dosing.

Ralinepag was granted orphan drug status for the treatment of PAH by the US Food and Drug Administration, or FDA, in September 2014, and by the European Medicines Agency in January 2019.

PAH is a progressive, life-threatening disorder characterized by increased pressure in the pulmonary arteries that carry blood from the heart to the lungs. PAH occurs when the pulmonary arteries thicken or grow rigid. This makes blood flow more difficult. The heart must work harder to push blood through the arteries, and the arteries are unable to carry adequate blood to the lungs. The increased pressure strains the heart, which can limit physical activity, result in heart failure and reduce life expectancy. PAH will continue to worsen over time, even with proper treatment. Based on data from the Registry to EValuate Early And Long-term PAH disease management, or REVEAL, of patients in the US, there is an estimated five-year survival rate of 57% from diagnosis.

PAH involves several interrelated mechanisms, with prostacyclin and thromboxane A2 playing a major role in maintaining pulmonary vascular tone through their balanced activity. Prostacyclin, released by endothelial cells, promotes vasodilation and inhibits platelet aggregation. Prostacyclin also has antiproliferative effects on vascular smooth muscle. Despite treatment guidelines, targeting the prostacyclin pathway has been primarily reserved for patients with advanced disease due to limitations of currently available options including parenteral prostacyclins which are the only PAH treatment that have demonstrated a mortality benefit.

Everest Collaboration

In December 2017, we entered into a Collaboration and License Agreement, or the Everest Agreement, with Everest regarding the development and commercialization of ralinepag and etrasimod in China, Taiwan, Hong Kong, Macau and South Korea, or the Everest Territories. In January 2019, we and Everest amended the Everest Agreement by entering into two separate agreements, one for each of ralinepag and etrasimod, with the terms for each program that are substantially the same as in the original Everest Agreement. Under the United Therapeutics Agreement, we assigned the separate Everest Agreement related to ralinepag to United Therapeutics.

Under the separate Everest Agreement related to etrasimod, we granted Everest an exclusive, royalty-bearing license to develop, manufacture and commercialize etrasimod (in oral formulations only), in the Everest Territories.

Everest is responsible for all development, manufacture and commercialization of the licensed products in the Everest Territories, and may participate in the portion of our global clinical trials that is conducted in the Everest Territories.

We are eligible to receive development, regulatory and commercial milestone payments from Everest, as well as tiered royalties on net sales ranging from the high single digits to low double digits. Following an initial royalty term, we are eligible to receive a lower trademark royalty if Everest continues to use our licensed product-related trademarks.

In the fourth quarter of 2018, the National Medical Products Administration of China, formerly known as the China Food and Drug Administration, or CFDA, accepted the initial clinical trial applications for an oral formulation of ralinepag and for etrasimod. Subsequently, in the fourth quarter of 2019, Everest announced that the first subject has been dosed in a Phase 3 trial evaluating etrasimod in development for the treatment of UC in Greater China and South Korea.

Boehringer Ingelheim Collaboration

In 2015, we entered into an exclusive agreement with Boehringer Ingelheim, to conduct joint research to identify drug candidates targeting a GPCR that belongs to a group of orphan central nervous system, or CNS, receptors. An “orphan receptor” is structurally related to a family of proteins that are known to act as functional cell-surface receptors but whose ligand has not yet been identified. In December 2018, Boehringer Ingelheim opted to start the preclinical development of the subject compound.

9

 

In the past, we contracted with Beacon to perform our research obligations under the Boehringer Ingelheim collaboration. In exchange, we agreed to share limited near-term milestones with Beacon as well as the full-time equivalent funding paid to us by Boehringer Ingelheim. We have retained the longer-term success milestones and all royalties.

Beacon Discovery Agreements

In January 2020, we entered into a new multi-year strategic Collaboration and License Agreement with Beacon, aimed at building novel medicines across a range of GPCR targets believed to play a role in immune and inflammatory diseases. Under the terms of this agreement, referred to as Project Cabrillo, Beacon is responsible for early drug discovery activities and Arena will be responsible for any potential future development and, ultimately, commercialization activities. We are required to pay to Beacon research initiation fees, make quarterly research funding payments for the duration of Beacon’s research activities as well as research, development and regulatory milestone payments. We are also obligated to pay Beacon tiered royalties on net sales of low single digits levels.

Prior to Project Cabrillo, beginning in September 2016, we entered into a series of agreements with Beacon.

In 2016, we entered into a License and Collaboration Agreement with Beacon, pursuant to which we granted Beacon a non-exclusive, non-assignable and non-sublicensable license to certain database information relating to compounds, receptors and pharmacology, and transferred certain equipment to Beacon. Beacon will seek to engage global partners to facilitate discovery and development. Beacon has agreed to assign to us any intellectual property relating to our existing research and development programs developed in the course of performing research for us, and grant us a non-exclusive license to any intellectual property developed outside the course of performing work for us that is reasonably necessary or useful for developing or commercializing the products under our research and development programs. We are also entitled to rights of negotiation and rights of first refusal to potentially obtain licenses to certain compounds discovered and developed by Beacon. In addition, we are entitled to receive (i) a percentage of any revenue received by Beacon on or after the second anniversary of the effective date of the agreement from any third party pursuant to a third-party license, including upfront payments, milestone payments and royalties; (ii) single-digit royalties on the aggregate net sales of any related products sold by Beacon and its affiliates; and (iii) in the event that Beacon is sold, a percentage of the consideration for such sale transaction.

In 2016, we also entered a Master Services Agreement with Beacon, pursuant to which Beacon performs certain other research services for us relating to our proprietary pipeline.

Beacon was founded and is owned by several of our former employees.

BELVIQ and BELVIQ XR (lorcaserin) Agreement

In December 2016, we entered into a Transaction Agreement with Eisai regarding lorcaserin. Pursuant to the Transaction Agreement, we granted Eisai an exclusive, royalty-bearing license, or transferred intellectual property, to develop, manufacture and commercialize lorcaserin in all countries and territories of the world. Under the Transaction Agreement we are entitled to receive tiered royalty payments starting at 9.5% on net sales of lorcaserin.

Eisai is solely responsible for all costs and expenses in connection with the development of lorcaserin. Eisai has the exclusive right and responsibility to plan and implement all research and development of lorcaserin at its own cost and expense, including conducting all regulatory activities and all clinical and development activities.

Under the Transaction Agreement, Eisai is solely responsible for development, manufacturing, and commercialization of lorcaserin including all regulatory activities.

Eisai is solely responsible for any expenses and losses associated with product liability claims, except we and Eisai share 50% of losses for any alleged defective manufacturing of lorcaserin that was manufactured by us prior to entering into the Transaction Agreement.  

Lorcaserin was approved for marketing in the U.S., and in certain other territories, for the indication of weight management. On February 13, 2020, the FDA issued a drug safety communication announcing that it requested Eisai voluntarily withdraw lorcaserin from the U.S. market based on the FDA’s analysis of data from the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients – Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) study, and that Eisai has submitted a request to voluntarily withdraw lorcaserin from the U.S. market.

Intellectual Property

Our success depends in large part on our ability to protect our compounds and information, and to operate without infringing the proprietary rights of third parties. We rely on a combination of patent, trade secret, copyright, and trademark laws, as well as

10

 

confidentiality, licensing and other agreements, to establish and protect our proprietary rights. We seek patent protection for our key inventions, including drug candidates we identify, routes for chemical synthesis, pharmaceutical formulations and methods of treatment.

There is no assurance that any of our patent applications will issue, or that any of the patents will be enforceable or will cover a drug or other commercially significant product or method. In addition, we regularly review our patent portfolio to identify patents and patent applications for potential abandonment that we deem to have relatively low value to our ongoing business operations. There is also no assurance that we will correctly identify which of our patents and patent applications should be maintained and which should be abandoned. The term of most of our current patents commenced, and most of our future patents, if any, will commence, on the date of issuance and terminate 20 years from the earliest effective filing date of the patent application. Because any marketing and regulatory approval for a drug often occurs several years after the related patent application is filed, the resulting exclusivity afforded by any patent on our drug candidates will likely be substantially less than 20 years.

In the United States, patent term adjustment is available for certain delays in patent office proceedings. In addition, under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, the term of a patent that covers an FDA-approved drug may be eligible for patent term extension, or PTE. PTE permits patent term restoration of a US patent as compensation for the patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act permits a PTE of up to five years beyond the expiration of the patent. This period is generally one-half the time between the effective date of an Investigational New Drug, or IND (falling after issuance of the patent), and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, provided the sponsor acted with diligence. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. The application for PTE is subject to approval by the US Patent and Trademark Office in conjunction with the FDA.

Outside of the United States, similar provisions may be available in the European Union, Japan, South Korea and some other jurisdictions to extend the term of a patent that covers an approved drug. The length of any such extension would vary by country. Our European patents may be eligible for supplemental protection certificates of up to five years in one or more countries.

Due to the specific requirements for obtaining these extensions, there is no assurance that our patents will be afforded extensions even if we encounter significant delays in patent office proceedings or marketing and regulatory approval.

In addition to patent protection, we rely on trade secrets, proprietary know-how and continuing technological advances to develop and maintain our competitive position. To maintain the confidentiality of our trade secrets and proprietary information, all of our employees are required to enter into and adhere to an employee confidentiality and invention assignment agreement, and invention disclosure procedures as a condition of employment. Additionally, our employee confidentiality and invention assignment agreements require that our employees not bring to us, or use without proper authorization, any third-party proprietary technology. We also generally require our consultants and collaborators that have access to proprietary property and information to execute confidentiality and invention rights agreements in our favor. While such arrangements are intended to enable us to better control the use and disclosure of our proprietary property and provide for our ownership of proprietary technology developed on our behalf, they may not provide us with meaningful protection for such property and technology in the event of unauthorized use or disclosure.

Competition

The biotechnology and pharmaceutical industries are highly competitive and are subject to rapid and significant change. We face significant competition from many organizations with drugs or drug candidates that do or may compete drug candidates we are developing. We may not be able to compete successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. Developments by others may render our drug candidates obsolete or noncompetitive, and we or our collaborators may not be successful in developing either first or best in class drugs.

Many of our existing and potential competitors have substantially greater drug development capabilities and financial, scientific and marketing resources than we do. Additional consolidation in the pharmaceutical industry may result in even more resources being concentrated with our competitors. As a result, our competitors may be able to devote greater resources than we can to the research, development, marketing and promotion of therapeutic products or drug discovery techniques, or to adapt more readily to technological advances than we can. Accordingly, our competitors may succeed in obtaining patent protection, receiving regulatory approval or commercializing drugs before we do.

We expect to encounter significant competition in the therapeutic areas targeted by our principal drug candidates. Companies that complete clinical trials, obtain regulatory approvals and commence commercial sales of their drug candidates before us may achieve a significant competitive advantage. Furthermore, we may be competing against companies with substantially greater

11

 

manufacturing, marketing, distribution and selling capabilities, and any drug candidate that we successfully develop may compete with existing therapies that have longer histories of safe and effective use.

We may rely on collaborators for support of development programs and for the manufacturing and marketing of drug candidates. Such collaborators may be conducting multiple drug development efforts within the same disease areas that are the subject of their agreements with us, which may negatively impact the development of drugs that are subject to our agreements. In addition, we face and will continue to face intense competition from other companies for such collaboration arrangements, and technological and other developments by others may make it more difficult for us to establish such relationships.

Government Regulation

We and our collaborators are subject to significant governmental regulation. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the preclinical and clinical development, pre-market approval, manufacture, import, export, marketing and distribution of pharmaceutical products. These agencies and other regulatory agencies regulate research and development activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, storage, tracking, recordkeeping, advertising, pricing and promotion of drug candidates and commercialized drugs. Failure to comply with applicable FDA or other regulatory requirements may result in inspectional notices of violation, warning letters, civil or criminal penalties, suspension or delays in clinical development, recall or seizure of products, partial or total suspension of production, withdrawal of a product from the market or other negative consequences.

In the United States

In the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FD&C Act, and its implementing regulations. The process required by the FDA before drug candidates may be marketed in the United States generally involves the following:

 

•

completion of extensive preclinical laboratory tests and preclinical animal studies, many of which are required to be performed in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations;

 

•

submission to the FDA of an IND, which must become effective before human clinical trials may begin and be updated annually;

 

•

performance of adequate and well-controlled human clinical trials, performed in accordance with the FDA’s Good Clinical Practice, or GCP, regulations, to establish the safety and efficacy of the drug candidate for each proposed indication;

 

•

submission to the FDA of a New Drug Application, or NDA, after completion of adequate and well-controlled human clinical trials, generally accompanied by payment of a substantial user fee to the FDA;

 

•

a determination by the FDA within 60 days of its receipt of the NDA to file the NDA for review;

 

•

satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the active pharmaceutical ingredient and finished drug product are produced and tested to assess compliance with Current Good Manufacturing Practices, or cGMP, regulations;

 

•

FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States; and

 

•

Prior to commercialization, centrally acting drugs may be subject to review and potential scheduling by the DEA.

The development and approval process requires substantial expertise, time, effort and financial resources, and we cannot be certain that any approvals for our drug candidates will be granted on a timely basis, if at all.

The results of preclinical tests (which include laboratory evaluation as well as GLP studies to evaluate toxicity in animals) for a particular drug candidate, together with related manufacturing information and analytical data, are submitted as part of an IND to the FDA. The initial IND becomes effective 30 days after receipt by the FDA, following its initial safety review. During the 30-day time period the FDA may require additional information. The FDA may institute a clinical hold at the 30-day time period if any questions are not fully addressed or because of other concerns about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may place an IND on partial or full clinical hold at any time during a product candidate’s development. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. Further, an independent institutional review board, or IRB, for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center and it must monitor the study until completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a

12

 

finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive Good Clinical Practice, or GCP, regulations and regulations for informed consent and privacy of individually identifiable information.

Clinical trials. For purposes of NDA submission and approval, clinical trials are typically conducted in the following sequential phases, which may overlap:

 

•

Phase 1 clinical trials. Studies are initially conducted in a limited population to test the drug candidate for safety, dose tolerance, absorption, metabolism, distribution and excretion, typically in healthy volunteers, but in some cases in patients.

 

•

Phase 2 clinical trials. Studies are generally conducted in a limited patient population to identify possible adverse effects and safety risks, explore the initial efficacy of the product for specific targeted indications and to determine dose range or pharmacodynamics. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.

 

•

Phase 3 clinical trials. These are commonly referred to as pivotal studies or adequate and well-controlled studies. When Phase 2 evaluations demonstrate that a dose range of the product is effective and has an acceptable safety profile, Phase 3 clinical trials are undertaken in large patient populations to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial centers.

 

•

Phase 4 clinical trials. The FDA may approve an NDA for a drug candidate but require that the sponsor conduct additional clinical trials to further assess the drug after NDA approval under a post-approval commitment. In addition, a sponsor may decide to conduct additional clinical trials after the FDA has approved an NDA. Post-approval trials are typically referred to as Phase 4 clinical trials.

New drug applications. The results of drug development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA. NDAs also must contain extensive chemistry, manufacturing and control, or CMC, information. An NDA is usually accompanied by a significant user fee. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing, which occurs, if at all, 60 days after submission by the NDA sponsor. Once the submission has been accepted for filing, the FDA’s goal is to review applications within 10 months from its acceptance of the filing or, if the application relates to an unmet medical need in a serious or life-threatening indication, six months from its acceptance of the filing. The review process can be significantly extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee. The FDA may deny approval of an NDA by issuing a Complete Response Letter, or CRL, if the applicable regulatory criteria are not satisfied. A CRL may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Data are not always conclusive, and the FDA may interpret data differently than we or our collaborators interpret data. Approval may occur with Risk Evaluation and Mitigation Strategies, or REMS, that may limit the labeling, distribution or promotion of a drug product. Once issued, the FDA may withdraw product approval if ongoing regulatory requirements are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing, including Phase 4 clinical trials, and surveillance programs to monitor the safety effects of approved products which have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these postmarketing programs or other information.

Expedited Development and Review Programs. The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new investigational drugs are eligible for Fast Track designation if they are intended to treat a serious or life threatening disease or condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The FDA may consider for review sections of the NDA for a Fast Track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

Any product submitted to the FDA for approval, including a product with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it is designed to treat a serious condition, and if approved, would provide a significant improvement in safety or effectiveness compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to NDAs for new molecular entities with priority review designations within six months of the filing date as compared to ten months under its standard review goals.

13

 

In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well controlled post marketing clinical trials to verify the predicted clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-market studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires, as a condition for accelerated approval, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

The Food and Drug Administration Safety and Innovation Act established a category of drugs and biologics referred to as “breakthrough therapies” that may be eligible to receive Breakthrough Therapy Designation. A sponsor may seek FDA designation of a drug candidate as a “breakthrough therapy” if the product is intended, alone or in combination with one or more other products, to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy Designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will expedite the development and review of such drug. All requests for breakthrough therapy designation will be reviewed within 60 days of receipt, and the FDA will either grant or deny the request.

Fast Track designation, Breakthrough Therapy designation and priority review do not change the standards for approval but may expedite the development or approval process.

Other US regulatory requirements. Products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including recordkeeping, annual product quality review and reporting requirements. Adverse event experience with the product must be reported to the FDA in a timely fashion and pharmacovigilance programs to proactively look for these adverse events are mandated by the FDA. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic inspections (which may be unannounced) by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Following such inspections, the FDA may issue notices on Form FDA 483 and warning letters that could cause us to modify certain activities. A Form FDA 483 notice, if issued at the conclusion of an FDA inspection or after the appropriate FDA office review of the Establishment Inspection Report prepared by the investigator, can list conditions the FDA believes may have violated cGMP or other FDA regulations. FDA guidelines specify that a warning letter be issued for violations of “regulatory significance,” also known as Official Action Indicated, or OAI. Failure to adequately and promptly correct the observation(s) can result in regulatory action. In addition to Form FDA 483 notices and warning letters, failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as suspension of manufacturing, recall of product, seizure of product, injunctive action or possible civil or criminal penalties.

The FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for healthcare professional marketing activities and materials, direct-to-consumer advertising, dissemination of off-label information, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for their approved indications and in accordance with the provisions of the confines of the pivotal studies and the approved label. Further, we may be required to develop additional data or conduct additional preclinical studies and clinical trials, and we may be required to submit and obtain FDA approval of a new or supplemental NDA for changes to, among other things, the indications, labeling, or manufacturing processes or facilities of a drug. Failure to comply with these requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, corrective advertising, suspension of manufacturing, seizure of product, injunctive action or potential civil and criminal penalties.

Physicians may prescribe legally available drugs for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA, if in their professional medical judgment, the physicians deem such use to be appropriate. Such off-label uses are common across certain medical specialties. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers’ communications regarding off-label use.

To distribute products commercially, we or our collaborators, as applicable, must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business

14

 

within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution.

Drug Enforcement Administration regulation. The DEA regulates drugs that are controlled substances. Controlled substances are those drugs that appear on one of the five schedules promulgated and administered by the DEA under the Controlled Substances Act, or CSA. The CSA governs, among other things, the inventory, distribution, recordkeeping, handling, security and disposal of controlled substances. Any drug that acts on the central nervous system has the potential to become a controlled substance based on an evaluation of its abuse potential, and scheduling by the DEA is a separate process that may delay the commercial launch of a drug even after FDA approval of the NDA. Companies with a scheduled drug are subject to periodic and ongoing inspections by the DEA and similar state drug enforcement authorities to assess ongoing compliance with the DEA’s regulations. Any failure to comply with these regulations could lead to a variety of sanctions, including the revocation or a denial of renewal of any DEA registration, injunctions, or civil or criminal penalties.

Hatch-Waxman Exclusivity. Market exclusivity provisions of the Hatch-Waxman Act can delay the submission or approval of applications seeking to rely upon the FDA’s findings of safety and effectiveness for a previously approved NDA. A new chemical entity, or NCE, subject to an NDA is entitled to a five-year period of non-patent marketing exclusivity in the United States. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement of patents listed with the FDA by the NDA holder. The Hatch-Waxman Act also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active ingredient. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Orphan drug designation and exclusivity. Under the Orphan Drug Act, the FDA may designate a drug product as an “orphan drug” if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication or the same product for the same indication if demonstrated to be clinically superior. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.

15

 

Pediatric exclusivity. Under Section 505(A) of the Food and Drug Administration Modernization Act (FDAMA), the FDA may issue Written Requests for pediatric studies prior to approval of a new drug application, if the FDA has determined that information related to the use of the drug in the pediatric population may produce health benefits. As an incentive to industry to conduct such studies requested by the FDA, Section 505(A) provides for a 6-month period as an add-on to existing marketing exclusivity periods and patent terms (“pediatric exclusivity”).

Outside of the United States

Outside of the United States, the ability to market a product is contingent upon obtaining marketing authorization from the appropriate regulatory authorities. The requirements governing marketing authorization, pricing and reimbursement vary widely from country to country. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign jurisdictions prior to the commencement of clinical studies or marketing and sale of the product in those countries. Approval in the United States does not guarantee approval in other countries and vice-versa.

Prescription drug reimbursement. In the United States and markets in other countries, sales of prescription drug products depend in part on the availability of reimbursement from third-party payers. Third-party payers include government health administrative authorities, managed care organizations, private health insurers and other organizations. The process for determining whether a payer will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the drug product. Third-party payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication. Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies to demonstrate the cost-effectiveness of our products. A payer’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payers to reimburse all or part of the costs associated with their prescription drugs. Patients are less likely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are important to new product acceptance.

If a drug is reimbursed by Medicare or Medicaid, pricing and rebate programs must comply with, as applicable, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 as well as the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, or VHCA, each as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Under the VHCA, drug companies are required to offer certain drugs at a reduced price to a number of federal agencies including US Department of Veterans Affairs and US Department of Defense, the Public Health Service and certain private Public Health Service designated entities in order to participate in other federal funding programs including Medicare and Medicaid. Participation under the VHCA requires submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as entry into government procurement contracts governed by the Federal Acquisition Regulations.

The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort, which has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was enacted in the United States in March 2010 and contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies’ share of sales to federal healthcare programs. There have been judicial and Congressional challenges to certain aspects of the ACA. For example, since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or TCJA, includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the PPACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. Further, the Bipartisan Budget Act of 2018, or the BBA, among other

16

 

things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. In December 2018, the United States Department of Health and Human Services’ Centers for Medicare & Medicaid Services, or CMS, published a new final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the TCJA. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. It is unclear how this decision, future decisions, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business. Even if favorable coverage and reimbursement status is attained for our products, less favorable coverage policies and reimbursement rates may be implemented in the future.

Further, the Trump administration’s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. The Trump administration previously released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. While some measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

In countries outside the United States, pricing of pharmaceutical products may be subject to governmental control. Evaluation criteria used by many government agencies for the purposes of pricing and reimbursement typically focus on a product’s degree of innovation and its ability to meet a clinical need unfulfilled by currently available therapies. Some countries operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular drug candidate to currently available therapies. Other countries allow companies to fix their own prices for medicines but monitor and control company profits. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products.

Healthcare fraud and abuse. Pharmaceutical companies are subject to various federal and state laws pertaining to healthcare fraud and abuse, including, but not limited to, anti-kickback and false claims laws.

The Federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, offer, receive or provide any remuneration, directly or indirectly, in exchange for, or to induce, the referral of business, including the purchase, order, lease of any good, facility, service or item, including the prescription of a particular drug, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. Some of the state prohibitions are broader in scope and apply to referral of patients for healthcare services reimbursed by any source, not only the Medicare and Medicaid programs.

In the course of practicing medicine, physicians may legally prescribe FDA-approved drugs for an indication that has not been approved by the FDA and which, therefore, is not described in the product’s approved labeling, so-called “off-label use” or “the practice of medicine,” if deemed appropriate in the physicians’ professional medical judgment. The FDA does not ordinarily regulate the behavior of physicians in their choice of treatments. The FDA and other government agencies do, however, restrict communications on the subject of off-label use by a manufacturer or those acting on behalf of a manufacturer. Companies may not promote FDA-approved drugs for off-label uses. The FDA and other governmental agencies do permit a manufacturer (and those acting on its behalf) to engage in some limited, non-misleading, non-promotional exchanges of scientific information regarding unapproved indications.

There are numerous federal false claims laws and civil monetary penalty laws that forbid, among other things, anyone from knowingly presenting, or causing to be presented for payment to third-party payers (including Medicare and Medicaid) claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services.

17

 

In addition, the federal transparency requirements under the Physician Payments Sunshine Act require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, with specific exceptions, to track and annually report to the Centers for Medicare & Medicaid Services, or CMS, payments and other transfers of value provided to physicians, as defined by such law, and teaching hospitals, and certain ownership and investment interests held by physicians or their immediate family members.

We may also be subject to state equivalents of these fraud and abuse laws.

Violations of fraud and abuse laws may be punishable by criminal, civil and/or administrative sanctions, including individual imprisonment, disgorgement, criminal fines and civil monetary penalties, possible exclusion from federal healthcare programs (including Medicare and Medicaid), and integrity oversight and reporting obligations to resolve allegations of non-compliance with these laws. In addition, under certain healthcare fraud and abuse laws, there is an ability for private individuals to bring similar actions. Additionally, many states have analogous fraud and abuse laws, some of which may be broader in scope. Further, there are an increasing number of state laws that require pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or register their sales representatives, as well as prohibiting certain other sales and marketing practices. The federal transparency requirements under the ACA require certain manufacturers of drugs, devices, biologics and medical supplies to annually report to the Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals and physician ownership and investment interests. Additionally, recent federal legislation imposes additional obligations on certain pharmaceutical manufacturers, among others, regarding drug product tracking and tracing.

Our activities are also potentially subject to federal and state consumer protection and unfair competition laws. We are also subject to the US Foreign Corrupt Practices Act, or the FCPA, which prohibits companies and individuals from engaging in specified activities to obtain or retain business or to influence a person working in an official capacity. Under the FCPA, it is illegal to pay, offer to pay, or authorize the payment of anything of value to any foreign government official, governmental staff members, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity.

Healthcare and other privacy and security laws. We are subject to numerous laws and regulations regarding the privacy, protection, and security of health information and other personal information. These laws and regulations impose obligations and restrictions on us with respect to the collection, storage, use, disclosure, transfer and security of personal information.

The Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, imposes obligations with respect to safeguarding the privacy, security and transmission of individually identifiable health information. We may be subject to, or our collaborators’ marketing activities may be limited by, HIPAA and its implementing regulations. In addition, many state laws apply to the use and disclosure of health and other personal information.

For example, as of January 1, 2020, we are subject to the California Consumer Privacy Act, or CCPA. The CCPA has created new individual privacy rights for California residents and places increased privacy and security obligations on entities handling the personal information of such residents. Among other obligations, the CCPA requires covered businesses to provide new disclosures to California residents and to respond to requests to access and/or delete personal information. The CCPA also allows for a private right of action for data breaches.

The European General Data Protection Regulation, or GDPR, imposes many requirements and restrictions that impact our collection, transfer, use and retention of personal data of clinical trial subjects and other individuals in the European Union.  For example, the GDPR dictates mandatory contractual terms for service providers that process personal data for us and restricts our ability to transfer data from the European Economic Area to our offices and service providers in the United States and other countries.  Penalties for non-compliance with the GDPR are steep, with potential fines of up to 4% of our global revenue.

Because we have operations in Switzerland, we also are required to comply with the data privacy and security laws and regulations of that country. As we conduct clinical trials and other activities that involve the collection of personal data from individuals in other countries and regions, we may be subject to additional data privacy and security laws and regulations.

Across the United States and globally, laws and regulations governing data privacy and security continue to develop and evolve. The data privacy and security laws and regulations to which we are subject will likely impact (possibly significantly) our business activities. Many of the laws and regulations that apply to us contain ambiguous provisions or impose requirements that differ from country to country, creating uncertainty. Compliance with the enhanced obligations imposed by such laws and regulations may require us to revise our business practices, allocate more resources to privacy and security, and implement new technologies. Such efforts may result in significant costs to our business.

18

 

Failure to comply with data privacy and security laws and regulations could result in regulatory penalties and significant legal liability, and could have a material adverse impact on our financial results.

Manufacturing, Revenues from External Customers, and Sources and Availability of Materials

Our revenues of $806.4 million for the year ended December 31, 2019, included $800.0 million of upfront payment from United Therapeutics, $5.0 million from Everest, and $1.7 million from Boehringer Ingelheim. Our revenues of $18.0 million for the year ended December 31, 2018, included $6.6 million from Eisai, $4.4 million from Boehringer Ingelheim, $2.8 million from Outpost Medicine, $2.2 million from Axovant, and $2.0 million from Everest. Our revenues of $21.3 million for the year ended December 31, 2017, included $12.0 million from Everest, $5.1 million from Boehringer Ingelheim and $1.7 million from Eisai. This information excludes revenue activity reported within discontinued operations. See Note 8 to our consolidated financial statements included in this Annual Report for additional information. We do not currently engage in manufacturing activities and we are not dependent on availability of materials for our core business operations.

Compliance with Environmental Regulations

Our business involves the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. In the United States, we are subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the US Environmental Protection Agency, the California Environmental Protection Agency, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the CSA and other federal, state or local regulations.

We may be subject to further such regulations in the future. Although we believe that our operations comply in all material respects with the applicable environmental laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. In the event of such an accident, we could be held liable for any damages that result, and the extent of that liability could exceed our resources. Our compliance with these laws and regulations has not had, and is not expected to have, a material effect upon our capital expenditures, results of operations or competitive position.

Employees

As of February 14, 2020, we had a total of 320 employees, including 233 in research and development and 87 in administration, which includes finance, legal, facilities, information technology and other general support areas.

Available Information

Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, are available free of charge on our website (www.arenapharm.com) as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.

 

 

Item 1A.    Risk Factors.

Investment in our stock involves a high degree of risk. You should consider carefully the risks described below, together with other information in this Annual Report on Form 10-K and other public filings, before making investment decisions regarding our stock. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose all or part of your investment. Moreover, the risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects or financial condition.

19

 

Risks Relating to Our Business

Drug development programs are expensive, time consuming, uncertain and susceptible to change, interruption, delay or termination.

Drug development programs are very expensive, time consuming and difficult to design and implement. Our drug candidates are in various stages of clinical and preclinical development and are prone to the risks of failure inherent in research and development. Clinical trials and preclinical studies are needed to demonstrate that drug candidates are safe and effective to the satisfaction of the FDA, and similar non-US regulatory authorities, and the FDA or other regulatory authority may require us to, or we or others may decide to, conduct additional research and development even after a drug is approved. The commencement or completion of our clinical trials or preclinical studies could be substantially delayed or prevented by several factors, including the following:

 

•

limited number of, and competition for, suitable patients required for enrollment in our clinical trials or animals to conduct our preclinical studies;

 

•

limited number of, and competition for, suitable sites to conduct our clinical trials or preclinical studies;

 

•

delay or failure to obtain a meeting, approval or agreement from the applicable regulatory authority to commence a clinical trial or approve a study protocol;

 

•

delay or failure to obtain sufficient supplies of drug candidates, drugs or other materials for the trial or study;

 

•

delay or failure to reach agreement on acceptable agreement terms or protocols; and

 

•

delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site.

 

For example, recruitment for the indications in our ongoing and planned clinical studies is competitive and challenging, and it is difficult to predict when such trials will be fully enrolled or when data will be available, if at all.

In addition, the FDA, other regulatory authorities, collaborators, or we may suspend, delay or terminate our development programs at any time for various reasons, including those listed above affecting the commencement or completion of trials and the following:

 

•

side effects experienced by study participants or other safety issues;

 

•

lack of effectiveness of any drug candidate during clinical trials;

 

•

slower than expected rates of patient recruitment and enrollment or lower than expected patient retention rates;

 

•

inadequacy of or changes in the manufacturing process or compound formulation;

 

•

delays in obtaining regulatory approvals to commence a study, or “clinical holds,” or delays requiring suspension or termination of a study by a regulatory authority, such as the FDA, after a study is commenced;

 

•

changes in applicable regulatory policies and regulations;

 

•

delays in identifying and reaching agreement on acceptable terms with prospective clinical trial sites;

 

•

uncertainty regarding proper dosing;

 

•

unfavorable results from clinical trials or preclinical studies, including those conducted by us, our partners or our licensees;

 

•

failure of our clinical research organizations to comply with all regulatory and contractual requirements or otherwise perform their services in a timely or acceptable manner;

 

•

scheduling conflicts with participating clinicians and clinical institutions;

 

•

failure to design appropriate clinical trial protocols;

 

•

insufficient data to support regulatory approval;

 

•

termination of clinical trials at one or more clinical trial sites;

 

•

inability or unwillingness of medical investigators to follow our clinical protocols;

 

•

failure of participating clinicians and clinical institutions to comply with all legal, regulatory and contractual requirements or otherwise perform in a timely or acceptable manner;

 

•

difficulty in maintaining contact with subjects during or after treatment, which may result in incomplete data;

20

 

 

•

lack of sufficient funding to continue clinical trials or preclinical studies; or

 

•

changes in business priorities or perceptions of the value of the program.

There is typically a high rate of attrition from the failure of drug candidates proceeding through clinical trials, and many companies have experienced significant setbacks in advanced development programs even after promising results in earlier studies or trials. We have experienced setbacks in our internal and partnered development programs and expect to experience additional setbacks from time to time in the future. In addition, even if the earlier-stage results of our development programs are favorable, these programs may take significantly longer than expected to complete or may not be completed at all. If we or our collaborators abandon or are delayed in our development efforts related to any drug or drug candidate, we may not be able to generate sufficient revenues to continue our operations at the current or planned level or be profitable, our reputation in the industry and in the investment community would likely be significantly damaged, additional funding may not be available to us or may not be available on terms we or others believe are favorable, and our stock price may decrease significantly.

We may not be successful in initiating, enrolling patients in, or completing our studies or trials or advancing our programs on our projected timetable, if at all. Any failure to initiate or delays in our studies, trials or development programs, or unfavorable results or decisions or negative perceptions regarding any of our programs, could cause our stock price to decline significantly. This is particularly the case with respect to our clinical programs.

We will need to obtain additional funds or enter into collaboration agreements to execute on our corporate strategy, and we may not be able to do so at all or on terms you view as favorable; your ownership may be substantially diluted if we do obtain additional funds; you may not agree with the manner in which we allocate our available resources; and we may not be profitable.

It takes many years and potentially hundreds of millions of dollars to successfully develop a compound into a marketed drug. We have accumulated a large deficit that has primarily resulted from the significant expenditures we have made in research and development since our inception. We expect that our losses and operating expenses will continue to be substantial.

All of our internal programs are in the development stage, and we may not have adequate funds to develop all of our compounds into marketed drugs.

We may seek to obtain additional funding through the capital markets or other financing sources. Additional funding may not be available to us or may not be available on terms we or others believe are favorable. Our ability to obtain additional funding may depend on many factors, including those outside our control. Should we obtain additional funding, your ownership interest may be diluted or otherwise negatively impacted.

We have entered into, and may in the future seek to enter into, collaboration or other agreements with other entities to continue to develop and, if successful, commercialize one or more of our drug candidates. We may not be able to enter into any such agreements on terms that we or third parties, including investors or analysts, view as favorable, if at all. Our ability to enter into any such agreement for any of our programs or drug candidates depends on many factors, potentially including the outcomes of additional testing (including clinical trial results) or regulatory applications for marketing approval, and we do not control these outcomes.

We may allocate our resources in ways that do not improve our results of operations or enhance the value of our assets, and our stockholders and others may also not agree with the manner in which we choose to allocate our resources or obtain additional funding. We may also eliminate, scale back or delay some or all of our research and development programs, and any such reductions or failure to apply our resources effectively or to obtain additional funding could narrow, slow or otherwise adversely impact the development and commercialization of one or more of our drug candidates, which could reduce our opportunities for success and have a material adverse effect on our business, our prospects and the market price of our common stock.

In addition, we cannot assure you that we will be profitable or, if we are profitable for any particular time period, that we will be profitable in the future.

Our business may be negatively impacted based on the clinical trials and preclinical studies of, and decisions affecting, one or more of our drug candidates.

The results and timing of clinical trials and preclinical studies obtained by us or our collaborators or licensees, as well as related decisions by us, collaborators, licensees and regulators, can affect our stock price. Results of clinical trials and preclinical studies are uncertain and subject to different interpretations by regulatory agencies, us or others. The design of these trials and studies (which may change significantly and be more expensive than anticipated depending on results and regulatory decisions), as well as related analyses of such results, including adverse effects, may not be viewed favorably by us or third parties, including investors, analysts,

21

 

current or potential collaborators, the academic and medical communities, and regulators, which could adversely impact the development and opportunities for regulatory approval of drug candidates and commercialization (and even result in withdrawal from the market) of approved drugs. The same may be true of decisions regarding the focus and prioritization of our research and development efforts. Stock prices of companies in our industry have declined significantly when such results and decisions were unfavorable or perceived negatively or when a drug candidate or product did not otherwise meet expectations.

The development, approval or commercialization of any of our drug candidates could be negatively affected by circumstances related to other drug candidates or approved products.

Information on our drug candidates in clinical development is preliminary and incomplete, and for such drug candidates, particularly in the earlier stages of development, information on approved products in the same or related drug classes may indicate potential risks related to the development of our drug candidates. In particular, safety issues affecting other drugs or drug candidates may result in increased regulatory scrutiny of the safety of our drugs or drug candidates, may raise potential adverse publicity and may affect product sales or result in litigation. For example, etrasimod is an orally available modulator of the S1P receptors. An approved drug that is also an orally available modulator of the S1P receptors, Gilenya, is associated with risks such as adverse cardiovascular effects, including lowering of the heart rate and heart blocks, infection, macular edema, respiratory effects, fetal risk, a rare brain infection, and elevations in liver enzymes. These adverse reactions and risks may be associated with S1P receptor modulation and could be found to be associated with the use of etrasimod. Such adverse reactions and risks, either actual or perceived, could negatively impact the development, approval or commercialization of etrasimod, or our ability to enter into a collaboration on acceptable terms.

Topline data may not accurately reflect the complete results of a particular study or trial.

We may publicly disclose topline or interim data from time to time, which are based on a preliminary analysis of then-available efficacy and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial.

We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and our company in general. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you, regulators or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business.

Our hypothesis that selectively targeting receptors can lead to more efficacious or safer drugs may not be correct.

In general, we have designed and optimized the drug candidates that we or our collaborators and licensees are developing (including etrasimod, olorinab, APD418 and ralinepag) to selectively target certain receptors found on cells in humans. Our hypothesis is that selectivity may allow our drug candidates to address diseases more efficaciously or without some of the negative effects associated with less selective drugs. In certain cases, we believe early research and, if available, early clinical testing, provides preliminary support for our hypothesis. However, our hypothesis may not be correct, early research and early phase clinical testing may not be predictive of efficacy or safety in later trials, and our drug candidates may not be approved or, if approved, have the desired efficacy or safety profile.

It is generally our strategy to develop drug candidates that we believe will be first-in-class, best-in-class, or similar descriptions, or otherwise have broad clinical utility, optimized pharmacology or optimized pharmacokinetics. Some or all of our drug candidates may not achieve these goals. For example, failure to complete enrollment in clinical trials on schedule or at all could prevent a drug candidate from being first-in-class. Similarly, comparing data from different trials, or making predictions based on preclinical data, may not allow us to correctly determine whether our drug candidates are superior to competitive drugs or drug candidates in the same way that comparisons can be made from conducting trials in which our and a competitive drug is tested “head to head” in the same trial. The failure of our drugs or drug candidates to be first-in-class, best-in-class, or similar descriptions, or have broad clinical utility, optimized pharmacology, or optimized pharmacokinetics, or a lack of “head to head” data, could adversely affect development, regulatory approval, third-party payor support, or market adoption, which would have a material adverse impact on our business.

22

 

The results of preclinical studies and completed clinical trials are not necessarily predictive of future results, and our current drug candidates or any approved drugs may not be further developed or have favorable results in later studies or trials.

Preclinical studies and Phase 1 and Phase 2 clinical trials are not primarily designed to test the efficacy of a drug candidate, but rather to test safety, to study pharmacokinetics and pharmacodynamics, and to understand the drug candidate’s side effects at various doses and schedules. Favorable results in early studies or trials may not be confirmed in later studies or trials, including preclinical studies that continue or that are initiated after earlier clinical trials and large-scale clinical trials, and our drug candidates or drugs in subsequent trials or studies may fail to show desired safety and efficacy despite having progressed through earlier-stage trials. For example, we have announced positive topline Phase 2 results for etrasimod in patients with ulcerative colitis, but these results may not be confirmed in any subsequent Phase 3 study. By way of another example, the impact of etrasimod on heart rate that was observed in completed clinical trials may not be observed in subsequent trials, and it could be viewed negatively by the FDA or other regulatory agencies.

Unfavorable results from clinical trials or preclinical studies could result in delays, modifications or abandonment of ongoing or future clinical trials, or abandonment of a program. Clinical and preclinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals or commercialization. Negative or inconclusive results or adverse medical events during such trials or studies could cause a clinical trial to be delayed, repeated or terminated; a program to be abandoned; or negatively impact a related marketed drug, which could have a material adverse effect on our business, financial condition and results of operations.

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

 

•

regulatory authorities may withdraw approvals of such product;

 

•

regulatory authorities may require additional warnings on the label;

 

•

we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;

 

•

we could be sued and held liable for harm caused to patients; and

 

•

our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.

Drug discovery and development is intensely competitive in the therapeutic areas on which we focus. If the number of our competitors increase or they develop treatments that are approved faster, marketed better, less expensive or demonstrated to be more effective or safer than our drugs or drug candidates, our commercial opportunities will be reduced or eliminated.

Many of the drugs we or our collaborators are attempting or may attempt to discover and develop may compete with existing therapies in the United States and other territories. In addition, many companies are pursuing the development of new drugs that target the same diseases and conditions that we target. For example, with regard to etrasimod, there are other drugs that have a similar mechanism of action that entered Phase 3 clinical development before etrasimod for the same indications that we are pursuing, such as ulcerative colitis.

Our competitors, particularly large pharmaceutical companies, may have substantially greater research, development and marketing and sales capabilities and greater financial, scientific and human resources than we do. Companies that complete clinical trials, obtain required regulatory agency approvals and commence commercial sale of their drugs before we do for the same indication may achieve a significant competitive advantage, including certain patent and marketing exclusivity rights. In addition, our competitors’ drugs may have fewer side effects, more desirable characteristics (such as efficacy, route of administration or frequency

23

 

of dosing), or be viewed more favorably by patients, healthcare providers, healthcare payers, the medical community, the media or others than our drug candidates or drugs, if any, for the same indication. Our competitors may also market generic or other drugs that compete with our drugs at a lower price than our drugs, which may negatively impact our drug sales, if any. Any results from our research and development efforts, or from our joint efforts with our existing or any future collaborators, may not compete successfully with existing or newly discovered products or therapies.

Our revenues in the future will be substantially dependent on the success of our or our collaborators’ and licensees’ marketing of drugs we have discovered or developed. To the extent such drugs are not commercially successful, our business, financial condition and results of operations may be materially adversely affected, and the price of our common stock may decline.

We believe our revenues will be substantially dependent on the success of the drugs we or our collaborators and licensees successfully develop. We do not know whether or when such drug candidates will be approved by regulatory authorities for sale or commercialized. Even if approved and commercialization begins, we do not know if such commercialization will be successful or otherwise meet our, your, analysts’ or others’ expectations, and the market price of our common stock could decline significantly. For example, sales of lorcaserin to date have been less than we and others initially anticipated, and, in February 2020, Eisai (as well as its distributor in South Korea) determined to withdraw lorcaserin (commercialized as BELVIQ and BELVIQ XR) from the market based on concerns raised by the FDA.

We cannot guarantee future product sales or achievement of milestones under our collaborations and license agreements. For example, our license agreement with United Therapeutics for ralinepag does not contain a covenant obligating United Therapeutics to use any particular efforts to develop or commercialize any product, and we may never receive any milestone or royalty payments under this license agreement. In addition, our collaboration and license agreements, may be terminated in certain circumstances, which may result in us not receiving additional milestone or other payments under the terminated agreement.

The degree of market acceptance and commercial success of a drug will depend on a number of factors, including the following, as well as risks identified in other risk factors:

 

•

the number of patients treated with the drug and their results;

 

•

market acceptance and use of the drug, which may depend on the public’s awareness and view of the drug, economic changes, national and world events, potentially seasonal and other fluctuations in demand, the timing and impact of current or new competition, and the drug’s perceived advantages or disadvantages over alternative treatments (including relative convenience, ease of administration, and prevalence and severity of any adverse events, including any unexpected adverse events);

 

•

the actual and perceived safety and efficacy of the drug on both a short- and long-term basis among actual or potential patients, healthcare providers and others in the medical community, regulatory agencies and insurers and other payers, including related decisions by any such entity or individual;

 

•

incidence and severity of any side effects, including as a result of off-label use or in combination with one or more drugs;

 

•

new data relating to the drug, including as a result of additional studies, trials or analyses of the drug or related drugs or drug candidates, whether conducted by us or by others;

 

•

physicians’ awareness of the drug, and the willingness of physicians to prescribe and of patients to use the drug;

 

•

the claims, limitations, warnings and other information in the drug’s current or future labeling;

 

•

any current or future scheduling designation for the drug by the U.S. Drug Enforcement Administration, or DEA, or any comparable foreign authorities;

 

•

our or our collaborators’ maintenance of an effective sales force, marketing team, strategy and program, and medical affairs group and related functions, as well as its sales, marketing and other representatives accurately describing the drug consistent with its approved labeling;

 

•

the price and perceived cost-effectiveness of the drug, including as compared to possible alternatives;

 

•

the ability of patients and physicians and other providers to obtain and maintain coverage and adequate reimbursement, if any, by third-party payers, including government payers;

 

•

the ability and desire of group purchasing organizations, or GPOs, including distributors and other network providers, to sell the drug to their constituencies;

 

•

introduction of counterfeit or unauthorized versions of the drug;

24

 

 

•

to the extent the drug is approved and marketed in a jurisdiction with a significantly lower price than in another jurisdiction, the impact of the lower pricing in the higher-priced territory, including on the pricing of reimbursement, if available, and by the diversion of lower-priced of the drug into the higher-priced territory; and

 

•

the availability of adequate commercial manufacturing and supply chain for the drug.

Our drugs may not be commercially successful if not widely covered and adequately reimbursed by third-party payers, and we may depend on others to obtain and maintain third-party payer access; inadequate third-party coverage and reimbursement could make entering into agreements with pharmaceutical companies to collaborate or commercialize our drugs more difficult and diminish our revenues.

Our and our collaborators’ and licensee’s ability to successfully commercialize any of our drugs that have been or may be approved will depend, in part, on government regulation and the availability of coverage and adequate reimbursement from third-party payers, including private health insurers and government payers, such as the Medicaid and Medicare programs, increases in government-run, single-payer health insurance plans and compulsory licenses of drugs. We expect government and third-party payers will continue their efforts to contain healthcare costs by limiting coverage and reimbursement levels for new drugs. In addition, many countries outside of the U.S. have nationalized healthcare systems in which the government pays for all such products and services and must approve product pricing, and some U.S. politicians advocate for implementation of a comparable system in the United States. A government or third-party payer decision not to approve pricing, or provide adequate coverage and reimbursements, for our drugs, if any, could limit market acceptance of and demand for our drugs.

It is increasingly difficult to obtain coverage and adequate reimbursement levels from third-party payers, and significant uncertainty exists as to the coverage and reimbursement of newly approved prescription drug products. We or our collaborators also face competition in negotiating for coverage from pharmaceutical companies and others with competitive drugs or other treatment, and these competitors may have significantly more negotiating leverage or success with respect to individual payers than we or our collaborators may have.

Federal and state healthcare reform measures that have been or may be implemented in the future, may result in more rigorous coverage criteria, more limited coverage and downward pressure on the price that we may receive for any approved product, which could seriously decrease our future revenues. The Patient Protection and Affordable Care Act, as amended, or the ACA, which was enacted in 2010, is one such healthcare reform measure that has made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. In the years since its enactment, there have been, and continue to be, significant developments in, and continued legislative, executive, and judicial activity around, attempts to repeal, replace, or modify the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or TCJA, includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. In December 2018, the United States Department of Health and Human Services’ Centers for Medicare & Medicaid Services, or CMS, published a new final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the TCJA. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. It is unclear how this decision, future decisions, subsequent appeals and other efforts to repeal and replace the ACA will impact the ACA and our business and operations.

Further, the Trump administration’s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. The Trump administration previously released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. While some measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that they will

25

 

continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

In addition, there has been heightened scrutiny in the United States and other countries of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. In the United States, such scrutiny has resulted in congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of additional cost containment measures or other healthcare reforms may also limit our commercial opportunities by reducing the amount a potential collaborator or licensee is willing to pay to license our programs or drug candidates in the future, which may prevent us from being able to establish and maintain collaborations and license agreements, generate revenue, attain profitability, or commercialize our products.

Forecasting potential sales for drugs will be difficult, and if our projections are inaccurate, our business may be harmed and our stock price may be adversely affected.

Our business planning requires us to forecast or make assumptions regarding demand and revenues for our drugs if they are approved despite numerous uncertainties. These uncertainties may be increased if we rely on our collaborators to conduct commercial activities and provide us with accurate and timely information. Actual results may deviate materially from projected results for various reasons, including the following, as well as risks identified in other risk factors:

 

•

the rate of adoption in the particular market, including fluctuations in demand for various reasons, such as fluctuations related to economic changes, national and world events, holidays and seasonal changes;

 

•

pricing (including discounting or other promotions), reimbursement, product returns or recalls, competition, labeling, DEA scheduling, adverse events and other items that impact commercialization;

 

•

lack of patient and physician familiarity with the drug;

 

•

lack of patient use and physician prescribing history;

 

•

lack of commercialization experience with the drug;

 

•

actual sales to patients may significantly differ from expectations based on sales to wholesalers;

 

•

uncertainty relating to when the drug may become commercially available to patients and rate of adoption in other territories; and

 

•

other changes in regulatory or commercial conditions.

Revenues from drug sales may be based in part on estimates, judgment and accounting policies, and incorrect estimates or regulators’ or others’ disagreement regarding such estimates or accounting policies may result in changes to guidance, projections or previously reported results. Expected and actual product sales and quarterly and other results may greatly fluctuate, and such fluctuations can adversely affect the market price of our common stock, perceptions of our ability to forecast demand and revenues, and our ability to maintain and fund our operations.

Our efforts will be seriously jeopardized if we are unable to attract and retain key and other employees.

Our success depends on the continued contributions of our principal management, development and scientific personnel, and the ability to hire and retain key and other personnel. We face competition for such personnel, and we believe that risks and uncertainties related to our business may impact our ability to hire and retain key and other personnel. If we do not recruit and retain effective management and other key employees, particularly our executive officers, our operations, our ability to generate or raise additional capital, and our business in general, may be adversely impacted. For example, to execute our clinical programs, our strategy is to maintain a sufficient and robust program management function with clinical expertise. We are in the process of modifying and building this function, and we may not be able to establish the function we believe necessary to support our clinical goals and meet our corporate objectives.

26

 

We are expanding our organization and may experience difficulties in managing this growth, which could disrupt our operations.

We are seeking to expand our employee base to increase our managerial, scientific, operational, manufacturing supply, commercial, financial and other resources and to hire more consultants and contractors, including in and outside of headquarters in San Diego, California. For example, in addition to our headquarters in San Diego, we currently have operations in Boston, Massachusetts and Zug, Switzerland. Future growth will impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. Moreover, if our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to develop and then commercialize any approved products and compete effectively will depend, in part, on our ability to effectively manage any future growth.

Data generated or analyzed with respect to product use in the market or required postmarketing or other studies or trials may result in decreased demand, lower sales, product recall, regulatory action or litigation.

An NDA holder (or the equivalent outside the United States) is responsible for assessing and monitoring the safety of a drug that has been approved for marketing, including reviewing reports of adverse safety events. In addition, NDA holders often conduct additional studies or trials or analyze new or previous data related to an approved drug, including with respect to required postmarketing studies and in connection with seeking additional regulatory approvals in new territories.

Any new data generated, including from adverse event reports or required postmarketing, registration or other studies or trials, may result in label changes, adversely affect sales or development, result in withdrawal of the drug from the market, or result in litigation. In addition, analyses of previous data can have similar risks. Regulatory agencies may consider the new data or analyses in reviewing marketing applications for drug candidates in their territories or impose post-approval requirements that require significant additional expenditures. For example, in February 2020, the FDA requested Eisai withdraw lorcaserin (commercialized as BELVIQ and BELVIQ XR) from the U.S. market. Furthermore, the discovery of significant problems with a product or class of products similar to any approved drug could have an adverse effect on our or our collaborator’s or licensee’s commercialization.

If we license or otherwise partner our drugs, our failure to maintain such agreements or poor performance or results under such agreements could negatively impact our business.

Our collaborators and licensees may have primary responsibility for the regulatory approval, marketing and distribution, and, in certain circumstances, development, of our drug candidate(s) in the territory or territories under the applicable collaboration. We may have limited or no control over our collaborator’s decisions, including the amount and timing of resources that any of these collaborators will dedicate to such activities. This is the case for our ralinepag exclusive license agreement with United Therapeutics and our lorcaserin Transaction Agreement with Eisai.

When we enter collaboration and license agreements, we are subject to a number of other risks, including:

 

•

our collaborators and licensees may not comply with applicable laws or regulatory guidelines, which could adversely impact the development or commercialization of the drug candidate;

 

•

there could be disagreements regarding the agreements or the study or development that delay or terminate the commercialization, research, study or development, delay or eliminate potential payments under the agreements or increase our costs under or outside of the agreements;

 

•

our collaborators and licensees may not effectively allocate adequate resources, may have limited experience in a particular territory, or may generate unfavorable data or results; and

 

•

our collaborators and licensees may not perform as expected, including with regard to making any required payments, and the agreements may not provide adequate protection or may not be effectively enforced.

We or our collaborators or licensees might terminate our agreements in certain circumstances or amend the terms of our agreement, and investors and analysts may not view any termination or amendment as favorable.

27

 

We rely on other companies, including third-party manufacturers and sole-source suppliers, to manufacture all our drugs and drug candidates, and we or such other companies may encounter failures or difficulties or not receive or provide adequate supply, which could adversely affect development or commercialization.

We do not own or operate manufacturing facilities that can produce active pharmaceutical ingredient, or API, intermediates and other material required to make our drug candidates or lorcaserin. Instead, we rely on other companies to supply API, intermediates and other materials. Certain of these materials are available from only one or a small number of suppliers, and using a new supplier, if available, could result in substantial delay and greater cost. Our and our manufacturers’ dependence on single or limited sources of materials may adversely affect our ability to develop and deliver drug products on a timely and competitive basis, or at all.

Any performance failure on the part of us or a third-party manufacturer could result in a product recall or seizure, delay or otherwise adversely affect sales of an approved product or the clinical development or regulatory approval of one or more of our other drug candidates. We or third-party manufacturers may encounter difficulties involving production yields, regulatory compliance, lot release, quality control and quality assurance, as well as shortages of qualified personnel.

The ability to adequately and timely manufacture and supply drug product is dependent on the uninterrupted and efficient operation of the manufacturing facilities, which is impacted by many manufacturing variables, including:

 

•

availability or contamination of raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier;

 

•

ability to accommodate changes in dosage or formulation;

 

•

capacity of our facilities or those of our contract manufacturers;

 

•

having the ability to adjust to changes in actual or anticipated use of the facility, including with respect to having sufficient capacity and a sufficient number of qualified personnel;

 

•

facility contamination by microorganisms or viruses or cross contamination;

 

•

compliance with regulatory requirements, including inspectional notices of violation and warning letters;

 

•

maintenance and renewal of any required licenses or certifications;

 

•

changes in actual or forecasted demand;

 

•

timing and number of production runs;

 

•

production success rates and bulk drug yields; and

 

•

timing and outcome of product quality testing.

In addition, we or our third-party manufacturers may encounter delays and problems in manufacturing our drug candidates or drugs for a variety of reasons, including accidents during operation, failure of equipment, delays in receiving materials, natural or other disasters, political or governmental unrest or changes, social unrest, intentional misconduct or other factors inherent in operating complex manufacturing facilities. Commercially available starting materials, reagents and excipients may be or become scarce or more expensive to procure, and we may not be able to obtain favorable terms in agreements with subcontractors. We or our third-party manufacturers may not be able to operate our respective manufacturing facilities in a cost-effective manner or in a time frame that is consistent with our expected future manufacturing needs. If we or our third-party manufacturers cease or interrupt production or if our third-party manufacturers and other service providers fail to supply materials, products or services to us for any reason, such interruption could delay progress on our programs, or interrupt the commercial supply, with the potential for additional costs and lost revenues. If this were to occur, we may also need to seek alternative means to fulfill our manufacturing needs.

We may not be able to enter into or maintain agreements with manufacturers whose facilities and procedures comply with applicable law. Manufacturers are subject to ongoing periodic inspection (which may be unannounced) by the FDA, the DEA, corresponding state and foreign authorities and other regulatory authorities to ensure strict compliance with Current Good Manufacturing Practices, or cGMPs, regulations and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer’s compliance with these regulations and standards. If we or one of our manufacturers or other company in the supply chain fail to maintain compliance or otherwise experience setbacks, we or they could be subject to civil or criminal penalties, the production of one or more of our drug candidates or any approved products could be interrupted or suspended, or our product could be recalled or withdrawn, resulting in delays, additional costs and potentially lost revenues.

28

 

Our drug candidates are subject to extensive regulation, and we may not receive required regulatory approvals, or timely approvals, for any of our drug candidates.

Preclinical and clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, marketing and distribution, and other activities relating to developing and manufacturing drugs are subject to extensive regulation by the FDA and other regulatory agencies. We and others we contract with are subject to periodic inspections (which may be unannounced) by the FDA, the DEA and other regulatory agencies. Failure to comply with applicable regulatory requirements may, either before or after product approval, subject us to administrative or judicially imposed sanctions that may negatively impact research and development or commercialization, or otherwise negatively impact our business. Regulatory agencies have in the past inspected certain aspects of our business, and we were provided with observations of objectionable conditions or practices with respect to our business. There is no assurance that regulatory agencies will not provide us with observations in future inspections or that we satisfactorily addressed observations provided to us in past inspections.

Regulatory approval of a drug candidate is not guaranteed, and our business and reputation may be harmed by any failure or significant delay in receiving regulatory approval. The number and types of preclinical studies and clinical trials that will be required for FDA approval varies depending on the drug candidate, the disease or condition that the drug candidate is designed to target and the regulations applicable to any particular drug candidate. Despite the time and expense exerted in preclinical and clinical studies, failure can occur at any stage, and we could encounter problems that cause us to abandon clinical trials or to repeat or perform additional preclinical studies and clinical trials.

We cannot predict when or whether, or assure you that, our collaborators’ or our past or any future regulatory submissions or responses will be sufficient to the applicable regulatory authority or others, that the applicable regulatory authority or others will consider data or our analyses, interpretations or procedures related to any of our drug candidates as sufficient or persuasive, or that any regulatory authority will ever approve any of our drug candidates in the future.

To market any drugs outside of the United States, we and our current or future collaborators must comply with numerous and varying regulatory requirements of other countries. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks associated with FDA approval as well as additional risks, some of which may be unanticipated. Approval by the FDA or any other regulatory authority does not assure or predict with any certainty that any other regulatory authority will approve the drug.

In addition, existing regulatory policies and laws may change. We cannot predict the likelihood, nature or extent of new government regulation, either in the United States or in other countries, or the impact on our drug candidates or drugs. For example, new FDA regulation could delay or prevent marketing approvals, increase the cost of research and development, and result in narrower product labeling and expensive post-marketing requirements.

Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, or similar designations by the FDA or other applicable regulatory agencies may not lead to a faster development or review process.

The FDA may grant Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, or other designation to product candidates that meet applicable guidelines in order to speed the availability of certain drugs. Other applicable regulatory agencies may grant similar designations. These designations may apply only to the combination of a product candidate and a specific indication or patient population. Product candidates that receive these designations may not actually receive faster clinical development or regulatory review or approval any sooner than other product candidates that do not have such designation, or at all. Furthermore, a product’s receipt of such a designation does not increase the likelihood that the product candidate will receive marketing approval. The FDA or other regulatory agency may also withdraw a designation if it determines that the product candidate no longer meets the relevant criteria.

For example, the FDA has granted Fast Track designation for APD418 for treatment of decompensated heart failure, or DHF, in patients who have heart failure with reduced ejection fraction, or HFrEF. Despite receiving Fast Track designation, such designation may be withdrawn in the future, and in any event APD418 may not actually receive faster clinical development or regulatory review or approval any sooner than other product candidates that do not have such designation, or at all.

Our activities and drugs will still be subject to extensive postmarketing regulation if approved.

Following regulatory approval of any of our drug candidates, we and our collaborators will be subject to ongoing obligations and continued regulatory review from the FDA and other applicable regulatory agencies, such as continued adverse event reporting requirements. There may also be additional postmarketing obligations imposed by the FDA or other regulatory agencies. These obligations may result in significant expense and limit the ability to commercialize such drugs.

29

 

The FDA or other regulatory agencies may also require that the sponsor of the NDA or foreign equivalent, as applicable, conduct additional clinical trials to further assess approved drugs after approval under a post-approval commitment. Such additional studies may be costly and may impact the commercialization of the drug. Unfavorable trial results from postmarketing studies could negatively impact market acceptance of the drug, limit the revenues we generate from sales, result in the drug’s withdrawal from the market, negatively impact the potential approval of the drug in other territories and result in litigation.

The FDA or other regulatory agencies may also impose significant restrictions on the indicated uses for which a drug may be marketed. Additionally, the FDA may require a Risk Evaluation and Mitigation Strategies, or REMS, study, including in connection with a drug’s approval, to help ensure that the benefits of the drug outweigh its risks. A REMS may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug’s risks, limitations on who may prescribe or dispense the drug, requirements that patients enroll in a registry or undergo certain health evaluations or other measures that the FDA deems necessary to ensure the safe use of the drug.

With regard to any of drug that receives regulatory approval, the labeling, packaging, adverse event reporting, storage, advertising and promotion for the drug will be subject to extensive regulatory requirements. We and the manufacturers of our products are also required to comply with cGMP regulations, which include requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation. Further, regulatory agencies must approve these manufacturing facilities before they can be used to manufacture our products, and these facilities are subject to ongoing regulatory inspections. In addition, regulatory agencies subject a drug, its manufacturer and the manufacturer’s facilities to continual review and inspections. The subsequent discovery of previously unknown problems with a drug, including adverse events of unanticipated severity or frequency, or problems with the facility where the drug is manufactured, may result in restrictions on the marketing of that drug, up to and including withdrawal of the drug from the market. In the United States, the DEA and comparable state-level agencies also heavily regulate the manufacturing, holding, processing, security, recordkeeping and distribution of drugs that are considered controlled substances, and the DEA periodically inspects facilities for compliance with its rules and regulations.

Our ability to generate revenues from any of our drugs that receive regulatory approval will be subject to a variety of risks, many of which are out of our control.

Any drug that may be approved for marketing may not gain market acceptance among patients, healthcare providers, healthcare payers or the medical community. We believe that the degree of market acceptance and our ability to generate revenues from such products will depend on a number of factors, including:

 

•

timing of market introduction of our drugs and competitive drugs and alternative treatments;

 

•

physician and patient awareness of our drugs;

 

•

actual and perceived efficacy and safety of our drugs;

 

•

incidence and severity of any side effects;

 

•

potential or perceived advantages or disadvantages as compared to alternative treatments;

 

•

effectiveness of sales, marketing and distribution support;

 

•

price of our future products, both in absolute terms and relative to alternative treatments;

 

•

the general marketplace for the particular drug;

 

•

the effect of current and future healthcare laws on our drug candidates;

 

•

availability of coverage and adequate reimbursement from government and other third-party payers; and

 

•

product labeling or product insert requirements of the FDA or other regulatory authorities.

If our approved drugs fail to achieve market acceptance, we may not be able to generate significant revenues to be profitable.

Collaboration and license agreement relationships may lead to disputes, divert management’s attention, expose us to liability and delay drug development and commercialization, and we may not realize the full commercial potential of our drug candidates or drugs.

We may have conflicts with our prospective, current or past collaborators or licensees, such as conflicts concerning rights and obligations under our agreements (including, for example, relating to indemnification for product liability claims and losses), the interpretation of preclinical or clinical data, the achievement of milestone or other payments, the ownership of intellectual property, or research and development, regulatory, commercialization, litigation or other strategy. Collaborators or licensees may stop supporting

30

 

our drug candidates or drugs, including if they no longer view the program as in their best financial or other interests or they develop or obtain rights to competing drug candidates or drugs. In addition, collaborators or licensees may fail to effectively develop, obtain approval for or commercialize our drugs, which may result in us not realizing their full commercial potential. If any conflicts arise with any of our current, past or prospective collaborators or licensees, the other party may act in a manner that is adverse to our interests. Any such disagreement could result in one or more of the following, each of which could delay, or lead to termination of, development or commercialization of our drug candidates or drugs, and in turn prevent us from generating revenues or cause us to incur liabilities:

 

•

unwillingness or inability on the part of a collaborator or licensee to pay for studies or other research, milestones, royalties or other payments that we believe are due to us under a collaboration;

 

•

uncertainty regarding ownership of intellectual property rights arising from our collaboration or license agreement activities, which could prevent us from entering into additional collaborations;

 

•

unwillingness on the part of a collaborator or licensee to keep us informed regarding the progress of its development, regulatory, commercialization, pharmacovigilance or other activities or to permit public disclosure of the results of those activities;

 

•

slowing or cessation of a collaborator’s or licensee’s research, development, regulatory or commercialization efforts with respect to our drug candidates or drugs; or

 

•

litigation or arbitration with our collaborator or licensee, or with third parties (including relating to product liability, intellectual property or other subject matters).

Setbacks and consolidation in the pharmaceutical and biotechnology industries could make entering into agreements with pharmaceutical companies to collaborate or commercialize our drugs more difficult and diminish our revenues.

Setbacks in the pharmaceutical and biotechnology industries, such as those caused by safety concerns relating to drugs or drug candidates, as well as competition from generic drugs, litigation and industry consolidation, may have an adverse effect on us, including by making it more difficult to enter into agreements with pharmaceutical companies to collaborate or commercialize our drugs and diminishing our revenues. For example, the FDA may be more cautious in approving our drug candidates based on safety concerns relating to these or other drugs or drug candidates, or pharmaceutical companies may be less willing to enter into new collaborations or continue existing collaborations if they are integrating a new operation as a result of a merger or acquisition or if their therapeutic areas of focus change following a merger.

We and our collaborators rely on third parties to conduct clinical trials and preclinical studies. If those parties do not comply with regulatory and contractual requirements, successfully carry out their contractual obligations or meet expected deadlines, our drug candidates may not advance in a timely manner or at all.

In the course of our discovery, preclinical testing and clinical trials, we and our collaborators rely on third parties, including investigators, clinical research organizations, manufacturers and laboratories, to perform critical services. For example, we rely on third parties to conduct our clinical trials and many of our preclinical studies. Clinical research organizations are responsible for many aspects of the trials, including finding and enrolling subjects for testing and administering the trials. Although we rely on these third parties to conduct our clinical trials, we are responsible for ensuring that each of our clinical trials is conducted in accordance with its investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, commonly referred to as Good Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. Our reliance on third parties does not relieve us of these responsibilities and requirements. These third parties may not be available when we need them or, if they are available, may not comply with all legal, regulatory and contractual requirements or may not otherwise perform their services in a timely or acceptable manner, and we may need to enter into new arrangements with alternative third parties and our preclinical studies or clinical trials may be extended, delayed or terminated. These independent third parties may also have relationships with other commercial entities, some of which may compete with us. In addition, if such third parties fail to perform their obligations in compliance with legal and regulatory requirements and our protocols, our preclinical studies or clinical trials may not meet regulatory requirements or may need to be repeated. As a result of our dependence on third parties, we may face delays or failures outside of our direct control. These risks also apply to the development activities of collaborators, and we do not control their research and development, clinical trial or regulatory activities.

31

 

We may participate in new strategic transactions that could impact our liquidity, increase our expenses, present significant distractions to our management and be viewed as unfavorable.

From time to time we consider strategic transactions, such as out-licensing or in-licensing of compounds or technologies, acquisitions of companies, asset purchases and spin-offs. Additional potential transactions we may consider include a variety of different business arrangements, such as strategic collaborations, joint ventures, restructurings, divestitures, business combinations and investments. In addition, another entity may pursue us as an acquisition target. Any such transaction may be viewed as unfavorable by our stockholders or others and may require us to incur non-recurring or other charges, may create potential liabilities, may increase our near- and long-term expenditures and may pose significant integration challenges, require additional expertise or disrupt our management or business, which could harm our operations and financial results.

When we evaluate significant proposed transactions we conduct business, legal and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from any transaction we may consummate, whether as a result of unidentified risks, integration difficulties, regulatory setbacks or other events, our business, results of operations and financial condition could be adversely affected.

We may incur substantial liabilities for any product liability claims or otherwise as a drug product developer.

We develop, test, manufacture and expect to commercialize drugs for use by humans. We face an inherent risk of product liability exposure related to the testing of our drug candidates in clinical trials, and a risk with the commercialization of lorcaserin (marketed as BELVIQ and BELVIQ XR) as well as any other drug that may be approved for marketing.

Whether or not we are ultimately successful in any product liability or related litigation, such litigation would consume substantial amounts of our financial and managerial resources, and might result in adverse publicity, all of which would impair our business. In addition, damages awarded in a product liability action could be substantial and could have a negative impact on our financial condition.

An individual may bring a liability claim against us if one of our drugs or drug candidates causes, or merely appears to have caused, an injury. Regardless of merit or eventual outcome, liability claims may result in:

 

•

decreased demand for our drug;

 

•

injury to our reputation;

 

•

increased difficulty to attract, or withdrawal of, clinical trial subjects;

 

•

costs of related litigation;

 

•

substantial monetary awards to subjects or other claimants;

 

•

loss of revenues; and

 

•

the inability to commercialize our drug candidates.

We have limited product liability insurance that covers our clinical trials and products, as well as indemnification protection in certain of our collaboration or license agreements. We may not be able to maintain or obtain insurance coverage at a reasonable cost, we may not have insurance coverage that will be adequate to satisfy any liability that may arise, and our collaborators or licensees may not indemnify us, which could have an adverse effect on our results of operations and financial condition.

Our subsidiary Arena Pharmaceuticals GmbH in Liquidation (“Arena GmbH”) manufactured BELVIQ and other products for commercialization or clinical trials, up until the sale of our manufacturing business to Siegfried effective March 31, 2018. We could be subject to liability for manufacturing defect claims relating to our manufacturing activities that preceded the closing of the sale. For example, under our agreement with Eisai, we and Eisai will each bear 50% of losses arising from any alleged defective manufacturing of BELVIQ by Arena GmbH prior to the date of the sale to Siegfried.

We have significant contractual obligations that may adversely affect our cash flow, cash position and stock price.

We have long-term leases on real properties and other contractual obligations, and limited revenues. If we are unable to generate cash from operations in the future sufficient to meet our financial obligations we will need to obtain additional funds from other sources, and we may not be able to do so at all or on terms favorable to our stockholders or us.

32

 

Also, if we do not have sufficient cash in the future and are unable to generate cash from operations or obtain additional funds from other sources sufficient to meet our contractual obligations, we may have to delay or curtail some or all of our development and commercialization programs, sell or license some or all of our assets on terms that you or others may view as unfavorable, or default on obligations under our agreements.

We may be subject, directly or indirectly, to federal and state healthcare laws, including but not limited to fraud and abuse and false claims laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties and prosecution.

In the United States, drug manufacturers and marketers are subject to various state and federal fraud and abuse laws, including, without limitation, the Federal Anti-Kickback Statute and Federal False Claims Act. There are similar laws in other countries. These laws may impact, among other things, the research, manufacturing, sales, marketing and education programs for our drugs.

The Federal Anti-Kickback Statute prohibits persons and entities from knowingly and willingly soliciting, offering, receiving or providing any remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the purchase, lease, order or the furnishing or arranging for, a good, item, facility or service, for which payment may be made, in whole or in part, under a federal healthcare program such as the Medicare and Medicaid programs. Several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Federal Anti-Kickback Statute is broad and, despite a series of narrow statutory exceptions and regulatory safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Moreover, the ACA, among other things, amended the intent requirement of the Federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them. The ACA also provides that the government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the Federal Civil False Claims Act. Many states have also adopted laws similar to the Federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.

The Federal Civil False Claims Act prohibits, among other things, persons or entities from knowingly presenting, or causing to be presented, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Suits filed under the Federal Civil False Claims Act can be brought by any individual on behalf of the government, known as “qui tam” actions, and such individuals, commonly known as “whistleblowers,” may share in any amounts paid by the entity to the government in fines or settlement. The filing of qui tam actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend a Federal Civil False Claims Act action. When an entity is determined to have violated the Federal Civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim, in addition to other penalties that may apply. Various states have also enacted laws modeled after the Federal Civil False Claims Act, some of which are broader in scope and may apply regardless of payer.

The Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Additionally, the civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. 

The Federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the U.S. Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.

We may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, impose specified requirements relating to the privacy, security and transmission of individually identifiable health information. Further, we may also be subject to state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.

33

 

Additionally, the Drug Supply Chain Security Act imposes obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements, manufacturers will be required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. The transfer of information to subsequent product owners by manufacturers will eventually be required to be done electronically. Manufacturers will also be required to verify that purchasers of the manufacturers’ products are appropriately licensed. Further, manufacturers will have drug product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.

We are unable to predict whether we could be subject to actions under any of these fraud and abuse or other laws, or the impact of such actions. If we are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, possible exclusion from government healthcare reimbursement programs, integrity oversight and reporting obligations to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, all of which could have a material adverse effect on our business and results of operations.

We may not be able to effectively integrate, manage or maintain our international operations, and such difficulty could adversely affect our business operations, financial condition, results of operations and stock price.

We have certain clinical operations personnel in Switzerland, and we engage in clinical trials and manufacturing activities in many territories outside of the United States. There are significant risks associated with foreign operations, including, but not limited to, compliance with local laws and regulations, the protection of our intellectual property, the ability to integrate our corporate culture with local customs and cultures, the distraction to our management, foreign currency exchange rates and the impact of shifts in the United States and local economies on those rates, and integration of our policies and procedures, including disclosure controls and procedures and internal control over financial reporting, with our international operations.

With respect to local laws and regulations, the European Union, Switzerland and certain other foreign territories have restrictions on the transfer, use and maintenance of certain personal data, including providing that transfers of personal data outside of their territories may only take place if the country to which the personal data is transferred ensures an “adequate” level of privacy protection. The European Commission has previously found that the United States did not provide adequate levels of protection. In addition, the European Commission has approved a data protection regulation, known as the General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR contains provisions specifically directed at the processing of health information, higher sanctions and extra-territoriality measures intended to bring non-EU companies under the regulation. We conduct clinical trials in the EU, and in the future we may expand our business operations to include additional operations in the EU. With such expansion, we would be subject to increased governmental regulation, including the GDPR, in the EU countries in which we operate, including restrictions on data transfers that may negatively impact our ability and increase our costs to maintain international operations. Penalties for non-compliance with the GDPR are steep, with potential fines of up to 4% of our global revenue.

Additionally, the California Consumer Privacy Act, or CCPA, went into effect on January 1, 2020. The CCPA creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. It requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. The CCPA may impact our business activities and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information.

Across the United States and globally, laws and regulations governing data privacy and security continue to develop and evolve. The data privacy and security laws and regulations to which we are subject will likely impact (possibly significantly) our business activities.  Many of the laws and regulations that apply to us contain ambiguous provisions or impose requirements that differ from country to country, creating uncertainty.  Compliance with the enhanced obligations imposed by such laws and regulations may require us to revise our business practices, allocate more resources to privacy and security, and implement new technologies.  Such efforts may result in significant costs to our business.

Failure to comply with data privacy and security laws and regulations could result in regulatory penalties and significant legal liability and could have a material adverse impact on our financial results.

34

 

We and third parties we contract with use hazardous materials in our operations.

Our activities involve the use of materials that could be hazardous to human health and safety or the environment. We cannot completely eliminate the risks associated with their use, storage or disposal, which could cause:

 

•

interruption of our development or manufacturing efforts;

 

•

injury to our employees and others;

 

•

environmental damage resulting in costly clean up; and

 

•

liabilities under domestic or foreign laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products.

In such an event, we may be held liable for any resulting damages, and any such liability could exceed our resources. Although we carry insurance in amounts and type that we consider commercially reasonable, we cannot be certain that the coverage or coverage limits of our insurance policies will be adequate, and we do not have insurance coverage for losses relating to an interruption of our research and development efforts caused by contamination.

Our business and operations might be disrupted or adversely affected by catastrophic events and security breaches, including any cybersecurity incidents.

Our U.S. operations are primarily located in a business park in San Diego. We also have certain operations in Boston, Massachusetts, and Zug, Switzerland. We depend on our facilities and on collaborators, licensees, contractors and vendors for the continued operation of our business, some of whom are located in Europe and Asia. As a result, natural disasters or other catastrophic events in various parts of the world, including interruptions in the supply of natural resources, political and governmental changes, disruption in transportation networks or delivery services, severe weather conditions, wildfires and other fires, explosions, actions of animal rights activists, terrorist attacks, earthquakes, wars and public health issues (including, for example, the outbreak of the novel strain of coronavirus first reported in Wuhan, China in December 2019) could disrupt our operations or those of our collaborators, contractors and vendors or contribute to unfavorable economic or other conditions that could adversely impact us.

We depend on the efficient and uninterrupted operation of our computer and communications systems, which we use for, among other things, sensitive company data, including our financial data, intellectual property and other proprietary business information.

While certain of our operations have business continuity and disaster recovery plans and other security measures intended to prevent and minimize the impact of IT-related interruptions, our IT infrastructure and the IT infrastructure of our current and any future collaborators, contractors and vendors are vulnerable to damage from cyberattacks, computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic events. We could experience failures in our information systems and computer servers, which could result in an interruption of our normal business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches can cause interruptions in our operations and can result in a material disruption of our research and development programs and other business operations. The loss of data from completed or future studies or clinical trials could result in delays in our research, development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Similarly, we and our licensees rely on third parties to conduct studies and clinical trials of our drug candidates, manufacture our drug candidates and lorcaserin, and warehouse, market and distribute lorcaserin, and similar events relating to these third parties’ computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the development of any of our other drug candidates and the commercialization of drugs could be delayed or otherwise adversely affected.

Even though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we might suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors’ insurance policies or for which we or our contractors do not have coverage. For example, we are not insured against a terrorist attack. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our research and development programs and adversely affect, which may include stopping, our commercial production.

We and our employees and directors may be named as defendants in litigation that could result in substantial costs and divert management’s attention.

Securities class action litigation may be brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because companies in the pharmaceuticals industry often experience significant stock price volatility. For example, beginning in 2010, a number of lawsuits were filed against us and certain of our employees and directors alleging we

35

 

and the other defendants violated the federal securities laws by making materially false and misleading statements regarding our lorcaserin trials, thereby artificially inflating the price of our common stock. These lawsuits were settled in 2018.

While we carry liability insurance, any losses we incur in connection with any future lawsuits may not be covered by insurance in an amount sufficient to cover our losses or at all, and our assets may be insufficient to cover any amounts that exceed our insurance coverage. We may have to pay damage awards or otherwise may enter into settlement arrangements in connection with any future claims. A settlement of any of future lawsuit against us could also involve the issuance of common stock or other equity, which may dilute your ownership interest. Any payments or settlement arrangements could have material adverse effects on our business, operating results, financial condition or your ownership interest. Even if the plaintiffs’ claims are not successful, any future lawsuit against us and/or our directors or executive officers could result in substantial costs and significantly and adversely impact our reputation and divert our management’s attention and resources, which could have a material adverse effect on our business, operating results or financial condition. In addition, any such lawsuits may make it more difficult to finance our operations, obtain certain types of insurance (including directors’ and officers’ liability insurance), and attract and retain qualified executive officers, other employees and directors.

Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from collaborators or the financial markets, and may create other financial risks for us.

Negative conditions in the U.S. or global economy, including financial markets, may adversely affect our business and the business of our current and prospective collaborators, distributors and licensees, which we sometimes refer to generally as our collaborators, and others with which we do or may conduct business. The duration and severity of these conditions is uncertain. If negative economic conditions persist or worsen, we may be unable to secure funding to sustain our operations or to find suitable collaborators to advance our internal programs, even if we achieve positive results from our research and development or business development efforts. Such negative conditions could also impact commercialization of any drugs we and our collaborators and licensees develop, as well as our financial condition.

From time to time, we may maintain a portfolio of investments in marketable debt securities, which are recorded at fair value. Although we have established investment guidelines relative to diversification and maturity with the objectives of maintaining safety of principal and liquidity, we rely on credit rating agencies to help evaluate the riskiness of investments, and such agencies may not accurately predict such risk. In addition, such agencies may reduce the credit quality of our individual holdings, which could adversely affect their value. Lower credit quality and other market events, such as changes in interest rates and deterioration in credit markets, may have an adverse effect on the fair value of our investment holdings and cash position.

Currency fluctuations may negatively affect our financial condition.

We primarily spend and generate cash in U.S. dollars and present our consolidated financial statements in U.S. dollars. However, a portion of our expected and potential payments and receipts, including relating to our Swiss operations and under certain of our agreements, are in foreign currencies. A fluctuation of the exchange rates of foreign currencies versus the U.S. dollar may, thus, adversely affect our financial results, including cash balances, expenses and revenues. We may in the future enter into hedging transactions to try to reduce our foreign currency exposure, but there is no assurance that such transactions will occur or be successful.

Laws, rules and regulations, including relating to public companies, may be costly and impact our ability to attract and retain directors and executive officers.

Laws and regulations affecting public companies, including rules adopted by the SEC and by Nasdaq, judicial rulings and other laws and regulations, including, for example, of state, federal and foreign governments and relating to privacy, may result in increased costs to us, particularly as we continue to develop the required capabilities in the United States and abroad to develop and commercialize our products. These laws, rules and regulations could make it more difficult or costly for us to obtain certain types of insurance, including directors’ and officers’ liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. These laws, rules and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on our board committees or as executive officers. We cannot estimate accurately the amount or timing of additional costs we may incur to respond to these laws, rules and regulations.

36

 

Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

The withdrawal of the United Kingdom, from the European Union, commonly referred to as “Brexit,” may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union, result in restrictions or imposition of taxes and duties for importing our product candidates into the European Union, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union.

Following the result of a referendum in 2016, the United Kingdom left the European Union on January 31, 2020, commonly referred to as “Brexit.” Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom will be subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules will continue to apply. Negotiations between the United Kingdom and the European Union are expected to continue in relation to the customs and trading relationship between the United Kingdom and the European Union following the expiry of the Transition Period.

Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, Brexit, following the Transition Period, could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the European Union. For example, as a result of the uncertainty surrounding Brexit, the EMA relocated to Amsterdam from London. Following the Transition Period, the United Kingdom will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products, including our product candidates, will be required in the United Kingdom, the potential process for which is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the European Union, or we may incur expenses in establishing a manufacturing facility in the European Union in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the European Union for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom.

Our disclosure controls and procedures and our internal control over financial reporting may not prevent potential errors and fraud

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all potential errors and fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. There are inherent limitations in all control systems, and no system of controls can provide absolute assurance that all control issues and instances of fraud, if any, or misstatements due to error, if any, within the company have been detected. While we believe that our disclosure controls and procedures and internal control over financial reporting are and have been effective at the reasonable assurance level, we intend to continue to examine and refine our disclosure controls and procedures and internal control over financial reporting and to monitor ongoing developments in these areas.

37

 

Our ability to use net operating losses to offset future taxable income may be subject to limitations.

As of December 31, 2019, we had federal and state net operating loss carryforwards of $933.2 million. Our federal net operating loss carryforwards of $539.3 million will begin to expire, if not utilized, beginning in 2029, and our state net operating loss carryforwards of $393.9 million begin expiring in 2028. Our net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. In January 2019, a taxable income-generating event, the transaction pursuant to the United Therapeutics Agreement, resulted in it being more likely than not that a portion of our net operating loss carryforwards would be used to offset our estimates of taxable income in 2019. If the estimates we have made, or the assumptions on which we relied, in estimating our taxable income in 2019 prove inaccurate, our net operating loss carryforwards to be used to offset our taxable income in 2019 may vary from our estimates. Under the TCJA, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the TCJA. In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past and we may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.

Current and future tax laws and regulation could adversely affect our business and financial condition.

The TCJA significantly revised the Internal Revenue Code of 1986, as amended. The TCJA among other things, contained significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the TCJA is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to this federal tax law.

Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.

From time to time, the Financial Accounting Standards Board, or FASB, either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our financial position, results of operations or reported cash flows. Any difficulties in adopting or implementing any new accounting standard, or updating or modifying our internal controls as needed on a timely basis, could result in our failure to meet our financial reporting obligations, which could result in regulatory discipline and harm investors’ confidence in us. In addition, if we were to change our critical accounting estimates, including those related to the recognition of revenue, our operating results could be significantly affected.

Risks Relating to Our Intellectual Property

Our success is dependent on intellectual property rights held by us and third parties and our interest in these rights is complex and uncertain.

Our success will depend on our own and on current or future collaborators’ abilities to obtain, maintain and defend patents. In particular, the patents directed to our drug candidates and drugs are important to developing and commercializing drugs and to our revenue. We have numerous U.S. and foreign patents issued and patent applications pending for our technologies. There is no assurance that any of our patent applications will issue, or that any of the patents will be enforceable or will cover a drug or other commercially significant technology or method, or that the patents will be held to be valid for their expected terms.

The procedures for obtaining a patent are complex. These procedures require an analysis of the scientific technology related to the invention and many sophisticated legal issues. Obtaining patent rights outside the United States often requires the translation of highly technical documents and an improper translation may jeopardize our patent protection. Ensuring adequate quality of translators and foreign patent attorneys is often very challenging. Consequently, the process for having our pending patent applications issue as patents will be difficult, complex, time consuming and expensive. Our patent position is very uncertain and we do not know when, or if, we will obtain additional patents, or if the scope of the patents obtained will be sufficient to protect our drugs, or be considered sufficient by parties reviewing our patent positions pursuant to a potential marketing, licensing or financing transaction.

38

 

In addition, other entities may challenge the validity or enforceability of our patents in litigation or administrative proceedings. We cannot make assurances as to how much protection, if any, our patents will provide if we attempt to enforce them or they are challenged. It is possible that a competitor or a generic pharmaceutical provider may successfully challenge our patents and those challenges may result in reduction or elimination of our patent coverage.

We also rely on confidentiality agreements and trade secrets to protect our technologies. However, such information is difficult to protect. We require our employees to contractually agree not to improperly use our confidential information or disclose it to others, but we may be unable to determine if our employees have conformed or will conform to their legal obligations under these agreements. We also enter into confidentiality agreements with prospective collaborators, collaborators, service providers and consultants, but we may not be able to adequately protect our trade secrets or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of this information. Many of our employees and consultants were, and many of them may currently be, parties to confidentiality agreements with other pharmaceutical and biotechnology companies, and the use of our technologies could violate these agreements. In addition, third parties may independently discover our trade secrets or other proprietary information.

Some of our research and development collaborators and scientific consultants have rights to publish data and information to which we have rights. We generally seek to prevent our collaborators and consultants from disclosing scientific discoveries before we have the opportunity to file patent applications on such discoveries. In some of our collaborations, we do not control our collaborators’ ability to disclose their own discoveries under the collaboration and in some of our academic relationships we are limited to relatively short periods to review a proposed publication and file a patent application. If we cannot maintain confidentiality in connection with our collaborations and relationships, our ability to receive patent protection or protect our proprietary information will be impaired.

We believe that the United States is by far the largest single market for pharmaceuticals in the world. Because of the critical nature of patent rights to our industry, changes in U.S. patent laws could have a profound effect on our future profits, if any. It is unknown which, if any, patent laws will change, how changes to the patent laws will ultimately be enforced by the courts and how it would impact our business.

A dispute regarding the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be costly and result in delays or termination of our future research, development, manufacturing and sales activities.

Our commercial success depends upon our ability to develop and manufacture our drugs and drug candidates, market and sell drugs, and conduct our research and development activities without infringing or misappropriating the proprietary rights of others. There are many issued patents and pending patent applications owned by others relating to research and development programs that could be determined to be similar, identical or superior to ours or our licensors or collaborators. We may be exposed to future litigation by others based on claims that our drugs, drug candidates, technologies or activities infringe the intellectual property rights of others. Numerous issued patents and pending patent applications owned by others exist in the areas of our research and development, including some which purport to allow the patent holder to control the use of all drugs that modulate a particular drug target regardless of whether the infringing drug bears any structural resemblance to a chemical compound known to the patent holder at the time of patent filing. Numerous issued patents and pending patent applications owned by others also exist in the therapeutic areas in which we are developing drugs. There are also numerous issued patents and pending patent applications owned by others that are directed to chemical compounds or synthetic processes that may be necessary or useful to our research, development, manufacturing or commercialization activities. These could materially affect our ability to develop our drug candidates or manufacture, import or sell drugs, and our activities, or those of our licensors or collaborators, could be determined to infringe these patents. Because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our drugs, drug candidates or technologies may infringe. There also may be existing patents owned by others, of which we are not aware, that our drug candidates or technologies may infringe. Further, there may be issued patents or pending patent applications owned by others in fields relevant to our business, of which we are or may become aware, that we believe (i) are invalid, unenforceable, or we do not infringe; (ii) relate to immaterial portions of our overall research and development, manufacturing and commercialization efforts; or (iii) in the case of pending patent applications, the resulting patent would not be granted or, if granted, would not likely be enforced in a manner that would materially impact such efforts. We cannot assure you that others holding any of these patents or patent applications will not assert infringement claims against us and seek damages or enjoinment of our activities. We also cannot assure you that, in the event of litigation, we will be able to successfully assert non-infringement, unenforceability, invalidity or immateriality, or that any infringement claims will be resolved in our favor.

In addition, others may infringe or misappropriate our proprietary rights. We may have to institute costly legal action to protect our intellectual property rights, or we may not be able to afford the costs of enforcing or defending our intellectual property rights.

39

 

There could be significant litigation and other administrative proceedings in our industry that affect us regarding patent and other intellectual property rights. Any legal action or administrative action against us, or our collaborators, claiming damages or seeking to enjoin commercial activities relating to our research and development, manufacturing and commercialization activities could:

 

•

require us, or our collaborators, to obtain a license which may not be available on commercially reasonable terms, if at all;

 

•

prevent us from importing, making, using, selling or offering to sell the subject matter claimed in patents held by others and subject us to potential liability for damages;

 

•

consume a substantial portion of our managerial, scientific and financial resources; or

 

•

be costly, regardless of the outcome.

Furthermore, because of the substantial amount of pre-trial document and witness discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised. In addition, during the course of intellectual property litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the trading price of our common stock.

We are aware of third-party patents, as well as third-party patent applications, that could adversely affect the potential commercialization of etrasimod. For example, we are aware of third-party patents, as well as a third-party patent application, with broad claims to administering an S1P modulator by starting with a lower dose and then increasing to a higher, standard daily dose. While we do not believe that any such claims that would cover the potential commercialization of etrasimod are valid and enforceable, we may be incorrect in this belief.

We have been contacted from time to time by third parties regarding their intellectual property rights, sometimes asserting that we may need a license to use their technologies. If we fail to obtain any required licenses or make any necessary changes to our technologies, we may become involved in expensive and time-consuming litigation or we may be unable to develop or commercialize some or all of our drugs or drug candidates.

We cannot predict the outcome of any litigation matter. For example, our existing patents could be invalidated, found unenforceable or found not to cover a generic form of our drugs.

We cannot protect our intellectual property rights throughout the world.

Filing, prosecuting, defending and enforcing patents on all of our drug candidates throughout the world would be prohibitively expensive. The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to “work” the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Compulsory licensing of life-saving drugs is also becoming increasingly popular in developing countries either through direct legislation or international initiatives. Such compulsory licenses could be extended to include some of our drug candidates, which could limit our potential revenue opportunities. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which makes it difficult for us to stop the infringement of our patents. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.

Risks Relating to Our Securities

Our stock price will likely be volatile, and your investment in our stock could decline in value.

Our stock price has fluctuated historically. From January 1, 2018, to February 21, 2020, the market price of our stock was as low as $30.00 per share and as high as $64.48 per share.

40

 

Very few drug candidates being tested will ultimately receive regulatory approval, and companies in our industry sometimes experience significant volatility in their stock price. Our stock price may fluctuate significantly depending on a variety of factors, including:

 

•

results or decisions affecting the development or commercialization of any of our drug candidates or drugs, including the results of studies, trials and other analyses;

 

•

the success, failure or setbacks of our or a perceived competitor’s drugs or drug candidates;

 

•

the timing of the development of our drug candidates;

 

•

discussions or recommendations affecting our drugs or drug candidates by the FDA or other reviewers of preclinical or clinical data or other information related to our drug candidates or drugs;

 

•

regulatory actions or decisions or legislation affecting drugs or drug candidates, including ours and those of our competitors;

 

•

the commercial availability and success or failure of any of our drug candidates or lorcaserin;

 

•

the development and implementation of our continuing development and research plans, including outcome studies for lorcaserin;

 

•

the entrance into, or failure to enter into, a new collaboration or the modification or termination of an existing collaboration or other material transaction;

 

•

the timing and receipt by us of milestone and other payments or failing to achieve and receive the same;

 

•

fluctuation in prescriptions, sales or financial results (including with respect to revenue recognition, expenses and other operating results) or inaccurate sales or cash forecasting;

 

•

accounting restatements and changes;

 

•

supply chain or manufacturing issues;

 

•

changes in our research and development budget or the research and development budgets of our existing or potential collaborators;

 

•

the introduction, development or withdrawal of drug candidates or drugs by others that target the same diseases and conditions that we or our collaborators target or the introduction of new drug discovery techniques;

 

•

expenses related to, and the results of, litigation, other disputes and other proceedings;

 

•

financing strategy or decisions;

 

•

the allocation of our resources;

 

•

our ability, or the perception by investors of our ability, to continue to meet all applicable requirements for continued listing of our common stock on The Nasdaq Stock Market, and the possible delisting of our common stock if we are unable to do so;

 

•

developments in intellectual property rights or related announcements; and

 

•

capital market and other macroeconomic conditions.

We are not able to control many of these factors. If our financial or scientific results in a particular period do not meet stockholders’ or analysts’ expectations, our stock price may decline, and such decline could be significant.

Any future equity or debt issuances or other financing transactions may have dilutive or adverse effects on our existing stockholders.

We have been opportunistic in our efforts to obtain cash, and we expect we will evaluate various funding alternatives from time to time. We may issue additional shares of common stock or convertible securities that could dilute your ownership in our company and may include terms that give new investors rights that are superior to yours. We have effective registration statements to sell shares of our common stock and certain other securities, and we may elect to sell shares pursuant to such registration from time to time.

Moreover, any issuances by us of equity securities may be at or below the prevailing market price of our common stock and in any event may have a dilutive impact on your ownership interest, which could cause the market price of our common stock to decline. In addition, we may also raise additional funds through the incurrence of debt or other financing transaction, and the investors may have rights superior to your rights in the event we are not successful and are forced to seek the protection of bankruptcy laws or the transaction may otherwise adversely affect our business prospects and existing stockholders.

41

 

Our executive officers and directors may sell shares of their stock, and these sales could adversely affect our stock price.

Sales of our stock by our executive officers and directors, or the perception that such sales may occur, could adversely affect the market price of our stock. Our executive officers and directors may sell stock in the future, either as part, or outside, of trading plans under Rule 10b5-1 of the SEC.

There are a substantial number of shares of our common stock that may become eligible for future sale in the public market, and the sale of our common stock could cause the market price of our common stock to fall.

As of February 21, 2020, there were (i) options to purchase 8,623,463 shares of our common stock outstanding under our equity incentive plans at a weighted-average exercise price of $34.76 per share, (ii) 23,564 restricted stock unit awards outstanding under our equity incentive plans, (iii) performance restricted stock units outstanding under our equity incentive plans under which up to 416,045 shares of common stock may be issuable upon achievement of all specified performance goals, (iv) 3,868,097 additional shares of common stock remaining issuable under our Amended and Restated 2017 Long-Term Incentive Plan, and (v) 1,000,000 shares issuable under our 2019 Employee Stock Purchase Plan.

Once issued, the shares described above will be available for immediate resale in the public market. The market price of our common stock could decline as a result of such resales due to the increased number of shares available for sale in the market. As of February 21, 2020, there were 50,249,149 shares of our common stock outstanding.

The holders of our common stock and other securities may take actions that are contrary to your interests, including selling their stock.

A small number of stockholders may hold or acquire a significant amount of our outstanding stock. From time to time, there is a large short interest in our stock. These holders of such stock or positions may seek control of us, may support transactions that we or you do not believe are favorable, and may have interests that are different from yours. In addition, sales of a large number of shares of our stock by these large stockholders or other stockholders within a short period of time could adversely affect our stock price.

We may also be involved in disagreements with the holders of our stock, warrants or other securities in the future. Such disagreements may lead to proxy contests or litigation, which may be expensive and consume management’s time, involve settlements, the terms of which may not be favorable to us, or result in other negative consequences to our business.

Certain of our agreements, provisions in our charter documents, possible future agreements and Delaware law could delay or prevent a change in management or a takeover attempt that you may consider to be in your best interests.

There is a standstill provision in our transaction agreement with Eisai, and we may enter into agreements with similar provisions. In addition, we may in the future adopt a stockholders’ rights agreement, which would cause substantial dilution to any person who attempts to acquire us in a manner or on terms not approved by our board of directors. These provisions or agreements, as well as other provisions in our certificate of incorporation and bylaws and under Delaware law, could delay or prevent the removal of directors and management and could make more difficult a merger, tender offer or proxy contest involving us that you may consider to be in your best interests. For example, our charter provisions:

 

•

allow our board of directors to issue preferred stock without stockholder approval;

 

•

limit who can call a special meeting of stockholders;

 

•

eliminate stockholder action by written consent; and

 

•

establish advance notice requirements for nomination for election to the board of directors or for proposing matters to be acted upon at stockholders’ meetings.

 

Item 1B.    Unresolved Staff Comments.

None.

42

 

Item 2.    Properties.

We lease real property to support our business, including research and development, sales, marketing and administration. We believe our leased properties are not material to our business. We believe our facilities are suitable and adequate for our current and near-term needs, and that we will be able to locate additional facilities as needed.

Item 3.    Legal Proceedings.

We are not currently subject to any material legal proceedings.

Item 4.    Mine Safety Disclosures.

Not applicable.

 

43

 

PART II

Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market information

Our common stock is listed on the Nasdaq Global Select Market under the symbol “ARNA.”

Holders

As of February 21, 2020, there were approximately 83 stockholders of record of our common stock, one of which is Cede & Co., a nominee for Depository Trust Company, or DTC. Shares of common stock that are held by financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are considered to be held of record by Cede & Co. as one stockholder.

Dividends

We have never paid cash dividends on our capital stock. We anticipate that we will retain earnings, if any, to support operations and finance the growth and development of our business and, therefore, do not expect to pay cash dividends in the foreseeable future.

Performance graph

The graph below compares the cumulative five-year total return on our common stock from December 31, 2014, through December 31, 2019, to the cumulative total return over such period for (i) the Nasdaq Composite Index and (ii) the Nasdaq Biotechnology Index. The graph assumes the investment of $100 on December 31, 2014, with the reinvestment of dividends, although dividends have not been declared on our common stock, and is calculated according to the Securities and Exchange Commission’s methodology. We caution that the stock price performance shown in the graph may not be indicative of future stock price performance. The graph, including each of the graph lines, was provided by Research Data Group, Inc.

44

 

This information, including the graph below, is not deemed to be “soliciting material” or to be “filed” with the Securities and Exchange Commission, or subject to the Securities and Exchange Commission’s proxy rules, other than as provided in such rules, or to the liabilities of Section 18 of the Securities Exchange Act of 1934, and shall not be deemed incorporated by reference into any prior or subsequent filing by us under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that we specifically incorporate it by reference into any such filing.

 

 

 

 

45

 

Item 6.    Selected Financial Data.

The following Selected Financial Data should be read in conjunction with “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Item 8. Financial Statements and Supplementary Data” included below in this Annual Report on Form 10-K.

The following amounts related to earnings per share and shares outstanding have been adjusted for all periods reported for the 1-for-10 reverse stock split that we effected in June 2017.

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

 

2016

 

 

2015

 

 

 

(In thousands, except per share data)

 

Consolidated Statement of Operations Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United Therapeutics revenue

 

$

800,000

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Collaboration revenue

 

 

7,284

 

 

 

11,402

 

 

 

19,632

 

 

 

92,163

 

 

 

13,398

 

Royalty revenue

 

 

(853

)

 

 

6,568

 

 

 

1,705

 

 

 

—

 

 

 

—

 

Total revenues

 

 

806,431

 

 

 

17,970

 

 

 

21,337

 

 

 

92,163

 

 

 

13,398

 

Operating Costs and Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

231,496

 

 

 

115,029

 

 

 

70,988

 

 

 

63,782

 

 

 

83,283

 

General and administrative

 

 

77,616

 

 

 

45,257

 

 

 

30,341

 

 

 

27,529

 

 

 

30,281

 

Transaction costs

 

 

14,573

 

 

 

2,467

 

 

 

—

 

 

 

—

 

 

 

—

 

Litigation settlement expense, net

 

 

—

 

 

 

—

 

 

 

11,975

 

 

 

—

 

 

 

—

 

Restructuring charges

 

 

—

 

 

 

—

 

 

 

—

 

 

 

6,115

 

 

 

3,346

 

Total operating costs and expenses

 

 

323,685

 

 

 

162,753

 

 

 

113,304

 

 

 

97,426

 

 

 

116,910

 

Interest and other income (expense), net

 

 

25,142

 

 

 

5,949

 

 

 

(3,887

)

 

 

(7,037

)

 

 

(7,195

)

Income (loss) from continuing operations before income taxes

 

 

507,888

 

 

 

(138,834

)

 

 

(95,854

)

 

 

(12,300

)

 

 

(110,707

)

Income tax (provision) benefit

 

 

(110,333

)

 

 

110,265

 

 

 

—

 

 

 

—

 

 

 

—

 

Income (loss) from continuing operations

 

 

397,555

 

 

 

(28,569

)

 

 

(95,854

)

 

 

(12,300

)

 

 

(110,707

)

Income (loss) from discontinued operations

 

 

—

 

 

 

(830

)

 

 

3,122

 

 

 

(10,596

)

 

 

2,728

 

Net income (loss)

 

 

397,555

 

 

 

(29,399

)

 

 

(92,732

)

 

 

(22,896

)

 

 

(107,979

)

Less net loss attributable to noncontrolling interest

     in consolidated variable interest entity

 

 

—

 

 

 

—

 

 

 

1,325

 

 

 

380

 

 

 

—

 

Net income (loss) attributable to common stockholders

 

$

397,555

 

 

$

(29,399

)

 

$

(91,407

)

 

$

(22,516

)

 

$

(107,979

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amounts attributable to stockholders of Arena:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations

 

$

397,555

 

 

$

(28,569

)

 

$

(94,529

)

 

$

(11,920

)

 

$

(110,707

)

Income (loss) from discontinued operations

 

 

—

 

 

 

(830

)

 

 

3,122

 

 

 

(10,596

)

 

 

2,728

 

 

 

$

397,555

 

 

$

(29,399

)

 

$

(91,407

)

 

$

(22,516

)

 

$

(107,979

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to stockholders of Arena

    per share, basic:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

7.99

 

 

$

(0.61

)

 

$

(2.87

)

 

$

(0.49

)

 

$

(4.60

)

Discontinued operations

 

 

—

 

 

 

(0.02

)

 

 

0.10

 

 

 

(0.44

)

 

 

0.11

 

 

 

$

7.99

 

 

$

(0.63

)

 

$

(2.77

)

 

$

(0.93

)

 

$

(4.49

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to stockholders of Arena

    per share, diluted:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

7.69

 

 

$

(0.61

)

 

$

(2.87

)

 

$

(0.49

)

 

$

(4.60

)

Discontinued operations

 

 

—

 

 

 

(0.02

)

 

 

0.10

 

 

 

(0.44

)

 

 

0.11

 

 

 

$

7.69

 

 

$

(0.63

)

 

$

(2.77

)

 

$

(0.93

)

 

$

(4.49

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in calculating net income (loss) per share

     allocable to common stockholders, basic

 

 

49,779

 

 

 

47,041

 

 

 

32,990

 

 

 

24,313

 

 

 

24,067

 

Shares used in calculating net income (loss) per share

     allocable to common stockholders, diluted

 

 

51,698

 

 

 

47,041

 

 

 

32,990

 

 

 

24,313

 

 

 

24,067

 

 

46

 

 

 

 

As of December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

 

2016

 

 

2015

 

 

 

(In thousands)

 

Consolidated Balance Sheet Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

243,274

 

 

$

161,037

 

 

$

158,837

 

 

$

90,712

 

 

$

156,184

 

Total available-for-sale securities

 

 

867,229

 

 

 

367,006

 

 

 

112,482

 

 

 

—

 

 

 

—

 

Total assets

 

 

1,174,123

 

 

 

686,903

 

 

 

339,275

 

 

 

169,010

 

 

 

256,792

 

Total lease financing obligations

 

 

49,427

 

 

 

52,709

 

 

 

61,748

 

 

 

65,266

 

 

 

68,245

 

Accumulated deficit

 

 

(1,102,997

)

 

 

(1,500,552

)

 

 

(1,490,187

)

 

 

(1,398,736

)

 

 

(1,376,220

)

Total equity

 

 

1,071,465

 

 

 

606,258

 

 

 

207,144

 

 

 

40,395

 

 

 

53,542

 

 

47

 

Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis in conjunction with “Item 8. Financial Statements and Supplementary Data” included below in this Annual Report on Form 10-K, or Annual Report. Operating results are not necessarily indicative of results that may occur in future periods.

This discussion and analysis contains forward-looking statements that involve a number of risks, uncertainties and assumptions. Actual events or results may differ materially from our expectations. Important factors that could cause actual results to differ materially from those stated or implied by our forward-looking statements include, but are not limited to, those set forth in “Item 1A. Risk Factors” in this Annual Report. All forward-looking statements included in this Annual Report are based on information available to us as of the time we file this Annual Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain.

OVERVIEW AND RECENT DEVELOPMENTS

We are a biopharmaceutical company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Our internally-developed pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility.

Our most advanced investigational clinical programs include:

 

•

Etrasimod, which we are evaluating in a Phase 3 program for ulcerative colitis, or UC, a Phase 2b/3 program for Crohn’s disease, or CD, and a Phase 2b program in atopic dermatitis, or AD. We also plan to evaluate etrasimod in a Phase 2b program for eosinophilic esophagitis, or EOE, and a Phase 2 program in alopecia areata, or AA.

 

 

•

Olorinab, which we are evaluating for a broad range of visceral pain conditions associated with gastrointestinal diseases and is currently in a Phase 2b trial for treatment of abdominal pain associated with irritable bowel syndrome, or IBS.

 

 

•

APD418, which we are evaluating in a Phase 1 trial for acute heart failure, or AHF.

We continue to leverage our two decades of world-class G-protein-coupled receptor, or GPCR, target discovery research to develop breakthrough drugs and ultimately deliver these to patients with large unmet needs. Our long-term pipeline prospects include an enhanced collaboration with Beacon Discovery across a broad range of immune-mediated inflammatory targets and compounds and the buildout of Arena Neuroscience to focus on treating neurological conditions with microglial neuroinflammation.

We have license agreements or collaborations with various companies, including:

 

•

United Therapeutics (ralinepag in a Phase 3 program for pulmonary arterial hypertension),

 

•

Everest Medicines Limited (etrasimod in Greater China and select countries in Asia),

 

•

Beacon Discovery (early research platform for GPCR targets),

 

•

Boehringer Ingelheim International GmbH (undisclosed orphan GPCR program for central nervous system – preclinical), and

 

•

Eisai Co., Ltd. and Eisai Inc., collectively, Eisai (BELVIQ®/BELVIQ XR®).

Program development update.

In January 2020, we announced acceptance of our investigational new drug application and were granted Fast Track designation for APD418. We have initiated a Phase 1 clinical trial.

In December 2019, we initiated our Phase 2/3 program to evaluate etrasimod in Crohn’s disease. The program consists of a Phase 2 dose ranging trial that is intended to provide an operationally seamless transition into the Phase 3. CULTIVATE is a Phase 2b dose-ranging multicenter, randomized, double-blinded, placebo-controlled study to assess the safety and efficacy of once-daily etrasimod in subjects with moderate to severely active Crohn’s disease. The primary efficacy endpoint in the CULTIVATE trial will be endoscopic response at Week 14, in addition to a variety of scales of Crohn’s disease activity, including abdominal pain and stool

48

 

frequency. The CULTIVATE trial aims to enroll approximately 225 patients in study sites globally. The Phase 3 will include two induction trials with re-randomization of clinical responders into a single maintenance trial.

In October 2019, we announced that the first subject has been dosed in the Phase 2 ADVISE trial evaluating two dose levels etrasimod in development for the treatment of AD. ADVISE is a multicenter, randomized, double-blinded, placebo-controlled 16-week study (with a 52-week open-label extension) to assess the safety and efficacy of once-daily etrasimod in approximately 120 subjects with moderate-to-severe AD.

In July 2019, we announced the first subject dosed in the Phase 2 CAPTIVATE trial evaluating olorinab in development for the treatment of visceral pain associated with IBS. The trial will evaluate the efficacy and safety of three dose levels of olorinab for 12-weeks in approximately 240 subjects experiencing abdominal pain associated with IBS, including IBS with constipation or IBS with diarrhea. CAPTIVATE is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, 12-week study. We expect data in the second half of 2020.

In June 2019, we announced that the first subject has been dosed in ELEVATE UC 52, the first of two planned pivotal trials within the Phase 3 ELEVATE UC registrational program evaluating etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis. ELEVATE UC 52 is a treat-through trial with a 12-week induction period followed by 40 weeks of maintenance.

Collaborations and license agreement update.

In October 2019, Everest announced that the first subject has been dosed in a Phase 3 trial evaluating etrasimod in development for the treatment of ulcerative colitis in Greater China and South Korea. Everest paid us a $5.0 million milestone payment earned from this achievement.

Other corporate events.

In January 2019, we announced that Steven Spector, our Executive Vice President, General Counsel and Secretary, will retire from his positions with Arena in March 2020. Joan Schmidt was appointed as Executive Vice President, General Counsel and Secretary and will join Arena in March 2020.

In general, developing drugs and obtaining marketing approval is a long, uncertain and expensive process, and our ability to execute on our plans and achieve our goals depends on numerous factors, many of which we do not control. To date, we have generated limited revenues. We expect to continue to incur substantial net losses for at least the short term as we advance our clinical development programs and support our collaborators.

See the above “Business” section for a more complete discussion of our business.

RESULTS OF OPERATIONS

We are providing the following summary of our revenues, research and development expenses and general and administrative expenses to supplement the more detailed discussion below. This summary excludes our revenues, research and development expenses and general and administrative expenses associated with our Manufacturing Operations, which are reported within loss from discontinued operations for the year ended December 31, 2018. See Note 5 to our consolidated financial statements included in this Annual Report for additional information regarding the Manufacturing Operations. The dollar values in the following tables are in millions.

For our discussion of the year ended December 31, 2018, compared to the year ended December 31, 2017, please read Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations located in our 2018 Form 10-K.

 

Research and development expenses

 

 

 

Years ended December 31,

 

 

% change from

 

Type of expense

 

2019

 

 

2018

 

 

2018 to 2019

 

External clinical and preclinical study fees

 

$

141.1

 

 

$

69.7

 

 

*

 

Salary and other personnel costs (excluding non-cash

   share-based compensation)

 

 

48.3

 

 

 

28.4

 

 

 

69.9

%

Non-cash share-based compensation

 

 

27.4

 

 

 

8.4

 

 

*

 

Facility and equipment costs

 

 

6.2

 

 

 

5.2

 

 

 

20.3

%

Other

 

 

8.5

 

 

 

3.3

 

 

*

 

Total research and development expenses

 

$

231.5

 

 

$

115.0

 

 

*

 

49

 

 

*

The change is more than 100%.

 

General and administrative expenses

 

 

 

Years ended December 31,

 

 

% change from

 

Type of expense

 

2019

 

 

2018

 

 

2018 to 2019

 

Non-cash share-based compensation

 

$

25.7

 

 

$

11.2

 

 

*

 

Legal, accounting and other professional fees

 

 

21.8

 

 

 

14.4

 

 

 

52.1

%

Salary and other personnel costs (excluding non-cash

   share-based compensation)

 

 

20.8

 

 

 

13.3

 

 

 

56.1

%

Facility and equipment costs

 

 

5.9

 

 

 

4.5

 

 

 

29.3

%

Other

 

 

3.4

 

 

 

1.9

 

 

 

82.2

%

Total general and administrative expenses

 

$

77.6

 

 

$

45.3

 

 

 

71.5

%

 

*

The change is more than 100%.

YEAR ENDED DECEMBER 31, 2019, COMPARED TO YEAR ENDED DECEMBER 31, 2018

Revenues. We recognized revenues of $806.4 million for the year ended December 31, 2019, compared to $18.0 million for the year ended December 31, 2018. This increase resulted primarily from the revenue associated with the upfront payment of $800.0 million we received in January 2019 pursuant to the collaboration and license agreement with United Therapeutics. In connection with the United Therapeutics transaction we incurred transaction expenses of $17.0 million, consisting of $14.6 million incurred in the first quarter of 2019 and $2.4 million incurred in the fourth quarter of 2018, which are presented as transaction costs in our consolidated statements of operations.

Absent any new collaborations, we expect our 2020 revenues will primarily consist of potential milestone payments from our existing collaborations and license agreements.

Revenues from milestones and royalties are difficult to predict, and our overall revenues will likely continue to vary from quarter to quarter and year to year. In the short term, we expect the amount of revenue we earn to fluctuate.

Research and development expenses. Research and development expenses, which account for the majority of our expenses, consist primarily of clinical trial costs (including payments to contract research organizations, or CROs), salaries and other personnel costs, preclinical study fees, manufacturing costs for non-commercial products, research supply costs and facility and equipment costs. We expense research and development costs as they are incurred when these expenditures have no alternative future uses. We generally do not track our earlier-stage, internal research and development expenses by project; rather, we track such expenses by the type of cost incurred.

Research and development expenses increased by $116.5 million to $231.5 million for the year ended December 31, 2019, from $115.0 million for the year ended December 31, 2018. This increase was primarily due to an increase of $71.4 million in external clinical and preclinical study fees, $19.9 million in salary and other personnel costs, and $19.0 million in non-cash share-based compensation expense. The increases in compensation costs are primarily due to an increase in the number of research and development employees, and an incremental expense associated with performance-based restricted stock units granted in the first quarter of 2019, which is reflected in the non-cash share-based compensation expense.

We expect to incur substantial research and development expenses in 2020 and for the aggregate amount in 2020 to be greater than the amount incurred in 2019. We expect our internal costs to be higher primarily due to higher external clinical trial costs and increasing headcount in connection with advancing the etrasimod and olorinab programs. Our actual expenses may be higher or lower than anticipated due to various factors, including our progress and results. For example, patient enrollment in our Phase 3 clinical program for etrasimod is expected to be competitive and challenging, and could take longer than originally projected, which may result in our related external expenses being lower in 2020 than anticipated (but which might increase the overall costs for completing this multi-year program).

50

 

Included in the $141.1 million of total external clinical and preclinical study fees noted in the table above in this section for the year ended December 31, 2019, were the following:

 

•

$108.6 million related to etrasimod, and

 

•

$17.8 million related to olorinab.

Included in the $69.7 million of total external clinical and preclinical study fees noted in the table above in this section for the year ended December 31, 2018, were the following:

 

•

$31.4 million related to ralinepag,

 

•

$25.7 million related to etrasimod, and

 

•

$3.9 million related to olorinab.

Cumulatively from our inception through December 31, 2019, we have recognized (i) external clinical and preclinical study fees of $307.8 million for lorcaserin, $196.5 million for etrasimod, $63.5 million for ralinepag, $43.8 million for nelotanserin and $31.9 million for olorinab and (ii) $53.2 million for non-commercial manufacturing and other development costs for lorcaserin and, to a lesser extent, nelotanserin.

While expenditures on current and future clinical development programs are expected to be substantial, they are subject to many uncertainties, including whether we have adequate funds and develop our drug candidates with one or more collaborators or independently. As a result of such uncertainties, we cannot predict with any significant degree of certainty the duration and completion costs of our research and development projects or whether, when and to what extent we will generate revenues from the commercialization and sale of any of our drug candidates. The duration and cost of clinical trials may vary significantly over the life of a project as a result of unanticipated events arising during clinical development and a variety of factors, including:

 

•

the nature and number of trials and studies in a clinical program;

 

•

the potential therapeutic indication;

 

•

the number of patients who participate in the trials;

 

•

the number and location of sites included in the trials;

 

•

the rates of patient recruitment, enrollment and withdrawal;

 

•

the duration of patient treatment and follow-up;

 

•

the costs of manufacturing drug candidates; and

 

•

the costs, requirements, timing of, and the ability to secure and maintain regulatory approvals.

General and administrative expenses. General and administrative expenses increased by $32.3 million to $77.6 million for the year ended December 31, 2019, from $45.3 million for the year ended December 31, 2018. This increase was primarily due to increases of $14.5 million in non-cash share-based compensation expenses, $7.5 million in salary and other personnel costs, and $7.4 million in legal, accounting and other professional fees. The increases in compensation costs are primarily due to an increase in the number of general and administrative employees, and an incremental expense associated with performance-based restricted stock units granted in the first quarter of 2019, which is reflected in the non-cash share-based compensation expense. We expect that our 2020 general and administrative expenses will be higher than in 2019.

Interest and other income (expense), net. Interest and other income, net, was $25.1 million for the year ended December 31, 2019, compared to $5.9 million for the year ended December 31, 2018. This change was primarily due to an increase of $18.1 million in interest income from our available-for-sale investments activity and a decrease of $0.9 million in interest expense.

Income tax expense. Income tax provision was $110.3 million for the year ended December 31, 2019, as a result of the treatment of the agreement with United Therapeutics income as a discrete item during the first quarter of 2019 and the utilization of the deferred tax assets that were recorded in the fourth quarter of 2018.

LIQUIDITY AND CAPITAL RESOURCES

We have accumulated a large deficit since inception that has primarily resulted from the significant research and development expenditures we have made in seeking to identify and develop compounds that could become marketed drugs. We expect to continue to incur substantial losses for at least the short term.

51

 

To date, we have obtained cash and funded our operations primarily through the sale of common and preferred stock, the issuance of debt and related financial instruments, payments from collaborators and customers and sale leaseback transactions. From our inception through December 31, 2019, we have generated $3.5 billion in cash from these sources, of which approximately $2.0 billion was through sales of equity, $1.4 billion was through payments from collaborators and customers, $96.9 million was through the issuance of debt and related financial instruments and $77.1 million was from sale and leaseback transactions.

We believe our cash resources are sufficient to allow us to continue operations for at least the next 12 months from the date this Annual Report is filed with the SEC. There is no guarantee that adequate funds will be available when needed from additional debt or equity financing, development and commercialization partnerships or from other sources, or on terms acceptable to us. If our efforts to obtain sufficient additional funds are not successful, we would be required to delay, scale back, or eliminate some or all of our research or development, manufacturing operations, administrative operations, and clinical or regulatory activities, which could negatively affect our ability to achieve certain corporate goals.

Short term liquidity

At December 31, 2019, we had $1.1 billion in cash and cash equivalents, and available-for-sale investments. Our potential sources of liquidity in the short term include (i) milestone and other payments from collaborators, (ii) entering into new collaboration, licensing or commercial agreements for one or more of our drug candidates or programs, (iii) the lease of our facilities or sale of other assets and (iv) sale of equity, issuance of debt or other transactions.

Long term liquidity

It will require substantial cash to achieve our objectives of discovering, developing and commercializing drugs, and this process typically takes many years and potentially several hundreds of millions of dollars for an individual drug. We may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. We will need to obtain significant funds under our existing collaborations, under new collaboration, licensing or other commercial agreements for one or more of our drug candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions.

In addition to potential payments from our current collaborators, as well as funds from public and private financial markets, potential sources of liquidity in the long term include (i) upfront, milestone, royalty and other payments from any future collaborators or licensees and (ii) revenues from sales of any drugs we obtain regulatory approval to commercialize on our own. The length of time that our current cash and cash equivalents and any available borrowings will sustain our operations will be based on, among other things, the rate of adoption and commercial success of any drugs we or our collaborators obtain regulatory approval to market, regulatory decisions affecting our and our collaborator’s drug candidates, prioritization decisions regarding funding for our programs, progress in our clinical and earlier-stage programs, the time and costs related to current and future clinical trials and nonclinical studies, our research, development, manufacturing and commercialization costs (including personnel costs), our progress in any programs under collaborations, costs associated with intellectual property, our capital expenditures, and costs associated with securing any in-licensing opportunities. Any significant shortfall in funding may result in us reducing our development and/or research activities, which, in turn, would affect our development pipeline and ability to obtain cash in the future.

We evaluate from time to time potential acquisitions, in-licensing and other opportunities. Any such transaction may impact our liquidity as well as affect our expenses if, for example, our operating expenses increase as a result of such acquisition or license or we use our cash to finance the acquisition or license.

Sources and uses of our cash

Net cash provided in operating activities was $568.7 million in the year ended December 31, 2019, compared to net cash used in operating activities of $132.2 million in the year ended December 31, 2018. This increase was primarily the result of an $800.0 million upfront payment from United Therapeutics received in 2019, partially offset by an increase of $66.0 million in payments made for external clinical study fees, an increase in cash expenditures of approximately $24.4 million for personnel costs resulting primarily from an increase in the number of employees, a payment of $14.6 million for the expenses related to the United Therapeutics transaction in the first quarter of 2019, reduced by a class action litigation settlement payment of $12.0 million in the second quarter of 2018.

Net cash used in investing activities increased by $245.6 million to $496.9 million in the year ended December 31, 2019, compared to $251.3 million in the year ended December 31, 2018. This increase was primarily due to $493.1 million in net purchases of available-for-sale investments, net of proceeds from the sales and maturity of available-for-sale investments in the year ended December 31, 2019, compared to $254.0 million in net purchases of available-for-sale investments in the year ended December 31, 2018.

52

 

Net cash of $9.9 million was provided by financing activities in the year ended December 31, 2019, as a result of net proceeds of $13.1 million from stock option exercises and stock award releases, partially offset by $3.3 million of principal payments on our lease financing obligations. Net cash of $385.0 million was provided by financing activities in the year ended December 31, 2018, as a result of net proceeds of $383.1 million from our March 2018 offering of our common stock and net proceeds of $5.9 million from stock option exercises, partially offset by $4.0 million of principal payments on our lease financing obligations.

Contractual Obligations

The following table summarizes our contractual obligations at December 31, 2019, in thousands:

 

 

 

Payments due by period

 

Contractual Obligations

 

Total

 

 

Less than 1

year

 

 

1-3

years

 

 

3-5

years

 

 

More than 5

years

 

Financing obligations

 

$

65,650

 

 

$

7,576

 

 

$

17,133

 

 

$

18,000

 

 

$

22,941

 

Operating leases

 

 

16,804

 

 

 

2,236

 

 

 

5,037

 

 

 

4,864

 

 

 

4,667

 

Total

 

$

82,454

 

 

$

9,812

 

 

$

22,170

 

 

$

22,864

 

 

$

27,608

 

 

Our financing obligations relate to sale and leaseback transactions for certain of our properties. We have applied the financing method to these sale and leaseback transactions, which requires that the book value of the properties and related accumulated depreciation remain on our balance sheet with no sale recognized. The sales price of the properties is recorded as a financing obligation and a portion of each lease payment is recorded as interest expense. At December 31, 2019, we expect our interest expense over the remaining term of these leases to total $21.2 million. Our other properties are under operating leases and are included under operating leases above.

Off-balance sheet arrangements

We do not have and did not have at December 31, 2019, any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

CRITICAL ACCOUNTING POLICIES AND MANAGEMENT ESTIMATES

The SEC defines critical accounting policies as those that are, in management’s view, important to the portrayal of our financial condition and results of operations and demanding of management’s judgment. Our discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with the US generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from those estimates.

Our significant accounting policies are more fully described in Note 1 of the consolidated financial statements included in this Annual Report. As disclosed in Note 1, the preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ significantly from those estimates. We believe that the following discussion addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require management’s most difficult, subjective and complex judgments.

Revenue recognition. Our revenues to date have been generated primarily through collaboration or license agreements. Our collaboration and license agreements frequently contain multiple types of promised goods or services including (i) intellectual property licenses, (ii) product research, development and regulatory services and (iii) product manufacturing. Consideration we receive under these arrangements may include upfront payments, research and development funding, cost reimbursements, milestone payments, payments for product sales and royalty payments. 

We recognize revenue when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that we expect to be entitled to receive in exchange for these services and excludes sales incentives and amounts collected on behalf of third parties. We analyze the nature of these performance obligations in the context of individual collaboration and license agreements in order to assess the distinct performance obligations. We apply the following five steps to recognize revenue:

53

 

i) Identify the contract with a customer. We consider the terms and conditions of our collaboration and license agreements to identify contracts within the scope of ASC 606. We consider that we have a contract with a customer when the contract is approved, we can identify each party's rights regarding the goods and services to be transferred, we can identify the payment terms for the goods and services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. We use judgment in determining the customer's ability and intent to pay, which is based upon factors including the customer's historical payment experience or, for new customers, credit and financial information pertaining to the customers.

ii) Identify the performance obligations in the contract. Performance obligations in our collaboration and license agreements are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. Our performance obligations generally consist of intellectual property licenses, research, development and/or regulatory services and manufacturing and supply commitments. Determining whether a promised goods or service is a separate performance obligation requires the use of significant judgment. A change in such judgment could result in a significant change in the period in which revenue is recognized.

Most of our collaboration and license agreements with customers contain multiple promised goods or services. Based on the characteristics of the promised goods and services we analyze whether they are separate or combined performance obligations. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price based on our overall pricing and discounting objectives, taking into consideration the type of services, estimates of hourly market rates, and stage of the research, development or clinical trials.

 iii) Determine the transaction price. We determine the transaction price based on the consideration to which we expect to be entitled in exchange for transferring goods and services to the customer. In determining the transaction price, any variable consideration would be considered, to the extent applicable, if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. In accordance with the royalty exception under ASC 606 for licenses of intellectual property, the transaction price excludes future royalty payments to be received from our customers. None of our collaboration and license agreements contain consideration payable to our customer or a significant financing component. The process for determining the transaction price involves significant judgment and includes consideration of multiple factors such as estimated revenues, market size, and development risk, among other factors contemplated in negotiating the arrangement with the customer.

Our contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone payments, which are due to us upon achievement of specific development and regulatory milestones and (ii) one-time sales-based payments and sales-based royalties associated with sold or licensed intellectual property.

Due to uncertainty associated with achievement of the development and regulatory milestones, the related milestone payments are excluded from the contract consideration and the corresponding revenue is not recognized until we conclude it is probable that reversal of such milestone revenue will not occur.

Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. We recognize revenue for sales-based royalties under licensed intellectual property and one-time payments at the later of when the sales occur or the performance obligation is satisfied or partially satisfied.

 iv) Allocate the transaction price to performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to that performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price.

 v) Recognize revenue when or as we satisfy a performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised goods or services to a customer. We recognize revenue when we transfer control of the goods or services to our customers for an amount that reflects the consideration that we expect to receive in exchange for those services.

Performance Obligations.

The following is a description of principal goods and services from which we generate revenue.

Intellectual property licenses

We generate revenue from licensing our intellectual property including know-how and development and commercialization rights. These licenses provide customers with a term-based license to further research, develop and commercialize our internally-

54

 

discovered drug candidates. The consideration we receive in the form of nonrefundable upfront consideration related to the functional intellectual property licenses is recognized when we transfer such license to the customer unless the license is combined with other goods or services into one performance obligation, in which case the revenue is recognized over a period of time based on our estimated pattern in which we satisfy the combined performance obligation. Our licensing agreements are generally cancelable. Customers have the right to terminate their contracts upon notice. We have the right to terminate the contracts generally only if the customer is in breach of the contract and fails to remedy the breach in accordance with the contractual terms.

Intellectual property sales

We generate royalty revenue from sales of our intellectual property. We estimate the future royalty payments and recognize revenue with a corresponding contract asset at a point in time when we transfer the intellectual property to the customer. We periodically reassess our estimate of the future royalty payments and recognize any estimate adjustments as revenue in the current period.

Research, development and regulatory services

We generate revenue from research, development and regulatory services we provide to our customers in connection with the licensed intellectual property. The services we provide to our customers primarily include scientific research activities, preparation for and management of clinical trials, and assistance during the regulatory approval application process. Revenue associated with these services is recognized based on our estimate of total consideration to be received for such services and the pattern in which we perform the services. The pattern of performance is generally determined to be the amount of incurred expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.

Clinical trial expenses. We accrue clinical trial expenses based on work performed. In determining the amount to accrue, we rely on estimates of total costs incurred based on enrollment, the completion of trials and other events. We follow this method because we believe reasonably dependable estimates of the costs applicable to various stages of a clinical trial can be made. However, the actual costs and timing of clinical trials are uncertain, subject to risks and may change depending on a number of factors. Differences between the actual clinical trial costs and the estimated clinical trial costs that we have accrued in any prior period are recognized in the subsequent period in which the actual costs become known. Historically, these differences have not been material; however, material differences could occur in the future.

Share-based compensation. Our share-based awards are measured at fair value and recognized over the requisite service or performance period. We estimate the fair value of each stock option on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Expected volatility is computed using historical volatility for a period equal to the expected term. The expected term of options is determined based on historical experience of similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and post-vesting terminations. The risk-free interest rates are based on the US Treasury yield curve, with a remaining term approximately equal to the expected term used in the option pricing model. We account for the forfeitures in the period they occur. The fair value of each restricted stock unit award is determined based on the market price of the underlying common stock on the date of the grant. We estimate the fair value of restricted stock unit awards that include market-based performance conditions on the date of grant using a Monte Carlo simulation model, based on the market price of the underlying common stock, expected performance measurement period, expected stock price volatility and expected risk-free interest rate.

Income taxes. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Our tax calculation is impacted by tax rates in the jurisdictions in which we are subject to tax and the relative amount of income earned in each jurisdiction. Our deferred tax assets and liabilities are determined using the enacted tax rates expected to be in effect for the years in which those tax assets are expected to be realized.

The effect of an uncertain income tax position is recognized at the largest amount that is “more-likely-than-not” to be sustained under audit by the taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

The realization of our deferred tax assets is dependent upon our ability to generate sufficient future taxable income. We establish a valuation allowance when it is more-likely-than-not that the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available evidence, both positive and negative.

On December 22, 2017, the US government enacted comprehensive tax legislation referred to as the Tax Cuts and Jobs Act, or the Tax Act. Shortly after the Tax Act was enacted, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act, or SAB 118, which provides guidance on accounting for the Tax Act’s impact. SAB 118

55

 

provides a measurement period, which should not extend beyond one year from the Tax Act enactment date, during which a company acting in good faith may complete the accounting for the impacts of the Tax Act under ASC Topic 740, Income Taxes, or ASC 740. In accordance with SAB 118, the companies are required to reflect the income tax effects of the Tax Act in the reporting period in which the accounting under ASC 740 is complete. In 2018, we completed our accounting analysis of the impacts of the Tax Act. See Note 9 to our consolidated financial statements included in this Annual Report for additional information.

The above listing is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP. See our audited consolidated financial statements and notes thereto included elsewhere in this Annual Report, which contain additional accounting policies and other disclosures required by GAAP.

Item 7A.    Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

We invest our excess cash in investment-grade, interest-bearing securities. The primary objective of our investment activities is to preserve principal and liquidity. To achieve this objective, we invest in money market funds, US Treasury notes, and high-quality marketable debt instruments of corporations and government-sponsored enterprises with contractual maturity dates of generally less than two years. All investment securities have a credit rating of at least A or better, as determined by Moody’s Investors Service, Standard & Poor’s or Fitch Ratings. If a 10% change in interest rates were to have occurred on December 31, 2019, this change would not have had a material effect on the fair value of our investment portfolio as of that date.

Foreign Currency Exchange Risk

We have a wholly owned subsidiary in Switzerland, which exposes us to foreign currency exchange risk. The functional currency of our subsidiary in Switzerland is the Swiss franc. Accordingly, all assets and liabilities of our Swiss subsidiary are translated to US dollars based on the applicable exchange rate on the balance sheet date. Revenue and expense components are translated to US dollars at weighted-average exchange rates in effect during the period. Gains and losses resulting from foreign currency translation are reported as a separate component of accumulated other comprehensive gain (loss) in the equity section of our consolidated balance sheets.

Foreign currency transaction gains and losses recorded in continuing operations are insignificant. If a 10% change in the US dollar-to-Swiss franc exchange rate were to have occurred on December 31, 2019, this change would not have had a material effect on the financial results of our continuing operations.

We have not hedged exposures denominated in foreign currencies, but may do so in the future.

 

56

 

Item 8.    Financial Statements and Supplementary Data.

ARENA PHARMACEUTICALS, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

57

 

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

Arena Pharmaceuticals, Inc.:

 

 

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Arena Pharmaceuticals, Inc. and subsidiaries (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive income (loss), equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 27, 2020 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Changes in Accounting Principle

As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for revenue recognition as of January 1, 2018 due to the adoption of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, and for leases as of January 1, 2019 due to the adoption of Accounting Standards Codification Topic 842, Leases.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Assessment of the United Therapeutics revenue recognition

As discussed in Note 8 to the consolidated financial statements, the Company entered into an exclusive license agreement with United Therapeutics Corporation in November 2018. Under the agreement, the Company received an upfront payment of $800.0 million. The upfront payment was recognized as revenue at a point in time upon the closing of this transaction in the first quarter of fiscal year 2019 when the performance obligation was satisfied upon providing access to the license.

We identified the assessment of the United Therapeutics revenue recognition as a critical audit matter.  The determination of the nature of the performance obligation and when it was satisfied was complex and involved subjective auditor judgment.

58

 

The primary procedures we performed to address this critical audit matter included the following. We tested certain internal controls over the Company’s process to record revenue, including controls related to the nature of the performance obligation and when it was satisfied. We examined the collaboration and license agreement between the Company and United Therapeutics. We evaluated the Company’s assessment of the accounting treatment of this transaction, including the determination that the Company’s performance obligation was satisfied upon the transfer of the license.

Evaluation of the accrued clinical and preclinical study fees

As discussed in Note 1 to the consolidated financial statements, research and development costs associated with the Company’s clinical trials are expensed as incurred when these expenditures have no alternative future uses. The Company has entered into various contracts with contract research organizations (CROs) to perform research and development activities. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of year-end to those CROs. These estimates are based on a number of factors, including the Company’s knowledge of the status of each of the clinical trials, invoicing to date, and the provisions in the contracts. The accrued clinical and preclinical study fees were $15.7 million and the clinical and preclinical study fees included within research and development expenses were $141.1 million as of and for the year ended December 31, 2019, respectively.

We identified the evaluation of the accrued clinical and preclinical study fees as a critical audit matter. Challenging auditor judgment was involved in evaluating the status of each of the clinical trials.

The primary procedures we performed to address this critical audit matter included the following. We tested certain internal controls over the Company’s process to estimate the outstanding obligations for the work performed by the CROs over clinical trials, including controls over the status of the clinical trials. We selected contracts with CROs, evaluated the provisions in the contracts, confirmed costs incurred with the respective CRO, and examined underlying invoices to assess the amount billed to date. Furthermore, to assess that services received prior to December 31, 2019 were included within the Company’s accrued clinical and preclinical study fees balance, we (1) inquired of the individuals who are responsible for monitoring and tracking the status of the clinical trials; (2) inspected government clinical trial databases; and (3) examined invoices received after December 31, 2019.

 

/s/ KPMG LLP

 

We have served as the Company’s auditor since 2010.

San Diego, California

February 27, 2020

 

 

59

 

ARENA PHARMACEUTICALS, INC.

Consolidated Balance Sheets

(In thousands, except share and per share data)

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

243,274

 

 

$

161,037

 

Short-term investments, available-for-sale

 

 

496,291

 

 

 

284,594

 

Accounts receivable

 

 

1,654

 

 

 

5,086

 

Prepaid expenses and other current assets

 

 

18,715

 

 

 

10,008

 

Total current assets

 

 

759,934

 

 

 

460,725

 

Investments, available-for-sale

 

 

370,938

 

 

 

82,412

 

Land, property and equipment, net

 

 

25,128

 

 

 

23,114

 

Deferred tax assets

 

 

—

 

 

 

110,333

 

Other non-current assets

 

 

18,123

 

 

 

10,319

 

Total assets

 

$

1,174,123

 

 

$

686,903

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable and other accrued liabilities

 

$

25,499

 

 

$

16,181

 

Accrued clinical and preclinical study fees

 

 

15,654

 

 

 

10,454

 

Current portion of lease financing obligations

 

 

3,814

 

 

 

3,283

 

Total current liabilities

 

 

44,967

 

 

 

29,918

 

Lease financing obligations, less current portion

 

 

45,613

 

 

 

49,426

 

Other long-term liabilities

 

 

12,078

 

 

 

1,301

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 7,500,000 shares authorized, no shares issued

   and outstanding at December 31, 2019, and 2018

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value, 73,500,000 shares authorized at December

   31, 2019, and 2018; 50,170,953 shares issued and outstanding at December 31,

   2019; 49,422,991 shares issued and outstanding at December 31, 2018

 

 

5

 

 

 

5

 

Additional paid-in capital

 

 

2,173,154

 

 

 

2,106,960

 

Accumulated other comprehensive income (loss)

 

 

1,303

 

 

 

(155

)

Accumulated deficit

 

 

(1,102,997

)

 

 

(1,500,552

)

Total stockholders' equity

 

 

1,071,465

 

 

 

606,258

 

Total liabilities and equity

 

$

1,174,123

 

 

$

686,903

 

 

See accompanying notes to consolidated financial statements.

 

 

60

 

ARENA PHARMACEUTICALS, INC.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(In thousands, except per share data)

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

United Therapeutics revenue

 

$

800,000

 

 

$

—

 

 

$

—

 

Collaboration and other revenue

 

 

7,284

 

 

 

11,402

 

 

 

19,632

 

Royalty revenue

 

 

(853

)

 

 

6,568

 

 

 

1,705

 

Total revenues

 

 

806,431

 

 

 

17,970

 

 

 

21,337

 

Operating costs and expenses

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

231,496

 

 

 

115,029

 

 

 

70,988

 

General and administrative

 

 

77,616

 

 

 

45,257

 

 

 

30,341

 

Transaction costs

 

 

14,573

 

 

 

2,467

 

 

 

—

 

Litigation settlement expense, net

 

 

—

 

 

 

—

 

 

 

11,975

 

Total operating costs and expenses

 

 

323,685

 

 

 

162,753

 

 

 

113,304

 

Income (loss) from operations

 

 

482,746

 

 

 

(144,783

)

 

 

(91,967

)

Interest and other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

26,872

 

 

 

8,772

 

 

 

492

 

Interest expense

 

 

(4,791

)

 

 

(5,695

)

 

 

(6,119

)

Other income

 

 

3,061

 

 

 

2,872

 

 

 

1,740

 

Total interest and other income (expense), net

 

 

25,142

 

 

 

5,949

 

 

 

(3,887

)

Income (loss) from continuing operations before income taxes

 

 

507,888

 

 

 

(138,834

)

 

 

(95,854

)

Income tax (provision) benefit

 

 

(110,333

)

 

 

110,265

 

 

 

—

 

Income (loss) from continuing operations

 

 

397,555

 

 

 

(28,569

)

 

 

(95,854

)

Income (loss) from discontinued operations

 

 

—

 

 

 

(830

)

 

 

3,122

 

Net income (loss)

 

 

397,555

 

 

 

(29,399

)

 

 

(92,732

)

Less net loss attributable to noncontrolling interest in consolidated

   variable interest entity

 

 

—

 

 

 

—

 

 

 

1,325

 

Net income (loss) attributable to stockholders of Arena

 

$

397,555

 

 

$

(29,399

)

 

$

(91,407

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Amounts attributable to stockholders of Arena:

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations

 

$

397,555

 

 

$

(28,569

)

 

$

(94,529

)

Income (loss) from discontinued operations

 

 

—

 

 

 

(830

)

 

 

3,122

 

 

 

$

397,555

 

 

$

(29,399

)

 

$

(91,407

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to stockholders of Arena per share, basic:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

7.99

 

 

$

(0.61

)

 

$

(2.87

)

Discontinued operations

 

 

—

 

 

 

(0.02

)

 

 

0.10

 

 

 

$

7.99

 

 

$

(0.63

)

 

$

(2.77

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to stockholders of Arena per share, diluted:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

7.69

 

 

$

(0.61

)

 

$

(2.87

)

Discontinued operations

 

 

—

 

 

 

(0.02

)

 

 

0.10

 

 

 

$

7.69

 

 

$

(0.63

)

 

$

(2.77

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in calculating net income (loss) attributable to stockholders of

     Arena per share, basic

 

 

49,779

 

 

 

47,041

 

 

 

32,990

 

Shares used in calculating net income (loss) attributable to stockholders of

     Arena per share, diluted

 

 

51,698

 

 

 

47,041

 

 

 

32,990

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive Income (Loss):

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

397,555

 

 

$

(29,399

)

 

$

(92,732

)

61

 

Foreign currency translation adjustment

 

 

(11

)

 

 

72

 

 

 

2,016

 

Unrealized gain (loss) on available-for-sale investments

 

 

1,469

 

 

 

(113

)

 

 

(133

)

Comprehensive income (loss)

 

 

399,013

 

 

 

(29,440

)

 

 

(90,849

)

Less comprehensive loss attributable to noncontrolling interest in

   consolidated variable interest entity

 

 

—

 

 

 

—

 

 

 

1,325

 

Comprehensive income (loss) attributable to stockholders of Arena

 

$

399,013

 

 

$

(29,440

)

 

$

(89,524

)

 

See accompanying notes to consolidated financial statements.

 

 

62

 

ARENA PHARMACEUTICALS, INC.

Consolidated Statements of Equity

(In thousands, except share data)

 

 

Common Stock

 

Additional

Paid-In

Capital

 

Accumulated

Other

Comprehensive

Income (Loss)

 

Accumulated

Deficit

 

Total Equity

Attributable to

Stockholders of

Arena

 

Equity Attributable to

Noncontrolling Interest

in Consolidated

Variable Interest Entity

 

Total Equity

 

 

Shares

 

Amount

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2016

 

24,340,080

 

$

2

 

$

1,441,737

 

$

(3,099

)

$

(1,398,736

)

$

39,904

 

$

491

 

$

40,395

 

Adoption of ASU No. 2016-09

 

—

 

 

—

 

 

44

 

 

—

 

 

(44

)

 

—

 

 

—

 

 

—

 

Issuance of common stock to underwriters, net

 

14,087,500

 

 

2

 

 

236,386

 

 

—

 

 

—

 

 

236,388

 

 

—

 

 

236,388

 

Issuance of common stock under the ATM facility, net

 

489,023

 

 

—

 

 

6,987

 

 

—

 

 

—

 

 

6,987

 

 

—

 

 

6,987

 

Issuance of common stock upon exercise of options

 

323,431

 

 

—

 

 

5,404

 

 

—

 

 

—

 

 

5,404

 

 

—

 

 

5,404

 

Issuance of common stock under employee stock

    purchase plan and upon vesting of restricted

    stock unit awards

 

40,653

 

 

—

 

 

12

 

 

—

 

 

—

 

 

12

 

 

—

 

 

12

 

Share-based compensation expense

 

—

 

 

—

 

 

7,973

 

 

—

 

 

—

 

 

7,973

 

 

17

 

 

7,990

 

Unrealized loss on available-for-sale investments

 

—

 

 

—

 

 

—

 

 

(133

)

 

—

 

 

(133

)

 

—

 

 

(133

)

Translation gain

 

—

 

 

—

 

 

—

 

 

2,016

 

 

—

 

 

2,016

 

 

—

 

 

2,016

 

Net loss

 

—

 

 

—

 

 

—

 

 

—

 

 

(91,407

)

 

(91,407

)

 

(1,325

)

 

(92,732

)

Deconsolidation of variable interest entity

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

817

 

 

817

 

Balance at December 31, 2017

 

39,280,687

 

 

4

 

 

1,698,543

 

 

(1,216

)

 

(1,490,187

)

 

207,144

 

 

—

 

 

207,144

 

Adoption of ASC 606

 

—

 

 

—

 

 

—

 

 

1,102

 

 

19,034

 

 

20,136

 

 

—

 

 

20,136

 

Issuance of common stock to underwriters, net

 

9,775,000

 

 

1

 

 

383,141

 

 

—

 

 

—

 

 

383,142

 

 

—

 

 

383,142

 

Issuance of common stock upon exercise of options

 

317,636

 

 

—

 

 

5,888

 

 

—

 

 

—

 

 

5,888

 

 

—

 

 

5,888

 

Issuance of common stock upon vesting of restricted

    stock unit awards

 

49,668

 

 

—

 

 

(166

)

 

—

 

 

—

 

 

(166

)

 

—

 

 

(166

)

Share-based compensation expense

 

—

 

 

—

 

 

19,554

 

 

—

 

 

—

 

 

19,554

 

 

—

 

 

19,554

 

Unrealized loss on available-for-sale investments

 

—

 

 

—

 

 

—

 

 

(113

)

 

—

 

 

(113

)

 

—

 

 

(113

)

Translation gain

 

—

 

 

—

 

 

—

 

 

72

 

 

—

 

 

72

 

 

—

 

 

72

 

Net loss

 

—

 

 

—

 

 

—

 

 

—

 

 

(29,399

)

 

(29,399

)

 

—

 

 

(29,399

)

Balance at December 31, 2018

 

49,422,991

 

 

5

 

 

2,106,960

 

 

(155

)

 

(1,500,552

)

 

606,258

 

 

—

 

 

606,258

 

Issuance of common stock upon exercise of options

 

625,757

 

 

—

 

 

15,184

 

 

—

 

 

—

 

 

15,184

 

 

—

 

 

15,184

 

Issuance of common stock upon vesting of restricted

    stock unit awards

 

122,205

 

 

—

 

 

(2,037

)

 

—

 

 

—

 

 

(2,037

)

 

—

 

 

(2,037

)

Share-based compensation expense

 

—

 

 

—

 

 

53,047

 

 

—

 

 

—

 

 

53,047

 

 

—

 

 

53,047

 

Unrealized gain on available-for-sale investments

 

—

 

 

—

 

 

—

 

 

1,469

 

 

—

 

 

1,469

 

 

—

 

 

1,469

 

Translation loss

 

—

 

 

—

 

 

—

 

 

(11

)

 

—

 

 

(11

)

 

—

 

 

(11

)

Net income

 

—

 

 

—

 

 

—

 

 

—

 

 

397,555

 

 

397,555

 

 

—

 

 

397,555

 

Balance at December 31, 2019

 

50,170,953

 

$

5

 

$

2,173,154

 

$

1,303

 

$

(1,102,997

)

$

1,071,465

 

$

—

 

$

1,071,465

 

 

See accompanying notes to consolidated financial statements.

 

 

63

 

ARENA PHARMACEUTICALS, INC.

Consolidated Statements of Cash Flows

(In thousands)

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

397,555

 

 

$

(29,399

)

 

$

(92,732

)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

(Income) loss from discontinued operations

 

 

—

 

 

 

830

 

 

 

(3,122

)

Depreciation and amortization

 

 

3,233

 

 

 

3,759

 

 

 

4,278

 

Deferred income taxes

 

 

110,333

 

 

 

(110,333

)

 

 

—

 

Non-cash collaboration revenue

 

 

—

 

 

 

(1,500

)

 

 

—

 

Non-cash royalty revenue

 

 

3,744

 

 

 

(3,315

)

 

 

—

 

Share-based compensation

 

 

53,047

 

 

 

19,543

 

 

 

7,855

 

Litigation settlement expense, net

 

 

—

 

 

 

—

 

 

 

11,975

 

Amortization of prepaid financing costs

 

 

90

 

 

 

110

 

 

 

136

 

Amortization of original issue discounts, net of premiums, on available-

        for-sale investments

 

 

(5,628

)

 

 

(664

)

 

 

—

 

Loss (gain) on disposal of property and equipment

 

 

112

 

 

 

(791

)

 

 

(379

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

3,432

 

 

 

(2,760

)

 

 

10,787

 

Prepaid expenses and other assets

 

 

(8,133

)

 

 

(2,929

)

 

 

585

 

Payables and accrued liabilities

 

 

12,347

 

 

 

10,871

 

 

 

1,803

 

Accrued litigation settlement

 

 

—

 

 

 

(11,975

)

 

 

—

 

Deferred revenues

 

 

(1,438

)

 

 

(2,061

)

 

 

(4,401

)

Other long-term liabilities

 

 

—

 

 

 

(1,265

)

 

 

(577

)

Net cash provided by (used in) operating activities - continuing operations

 

 

568,694

 

 

 

(131,879

)

 

 

(63,792

)

Net cash used in operating activities - discontinued operations

 

 

—

 

 

 

(333

)

 

 

(2,850

)

Net cash provided by (used in) operating activities

 

 

568,694

 

 

 

(132,212

)

 

 

(66,642

)

Investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of available-for-sale investments

 

 

(1,469,220

)

 

 

(364,539

)

 

 

(112,615

)

Proceeds from sale and maturity of available-for-sale investments

 

 

976,093

 

 

 

110,564

 

 

 

—

 

Deconsolidation of variable interest entity

 

 

—

 

 

 

—

 

 

 

(406

)

Purchases of property and equipment

 

 

(4,819

)

 

 

(692

)

 

 

(113

)

Proceeds from sale of property and equipment

 

 

—

 

 

 

—

 

 

 

789

 

Other non-current assets

 

 

—

 

 

 

(11

)

 

 

(5

)

Net cash used in investing activities - continuing operations

 

 

(497,946

)

 

 

(254,678

)

 

 

(112,350

)

Net cash provided by (used in) investing activities - discontinued

        operations

 

 

997

 

 

 

3,405

 

 

 

(40

)

Net cash used in investing activities

 

 

(496,949

)

 

 

(251,273

)

 

 

(112,390

)

Financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Principal payments on lease financing obligations

 

 

(3,282

)

 

 

(4,000

)

 

 

(3,518

)

Proceeds from issuance of common stock

 

 

13,147

 

 

 

389,031

 

 

 

248,805

 

Net cash provided by financing activities

 

 

9,865

 

 

 

385,031

 

 

 

245,287

 

Effect of exchange rate changes on cash

 

 

(10

)

 

 

654

 

 

 

1,870

 

Net increase in cash, cash equivalents and restricted cash

 

 

81,600

 

 

 

2,200

 

 

 

68,125

 

Cash, cash equivalents and restricted cash at beginning of year

 

 

161,900

 

 

 

159,700

 

 

 

91,575

 

Cash, cash equivalents and restricted cash at end of year

 

$

243,500

 

 

$

161,900

 

 

$

159,700

 

64

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Interest paid

 

$

4,787

 

 

$

5,696

 

 

$

5,967

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing and financing

   information:

 

 

 

 

 

 

 

 

 

 

 

 

Disposition of property and land upon lease expiration

 

$

—

 

 

$

3,944

 

 

$

—

 

Reduction in lease financing obligation from release of residual value

   upon lease expiration

 

$

—

 

 

$

5,039

 

 

$

—

 

 

See accompanying notes to consolidated financial statements.

 

65

 

ARENA PHARMACEUTICALS, INC.

Notes to Consolidated Financial Statements

 

1. The Company and Summary of Significant Accounting Policies

The Company

Arena Pharmaceuticals, Inc., or Arena, was incorporated on April 14, 1997, and commenced operations in July 1997. We are a biopharmaceutical company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Our proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility.

Our most advanced investigational clinical programs include: etrasimod, which is being evaluated in a Phase 3 program for ulcerative colitis, a Phase 2b/3 program for Crohn’s disease, and a Phase 2b program in atopic dermatitis. We also plan to evaluate etrasimod in a Phase 2b program for eosinophilic esophagitis, and a Phase 2 program in alopecia areata. Olorinab is being evaluated for a broad range of visceral pain conditions associated with gastrointestinal diseases, currently in a Phase 2b trial for treatment of abdominal pain associated with irritable bowel syndrome. APD418 is being evaluated in a Phase 1 trial for acute heart failure. Additionally, we have collaboration or license agreements with various companies.

We operate in one business segment. Our primary clinical operations are conducted in San Diego, California and Boston, Massachusetts; and in Zug, Switzerland by Arena Pharmaceuticals Development GmbH, or APD GmbH, our wholly-owned subsidiary.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with the US generally accepted accounting principles, or GAAP, and reflect all of our activities, including those of our wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. As a result of the sale of our Manufacturing Operations (see Note 5), the operations and cash flows of the Manufacturing Operations are reflected as discontinued operations for the years ended December 31, 2018, and 2017.

The accompanying consolidated financial statements also include the activity of Beacon Discovery, Inc., or Beacon, a variable interest entity in which we had a controlling financial interest until December 2017 at which point we deconsolidated Beacon (see Note 12). The results of operations and comprehensive loss attributable to the noncontrolling interest in Beacon are presented as separate components from the results of operations and comprehensive loss attributable to the stockholders of Arena in the consolidated statements of operations and comprehensive loss.

Liquidity

As of December 31, 2019, we had cash, cash equivalents and available-for-sale investments of approximately $1.1 billion. We believe our cash, cash equivalents and available-for-sale investments will be sufficient to fund our operations for at least the next 12 months from the date these consolidated financial statements are issued.

We will require substantial cash to achieve our objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. We may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. We will need to obtain significant funds under our existing collaborations and license agreements, under new collaboration, licensing or other commercial agreements for one or more of our drug candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions.

66

 

Changes in Accounting Policies - Leases.

Effective January 1, 2019, we adopted Accounting Standard Codification Topic 842, Leases, or ASC 842, issued by the Financial Accounting Standards Board, or FASB. ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard established a right-of-use model that requires a lessee to recognize a right-of-use asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. As a result, we have changed our accounting policy for leases as detailed below.

We implemented ASC 842 using the modified retrospective transition approach by applying the new standard to leases existing at the date of initial application. We used the effective date as our date of initial application. Therefore, we did not update the financial information and did not provide the disclosures required under the new standard for dates and periods before January 1, 2019.

We applied ASC 842 using a package of practical expedients, which permitted us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.

Upon adoption of ASC 842, we recorded an operating lease liability of $6.3 million based on the present value of the remaining minimum rental payments under the terms of our existing operating lease pertaining to one of our leased properties with a corresponding right-of-use asset of $5.9 million. Adoption of this standard did not have a material impact on our consolidated statements of operations or cash flows.

The new standard also provides practical expedients for an entity’s ongoing accounting. We elected the short-term lease recognition exemption for our office equipment leases and short-term office space leases. This means, for those leases that qualify, we do not recognize right-of-use assets or lease liabilities. See Note 6 for disclosures related to our leases.

Recent Accounting Pronouncements

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers, or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. The amendments in ASU No. 2018-18 are applied retrospectively to the date of initial application of ASC 606, which for us was January 1, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12 which modifies ASC 740, Income Taxes to simplify the accounting for income taxes in various areas. The amendments in ASU 2019-12 are effective for us for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. We are currently evaluating the impact of adoption on our consolidated financial statements. 

Use of Estimates

The preparation of financial statements in conformity with GAAP requires our management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. The amounts reported could differ under different estimates and assumptions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in our consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows, in thousands:

 

67

 

 

 

December 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Cash and cash equivalents

 

$

243,274

 

 

$

161,037

 

Restricted cash included in other non-current assets

 

 

226

 

 

 

863

 

Total cash, cash equivalents and restricted cash presented in the consolidated

      statement of cash flows

 

$

243,500

 

 

$

161,900

 

The restricted cash relates to our property leases. The restriction will lapse when the related leases expire.

Available-for-Sale Investments

We define investments as income-yielding securities that can be readily converted to cash, and classify such investments as available-for-sale. We carry these securities at fair value, and report unrealized gains and losses as a separate component of accumulated other comprehensive income or loss. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in securities judged to be other than temporary are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on available-for-sale securities are included in interest income.

Concentrations of Risk

Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents and available-for-sale investments. We limit our exposure to credit loss by holding our cash primarily in US dollars or placing our cash and investments in US government, agency or government-sponsored enterprise obligations and in corporate debt instruments that are rated investment grade, in accordance with an investment policy approved by our Board of Directors.

Our customers are typically other biopharmaceutical companies to which we license our intellectual property, or sell research and development services or other services under license or collaboration agreements. For the year ended December 31, 2019, more than 99% of our annual revenues was from United Therapeutics. For the year ended December 31, 2018, Eisai, Boehringer Ingelheim, Outpost Medicine, Axovant and Everest accounted for 36.6%, 24.8%, 15.3%, 12.1% and 11.1%, respectively, of our total revenues. For the year ended December 31, 2017, Everest, Boehringer Ingelheim and Axovant accounted for 56.2%, 23.8%, and 10.5%, respectively, of our total revenues.

We monitor our customers’ financial credit worthiness in order to assess and respond to any changes in their credit profile. During the years ended December 31, 2019, 2018, and 2017, we did not record any write-offs or reserves against accounts receivable.

Property and Equipment

Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (generally 3 to 15 years) using the straight-line method. Buildings are stated at cost and depreciated over an estimated useful life of approximately 20 years using the straight-line method. Leasehold improvements are stated at cost and amortized over the shorter of the estimated useful lives of the assets or the lease term using the straight-line method. Capital improvements are stated at cost and amortized over the estimated useful lives of the underlying assets using the straight-line method.

Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted cash flows. If impairment is indicated, we measure the impairment loss by comparing the fair value to the carrying value of the asset.

Foreign Currency

The functional currency of our wholly owned subsidiaries in Switzerland, APD GmbH and, until March 31, 2018, Arena Pharmaceuticals GmbH, or Arena GmbH, was the Swiss franc. Accordingly, all assets and liabilities of these subsidiaries are translated to US dollars based on the applicable exchange rate on the balance sheet date. Revenue and expense components are translated to US dollars at weighted-average exchange rates in effect during the period. Gains and losses resulting from foreign currency translation are reported as a separate component of accumulated other comprehensive income or loss in the equity section of our consolidated balance sheets.

68

 

Foreign currency transaction gains and losses are primarily the result of remeasuring US dollar-denominated receivables and payables of our foreign subsidiaries. Foreign currency transaction gains and losses recorded by Arena GmbH are included in net income (loss) from discontinued operations.

Share-based Compensation

Our share-based awards are measured at fair value and recognized over the requisite service or performance period. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model, based on the market price of the underlying common stock, expected term, expected stock price volatility and expected risk-free interest rate. Expected volatility is computed using historical volatility for a period equal to the expected term. The expected term of options is determined based on historical experience of similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and post-vesting terminations. The risk-free interest rates are based on the US Treasury yield curve, with a remaining term approximately equal to the expected term used in the option pricing model. We account for the forfeitures in the period they occur. The fair value of each restricted stock unit award is estimated based on the market price of the underlying common stock on the date of the grant. The fair value of restricted stock unit awards that include market-based performance conditions is estimated on the date of grant using a Monte Carlo simulation model, based on the market price of the underlying common stock, expected performance measurement period, expected stock price volatility and expected risk-free interest rate.

Revenue Recognition

Our revenues to date have been generated primarily through collaboration and license agreements. Our collaboration and license agreements frequently contain multiple types of promised goods or services including (i) intellectual property licenses, (ii) product research, development and regulatory services and (iii) product manufacturing. Consideration we receive under these arrangements may include upfront payments, research and development funding, cost reimbursements, milestone payments, payments for product sales and royalty payments.

Effective January 1, 2018, we adopted Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, issued by the Financial Accounting Standards Board, or FASB. As a result, we have changed our accounting policy for revenue recognition as detailed below.

We implemented ASC 606 using the modified retrospective method by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of our accumulated deficit at January 1, 2018. Therefore, the comparative period information has not been adjusted.

We applied ASC 606 using a practical expedient for contracts that were modified before the implementation date, which allowed us to determine an aggregate effect of all modifications that occurred before January 1, 2018, when determining the satisfied and unsatisfied performance obligations, the transaction price, and allocating that transaction price to the performance obligations instead of retrospectively restating the contracts for such contract modifications.  

The cumulative impact to our accumulated deficit balance at January 1, 2018, as a result of the adoption of ASC 606 was a decrease of $19.0 million. The decrease arose primarily from a reduction of deferred revenue balances related to upfront payments received from customers and recognition of contract assets due to a combination of (i) the effects of applying the practical expedient for contract modifications and our conclusions related to satisfied and unsatisfied performance obligations, which resulted in a relatively higher portion of the total transaction price recognized as revenue in periods prior to our adoption of ASC 606, (ii) the effect of the bill-and-hold accounting guidance for inventory in ASC 606 and (iii) the inclusion of estimated future royalty payments related to our intellectual property in the total transaction price to the extent such intellectual property was legally sold to our customer rather than licensed. The cumulative effect adjustment is net of an impairment loss of $13.1 million which was a direct effect of the adoption of ASC 606 on the asset group of the Manufacturing Operations, which was classified as assets of disposal group held for sale since December 2017.

The following table summarizes the impacts of adopting ASC 606 on our consolidated financial statements, in thousands.

69

 

 

 

Impact of Changes in Accounting Policies

 

Year ended December 31, 2018

 

As reported

 

 

Adjustments

 

 

Balances without adoption of ASC 606

 

Collaboration and other revenue

 

$

11,402

 

 

$

105

 

 

$

11,507

 

Royalty revenue

 

 

6,568

 

 

 

(1,847

)

 

 

4,721

 

Total revenues

 

 

17,970

 

 

 

(1,742

)

 

 

16,228

 

Loss from operations

 

 

(144,783

)

 

 

(1,742

)

 

 

(146,525

)

Loss from continuing operations

 

 

(28,569

)

 

 

(594

)

 

 

(29,163

)

Income (loss) from discontinued operations

 

 

(830

)

 

 

13,660

 

 

 

12,830

 

Net loss

 

 

(29,399

)

 

 

13,066

 

 

 

(16,333

)

Net loss attributable to stockholders of Arena

 

 

(29,399

)

 

 

13,066

 

 

 

(16,333

)

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2018

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

$

10,008

 

 

$

(1,484

)

 

$

8,524

 

Total current assets

 

 

460,725

 

 

 

(1,484

)

 

 

459,241

 

Other non-current assets

 

 

10,319

 

 

 

(4,471

)

 

 

5,848

 

Total assets

 

 

686,903

 

 

 

(5,955

)

 

 

680,948

 

Total current liabilities

 

 

29,918

 

 

 

10

 

 

 

29,928

 

Accumulated deficit

 

 

(1,500,552

)

 

 

(5,965

)

 

 

(1,506,517

)

Total stockholders' equity

 

 

606,258

 

 

 

(5,965

)

 

 

600,293

 

Total liabilities and stockholders' equity

 

 

686,903

 

 

 

(5,955

)

 

 

680,948

 

 

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that we expect to be entitled to receive in exchange for these services and excludes sales incentives and amounts collected on behalf of third parties. We analyze the nature of these performance obligations in the context of individual collaboration and license agreements in order to assess the distinct performance obligations. We apply the following five steps to recognize revenue:

i) Identify the contract with a customer. We consider the terms and conditions of our collaboration and license agreements to identify contracts within the scope of ASC 606. We consider that we have a contract with a customer when the contract is approved, we can identify each party's rights regarding the goods and services to be transferred, we can identify the payment terms for the goods and services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. We use judgment in determining the customer's ability and intent to pay, which is based upon factors including the customer's historical payment experience or, for new customers, credit and financial information pertaining to the customers.

ii) Identify the performance obligations in the contract. Performance obligations in our collaboration and license agreements are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. Our performance obligations generally consist of intellectual property licenses, research, development and/or regulatory services and manufacturing and supply commitments.

 iii) Determine the transaction price. We determine the transaction price based on the consideration to which we expect to be entitled in exchange for transferring goods and services to the customer. In determining the transaction price, any variable consideration would be considered, to the extent applicable, if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. In accordance with the royalty exception under ASC 606 for licenses of intellectual property, the transaction price excludes future royalty payments to be received from our customers. None of our collaboration and license agreements contain consideration payable to our customer or a significant financing component.

 iv) Allocate the transaction price to performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to that performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price.

 v) Recognize revenue when or as we satisfy a performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised goods or services to a customer. We recognize revenue when we transfer control of the goods or services to our customers for an amount that reflects the consideration that we expect to receive in exchange for those services.

70

 

Performance Obligations

The following is a description of principal goods and services from which we generate revenue.

 

Intellectual property licenses

We generate revenue from licensing our intellectual property including know-how and development and commercialization rights. These licenses provide customers with a term-based license to further research, develop and commercialize our internally-discovered drug candidates. The consideration we receive in the form of nonrefundable upfront consideration related to the functional intellectual property licenses is recognized when we transfer such license to the customer unless the license is combined with other goods or services into one performance obligation, in which case the revenue is recognized over a period of time based on our estimated pattern in which we satisfy the combined performance obligation. Our licensing agreements are generally cancelable. Customers have the right to terminate their contracts upon notice. We have the right to terminate the contracts generally only if the customer is in breach of the contract and fails to remedy the breach in accordance with the contractual terms.

 

Intellectual property sales

We generate royalty revenue from sales of our intellectual property. We estimate the future royalty payments and recognize revenue with a corresponding contract asset at a point in time when we transfer the intellectual property to the customer. We periodically reassess our estimate of the future royalty payments and recognize any estimate adjustments as revenue in the current period.

 

Research, development and regulatory services

We generate revenue from research, development and regulatory services we provide to our customers in connection with the licensed intellectual property. The services we provide to our customers primarily include scientific research activities, preparation for and management of clinical trials, and assistance during the regulatory approval application process. Revenue associated with these services is recognized based on our estimate of total consideration to be received for such services and the pattern in which we perform the services. The pattern of performance is generally determined to be the amount of incurred expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.

 

Product manufacturing

In the past, we generated revenue from manufacturing and clinical supply promises to our customers in connection with securing a supply of drug products for development and clinical trial purposes. The drug products were generally manufactured by our contract manufacturing organizations. We used our product manufacturing facility in Zofingen, Switzerland for a portion of the product manufacturing requirements until we sold the Manufacturing Operations on March 31, 2018 (see Note 5). Revenue associated with product manufacturing obligations is recognized at a point in time as control of the related product is transferred to the customer.

Contracts with Multiple Performance Obligations

Most of our collaboration and license agreements with customers contain multiple promised goods or services. Based on the characteristics of the promised goods and services we analyze whether they are separate or combined performance obligations. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price based on our overall pricing and discounting objectives, taking into consideration the type of services, estimates of hourly market rates, and stage of the research, development or clinical trials.

Variable Consideration

Our contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone payments, which are due to us upon achievement of specific development and regulatory milestones and (ii) one-time sales-based payments and sales-based royalties associated with sold or licensed intellectual property.

Due to uncertainty associated with achievement of the development and regulatory milestones, the related milestone payments are excluded from the contract consideration and the corresponding revenue is not recognized until we conclude it is probable that reversal of such milestone revenue will not occur.

Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. We recognize revenue for sales-based royalties under licensed intellectual property and one-time payments at the later of when the sales occur or the performance obligation is satisfied or partially satisfied.

71

 

Disaggregation of Revenue

We operate in one reportable business segment. We provide goods and services to our customers in collaboration and license agreements pursuant to various geographical markets.

 

Contract Assets

We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed. Product sales are generally billed as completed. Payment terms on invoiced amounts are typically 30 days. Contract assets include amounts related to our contractual right to consideration for both completed and partially completed performance obligations that have not been invoiced and for which we do not yet have the right to payment. The current portion of contract asset is included in prepaid expenses and other current assets in the consolidated balance sheet. The non-current portion of contract assets is included in other non-current assets in the consolidated balance sheet. We estimate the amount of the contract asset by applying the expected value method to our estimate of future royalty payments we will receive from this customer. Any changes to this estimate are recorded as an adjustment to revenue in the period in which the change in estimate is made.

Cost to Obtain and Fulfill a Contract

We generally do not incur costs to obtain new contracts. Costs to fulfill contracts are expensed as incurred.

Remaining Performance Obligations

The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to our existing collaboration and license agreements as of December 31, 2019 is immaterial.

Under the royalty exception in ASC 606 for licensed intellectual property we do not recognize any revenue for the variable amounts related to sales-based royalties and milestones until the later of when the sales occur or the performance obligation is satisfied or partially satisfied. Accordingly, the revenue related to future sales-based royalties and milestones are excluded from the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied.

Previous Revenue Recognition Policy

Prior to January 1, 2018, we recognized revenue when (i) persuasive evidence of an arrangement existed, (ii) delivery had occurred and title had passed, (iii) the price was fixed or determinable and (iv) collectability was reasonably assured. Any advance payments we received in excess of amounts earned were classified as deferred revenues.

We historically evaluated deliverables in a multiple-element arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered element does not have standalone value without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the inception of the arrangement based on the relative selling price.

To determine the selling price of a separate deliverable, we used the hierarchy as prescribed in Accounting Standards Codification Topic 605-25 based on vendor-specific objective evidence, or VSOE, third-party evidence, or TPE, or best estimate of selling price, or BESP. VSOE was based on the price charged when the element was sold separately and was the price actually charged for that deliverable. TPE was determined based on third-party evidence for a similar deliverable when sold separately. BESP was the estimated selling price at which we would transact a sale if the elements of collaboration and license arrangements were sold on a stand-alone basis to the buyer.

Non-refundable upfront payments received under our collaboration and license agreements for commercialization rights were deferred if such rights were not deemed to have standalone value without ongoing services which may be required under the agreement. If deferred, such amounts were recognized as revenues on a straight-line basis over the period in which we expected to perform the services.

Amounts we received as reimbursement for our research and development expenditures were recognized as revenue as the services are performed.

72

 

Under the milestone method, we recognized revenue that was contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone was achieved. A milestone is an event (i) that can be achieved in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due us. A milestone payment is considered substantive when the consideration payable to us for each milestone (a) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (b) relates solely to our past performance and (c) is reasonable relative to all of the other deliverables and payments under the arrangement. In making this assessment, we considered all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables. Other contingent-based payments received were recognized when earned.

Research and Development Expenses

Research and development expenses, which consist primarily of salaries and other personnel costs, clinical trial costs and preclinical study fees, manufacturing costs for non-commercial products, and the development of earlier-stage programs and technologies, are expensed as incurred when these expenditures have no alternative future uses.

We accrue clinical trial expenses based on work performed. In determining the amount to accrue, we rely on estimates of total costs incurred based on enrollment, the completion of trials and other events. We follow this method because we believe reasonably dependable estimates of the costs applicable to various stages of a clinical trial can be made. However, the actual costs and timing of clinical trials are uncertain, subject to risks and may change depending on a number of factors. Differences between the actual clinical trial costs and the estimated clinical trial costs that we have accrued in any prior period are recognized in the subsequent period in which the actual costs become known. Historically, these differences have not been material; however, material differences could occur in the future. Payments made to reimburse collaborators for our share of their research and development activities are recorded as research and development expenses, and are recognized as the work is performed.

Comprehensive Income (Loss)

Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report components of comprehensive income or loss in the period in which they are recognized. For the years ended December 31, 2019, 2018 and 2017, comprehensive income (loss) consisted of net income (loss), foreign currency translation gains and losses, and unrealized gains and losses related to available-for-sale investments.

Income (Loss) Per Share

We calculate basic and diluted income (loss) from continuing operations, income (loss) from discontinued operations and net income (loss) per share using the weighted-average number of shares of common stock outstanding during the period.

Since we report a loss from continuing operations for the years ended December 31, 2018, and 2017, in addition to excluding potentially dilutive out-of-the money securities, we have excluded from our calculation of income (loss) per share all potentially dilutive in-the-money (i) stock options, (ii) restricted stock unit awards, or RSUs, (iii) Performance-Based Restricted Stock Units, or PRSUs, (iv) Total Stockholder Return performance restricted stock unit awards, or TSR PRSUs, and (v) unvested restricted stock in our deferred compensation plan, and our diluted net loss per share is the same as our basic net loss per share. The table below presents the weighted-average number of potentially dilutive securities that were excluded from our calculation of diluted income (loss) per share for the years presented, in thousands.

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Stock options

 

 

3,962

 

 

 

5,835

 

 

 

3,664

 

RSUs and unvested restricted stock

 

 

—

 

 

 

20

 

 

 

3

 

Total

 

 

3,962

 

 

 

5,855

 

 

 

3,667

 

 

Because the market condition for the outstanding PRSUs was not satisfied at December 31, 2019, such securities are excluded from the table above. Because the market condition for the TSR PRSUs was not satisfied at December 31, 2017, such securities are excluded from the table above.

73

 

Income Taxes

We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our deferred tax assets and liabilities are determined using the enacted tax rates expected to be in effect for the years in which those tax assets are expected to be realized.

The realization of our deferred tax assets is dependent upon our ability to generate sufficient future taxable income. We establish a valuation allowance when it is more-likely-than-not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available evidence, both positive and negative.

The impact of an uncertain income tax position is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

 

 

2. Fair Value Disclosures

We measure our financial assets and liabilities at fair value, which is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

We use the following three-level valuation hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value our financial assets and liabilities:

 

Level 1

 

-

 

Observable inputs such as unadjusted quoted prices in active markets for identical instruments.

Level 2

 

-

 

Quoted prices for similar instruments in active markets or inputs that are observable for the asset or liability, either directly or indirectly.

Level 3

 

-

 

Significant unobservable inputs based on our assumptions.

The following tables present our valuation hierarchy for our financial assets and liabilities that are measured at fair value on a recurring basis, in thousands:

 

 

 

Fair Value Measurements

 

December 31, 2019

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

147,752

 

 

$

147,752

 

 

$

—

 

 

$

—

 

US government and government agency notes(2)

 

 

398,419

 

 

 

398,419

 

 

 

—

 

 

 

—

 

Corporate debt instruments(2)

 

 

483,788

 

 

 

—

 

 

 

483,788

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements

 

December 31, 2018

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

62,438

 

 

$

62,438

 

 

$

—

 

 

$

—

 

US government and government agency notes(2)

 

 

171,278

 

 

 

171,278

 

 

 

—

 

 

 

—

 

Corporate debt instruments(2)

 

 

240,481

 

 

 

—

 

 

 

240,481

 

 

 

—

 

 

 

 

(1)

Included in cash and cash equivalents in the accompanying consolidated balance sheets.

 

(2)

Included in either cash and cash equivalents or available-for-sale investments in the accompanying consolidated balance sheet.

 

 

74

 

3. Investments, Available-for-Sale

Investments, available-for-sale, consisted of the following, in thousands:

 

December 31, 2019

 

Maturity

in years

 

Amortized

Cost

 

 

Gross

Unrealized Gains

 

 

Gross

Unrealized Losses

 

 

Estimated

Fair Value

 

US government and government agency

    notes

 

Less than 1

 

$

201,046

 

 

$

292

 

 

$

(5

)

 

$

201,333

 

Corporate debt securities

 

Less than 1

 

 

294,481

 

 

 

495

 

 

 

(18

)

 

 

294,958

 

Short-term investments, available-for-sale

 

 

 

$

495,527

 

 

$

787

 

 

$

(23

)

 

$

496,291

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

US government and government agency

    notes

 

1 - 5

 

$

197,157

 

 

$

85

 

 

$

(155

)

 

$

197,087

 

Corporate debt securities

 

1 - 5

 

 

173,322

 

 

 

603

 

 

 

(74

)

 

 

173,851

 

Investments, available-for-sale

 

 

 

$

370,479

 

 

$

688

 

 

$

(229

)

 

$

370,938

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2018

 

Maturity

in years

 

Amortized

Cost

 

 

Gross

Unrealized Gains

 

 

Gross

Unrealized Losses

 

 

Estimated

Fair Value

 

US government and government agency

    notes

 

Less than 1

 

$

139,274

 

 

$

—

 

 

$

(18

)

 

$

139,256

 

Corporate debt securities

 

Less than 1

 

 

145,468

 

 

 

—

 

 

 

(130

)

 

 

145,338

 

Short-term investments, available-for-sale

 

 

 

$

284,742

 

 

$

—

 

 

$

(148

)

 

$

284,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

US government and government agency

    notes

 

1 - 5

 

$

16,998

 

 

$

6

 

 

$

—

 

 

$

17,004

 

Corporate debt securities

 

1 - 5

 

 

65,512

 

 

 

—

 

 

 

(104

)

 

 

65,408

 

Investments, available-for-sale

 

 

 

$

82,510

 

 

$

6

 

 

$

(104

)

 

$

82,412

 

 

4. Balance Sheet Details

Land, property and equipment, net consisted of the following, in thousands:

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Land

 

$

4,950

 

 

$

4,950

 

Building and capital improvements

 

 

45,246

 

 

 

45,246

 

Leasehold improvements

 

 

19,277

 

 

 

14,915

 

Machinery and equipment

 

 

169

 

 

 

173

 

Computers and software

 

 

2,749

 

 

 

3,083

 

Furniture and office equipment

 

 

1,531

 

 

 

1,175

 

 

 

 

73,922

 

 

 

69,542

 

Less accumulated depreciation and amortization

 

 

(48,794

)

 

 

(46,428

)

Land, property and equipment, net

 

$

25,128

 

 

$

23,114

 

As of December 31, 2019, majority of our long-lived assets were located in the United States.

Accounts payable and other accrued liabilities consisted of the following, in thousands:  

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Accounts payable

 

$

6,043

 

 

$

6,192

 

Accrued compensation

 

 

14,329

 

 

 

8,622

 

Other accrued liabilities

 

 

5,127

 

 

 

1,367

 

Total accounts payable and other accrued liabilities

 

$

25,499

 

 

$

16,181

 

 

 

75

 

5. Sale of Manufacturing Operations

In order to further focus our efforts and resources on our strategic objectives of developing our pipeline drug candidates, in March 2018, we entered into an Asset Purchase Agreement, or Sale Agreement, with Siegfried Pharma AG and Siegfried AG, (collectively and individually, Siegfried). Under the Sale Agreement, we agreed to sell and assign to Siegfried, and Siegfried agreed to purchase and assume from Arena GmbH, certain drug product finishing facility assets and know-how, including fixtures, equipment, other personal property and real estate assets located in Zofingen, Switzerland and related contracts and certain related liabilities, or collectively, the Manufacturing Operations. We refer to this transaction as the Siegfried Transaction. The Siegfried Transaction was completed on March 31, 2018. In connection with the Siegfried Transaction, all of Arena GmbH’s approximately 50 employees transferred to Siegfried. We have excluded from our continuing operations for all periods presented in this report revenues and expenses associated with the disposed Manufacturing Operations, which are reported as discontinued operations. The total sales price for the Manufacturing Operations was approximately CHF 4 million of which approximately CHF 3 million was received in cash in March 2018 and the remaining portion was received in March 2019.

The following table summarizes the results of discontinued operations for the periods presented in the consolidated statements of operations for the years ended December 31, 2018, and 2017, in thousands:

 

 

Years ended December 31,

 

Revenues

 

2018

 

 

2017

 

Net product sales

 

$

1,129

 

 

$

9,189

 

Other collaboration revenue

 

 

372

 

 

 

6,671

 

Toll manufacturing

 

 

1,006

 

 

 

3,179

 

Total revenues

 

 

2,507

 

 

 

19,039

 

Operating costs and expenses

 

 

 

 

 

 

 

 

Cost of product sales

 

 

1,858

 

 

 

7,472

 

Cost of toll manufacturing

 

 

1,411

 

 

 

4,756

 

Research and development

 

 

—

 

 

 

643

 

General and administrative

 

 

329

 

 

 

1,672

 

Other (income) expense, net

 

 

464

 

 

 

1,374

 

Total costs and expenses

 

 

4,062

 

 

 

15,917

 

Income (loss) from operations of discontinued operations

 

 

(1,555

)

 

 

3,122

 

Gain on sale of discontinued operations

 

 

725

 

 

 

—

 

Income (loss) from discontinued operations

 

$

(830

)

 

$

3,122

 

 

 

6. Leases

San Diego, California

We have three properties in San Diego, California, under sale and leaseback agreements. The terms of these leases contain a purchase option and stipulate annual increases in monthly lease payments of 2.5%. We account for our sale and leaseback transactions using the financing method. Under the financing method, the book value of the properties and related accumulated depreciation remain on our balance sheet and no sale is recognized. The adoption of ASC 842 did not result in a change to our current accounting policy related to our sale and leaseback agreements. The sales price of the properties is recorded as a financing obligation, and a portion of each lease payment is recorded as interest expense. For the years ended December 31, 2019, 2018, and 2017, we recorded interest expense of $4.8 million, $5.7 million, and $6.1 million respectively, related to these leases. We expect interest expense related to our facilities to total $21.2 million from December 31, 2019, through the remaining terms of the leases in fiscal year 2027. At December 31, 2019, the total financing obligation associated with these sale and leaseback agreements was $49.4 million. The aggregate residual value of the facilities at the end of the lease terms is $5.0 million.

We lease an additional property in San Diego, California under an operating lease, which expires in May 2027, contains a purchase option and stipulates annual increases in monthly lease payments of 2.5%. Upon adoption of ASC 842, we recorded an operating lease liability of $6.3 million based on the present value of the remaining minimum lease payments under the terms of our existing operating lease with a corresponding right-of-use asset of $5.9 million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available at effective date of adoption in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was 7.25%.

Boston, Massachusetts

In the third quarter of 2019, we entered into a new lease agreement for approximately 12,755 square feet of office space in Boston, Massachusetts with the lease inception date of September 1, 2019. This lease is classified as an operating lease and expires in December 2026. The lease stipulates annual increases in monthly lease payments of 2.0%. At the lease inception date, we recorded an

76

 

operating lease liability of $5.2 million based on the present value of the remaining minimum lease payments under the terms of this lease with a corresponding right-of-use asset of $5.2 million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available at effective date of adoption in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was also 7.25%.

Zug, Switzerland

In the second quarter of 2019, we entered into a lease in Zug, Switzerland, for approximately 10,500 square feet of office space with the lease inception date of June 1, 2019. This lease expires in May 2024. At the lease inception, we recorded an operating lease liability of $1.4 million based on the present value of the remaining minimum lease payments under the terms of this operating lease with a corresponding right-of-use asset of $1.5 million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available as of the lease inception in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was 7.25%. In the third quarter of 2019, we entered into an addendum to this lease for approximately 4,050 square feet of additional office space in the same location with the same landlord and the lease inception date of January 1, 2020.

As of December 31, 2019, the balance of the right-of-use assets associated with the leases described above was $11.8 million and is included in other non-current assets in the accompanying consolidated balance sheet. As of December 31, 2019, the current portion of the corresponding lease liabilities of $1.3 million is included in accounts payable and other accrued liabilities and the non-current portion of the lease liabilities of $11.4 million is included in other long-term liabilities in the accompanying consolidated balance sheet. The operating lease costs and cash paid for the amounts included in the measurement of lease liabilities are classified as operating activities in the accompanying consolidated cash flow statement. We recognize rent expense on a straight-line basis over the term of each lease. Rent expense of $1.9 million, $1.2 million and $1.5 million was recognized for the years ended December 31, 2019, 2018, and 2017, respectively. The weighted-average remaining lease term for all operating leases as of December 31, 2019 was 6.8 years.

At December 31, 2019, the future lease payments under our existing financing and non-cancellable operating leases were as follows, in thousands:

 

Year ending December 31,

 

Financing

Obligations

 

 

Operating

Leases

 

2020

 

$

7,576

 

 

$

2,236

 

2021

 

 

8,461

 

 

 

2,497

 

2022

 

 

8,672

 

 

 

2,540

 

2023

 

 

8,889

 

 

 

2,584

 

2024

 

 

9,111

 

 

 

2,280

 

Thereafter

 

 

22,941

 

 

 

4,667

 

Total minimum lease payments

 

 

65,650

 

 

$

16,804

 

Less amounts representing interest

 

 

(21,173

)

 

 

 

 

Add amounts representing residual value

 

 

4,950

 

 

 

 

 

Lease financing obligations

 

 

49,427

 

 

 

 

 

Less current portion

 

 

(3,814

)

 

 

 

 

 

 

$

45,613

 

 

 

 

 

Under the prior lease guidance, at December 31, 2018, the future minimum lease payments under our existing financing and operating lease obligations were as follows, in thousands:

 

77

 

Year ending December 31,

 

Financing

Obligations

 

 

Operating

Leases

 

2019

 

$

7,391

 

 

$

1,050

 

2020

 

 

8,254

 

 

 

1,100

 

2021

 

 

8,461

 

 

 

976

 

2022

 

 

8,672

 

 

 

1,000

 

2023

 

 

8,889

 

 

 

1,025

 

Thereafter

 

 

32,052

 

 

 

3,698

 

Total minimum lease payments

 

 

73,719

 

 

$

8,849

 

Less amounts representing interest

 

 

(25,960

)

 

 

 

 

Add amounts representing residual value

 

 

4,950

 

 

 

 

 

Lease financing obligations

 

 

52,709

 

 

 

 

 

Less current portion

 

 

(3,283

)

 

 

 

 

 

 

$

49,426

 

 

 

 

 

Subleases

In 2016 and 2017, we entered into agreements to sublease several of our California properties. All our subleases expire in May 2027. The terms of the subleases stipulate annual increases in monthly rental payments. For the years ended December 31, 2019, 2018 and 2017, we recognized rent income from our subleases of $3.0 million, $2.5 million and $1.7 million, respectively

We recognize rent income on a straight-line basis over the term of the subleases. Expected minimum rental payments to be received under the sublease are as follows:

 

Year ending December 31,

 

 

 

 

2020

 

$

1,873

 

2021

 

 

2,477

 

2022

 

 

3,487

 

2023

 

 

3,794

 

2024

 

 

3,896

 

Thereafter

 

 

9,839

 

Total

 

$

25,366

 

 

7. Stockholders’ Equity

In March 2018, we completed the sale of an aggregate of 9,775,000 shares of our common stock under an underwritten public offering. Net proceeds from the offering were approximately $383.1 million after deducting underwriting discounts and commissions and offering expenses payable by us. 

In July 2017, we completed the sale of an additional 7,187,500 shares of our common stock under an underwritten public offering. Net proceeds from the offering were $162.0 million after deducting underwriting discounts and commissions, and offering expenses payable by us.

In April 2017, we completed the sale of an aggregate of 6,900,000 shares of our common stock under an underwritten public offering. Net proceeds from the offering were approximately $74.4 million after deducting underwriting discounts and commissions, and offering expenses payable by us. 

In January 2017, we entered into an Equity Distribution Agreement, or ATM, with Citigroup Global Markets, Inc., or the Sales Agent, under which we could sell common stock through our Sales Agent. Sales of the shares under the ATM were made in transactions that are deemed to be “at‑the‑market” equity offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including on the Nasdaq Stock Market. During the period from February through April 2017, we sold 489,023 shares of our common stock at an average market price of $15.05 per share under the ATM for aggregate net proceeds of approximately $7.0 million after deducting commissions and expenses.

78

 

Equity Compensation Plans

In June 2017, our stockholders approved our 2017 Long-Term Incentive Plan, or 2017 LTIP. Upon such approval, our 2013 Long-Term Incentive Plan, or 2013 LTIP, was terminated. Notwithstanding such termination or the previous termination of our 2012 Long-Term Incentive Plan, 2009 Long-Term Incentive Plan, and 2006 Long-Term Incentive Plan, as amended, or, together with the 2013 LTIP, the Prior Plans, all outstanding awards under the Prior Plans continue to be governed under the terms of the Prior Plans. In June 2018, our stockholders approved amendment and restatement of our 2017 Long-Term Incentive Plan, to, among other things, increase the number of shares authorized for issuance under the 2017 LTIP. The number of shares of common stock authorized for issuance under the 2017 LTIP may be increased by the number of shares subject to any stock awards under the Prior Plans that are forfeited, expire or otherwise terminate without the issuance of such shares and would otherwise be returned to the share reserve under the Prior Plans but for their termination and as otherwise provided in the 2017 LTIP.

The aggregate number of shares of our common stock that initially may be issued pursuant to stock awards granted under the 2017 LTIP is 6,958,560 shares, less 1 share for every share that was subject to an option or stock appreciation right granted under the 2017 Plan and 1.9 shares for every 1 share that share that was subject to an award other than an option or stock appreciation right granted under the 2017 LTIP after March 31, 2018. Shares issued pursuant to the exercise of stock options and stock appreciation rights granted under the 2017 LTIP reduce the available number of shares by 1 share for every share issued while awards other than stock options and stock appreciation rights granted under the 2017 LTIP reduce the available number of shares by 1.9 shares for every share issued.

Shares under the 2017 LTIP may be granted as incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Performance awards may be based on the achievement of operational, financial, research and development, collaboration and license arrangements and other performance metrics provided under the 2017 LTIP, such as total stockholder return, revenue, research, development and regulatory achievements and strategic and operational initiatives.

A total of 3,024,775 shares of our common stock were reserved for future issuance at December 31, 2019, pursuant to our Equity Compensation Plans.

Stock options granted under the 2017 LTIP generally vest over four years with 25% of the shares subject to each option vesting on the first anniversary of the grant date and the remainder of the shares vesting monthly over the following three years in equal installments and, to the extent vested, are exercisable for up to seven years from the date of grant. The recipient of a restricted stock award has all rights of a stockholder at the date of grant, subject to certain restrictions on transferability and a risk of forfeiture. Restricted stock unit awards generally vest over one or four years from the date of grant. The minimum performance period under a performance award is 12 months. Neither the exercise price of an option nor the grant price of a stock appreciation right may be less than 100% of the fair market value of the common stock on the date such equity award is granted, except in specified situations. The 2017 LTIP prohibits option and stock appreciation right repricings (other than to reflect stock splits, spin-offs or certain other corporate events) without stockholder approval.

The following table summarizes our stock option activity under the Prior Plans and the 2017 LTIP, or collectively, our Equity Compensation Plans, for the year ended December 31, 2019, in thousands (except per share data):

 

 

 

Options

 

 

Weighted-

Average

Exercise Price

 

 

Weighted-Average

Remaining

Contractual

Term (in years)

 

 

Aggregate

Intrinsic

Value

 

Outstanding at December 31, 2018

 

 

6,541

 

 

$

28.83

 

 

 

 

 

 

 

 

 

Granted

 

 

3,070

 

 

$

44.53

 

 

 

 

 

 

 

 

 

Exercised

 

 

(626

)

 

$

24.27

 

 

 

 

 

 

 

 

 

Forfeited/cancelled/expired

 

 

(450

)

 

$

38.37

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2019

 

 

8,535

 

 

$

34.31

 

 

 

5.08

 

 

$

104,380

 

Vested and expected to vest at December 31, 2019

 

 

8,535

 

 

$

34.31

 

 

 

5.08

 

 

$

104,380

 

Vested and exercisable at December 31, 2019

 

 

3,194

 

 

$

26.37

 

 

 

4.18

 

 

$

63,866

 

 

The aggregate intrinsic value in the above table is calculated as the difference between the closing price of our common stock at December 31, 2019, of $45.42 per share and the exercise price of stock options that had strike prices below the closing price. The intrinsic value of all stock options exercised during the years ended December 31, 2019, 2018, and 2017, was $17.2 million, $7.1 million, and $2.8 million, respectively. During the year ended December 31, 2019, cash of $15.2 million was received from stock option exercises. There is no tax impact related to share-based compensation or stock option exercises because we are in a net operating loss position with a full valuation allowance on our deferred tax assets.

79

 

In January 2019, a total of 297,000 target Performance-Based Restricted Stock Units, or PRSUs, were granted to employees in a company-wide grant. The PRSUs vest upon the closing price of our common stock, or the Closing Price, reaching certain price thresholds during the three-year performance period beginning January 4, 2019, and ending January 3, 2022, or the Performance Period, and the participant’s subsequent satisfaction of a continuing service requirement of generally 90 calendar days. If, on five consecutive trading days or ten non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60.00, $67.50 or $75.00, and the participant thereafter satisfies a continuing service requirement, then the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the participant’s respective target PRSU amount. The shares may be issued following achievement of each price threshold, and the maximum number of common shares that may be issued pursuant to each PRSU grant equals 200% of the number of PRSUs granted. As these awards contain a market condition, we used a Monte Carlo simulation model to estimate the grant-date fair value, which totaled $18.1 million. The grant-date fair value is recognized as compensation expense over the requisite service period of approximately 1.2 years which was derived from the Monte Carlo simulation; no compensation expense is recognized for service not provided in case of separation from the Company. There is no adjustment of compensation expense recognized for service performed regardless of the number of PRSUs, if any, that ultimately vest. The $60.00 market condition threshold was achieved in the third quarter of 2019. As a result, a total of 140,900 shares were issued to employees upon the satisfaction of the continuing service requirement.

In March 2015, we granted our executive officers TSR PRSU awards. The TSR PRSUs could be earned and converted into outstanding shares of our common stock based on the total stock return, or TSR, of our common stock relative to the TSR over a three-year performance period beginning March 1 of the year granted of the Nasdaq Biotechnology Index. In March 2018, 32,322 shares were issued to the holders of the remaining TSR PRSUs based on the TSR of our common stock relative to the TSR Nasdaq Biotechnology Index over the three-year performance period.

Employee Stock Purchase Plan

In June 2015, our stockholders approved our 2009 Employee Stock Purchase Plan, as amended, or 2009 ESPP. Under the 2009 ESPP substantially all employees could choose to have up to 15% of their annual compensation withheld to purchase up to 625 shares of our common stock per purchase period, subject to certain limitations. The shares of our common stock could be purchased over an offering period with a maximum duration of 24 months and at a price of not less than 85% of the lesser of the fair market value of the common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of the applicable three-month purchase period. Under applicable accounting guidance, the 2009 ESPP was considered a compensatory plan. In June 2017, the 2009 ESPP was terminated.

In June 2019, our stockholders approved our 2019 Employee Stock Purchase Plan, or 2019 ESPP. Under the 2019 ESPP substantially all employees can elect to have up to 15% of their annual compensation withheld to purchase up to 2,000 shares of our common stock per purchase period, subject to certain limitations. The shares of our common stock can be purchased over an offering period with a maximum duration of 12 months and at a price of not less than 85% of the lesser of the fair market value of the common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of the applicable six-month purchase period. Under applicable accounting guidance, the 2019 ESPP is considered a compensatory plan.

During the years ended December 31, 2017, a total of 2,236 shares, respectively, were purchased by our employees under the 2009 ESPP. There were no purchases under the 2019 ESPP in 2019. The amount of compensation expense associated with the 2009 ESPP and 2019 ESPP for the years ended December 31, 2019, 2018, and 2017 was immaterial.  

Share-based Compensation

We estimate the grant-date fair value of all of our share-based awards in determining our share-based compensation expense. Our share-based awards include stock options, options to purchase stock granted under our employee stock purchase plan, RSUs, and PRSU awards.

 

The table below sets forth the weighted-average assumptions and estimated fair value of stock options we granted under our Equity Compensation Plans during the years presented:

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Risk-free interest rate

 

 

2.3

%

 

 

2.6

%

 

 

1.9

%

Dividend yield

 

 

—

%

 

 

—

%

 

 

—

%

Expected volatility

 

 

64

%

 

 

63

%

 

 

69

%

Expected life (years)

 

4.47

 

 

4.58

 

 

4.58

 

Weighted-average estimated fair value per share of stock options granted

 

$

23.47

 

 

$

20.01

 

 

$

9.17

 

80

 

 

 

We recognized share-based compensation expense as follows for the years presented, in thousands, except per share data:

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Research and development

 

$

27,361

 

 

$

8,385

 

 

$

1,945

 

General and administrative

 

 

25,686

 

 

 

11,158

 

 

 

5,925

 

Discontinued operations

 

 

—

 

 

 

11

 

 

 

120

 

Total share-based compensation expense

 

$

53,047

 

 

$

19,554

 

 

$

7,990

 

Impact on net loss per share, basic

 

$

1.07

 

 

$

0.42

 

 

$

0.24

 

Impact on net loss per share, diluted

 

$

1.03

 

 

$

0.42

 

 

$

0.24

 

The table below sets forth our total unrecognized estimated compensation expense at December 31, 2019, by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized:

 

 

 

Unrecognized

Expense (in

thousands)

 

 

Remaining

Weighted-Average

Recognition

Period (in years)

 

Unvested stock options

 

$

95,703

 

 

 

2.62

 

PRSUs

 

 

1,750

 

 

 

0.21

 

RSUs

 

 

613

 

 

 

0.57

 

 

 

 

8. Collaborations and License Agreements

We have collaborations or license agreements with the following companies: United Therapeutics Corporation, or United Therapeutics, Everest Medicines Limited, Eisai Co., Ltd. and Eisai Inc., or collectively, Eisai, and Boehringer Ingelheim International GmbH, or Boehringer Ingelheim.  

In the following table, revenue is disaggregated by major customers, timing of revenue recognition and revenue classification, in thousands:

 

Year ended December 31,

 

Customers

2019

 

 

2018

 

United Therapeutics

$

800,000

 

 

$

—

 

Everest

 

5,000

 

 

 

2,000

 

Eisai

 

(1,077

)

 

 

8,070

 

Other

 

2,508

 

 

 

10,407

 

    Total

$

806,431

 

 

$

20,477

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

Revenue recognized at a point in time

$

803,580

 

 

$

14,092

 

Revenue recognized over time

 

2,851

 

 

 

6,385

 

    Total

$

806,431

 

 

$

20,477

 

 

 

 

 

 

 

 

 

Classification

 

 

 

 

 

 

 

Revenue from continuing operations

$

806,431

 

 

$

17,970

 

Revenue reported under discontinued operations

 

—

 

 

 

2,507

 

    Total

$

806,431

 

 

$

20,477

 

 

United Therapeutics Corporation

In November 2018, we entered into an exclusive license agreement with United Therapeutics. Under this agreement, we granted United Therapeutics an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize ralinepag in any formulation. This transaction was completed in January 2019. United Therapeutics is responsible for all development, manufacturing and commercialization of the licensed products globally. In connection with this transaction we incurred transaction fees of

81

 

approximately $17.0 million, of which $14.6 million was incurred in 2019 and $2.4 million was incurred in 2018, and are presented as transaction costs in the accompanying consolidated statement of operations.

We received an upfront payment of $800.0 million under the agreement in the first quarter of 2019. We are also eligible to receive up to an aggregate of $400.0 million in regulatory milestone payments related to ralinepag, consisting of a payment of $150.0 million upon first marketing approval of an oral formulation of ralinepag in a major non-U.S. market, and a payment of $250.0 million upon U.S. marketing approval of an inhaled formulation of ralinepag to treat pulmonary arterial hypertension, as well as low double-digit, tiered royalties on net sales of ralinepag products, subject to certain adjustments for third party license payments.

The promised goods and services under this agreement are accounted for as a single performance obligation consisting of a research, development and commercialization license. Our performance obligation under this agreement was satisfied upon the closing of the transaction in January 2019, and accordingly, the estimated total transaction price of the agreement of $800.0 million was recognized as revenue at the commencement of this agreement in 2019. The future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained. Under the royalty exception in ASC 606 for licensed intellectual property, we do not include any variable amounts related to sales-based royalties in the transaction price until the later of when the sales occur or the performance obligation is satisfied or partially satisfied.

 

Everest

In December 2017, we and Everest entered into an exclusive agreement, or the Everest Agreement, to conduct joint development for the ralinepag and etrasimod programs. Under the Everest Agreement, we granted Everest an exclusive, royalty-bearing license to develop and commercialize ralinepag (in any formulation) and etrasimod (in oral formulations), in mainland China, Taiwan, Hong Kong, Macau and South Korea, or collectively, the Territories. Everest is generally responsible for development and commercialization of the licensed products in the Territories, and may participate in the portion of our global clinical trials that is conducted in the Territories. In January 2019, we and Everest amended the Everest Agreement by entering into two separate agreements, one for each development program with the terms identical to the original Everest Agreement. Under the agreement with United Therapeutics described above, we assigned all our rights and obligations with respect to the ralinepag program under the Everest Agreement, to United Therapeutics.  

In connection with entering into the Everest Agreement, we received from Everest an upfront payment of $12.0 million in December 2017.

In the fourth quarter of 2018, the Chinese National Medical Products Administration accepted the initial clinical trial applications for etrasimod and the oral formulation of ralinepag. Under the terms of the Everest Agreement, we recognized revenue of $2.0 million from the achievement of these milestones.

In October 2019, Everest announced that the first subject has been dosed in a Phase 3 trial evaluating etrasimod in development for the treatment of UC in Greater China and South Korea. Everest paid us a $5.0 million milestone payment due from this achievement, which we recognized as revenue in the fourth quarter of 2019.

We are also eligible to receive up to an aggregate of $110.0 million in success milestones in case of full commercial success of etrasimod products. We are also eligible to receive tiered royalties on net sales of etrasimod products in the Territories.

The promised goods and services under the Everest Agreement are accounted for as a single performance obligation consisting of a development and commercialization license. The amount of the upfront payment was recognized as revenue in December 2017 as we determined (i) that the license is a deliverable with standalone value to Everest and (ii) the upfront payment represents consideration to be allocated to the delivered license. As of December 31, 2019, all remaining future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained.

For the years ended December 31, 2019, 2018, and 2017, we recognized revenues of $5.0 million, $2.0 million and $12.0 million, respectively from the Everest Agreement.

Eisai

In July 2010, we granted Eisai exclusive commercialization rights for lorcaserin (marketed as BELVIQ/BELVIQ XR) solely in the United States and its territories and possessions. In May 2012, we and Eisai entered into the first amended and restated agreement, which expanded Eisai’s exclusive commercialization rights to include most of North and South America. In November 2013, we and Eisai entered into the second amended and restated agreement, or Second Amended Agreement, which expanded Eisai’s exclusive

82

 

commercialization rights for lorcaserin to all countries in the world, except for South Korea, Taiwan, Australia, New Zealand and Israel.

In December 2016, we and Eisai amended and restated the terms of marketing and supply agreement for lorcaserin with Eisai by entering into a Transaction Agreement and a Supply Agreement (collectively, the Eisai Agreement) with Eisai. Under the Transaction Agreement, Eisai acquired an exclusive royalty-bearing license or transfer of intellectual property to global commercialization and manufacturing rights to lorcaserin, including in the territories retained by us under the prior agreement, with control over global development and commercialization decisions. Eisai is responsible for all lorcaserin development expenses in the future. We also assigned to Eisai our rights under the commercial lorcaserin distribution agreements with Ildong Pharmaceutical Co., Ltd., or Ildong, for South Korea; CY Biotech Company Limited, or CYB, for Taiwan; and Teva Pharmaceuticals Ltd.’s Israeli subsidiary, Abic Marketing Limited, or Teva, for Israel.

Under the Supply Agreement, Eisai paid us for finished drug product plus monthly manufacturing support payments through March 2018 totaling CHF 8.7 million.

Until March 31, 2018, when we sold the Manufacturing Operations, including the assignment of the Supply Agreement, to Siegfried (see Note 5), we manufactured lorcaserin at our manufacturing facility in Zofingen, Switzerland. Revenues earned for (i) lorcaserin sold by us to Eisai under the manufacturing and supply commitment within the Supply Agreement and (ii) the manufacturing support payments are classified within discontinued operations as part of the Manufacturing Operations in the consolidated statements of operations (see Note 5). All other revenues earned under the Transaction Agreement, such as royalties, are classified within continuing operations in the consolidated statements of operations.

Royalty payments.

Pursuant to the Transaction Agreement, we are eligible to receive tiered royalty payments from Eisai starting at 9.5% on the global net sales of lorcaserin.

Upfront payments.

Prior to the Transaction Agreement, we received from Eisai total upfront payments of $115.0 million under prior lorcaserin collaboration agreements and $7.5 million from the prior commercial lorcaserin distribution agreements with Ildong and CYB described below, and Teva. Revenues from these upfront payments were previously deferred, as we determined that the exclusive rights did not have standalone value without our ongoing development and regulatory activities. Accordingly, these payments were recognized ratably as revenue over the periods in which we expected the services to be rendered. The Transaction Agreement effectively eliminated our obligation to continue performing the development and regulatory activities required in the original agreement.

In total, prior to the Transaction Agreement, we received a total of $102.1 million in milestone payments from Eisai, and other lorcaserin distributors. These payments were recognized as revenue upon the achievement of the milestones.

Accounting for Eisai Agreement under ASC 606.

Upon implementation of ASC 606 on January 1, 2018, we applied a practical expedient for contract modifications applicable to contracts that were modified before the implementation date. The promised goods and services under the Eisai Agreement were assessed in combination with promised goods and services under our previous agreements with Eisai and commercial lorcaserin distribution agreements with Ildong, CYB, and Teva. The total estimated transaction price of these contracts at the implementation date was $344.4 million, which included previously received upfront payments, milestone payments, proceeds from net products sales, reimbursement of development expenses, reimbursement of patent expenses, manufacturing support payments received and expected to be received under the Supply Agreement, proceeds from the sale of on-hand inventory of bulk lorcaserin and the precursor material, royalty payments received through December 31, 2017, and estimated future royalty payments related to intellectual property sold to Eisai. The future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained due to our assessment of the probability of a significant revenue reversal. The future royalties related to licensed intellectual property were excluded from the estimated total transaction price under the royalty exception in ASC 606. The estimated future royalties that relate to intellectual property sold to Eisai do not qualify for the royalty exception in ASC 606 and were included in the estimated total transaction price.

The estimated total transaction price was allocated between satisfied and unsatisfied performance obligations based on the relative standalone selling prices of the identified performance obligations. The remaining manufacturing and supply obligations under the Supply Agreement was the only unsatisfied performance obligation. As a result of this allocation, on January 1, 2018, we reduced the balance of deferred revenues associated with the Eisai Agreement at the implementation date by $25.5 million, recognized a contract asset of $6.1 million related to future manufacturing support payments under the Supply Agreement and recognized a contract

83

 

asset of $4.1 million related to estimated future royalty payments from intellectual property sold to Eisai under the Transaction Agreement. In connection with the sale of the Manufacturing Operations on March 31, 2018, we derecognized the remaining portion of the contract asset associated with the Supply Agreement. During 2018, we adjusted our estimate of future royalty payments from intellectual property sold to Eisai under the Transaction Agreement based on the CVOT study results reported by Eisai and our estimate of the qualifying sales of BELVIQ in the future years and recorded associated royalty revenue and an increase to the contract asset of $3.3 million. As of December 31, 2018, the contract asset balance was $6.0 million. Subsequent to year end, Eisai agreed to voluntarily withdraw BELVIQ products from the U.S. market based on a change in the FDA’s risk-benefit assessment of BELVIQ, and as requested by the FDA. As a result, we revised our estimate of future royalties and recorded a $3.7 million reduction to our contract asset as of December 31, 2019.

Based on the bill-and-hold accounting guidance in ASC 606, effective January 1, 2018, we derecognized $3.6 million of inventory of bulk lorcaserin and the precursor material previously sold to Eisai for which the revenue recognition criteria were met on the implementation date under ASC 606.

For the years ended December 31, 2019, 2018 and 2017, we recorded royalty revenues of $(1.1) million, $6.6 million and $1.7 million, respectively related to the Transaction Agreement. For the year ended December 31, 2018 and 2017, we recognized revenue of $1.5 million and $15.9 million, respectively, related to the Supply Agreement (classified under discontinued operations), all of which was recorded during the first quarter of 2018 and primarily consisting of net product sales and other collaboration revenue.

 

 

Accounting for Eisai Agreement under previous revenue recognition policy.

The total arrangement consideration of $115.6 million primarily consists of (i) the December 28, 2016, balances of deferred revenues from the upfront payments received under the prior Eisai agreements and the distribution agreements with other distributors; (ii) the $10.0 million payment received from Eisai on December 28, 2016; and (iii) the product purchase payments and manufacturing support payments we expect to receive from Eisai for the initial two-year manufacturing and supply commitment period.

All of the deliverables were determined to have standalone value and to meet the criteria to be accounted for as separate units of accounting. Factors considered in the determination included, among other things, for the license, the manufacturing experience and capabilities of Eisai and their sublicense rights, and for the remaining deliverables the fact that they are not proprietary and can be provided by other vendors. The total arrangement consideration was allocated to the units of accounting, consisting of the License Deliverable, the Inventory Deliverable the Manufacturing and Supply Commitment Deliverable, and on the basis of their relative estimated selling prices.

For the year ended December 31, 2017, we recognized $6.4 million as revenue of discontinued operations related to this deliverable and $0.9 million of the carrying value of this inventory as cost of product sales of discontinued operations.

The Manufacturing and Supply Commitment Deliverable was provided over 2017 and 2018 as product was shipped to Eisai until March 31, 2018. For the year ended December 31, 2017, we recognized $9.5 million as revenue of discontinued operations related to this deliverable.

Under the Eisai Agreement, Eisai is solely responsible for all costs and expenses in connection with further development of lorcaserin.

Boehringer Ingelheim International GmbH

In December 2015, we and Boehringer Ingelheim entered into a collaboration and license agreement, or Boehringer Ingelheim Agreement, under which we and Boehringer Ingelheim conduct joint research to identify drug candidates targeting an undisclosed G-protein-coupled receptor, or GPCR, that belongs to the group of orphan central nervous system receptors. Under Boehringer Ingelheim Agreement, we granted Boehringer Ingelheim exclusive rights to our internally discovered, novel compounds and intellectual property for an orphan CNS receptor. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.

In December 2018 and October 2019, we earned a milestone payment of $3.5 million and $1.5 million, respectively upon Boehringer Ingelheim’s initiation of preclinical development of a first and an additional compound.

We are also eligible to receive up to an aggregate of $246.0 million (of which the first $7.0 million is also payable to Beacon – see Note 12) in additional success milestone payments in case of full commercial success of multiple drug products.

84

 

The promised goods and services under the Boehringer Ingelheim Agreement are accounted for as a single combined performance obligation consisting of a research license, a development and commercialization license and research services. Our research services performance obligation under the original term of the Boehringer Ingelheim Agreement was completely satisfied as of January 2018, and accordingly the estimated total transaction price of the Boehringer Ingelheim Agreement under the original contractual term was fully recognized as revenue over the period from January 2016 through January 2018. We recognize revenue for the combined performance obligation based on the amount of incurred development expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract. As of December 31, 2019, all future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained.

For the years ended December 31, 2019, 2018, and 2017, we recognized revenues of $1.7 million, $4.4 million and $5.1 million, respectively from the Boehringer Ingelheim Agreement.

Outpost Medicine LLC

In April 2018, we and Outpost Medicine entered into a license agreement, or Outpost Agreement, under which Outpost Medicine has an exclusive right to advance an undisclosed, preclinical compound with potential utility in treating genitourinary disorders.

Under the Outpost Agreement, we received an upfront payment of $3.0 million, of which $1.5 million was in the form of an equity interest in Outpost Medicine. In September 2019, we earned a milestone payment of $0.5 million upon Outpost’s initiation of Phase 1 clinical trials.

The promised goods and services under the Outpost Agreement are accounted for as a single performance obligation consisting of a research, development and commercialization license. Our performance obligation under the Outpost Agreement was fully satisfied at the inception of the Outpost Agreement and, accordingly, the estimated total transaction price of the Outpost Agreement was fully recognized as revenue in the second quarter of 2018. As of December 31, 2019, all future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained.

For the years ended December 31, 2019, 2018 and 2017, we recognized revenues of $0.5 million, $2.8 million and $0.2 million, respectively from the Outpost Agreement. Subsequent to year end, the Outpost Agreement was terminated.

Axovant Sciences GmbH

In 2015, we entered into a development, marketing and supply agreement with Roivant Sciences Ltd., which subsequently assigned the exclusive rights to develop and commercialize nelotanserin to its subsidiary, Axovant. Under this agreement, Axovant had exclusive worldwide rights to develop and commercialize nelotanserin, subject to regulatory approval. We also provided certain services and manufactured and sold nelotanserin to Axovant. We refer to this agreement as the Axovant Agreement.

The promised goods and services under the Axovant Agreement were accounted for as two separate performance obligations: (i) a combined performance obligation consisting of commercialization rights and development and regulatory services and (ii) a manufacturing and supply commitment. We recognized revenue for the combined performance obligation consisting of commercialization rights and development and regulatory services based on the amount of incurred development expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract. In December 2018, Axovant announced negative results of an exploratory Phase 2 clinical study and a discontinuation of further clinical development activities under the nelotanserin program. As a result, we revised our estimate of the total transaction price as of December 31, 2018, based on our assessment that we will not perform any research and development services for Axovant in the future and concluded that all our performance obligations have been satisfied. As of December 31, 2018, all future potential purchase price adjustment payments and milestone payments were excluded from the estimated total transaction price as they were considered constrained.

For the years ended December 31, 2018, and 2017, and we recognized revenues of $2.2 million, and $2.2 million, respectively, from the Axovant Agreement. No revenue was recognized under this agreement for the year ended December 31, 2019. In the fourth quarter of 2019, the Axovant Agreement was terminated.

 

85

 

9. Income Taxes

The following table summarizes our income (loss) attributable to stockholders of Arena before provision (benefit) for income taxes by region for the years presented, in thousands:

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

United States

 

$

298,315

 

 

$

(138,522

)

 

$

(62,109

)

Foreign

 

 

209,573

 

 

 

(1,142

)

 

 

(29,298

)

Total income (loss) attributable to stockholders of Arena before income taxes

 

$

507,888

 

 

$

(139,664

)

 

$

(91,407

)

 

For the year ended December 31, 2019, we have recorded an expense for income taxes for the usage of the deferred tax assets that were set up in 2018 related to the taxable gain pursuant to the United Therapeutics transaction. We recorded a benefit for income taxes for the year ended December 31, 2018, due to the estimated taxable gain pursuant to the United Therapeutics transaction. We did not record a benefit for income taxes for the year ended December 31, 2017, because we had a full valuation allowance.

Our effective income tax rate differs from the statutory federal rate of 21% for 2019 and 2018, and 34% for 2017 due to the following, in thousands:

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Benefit for income taxes at statutory federal rate

 

$

106,657

 

 

$

(29,090

)

 

$

(32,140

)

Change in valuation allowance due to tax reform

 

 

—

 

 

 

—

 

 

 

96,333

 

Change in federal and foreign valuation allowance

 

 

34,712

 

 

 

(76,336

)

 

 

(68,604

)

Permanent differences and other

 

 

601

 

 

 

1,963

 

 

 

(782

)

Deferred adjustment related to foreign net operating losses

 

 

15,133

 

 

 

—

 

 

 

—

 

Capital loss on foreign subsidiary liquidation

 

 

(43,685

)

 

 

—

 

 

 

—

 

Share-based compensation expense

 

 

1,624

 

 

 

889

 

 

 

7,071

 

Foreign losses at lower effective rates

 

 

21

 

 

 

257

 

 

 

1,428

 

Research and development and Orphan Drug credits

 

 

(4,730

)

 

 

(7,948

)

 

 

(3,306

)

Benefit for income taxes

 

$

110,333

 

 

$

(110,265

)

 

$

—

 

 

The components of our net deferred tax assets are as follows, in thousands:  

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Federal and California NOL carryforwards

 

$

140,762

 

 

$

210,853

 

Federal and California research and development credit carryforwards

 

 

73,956

 

 

 

69,221

 

Foreign NOL carryforwards

 

 

—

 

 

 

15,131

 

Share-based compensation expense

 

 

11,010

 

 

 

6,124

 

Depreciation

 

 

3,183

 

 

 

2,914

 

Lease liability

 

 

2,359

 

 

 

—

 

Other, net

 

 

354

 

 

 

784

 

Total deferred tax assets

 

 

231,624

 

 

 

305,027

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use assets

 

 

(2,218

)

 

 

—

 

Total deferred tax liabilities

 

 

(2,218

)

 

 

—

 

Net deferred tax assets

 

 

229,406

 

 

 

305,027

 

Valuation allowance

 

 

(229,406

)

 

 

(194,694

)

Net deferred tax assets

 

$

—

 

 

$

110,333

 

 

A valuation allowance is recorded against a portion of our deferred tax assets, as realization of a portion of these assets is not more-likely-than-not. The realization of our deferred tax assets is dependent upon future taxable income. In January 2019, a taxable income generating event, the transaction pursuant to the United Therapeutics Agreement created taxable income, resulting in the realization of a portion of our deferred tax assets. A portion of the valuation allowance in 2018 was released for the anticipated taxable

86

 

income generating event. We utilized net operating losses to offset taxable income in 2019. Our ability to generate taxable income is analyzed regularly on a jurisdiction-by-jurisdiction basis. At such time as it is more-likely-than-not that we will generate taxable income in a jurisdiction, we will further reduce or remove the valuation allowance. The valuation allowance increased by $34.7 million from December 31, 2018, to December 31, 2019.

At December 31, 2019, we had federal NOL carryforwards of $539.3 million that will begin to expire in 2029 unless previously utilized. At the same date, we had California NOL carryforwards of $393.9 million, which begin expiring in 2028. Net operating losses generated after December 31, 2017 carry forward indefinitely. At December 31, 2019, we had $151.4 million of net operating losses with no expiration. Net operating losses generated in 2018 are subject to an 80% limitation. At December 31, 2019, we also had federal and California research and development tax credit carryforwards, net of reserves, of $38.7 million and $25.1 million, respectively. At December 31, 2019, we had a Federal Orphan Drug Credit carryforward, net of reserves, of $15.0 million. Federal credit carryforwards will begin to expire after 2026 unless previously utilized. The California research and development credit carries forward indefinitely.

Sections 382 and 383 of the IRC limit the utilization of tax attribute carryforwards that arise prior to certain cumulative changes in a corporation’s ownership. We have completed an IRC Section 382/383 analysis through 2019 and did not identify any ownership changes that limit our utilization of tax attribute carryforwards since 2010. Pursuant to IRC Section 382 and 383, use of our net operating loss and research and development income tax credit carryforwards may be limited in the event of cumulative changes in ownership subsequent to 2019 of more than 50% within a three-year period.

In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

The following table reconciles the beginning and ending amount of unrecognized tax benefits for the years presented, in thousands:  

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Gross unrecognized tax benefits at the beginning of the year

 

$

9,033

 

 

$

7,762

 

 

$

5,906

 

Additions from tax positions taken in the current year

 

 

1,017

 

 

 

1,269

 

 

 

1,133

 

Additions from tax positions taken in prior years

 

 

—

 

 

 

2

 

 

 

723

 

Reductions from tax positions taken in prior years

 

 

(96

)

 

 

—

 

 

 

—

 

Tax settlements

 

 

—

 

 

 

—

 

 

 

—

 

Gross unrecognized tax benefits at end of the year

 

$

9,954

 

 

$

9,033

 

 

$

7,762

 

 

Of our total unrecognized tax benefits at December 31, 2019, $8.6 million will impact our effective tax rate in the event the valuation allowance is removed. We do not anticipate that there will be a substantial change in unrecognized tax benefits within the next 12 months.

Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Because we have incurred net losses since our inception, we did not have any accrued interest or penalties included in our consolidated balance sheets at December 31, 2019, or 2018, and did not recognize any interest and/or penalties in our consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2019, 2018, and 2017.

We are subject to income taxation in the United States at the Federal and state levels. All tax years are subject to examination by US and California tax authorities due to the carryforward of unutilized NOLs and tax credits. We are also subject to foreign income taxes in the countries in which we operate. To our knowledge, we are not currently under examination by any taxing authorities.

 

 

10. Legal Proceedings

Beginning in September 2010, a number of complaints were filed in the US District Court for the Southern District of California, or District Court, against us and certain of our current and former employees and directors on behalf of certain purchasers of our common stock. The complaints were brought as purported stockholder class actions, and, in general, include allegations that we and certain of our current and former employees and directors violated federal securities laws by making materially false and misleading statements regarding our BELVIQ program, thereby artificially inflating the price of our common stock. The plaintiffs sought unspecified monetary damages and other relief. In August 2011, the District Court consolidated the actions and appointed a lead plaintiff and lead counsel. In November 2017, we and the Lead Plaintiff signed a stipulation and agreement of settlement, or Stipulation, to resolve the consolidated class action. Under the terms of the Stipulation, and in exchange for a release of all claims

87

 

by class members and a dismissal of the consolidated class action with prejudice, we have agreed that (i) our insurers would pay class members and their attorneys a total of approximately $12.025 million and (ii) Arena would pay class members and their attorneys approximately $11.975 million in either shares of our common stock or cash at our election. On November 30, 2017, the District Court preliminary approved the settlement and the form of notice to potential class members of the proposed settlement and the procedure by which they can become class members. On March 8, 2018, the lead plaintiff filed motions for final approval of the settlement, the plan of allocation and award of attorney fees. On April 12, 2018, the District Court entered its final approval order approving the settlement and the plan of allocation and request for attorneys’ fees and expense. We recognized $11.975 million of net expense for the portion of the settlement that we agreed to pay in either common stock or cash in the consolidated statements of operations for the year ended December 31, 2017, and $24.0 million as a current liability in the consolidated balance sheet as of December 31, 2017 for the gross settlement liability, with a corresponding $12.025 million insurance recovery receivable. In the second quarter of 2018, we and our insurer made settlement payments in cash to the class members and their attorneys to settle our liability under the Stipulation.

We are not currently subject to any material legal proceedings

 

 

11. Quarterly Financial Data (Unaudited)

The following tables present selected quarterly financial data for the years presented, in thousands, except per share data:  

 

2019

 

Quarter ended

December 31

 

 

Quarter ended

September 30

 

 

Quarter ended

June 30

 

 

Quarter ended

March 31

 

Revenues

 

$

3,002

 

 

$

1,350

 

 

$

1,022

 

 

$

801,057

 

Operating costs and expenses

 

 

96,875

 

 

 

80,685

 

 

 

69,578

 

 

 

76,547

 

Net income (loss)

 

 

(88,311

)

 

 

(72,865

)

 

 

(61,403

)

 

 

620,134

 

Net income (loss) per share, basic

 

 

(1.76

)

 

 

(1.46

)

 

 

(1.24

)

 

 

12.53

 

Net income (loss) per share, diluted

 

 

(1.76

)

 

 

(1.46

)

 

 

(1.24

)

 

 

12.10

 

 

 

2018

 

Quarter ended

December 31

 

 

Quarter ended

September 30

 

 

Quarter ended

June 30

 

 

Quarter ended

March 31

 

Revenues

 

$

8,648

 

 

$

3,573

 

 

$

3,994

 

 

$

1,755

 

Operating costs and expenses

 

 

53,292

 

 

 

39,577

 

 

 

37,160

 

 

 

32,724

 

Income (loss) from continuing operations

 

 

68,711

 

 

 

(34,314

)

 

 

(31,833

)

 

 

(31,133

)

Loss from discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(830

)

Net income (loss)

 

 

68,711

 

 

 

(34,314

)

 

 

(31,833

)

 

 

(31,963

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share, basic

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.39

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.78

)

Discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(0.02

)

 

 

$

1.39

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.80

)

Net income (loss) per share, diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.35

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.78

)

Discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(0.02

)

 

 

$

1.35

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.80

)

 

 

12. Beacon Discovery, Inc.

In September 2016, we entered into a series of agreements with Beacon, a privately held drug discovery incubator which focuses on identifying and advancing molecules targeting GPCRs. Beacon was founded in 2016 by several of our former employees.

We entered into an agreement, or License and Collaboration Agreement, with Beacon, pursuant to which we transferred certain equipment to Beacon and granted Beacon a non-exclusive, non-assignable and non-sublicensable license to certain database information relating to compounds, receptors and pharmacology, and transferred certain equipment to Beacon. Beacon will seek to engage global partners to facilitate discovery and development. Beacon has agreed to assign to us any intellectual property relating to our existing research and development programs developed in the course of performing research for us, and grant us a non-exclusive license to any intellectual property developed outside the course of performing work for us that is reasonably necessary or useful for developing or commercializing the products under our research and development programs. We are also entitled to rights of negotiation and rights of first refusal to potentially obtain licenses to compounds discovered and developed by Beacon. In addition, we are entitled to receive (i) a percentage of any revenue received by Beacon on or after the second anniversary of the effective date of

88

 

the agreement from any third party pursuant to a third-party license, including upfront payments, milestone payments and royalties; (ii) single-digit royalties on the aggregate net sales of any related products sold by Beacon and its affiliates; and (iii) in the event that Beacon is sold, a percentage of the consideration for such sale transaction.

We entered a services agreement with Beacon, or Master Services Agreement, pursuant to which Beacon performs certain research services for us.

We also entered into a separate services agreement with Beacon, or Beacon Services Agreement, pursuant to which Beacon performed our research obligations under our agreement with Boehringer Ingelheim. In consideration for performing these research obligations, Beacon is entitled to receive the applicable FTE payments that are paid to us by Boehringer Ingelheim for the research services and certain milestone payments.

We also entered into a sublease agreement, or Sublease, with Beacon, pursuant to which we sublease approximately 30,000 square feet of laboratory, office and meeting room space to Beacon until May 2027.

As Beacon’s equity investment at risk in September 2016 was not sufficient to permit Beacon to finance its activities without subordinated financial support, Beacon was considered a variable interest entity in which we held a significant variable interest pursuant to the License and Collaboration Agreement. We do not own any equity interest in Beacon; however, as the agreements described above provided us the controlling financial interest in Beacon until December 2017, we consolidated Beacon’s balances and activity within our consolidated financial statements until December 2017 as we were determined to be the primary beneficiary of Beacon. Pursuant to a contract Beacon entered into with a third party in December 2017, we determined we no longer held the controlling financial interest as of that date and, therefore, deconsolidated Beacon from our consolidated financial statements as we were no longer deemed to be the primary beneficiary. Our consolidated financial statements for the year ended December 31, 2017, include Beacon’s results of operations and cash flows until the December 2017 deconsolidation. Beacon’s net and comprehensive loss of $1.3 million for the year ended December 31, 2017 is presented as net loss attributable to noncontrolling interest in consolidated variable interest entity in our consolidated statement of operations and comprehensive loss as we do not own any equity interest in Beacon.

In January 2020, we entered into a new multi-year strategic Collaboration and License Agreement with Beacon, aimed at building novel medicines across a range of GPCR targets believed to play a role in immune and inflammatory diseases. Under the terms of this agreement Beacon is responsible for early drug discovery activities and we will be responsible for any potential future development and, ultimately, commercialization activities. We are required to pay to Beacon research initiation fees, make quarterly research funding payments for the duration of Beacon’s research activities as well as research, development and regulatory milestone payments depending on the future research and development progress. We are also obligated to pay Beacon tiered royalties on net sales of low single digits levels.

 

13. Subsequent Events

See Note 12 regarding the collaboration and license agreement with Beacon, which was executed in January 2020.

 

 

Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A.    Controls and Procedures.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of December 31, 2019, we conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Annual Report on Form 10-K.

89

 

Management’s Report on Internal Control Over Financial Reporting

Our management is also responsible for establishing and maintaining for us adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the Internal Control—Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2019.

The registered public accounting firm that audited our financial statements as of and for the year ended December 31, 2019, included in this Annual Report on Form 10-K, has issued an attestation report on our internal control over financial reporting, and such report is included below.

Changes in Internal Control Over Financial Reporting

An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any changes in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting during the fourth quarter of the year ended December 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

90

 

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

Arena Pharmaceuticals, Inc.:

 

 

Opinion on Internal Control Over Financial Reporting

We have audited Arena Pharmaceuticals, Inc. and subsidiaries’ (the Company) internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.  

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive income (loss), equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes (collectively, the consolidated financial statements), and our report dated February 27, 2020 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

 

 

 

/s/ KPMG LLP

 

 

San Diego, California

 

February 27, 2020

 

 


91

 

Item 9B.    Other Information.

Sales Agreement

On February 27, 2020, we entered into a Sales Agreement (the “Sales Agreement”) with Credit Suisse Securities (USA) LLC, SVB Leerink LLC and Cantor Fitzgerald & Co., as sales agents (collectively, the “Sales Agents”), pursuant to which we may offer and sell up to $250.0 million of shares of our common stock from time to time through the Sales Agents. Sales of shares of our common stock may be made at market prices by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including, without limitation, sales made directly on or through The Nasdaq Global Select Market or any other existing trading market for our common stock. The shares will be offered and sold only pursuant to an effective shelf registration statement on Form S-3.

We are not obligated to sell any shares under the Sales Agreement. Each of the Sales Agents has agreed to use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms among the Sales Agents and us.  We will pay the Sales Agents commissions of up to 3.0% of the gross sales price per share sold under the Sales Agreement.

We and the Sales Agents may each terminate the Sales Agreement at any time upon five days’ prior notice.

This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions.

Management Transition

On February 26, 2020, we announced that Kevin R. Lind, our Executive Vice President and Chief Financial Officer, has been appointed the President and Chief Executive Officer of our wholly owned subsidiary, Arena Neuroscience, Inc. Arena Neuroscience, Inc. was formed in January 2020 to focus on programs and platforms in the area of neuroscience.

On February 26, 2020, we appointed Laurie D. Stelzer as our Executive Vice President and Chief Financial Officer, effective upon her commencing employment with us (the “Commencement Date”), which is expected to occur in March 2020, replacing Mr. Lind in that capacity.

Ms. Stelzer, age 52, currently serves as the Senior Vice President, Chief Financial Officer of Halozyme Therapeutics, Inc. (Nasdaq: HALO). Ms. Stelzer joined Halozyme in June 2015 as Senior Vice President, Chief Financial Officer. Prior to joining Halozyme, Ms. Stelzer served from April 2014 to January 2015 as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc., a biopharmaceutical company. Prior to that, she was the Division CFO for the Regenerative Medicine Division and the Head of Investor Relations at Shire from March 2012 to April 2014. Prior to Shire, Ms. Stelzer held positions of increasing responsibility for 15 years at Amgen, Inc., a biopharmaceutical company, including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. Early in her career, Ms. Stelzer held various finance and accounting positions in the real estate and banking industries. Ms. Stelzer serves on the board of directors of Surface Oncology, Inc., an immuno-oncology company. Ms. Stelzer received her MBA from the Anderson School at the University of California, Los Angeles, and a Bachelor of Science in Accounting from Arizona State University.

In connection with her appointment as our Executive Vice President and Chief Financial Officer, we entered into an offer letter agreement with Ms. Stelzer.  Pursuant to her offer letter, Ms. Stelzer will be entitled to: (i) an annual base salary of $480,000; (ii) participation under our Annual Incentive Plan with a target bonus of up to 50% of her then-current base salary; (iii) an option to purchase up to 132,000 shares of our common stock under our Amended and Restated 2017 Long-Term Incentive Plan, as amended, subject to a four-year vesting period; and (iv) PRSUs under our Amended and Restated 2017 Long-Term Incentive Plan, as amended, pursuant to which 6,300 shares will vest if our stock price closes at or above $67.50 for five consecutive trading days or ten non-consecutive trading days during the performance period, and an aggregate of 12,600 shares will vest if our stock price closes at or above $75.00 for five consecutive trading days or ten non-consecutive trading days during the performance period, subject to her continuous service with us and the other terms and conditions of the PRSUs. In addition, Ms. Stelzer’s position as Executive Vice President will entitle her to participate under our Amended and Restated Severance Benefit Plan, which is filed as Exhibit 10.20 to this Annual Report on Form 10-K. Ms. Stelzer’s severance period under our Amended and Restated Severance Benefit Plan will be 18 months.

92

 

PART III

Item 10.    Directors, Executive Officers and Corporate Governance.

We have adopted a Code of Business Conduct and Ethics that applies to our directors and employees (including our principal executive officer, principal financial officer, principal accounting officer and controller), and have posted the text of the policy on our website (www.arenapharm.com) in connection with “Investor” materials. In addition, we intend to promptly disclose on our website in the future (i) the date and nature of any amendment (other than technical, administrative or other non-substantive amendments) to the policy that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions and relates to any element of the code of ethics definition enumerated in Item 406(b) of Regulation S-K, and (ii) the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals that relates to one or more of the elements of the code of ethics definition enumerated in Item 406(b) of Regulation S-K, the name of such person who is granted the waiver and the date of the waiver.

The other information required by this item will be included under the captions “Election of Directors,” “Compensation and Other Information Concerning Executive Officers, Directors and Certain Stockholders” and “Delinquent Section 16(a) Reports” in our definitive proxy statement for the annual meeting of stockholders to be held in June 2020 to be filed with the SEC on or before April 29, 2020, or the Proxy Statement, and is incorporated herein by reference.

Item 11.    Executive Compensation.

The information required by this item will be included under the captions “Compensation and Other Information Concerning Executive Officers, Directors and Certain Stockholders” and “Compensation Committee Interlocks and Insider Participation” in the Proxy Statement and is incorporated herein by reference.

Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this item will be included under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Securities Authorized for Issuance Under Equity Compensation Plans” in the Proxy Statement and is incorporated herein by reference.

Item 13.    Certain Relationships and Related Transactions, and Director Independence.

The information required by this item will be included under the captions “Certain Relationships and Related Transactions” and “Election of Directors” in the Proxy Statement and is incorporated herein by reference.

Item 14.    Principal Accounting Fees and Services.

The information required by this item will be included under the captions “Independent Auditors’ Fees” and “Pre-approval Policies and Procedures” in the Proxy Statement and is incorporated herein by reference.

 

 

PART IV

Item 15.    Exhibits, Financial Statement Schedules.

(a)

1. FINANCIAL STATEMENTS

Reference is made to the Index to Financial Statements under Item 8, Part II hereof.

2. FINANCIAL STATEMENT SCHEDULES

The financial statement schedules have been omitted either because they are not required or because the information has been included in the consolidated financial statements or the notes thereto included in this annual report.

93

 

 

 

3. EXHIBITS

 

Exhibit

No.

 

Exhibit Description

 

 

2.1*

 

Agreement of Purchase and Sale, dated as of March 21, 2007, by and between Arena and BMR-6114-6154 Nancy Ridge Drive LLP (as assignee of BioMed Realty, L.P.) (incorporated by reference to Exhibit 2.1 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on May 8, 2007, Commission File No. 000-31161)

 

 

2.2+*

 

Exclusive License Agreement, dated as of November 15, 2018, by and between Arena and United Therapeutics Corporation (incorporated by reference to Exhibit 2.1 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on January 25, 2019, Commission File No. 000-31161)

 

 

3.1

 

Fifth Amended and Restated Certificate of Incorporation of Arena (incorporated by reference to Exhibit 3.1 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2002, filed with the Securities and Exchange Commission on August 14, 2002, Commission File No. 000-31161)

 

 

 

 

3.2

 

Certificate of Amendment of the Fifth Amended and Restated Certificate of Incorporation of Arena (incorporated by reference to Exhibit 4.2 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 28, 2006, Commission File No. 333-135398)

 

 

3.3

 

Certificate of Amendment No. 2 of the Fifth Amended and Restated Certificate of Incorporation of Arena, as amended (incorporated by reference to Exhibit 4.3 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 30, 2009, Commission File No. 333-160329)

 

 

3.4

 

Certificate of Amendment No. 3 of the Fifth Amended and Restated Certificate of Incorporation of Arena, as amended (incorporated by reference to Exhibit 3.4 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 20, 2012, Commission File No. 333-182238)

 

 

3.5

 

Certificate of Amendment No. 4 of the Fifth Amended and Restated Certificate of Incorporation of Arena, as amended (incorporated by reference to Exhibit 3.1 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on June 15, 2017, Commission File No. 000-31161)

 

 

3.6

 

Amended and Restated Bylaws of Arena (incorporated by reference to Exhibit 3.1 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on October 9, 2014, Commission File No. 000-31161)

 

 

4.1

 

Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5 and 3.6

 

 

4.2

 

Form of common stock certificate (incorporated by reference to Exhibit 4.7 to Arena’s registration statement on Form S-8, filed with the Securities and Exchange Commission on June 22, 2017, Commission File No. 333-218905)

 

 

4.3

 

Description of Arena’s common stock

 

 

10.1**

 

Form of Indemnification Agreement between Arena and its directors (incorporated by reference to Exhibit 10.1 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2007, Commission File No. 000-31161)

 

 

 

10.2**

 

Form of Indemnification Agreement between Arena and its executive officers (incorporated by reference to Exhibit 10.2 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2007, Commission File No. 000-31161)

 

 

 

10.3**

 

Form of Indemnification Agreement between Arena and individuals serving as its directors and executive officers (incorporated by reference to Exhibit 10.3 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2007, Commission File No. 000-31161)

 

 

 

10.4

 

Lease agreement between BMR-6114-6154 Nancy Ridge Drive LLC and Arena for 6114 Nancy Ridge Drive, San Diego, California (incorporated by reference to Exhibit 10.5 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission on August 9, 2007, Commission File No. 000-31161)

 

 

 

10.5

 

Lease agreement between BMR-6114-6154 Nancy Ridge Drive LLC and Arena for 6118 Nancy Ridge Drive, San Diego, California (incorporated by reference to Exhibit 10.6 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission on August 9, 2007, Commission File No. 000-31161)

94

 

Exhibit

No.

 

Exhibit Description

 

 

 

10.6

 

Lease agreement between BMR-6114-6154 Nancy Ridge Drive LLC and Arena for 6122, 6124 and 6126 Nancy Ridge Drive, San Diego, California (incorporated by reference to Exhibit 10.7 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission on August 9, 2007, Commission File No. 000-31161)

 

 

 

10.7

 

Lease agreement between BMR-6114-6154 Nancy Ridge Drive LLC and Arena for 6154 Nancy Ridge Drive, San Diego, California (incorporated by reference to Exhibit 10.8 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission on August 9, 2007, Commission File No. 000-31161)

 

 

 

10.8**

 

Arena’s 2009 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.1 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 30, 2009, Commission File No. 333-160329)

 

 

 

10.9**

 

Form of Incentive Stock Option Grant Agreement for Employees under the Arena 2009 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.7 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2009, filed with the Securities and Exchange Commission on August 7, 2009, Commission File No. 000-31161)

 

 

 

10.10**

 

Form of Stock Option Grant Agreement for Employees or Consultants under the Arena 2009 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.8 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2009, filed with the Securities and Exchange Commission on August 7, 2009, Commission File No. 000-31161)

 

 

 

10.11**

 

Arena’s 2012 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.1 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 20, 2012, Commission File No. 333-182238)

 

 

 

10.12**

 

Form of Stock Option Grant Agreement for Employees or Consultants for grants prior to December 13, 2012, under the Arena 2012 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on June 20, 2012, Commission File No. 000-31161)

 

 

 

10.13**

 

Arena’s 2013 Long-Term Incentive Plan, as amended (incorporated by reference to Exhibit 10.3 to Arena’s quarterly report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 9, 2017, Commission File No. 000-31161)

 

 

 

10.14**

 

Form of Stock Option Grant Agreement for Employees or Consultants under the Arena 2013 Long-Term Incentive Plan, as amended (incorporated by reference to Exhibit 10.3 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2016, filed with the Securities and Exchange Commission on August 9, 2016, Commission File No. 000-31161)

 

 

 

10.15**

 

Form of Incentive Stock Option Grant Agreement for Employees under the Arena 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on June 14, 2013, Commission File No. 000-31161)

 

 

 

10.16**

 

Executive Employment Agreement, dated as of May 6, 2016, by and between Arena and Amit D. Munshi (incorporated by reference to Exhibit 10.1 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on May 9, 2016, Commission File No. 000-31161)

 

 

 

10.17**

 

Amended and Restated Severance Agreement, dated as of January 4, 2019, by and between Arena and Amit D. Munshi (incorporated by reference to Exhibit 10.1 to Arena’s quarterly report on Form 10-Q for the quarter ended March 31, 2019, filed with the Securities and Exchange Commission on May 9, 2019, Commission File No. 000-31161)

 

 

 

10.18**

 

Form of Amended and Restated Termination Protection Agreement, dated December 30, 2008, by and between Arena and Mr. Spector (incorporated by reference to Exhibit 10.2 to Arena’s Form 8-K filed with the Securities and Exchange Commission on December 31, 2008, Commission File No. 000-31161)

 

 

 

10.19**

 

Form of Amendment to Amended and Restated Termination Protection Agreement, dated May 9, 2016, by and between Arena and Steven W. Spector (incorporated by reference to Exhibit 10.3 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on May 9, 2016, Commission File No. 000-31161)

 

 

 

10.20**

 

Amended and Restated Severance Benefit Plan, effective January 4, 2019, and providing benefits for certain of Arena’s executive officers (incorporated by reference to Exhibit 10.2 to Arena’s quarterly report on Form 10-Q for the quarter ended March 31, 2019, filed with the Securities and Exchange Commission on May 9, 2019, Commission File No. 000-31161)

 

 

 

10.21**

 

Annual Incentive Plan for Arena’s executive officers, approved February 11, 2019 (incorporated by reference to Exhibit 10.28 to Arena’s annual report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on February 28, 2019, Commission File No. 000-31161)

95

 

Exhibit

No.

 

Exhibit Description

10.22**

 

Employment Agreement, dated as of June 14, 2016, by and between Arena and Kevin R. Lind (incorporated by reference to Exhibit 10.1 to Arena’s current report on Form 8-K filed with the Securities and Exchange Commission on June 16, 2016, Commission File No. 000-31161)

 

 

 

10.23**

 

Summary of compensation for Arena’s non-employee directors, approved June 13, 2019 (incorporated by reference to Exhibit 10.4 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2019, filed with the Securities and Exchange Commission on August 9, 2019, Commission File No. 000-31161)

 

 

 

10.24**

 

Employment Agreement, dated as of August 9, 2016, by and between Arena and Vincent E. Aurentz (incorporated by reference to Exhibit 10.3 to Arena’s quarterly report on Form 10-Q for the quarter ended September 30, 2016, filed with the Securities and Exchange Commission on November 9, 2016, Commission File No. 000-31161)

 

 

 

10.25**

 

Employment Agreement, dated as of February 15, 2017, by and between Arena and Preston Klassen, M.D. (incorporated by reference to Exhibit 10.1 to Arena’s quarterly report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 9, 2017, Commission File No. 000-31161)

 

 

 

10.26**

 

Employment Agreement, dated as of October 30, 2018, by and between Arena and Robert Lisicki (incorporated by reference to Exhibit 10.3 to Arena’s quarterly report on Form 10-Q for the quarter ended June 30, 2019, filed with the Securities and Exchange Commission on August 9, 2019, Commission File No. 000-31161)

 

 

 

10.27+

 

Transaction Agreement, dated as of December 28, 2016, by and among 356 Royalty Inc., Eisai Inc. and Eisai Co., Ltd. (incorporated by reference to Exhibit 10.52 to Arena’s annual report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 15, 2017, Commission File No. 000-31161)

 

 

 

10.28

 

Amendment No. 1 dated as of March 9, 2018, to Transaction Agreement, dated as of December 28, 2016, by and among 356 Royalty Inc., Eisai Inc. and Eisai Co. Ltd. (incorporated by reference to Exhibit 10.46 to Arena’s annual report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 14, 2018, Commission File No. 000-31161)

 

 

 

10.29

 

Amendment, dated October 5, 2018, to Transaction Agreement, dated as of December 28, 2016 and amended as of March 9, 2018, by and among 356 Royalty Inc., Eisai Inc. and Eisai Co. Ltd. (incorporated by reference to Exhibit 10.33 to Arena’s annual report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on February 28, 2019, Commission File No. 000-31161)

 

 

 

10.30+

 

Supply Agreement, dated as of December 28, 2016, by and among Arena Pharmaceuticals GmbH, Eisai Inc. and Eisai Co., Ltd. (incorporated by reference to Exhibit 10.53 to Arena’s annual report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 15, 2017, Commission File No. 000-31161)

 

 

 

10.31

 

Amendment No. 1 dated as of March 9, 2018, to Supply Agreement, dated as of December 28, 2016, by and among Arena Pharmaceuticals GmbH, Eisai Inc. and Eisai Co., Ltd. (incorporated by reference to Exhibit 10.48 to Arena’s annual report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 14, 2018, Commission File No. 000-31161)

 

 

 

10.32**

 

Arena’s 2017 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.1 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 22, 2017, Commission File No. 333-218905)

  

 

 

10.33**

 

Arena’s Amended and Restated 2017 Long-Term Incentive Plan, effective June 13, 2018 (incorporated by reference to Exhibit 99.1 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 14, 2018, Commission File No. 333-225608)

  

 

 

10.34**

 

Arena’s Amended and Restated 2017 Long-Term Incentive Plan, effective June 13, 2019 (incorporated by reference to Exhibit 99.1 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 14, 2019, Commission File No. 333-232142)

 

 

 

10.35**

 

Form of Nonqualified Stock Option Grant Agreement for Employees and Consultants under the Arena 2017 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.2 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 22, 2017, Commission File No. 333-218905)

  

 

 

10.36**

 

Form of Incentive Stock Option Grant Agreement under the Arena 2017 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.3 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 22, 2017, Commission File No. 333-218905)

96

 

Exhibit

No.

 

Exhibit Description

  

 

 

10.37**

 

Form of Restricted Stock Unit Grant Agreement (other than for non-employee directors) under the Arena 2017 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.4 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 22, 2017, Commission File No. 333-218905)

 

 

 

10.38**

 

Form of Performance Restricted Stock Unit Grant Agreement under the Arena 2017 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.45 to Arena’s annual report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on February 28, 2019, Commission File No. 000-31161)

 

 

 

10.39**

 

Form of Restricted Stock Unit Grant Agreement for Non-Employee Directors under the Arena 2017 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.5 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 22, 2017, Commission File No. 333-218905)

  

 

 

10.40**

 

Form of Nonqualified Stock Option Grant Agreement for Non-Employee Directors under the Arena 2017 Long-Term Incentive Plan (incorporated by reference to Exhibit 99.6 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 22, 2017, Commission File No. 333-218905)

  

 

 

10.41**

 

Arena’s 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.2 to Arena’s registration statement on Form S-8 filed with the Securities and Exchange Commission on June 14, 2019, Commission File No. 333-232142)

 

 

 

21.1

 

Subsidiaries of the Registrant

 

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

 

31.1

 

Certification of principal executive officer pursuant to Rule 13a-14(A) promulgated under the Securities Exchange Act of 1934

 

 

 

31.2

 

Certification of principal financial and accounting officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(B) promulgated under the Securities Exchange Act of 1934

 

 

 

32.1

 

Certification of principal executive officer and principal financial and accounting officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(B) promulgated under the Securities Exchange Act of 1934

 

 

 

101.INS

 

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

104

 

Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibit 101.INS)

 

+

Confidential treatment has been requested or granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.

*

Exhibits and schedules to this agreement have been omitted pursuant to the rules of the Securities and Exchange Commission. We will submit copies of such exhibits and schedules to the Securities and Exchange Commission upon request.

**

Management contract or compensatory plan or arrangement.

(b)EXHIBITS

See Item 15(a)(3) above.

(c)FINANCIAL STATEMENT SCHEDULES

See Item 15(a)(2) above.

Item 16.    Form 10-K Summary.

None.

97

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ARENA PHARMACEUTICALS, INC.

 

 

 

Date: February 27, 2020

By:

/ S /    AMIT D. MUNSHI

 

 

Amit D. Munshi

President and Chief Executive Officer

(principal executive office)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signatures

 

Title

 

Date

 

 

 

 

 

 

 

By:

 

/ S /    AMIT D. MUNSHI

 

President and Chief Executive Officer and Director (principal executive officer)

 

February 27, 2020

 

 

Amit D. Munshi

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /   KEVIN R. LIND

 

Executive Vice President and Chief Financial Officer (principal financial and accounting officer)

 

February 27, 2020

 

 

Kevin R. Lind

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /    JAYSON DALLAS

 

Director

 

February 27, 2020

 

 

Jayson Dallas, M.D.

 

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /    OLIVER FETZER

 

Director

 

February 27, 2020

 

 

Oliver Fetzer, Ph.D.

 

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /    KIERAN T. GALLAHUE

 

Director

 

February 27, 2020

 

 

Kieran T. Gallahue

 

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /    JENNIFER JARRETT

 

Director

 

February 27, 2020

 

 

Jennifer Jarrett

 

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /    GARRY A. NEIL

 

Director

 

February 27, 2020

 

 

Garry A. Neil, M.D.

 

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /    TINA S. NOVA

 

Director

 

February 27, 2020

 

 

Tina S. Nova, Ph.D.

 

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /    MANMEET S. SONI

 

Director

 

February 27, 2020

 

 

Manmeet S. Soni

 

 

 

 

 

 

 

 

 

 

 

By:

 

/ S /    RANDALL E. WOODS

 

Director

 

February 27, 2020

 

 

Randall E. Woods

 

 

 

 

 

 

98

 EX-4.3 2 arna-ex43_819.htm EX-4.3 arna-ex43_819.htm

Exhibit 4.3

 

DESCRIPTION OF THE REGISTRANT’S COMMON STOCK

The following summary describes the material terms of the common stock, par value $0.0001 per share, of Arena Pharmaceuticals, Inc. (“we,” “us” and “our”). The description of common stock is qualified by reference to our amended and restated certificate of incorporation and our amended and restated bylaws, which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part.

General

Our amended and restated certificate of incorporation, as amended, authorizes us to issue 73,500,000 shares of common stock. In addition, under our amended and restated certificate of incorporation, as amended, our board of directors has the authority, without further action by stockholders, to designate up to 7,500,000 shares of preferred stock, par value $0.0001 per share, in one or more series and to fix the rights, preferences, privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preference and sinking fund terms, any or all of which may be greater than the rights of our common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation.  The issuance could also have the effect of decreasing the market price of the common stock. The issuance of preferred stock also could have the effect of delaying, deterring or prevent a change in control of us. All of our authorized shares of preferred stock are currently undesignated and no shares of preferred stock are issued and outstanding.  

Our common stock is listed on the Nasdaq Global Select Market under the symbol “ARNA.”

Voting

Common stockholders are entitled to one vote per share for the election of directors and on all other matters that require common stockholder approval.

Dividends and Other Distributions

Holders of our common stock are entitled to share in an equal amount per share in any dividends declared by our board of directors on the common stock and paid out of legally available assets.

Distribution on Dissolution

Subject to any preferential rights of any outstanding preferred stock, in the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any outstanding preferred stock.

Other Rights

Our common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights.

Anti-Takeover Provisions

Delaware Law. We are governed by the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless (i) before the date that the person became an “interested stockholder,” our board of directors approved either the “business combination” or the transaction which makes the person an “interested stockholder,” (ii) the “interested stockholder” owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares

 

 

 

outstanding (a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer, or (iii) after the date that the person became an “interested stockholder,” the business combination is approved by our board of directors and the vote of at least 66 2/3% of our outstanding voting stock that is not owned by the “interested stockholder.” Generally, a “business combination” includes (A) any merger or consolidation involving the corporation and the interested stockholder, (B) any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation, (C) subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder, (D) any transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested stockholder, or (E) the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. An “interested stockholder” is a person who either owns 15% or more of our outstanding voting stock or, together with affiliates and associates, owns or, within three prior years, did own, 15% or more of our outstanding voting stock. The statute could have the effect of delaying, deferring or preventing a change in our control.

Bylaw and Certificate of Incorporation Provisions. Our amended and restated bylaws provide that special meetings of our stockholders may be called by our board of directors or President. Our amended and restated certificate of incorporation (i) specifies that the authorized number of directors shall be fixed by our board of directors in the manner provided by our amended and restated bylaws, which provide that the number of directors constituting our board of directors shall be fixed from time to time by resolution passed by a majority of our board of directors and (ii) does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. These and other provisions contained in our amended and restated certificate of incorporation and amended and restated bylaws could delay or discourage transactions involving an actual or potential change in control of us or our management, including transactions in which stockholders might otherwise receive a premium for their shares over then current prices. Such provisions could also limit the ability of stockholders to remove current management or approve transactions that stockholders may deem to be in their best interests and could adversely affect the price of our common stock.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

 

 

 EX-21.1 3 arna-ex211_11.htm EX-21.1 arna-ex211_11.htm

Exhibit 21.1

Subsidiaries of Arena Pharmaceuticals, Inc.

As of December 31, 2019

 

125 Royalty Inc., a Delaware corporation

356 Royalty Inc., a Delaware corporation

Arena Pharmaceuticals Development GmbH, a limited liability company organized under the laws of Switzerland and having its domicile in Zug

Arena Pharmaceuticals GmbH in Liquidation, a limited liability company organized under the laws of Switzerland and having its domicile in Zofingen

Arena Pharmaceuticals Limited, a limited liability company organized under the laws of Ireland and having its domicile in Dublin

API Development LTD, a company incorporated in the Cayman Islands with limited liability

 

 EX-23.1 4 arna-ex231_7.htm EX-23.1 arna-ex231_7.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

Arena Pharmaceuticals, Inc.:

We consent to the incorporation by reference in the registration statements (Nos. 333-160329, 333-182238, 333-189213, 333-204999, 333-212012, 333-214529, 333-217805, 333-218905, 333-225608, and 333-232142) on Form S-8 and (Nos. 333-112542, 333-136023, 333-160983, 333-167498, and 333-219237) on Form S-3 of Arena Pharmaceuticals, Inc. of our reports dated February 27, 2020, with respect to the consolidated balance sheets of Arena Pharmaceuticals, Inc. as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive income (loss), equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2019, which reports appear in the December 31, 2019 annual report on Form 10‑K of Arena Pharmaceuticals, Inc. Our report refers to the adoption of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, and Accounting Standards Codification Topic 842, Leases.

/s/ KPMG LLP

San Diego, California

February 27, 2020

 

 EX-31.1 5 arna-ex311_15.htm EX-31.1 arna-ex311_15.htm

Exhibit 31.1

CERTIFICATION

I, Amit D. Munshi, certify that:

1.    I have reviewed this annual report on Form 10-K of Arena Pharmaceuticals, Inc.;

2.    Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3.    Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

 

d)

Disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 27, 2020

 

/s/ Amit D. Munshi     

 

 

Amit D. Munshi, President and Chief Executive Officer

 

 

(principal executive officer)

 

 EX-31.2 6 arna-ex312_12.htm EX-31.2 arna-ex312_12.htm

Exhibit 31.2

CERTIFICATION

I, Kevin R. Lind, certify that:

1.    I have reviewed this annual report on Form 10-K of Arena Pharmaceuticals, Inc.;

2.    Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3.    Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

 

d)

Disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 27, 2020

 

/s/ Kevin R. Lind     

 

 

Kevin R. Lind, Executive Vice President and Chief Financial Officer

 

 

(principal financial and accounting officer)

 

 EX-32.1 7 arna-ex321_14.htm EX-32.1 arna-ex321_14.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Arena Pharmaceuticals, Inc. (“the Company”) for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Amit D. Munshi, as President and Chief Executive Officer (principal and financial officer) of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1.

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Amit D. Munshi         

 

Amit D. Munshi

 

President and Chief Executive Officer

 

(principal executive officer)

 

 

 

 

 

Date: February 27, 2020

 

 

In connection with the Annual Report on Form 10-K of Arena Pharmaceuticals, Inc. (“the Company”) for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Kevin R. Lind, as Executive Vice President and Chief Financial Officer (principal financial and accounting officer) of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1.

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Kevin R. Lind

 

Kevin R. Lind

 

Executive Vice President and Chief Financial Officer

 

(principal financial and accounting officer)

 

 

 

 

 

Date: February 27, 2020

 

 

 GRAPHIC 8 gbcvmkcqbvay000003.jpg GRAPHIC begin 644 gbcvmkcqbvay000003.jpg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end GRAPHIC 9 gbcvmkcqbvay000004.jpg GRAPHIC begin 644 gbcvmkcqbvay000004.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH ***QO$OB?3/"FF"^U.23#N(H8 M84+RSR'HB*.K''T]2* -FBN0\/?$;2M>ULZ++8:MI&J&/S8K75;7R'F3G)3D MYQ@^G?&<'%&_^+>AV=_>00:=K>H6MBYCO-0L;(R6UNP^]N?(^[U. >.F: .] MHKBO$?Q2\/>&['1KZ47=Y::NK/;36:*PVJ%)+!F4C[P[9&#G%6/$/Q#TCPWX MGTK0+N"]EN]2:-8G@13&F]]B[R6!'(/0'@&@#K:*\]N/BWI\6HZG9V_AGQ/? M_P!FW$EO<3V5@LL2LA(/S!^!QGG'%:MW\1]!M?!%OXL1KBYL+AECBC@C!F9R MVW8%)'S @Y&>QQF@#K:*YBZ\=Z3:^ %\9[+F733#'+LC53*-S!<8+ 9!.#SV M/6L6/XN::LMM_:'ASQ/I5I<2+&+V_P!.\N!2WWM_$S2M(UJ?2;;3-9UF\M5#72:39^>+?/( M#G(P2/3/O1J?Q2\-:=X0L_%"RW%WIEU<"V5K>,;T_3 (- ': M45@:GXPTS2[C0HG$TZZW,L-I) H9>0"&;)'RX(Y&:NZ]KVF^&M&GU75;@06D M(&YL$DDG Y))H TJ*XK1/B;I.KZO;:7@455TZ]_M M'3;:]^S7-KY\:R>1$TL)M2AN?LMW)_&^F^%M!LM8G@N[VWO9HX8%LD5W169IOQ/T^]UFSTR]T+Q#HTMZYCMI=5L/)CE?^X#N/S&@#N**@O; MRWTZQGO;R98;:",R2R.>%4#))KA8?C#H#W-M]IT[7+'3KJ3R[?5;NQ,=I*3G M:0^*+'4/%>J^'88K@7FF)$\SLJ^6PD7<-I!SGUR!6 M1>_$K1K&R\274MM?-'X?FCANPJ)EV=@HV9;D9/.<4 =E17%7GQ/T.R\"VGBZ M2WOVL;J0Q1PK$OG!@6!!7=CC8Q//05>TSQWI>JZUI>EP07BSZEI:ZK"SHH58 MFZ!L,2&]@"/>@#IZ*YF\\<:99:SK.ER079GTG3SJ,[*B[6C SA3N^][' ]ZU MM#UBW\0:'9:O:)*EO>1++&LH 8 ^H!(S^- &A17*>*/B%HOA'6--TS44NFFO MB,/"BE(5+A-\A+#"Y/4 ]#3_ !;XWA\(%6N="UR^@,32R7&GV@EBA4==[%@% M]?I0!U%%>=VOQ@TJX2PED\/>)+6WO[B*WMKBYLE2*1I,[2K;\$<9XSQ73^&? M%EAXJMKZ6SCN(&L;M[2XBN5571TQGH2,<]<^M &[17GDGQAT46.G7<&CZ[=K MJ-Q/!:QVULDDDIBV[B%#Y(^;C'H>!6WX<\:_\)%J+V?_ C/B33-D1E\[4[# MR8S@@;0VX_-SG'H#0!U%%<7XM^)-GX.N94O] \036T2JSWUM9AK<;N@\PL!G M/%1GXHZ5!HE:HL?FK9:K:F"62/^^HR01GWSP>,"L:]^+]EI^IQZ=/X2\6BZF=T M@3^S5S/MZF,%\L,<\#I0!Z+17$:G\4M%T:318M1L=5M9M54.(I8%5[52X0-, M"WR#)[9Z5N:OXHL=&U[1='N(KA[C5WD2!HU4JI0 G=D@@<\8!H VZ**X?5_B M?8Z7XEO=!A\/^(M4O+((TQTVS6=5#J&'1\CKW Y!H [BBN(3XIZ&?"NJZ[): MZE#_ &5(L=Y83P".ZB9F"KE"V.>+>*XBL%,4[GH(V+C M<3V YJ]HGQ"LM:U^WT1M'UK3KZ>U:Z6/4+982$5BO(W$\D<<8]Z .OHKF;SQ MQIEEK.LZ7)!=F?2=/.HSLJ+M:,#.%.[[WL<#WKG(_C-IC6*:A)X6\60Z:P#F M^?31Y"H?XRP<_+[C- 'I-%FV@#H:*R?#OB*Q\ M3Z3'J6G>:8)!P9$Q^&>5)'0X)P<@X((K6H **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"O-?B/-%I7C7P1KVH\:/:74\=Q*<[8GD3$;-Z#(SGVKTJH[BWAN[>2WN88YH M)5*21R*&5U/4$'@B@#E8O&?AC5_%*:/I5W!?:K+8R.EW9@3)$F1\K2IG;DX. M.G S@E<\;\-/&/ASPQ\.#I>N7MOIVHZ5)/'>6=PX69VWLWRH>7R"!Q]*]1TS M0](T42C2M*L; 2X\P6MND6_&<9V@9QD_G45[X;T+4KY;V^T73KJ[7&V>>U1Y M!CIAB,\4 > 6^@SW6@_#C2KNW,(U ZIY<$AY2.5T1(XXUT?3U2*X^U1J+5 $F_YZ 8X?\ VNM 'D7A/0O$VK^(/'!T M/Q<=$MQKMPDD2Z?'<%V)/S;F(*G'I3=8TJX\/^(?"?@[PSI4VNC1$?5KJ![I M(#*[$JK,[<##$G'H0/>O8XK?2])F;R8;.SDOIRS;%6,W$Q!8DXQO<@$]S@&I M8].LHK^:_CL[=+R90DMPL2B1U'0,V,D#WH ^>Y[R[L_@]XZ\*ZE8G3[K2[N* M:.S:19/)AGF1T4,O#8.>?<5I:_::]I]_X;T[QQXEN-0\'W[19D@M(K<1S+@I M'+@$[.G.><$\;DV%Q)<1B*=YK9',J @A6)'(! (!]!4]Y MIEAJ-B;&]L;:YM#C,$\2O&<=/E(QQ@4 >9:7+;P_$CXGRW-K+=VR6=L98(0" MTJ" Y51DD7M\BPZ-J,4.-V9V P7P"2S$#KR30!Y[X#\0Z/X6U;QAI/B&^MM,U'^V)K MS=>2B/SXI,%&4L?FX'0>H]:X>_BCU+PDVI"UVZ3K'CE)[2.5,"6)@REL'H&P M1CVKZ U/P_HNM/&^JZ/I]^\8(1KJV24J#U W XJ:XTO3[RW@M[FPM9X;=U>& M.6%66-E^Z5!& 1V(Z4 >$7\-WX<^(7A3P;<)(]E9ZT+O2YSR/LTA_P!62>24 M;(^GH,5W?Q@W6^E>']5E@>;3],UJWNKU4!.V,9&XCN 2/SKO+K2].OKJVNKN MPM;BXM6W6\LL*N\)XY0D94\#IZ59D5'C99 K1D$,&'!'?/M0!Y5X\\1:-XKO M?">C^'[^VU/4GUB"[4VDHD\B./)=V(/RX!Z'T/I63X0T7Q/J?B/QM)H7B[^Q M84UZX62+^S8[GS&W?>RYR/3%>B>'KCP%%?/%X:F\-I=R(=ZZ:T D91RF0VBQWK?:'FMD4"U?.NBWL.B1Z-?^&_%VJ3ZU>ZYY-YHET516#NPA:1#JKZI%I5BFHOG?=K;H)6SPYA96 M]5/4,/<$ CW%>3> ]/3_ (4=XDUV>22XU/4[*[%Q<2G+%8HWC1?H OZ_2O;" M 001D'J#52#2--M=-;3;?3[2&P=65K6.%5B(;.X% ,8.3GCG- 'BO@F^O(/# M&BEOC#I&GVZ0QDZ;+:VF^)1UC+,^[..,D9J[XJN]5\1_%"\BTCPZ?$%EI&FM M9RQ"]2W5)+A?F;8@ZA>ZA\(O#FCSR&TU?2/$L.EREE#F%T#A M#C."%! ]#M-=#Y&L6OQ8T72/'^O3ZE:JWVK1)X[>*WAFN!QB157[PSP,GDK_ M 'L5ZC%IWAC4I7DALM(NI)FBOG9(HG+DY\N8D#D_>VM]<&K]_I>GZHD2:A86 MMXL3B2,7$*R!''1AN!P?>@#E/B[8W>H_"[6[>R1Y)1&DA1,Y**ZLV,=?E!JO M)\2? W]BZ0_VRUO/M$MNEO8VZK--$Y(VDQ#YE*'GIGCC)P#W*W$#7,ELLT9G MC57>(,-RJV0I(Z@':V#WP?2J$/AS0;34FU2#1=-@OB6=KM+5%ERV=QW@9R@#S^TU?3?#?QQ\4-K5_!I\>HV-K+;27;B)'"*%.&8@9R#^1]*XO5YHM0\ M"_%75[202V=UJ<"03+]R39(F2I[CG_.:]UN]+T/Q):6\M[8Z=JEMCS('FA2= M,,/O*2",$8Y'6I3HNE'2?[).F61TW&/L?V=?)QG.-F-O7GIUH \ UI=UMK'A MLQG9I4%_J^"/D5)K9/+QV^_-)QVQ6YHM_9Z!XO\ A_J>JW"6=E<^$H[5+B<[ M(_,4!L%CP.".OJ/6O8GT/2)9)Y)-+LGDGA^SS,UNA,D7]QCCE?8\56>T\-ZI M90:1);Z5=VJ!O)LV2.1%$1V':G(&PG:<#Y2<<4 >5W=[::WXM^)&J:;A]?2NI^'7B[PU;^ /#]E/XATF*[6TCC:![V-9 V M,;2I.<^U=K:Z+I5CI\FGV>F65O8R[O,MH;=4C?<,-E0,'(X/K62_A+P38SV^ M_P />'[>:60)!NLH49W + +QDM@$\<\4 >1ZXFO>-=?\;7&E^%WUFPF0:1;W M(OHX1;F(AF(5N7^?:W&/3O7<1Z__ ,)-\ KO5';=.^CS1SD]?-1&5S^)!/XU MW=A;Z7I[2:?IT-G;%,326]NJIMWD_,57^\5;GO@^E4]OAFP\.S3 :1;Z'< R M3/B-+:4/@%F/W3NR!D] M)M/26Q51R;LL(6"^YW%C]!7IT][X,&A:?<7%UH(T>*5?L,DDD/V=)$R!Y9/R MAEPV-O(P:NI%X?\ $R6FI)'IFJK;N6MKI5CG$3@C)1^<'('0]0* /(_'.CCP MQ=?#32;/68-%-F+B/^T98T9(VV1[G*N0IR<]?[U=QX)O9Y-1N(;KXDZ;XH=H MLQVUM#;Q-%@\M^[8DCD#GBM_5;7PSK&F1:CJ\&D7UA"AECN;M(Y8D0XRP9L@ M X'.>PJ/P_I7A)%&I^&[#1%#@QB[TZ&+YAGE=Z#U'(SVH YOXW?\DFUCZP_^ MC4K/\;W,6B^,_ &OZDI&D6WG02SG)2"22-0C-V ]_8GM7>^(+GP_#IWE>))M M,2QF8+LU%XQ%(PY P_!/&?PJVT5AJFF"-H[:\L+B,84JLD4J$<<<@J1^% 'F M^K:QIOBKXM^#XO#]U!J#Z8MS,=LCUJUXU_Y*[\/? M]^\X_P"V0KNM-T72M%CDCTK3+*P20[G6U@6(,?4A0,U+/IUEU"\B@4&Z2[FG<(JR(B(Q8G@989Y]:]LL=.L MM,MS;Z?9V]I"6+F.WB6-=QZG &,FL^;PEX;N(%AF\/:3+$LC2JCV494.V-S M$=3@9/? H GTWQ#HFM2/'I6L:??21CI"DX%>376G^)]0^,'C=O" MVO)I=Y#:VK;'M8YEG/E#:I+9VE>H:?IWA?0M1-OIMGH^G7TRA3%;11 M0RR [B!A0"1\CD?[K>AK2BT^RAOI[Z*SMX[RX"K-<)$HDD"\ ,V,G';- 'S] M)/:WOP0\:7]Q<7@?V+X=U/[9<4 M;&USCYMK+C!Z%?:JW_"'^$-/_P!-_P"$7MYW;MO&,9SV MQ0!R_P 7_P#4>$?^QBM?_9JK^)+^ST#XYZ)J>JW*6=CV^X-Y5S"LBY'0X8$9H \>N[VTUOQ;\2-4TVYBN[&+PV;;[1"P:)G,9. XX M/0]#Z^ESLXHYK2%L /@EAV)..PP7Y7 MV7RE\K9TV[,8Q[8H \:\2^&=,\2_$[3-%M9%%M_PBH-A.A)\EED8Q2 CGC@^ MX^M'P[OYO$WQ1UZ/7K$&\CT=++4()XP4DD1U5SCH5;KCIS7L%MHFDV4\,UKI M=E!+!%Y$+Q6Z*T<><[%('"Y).!Q4D6EZ?#J,VHQ6%K'?3J$EN4A42R*,8#-C M)' ZGL* )+>RM;1IFMK:&%IFWRF.,*7; &6QU. !D]@*GHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** .%\60:[JNKR?V+:VLXTN ,IGNFBVW) M99!A1&P8A448)7B4C//%"[N3K$>IZW9:QJ<2"[L?L9@NV6-$E6#=^[^XV0YX M8'!Z8.:])HH \WN;@Z=+J6FW.IWD&AVVM0Q7%U+J$HD@A:U1P#.6WJIF*#.X M8#XS@TRQ^T:S>Z59W&J:I_9YM-1E@>&\DB:>*.>)8'9U8,_R-D-G+#!).XY] M+HH \EO]::X\+V=WK&MWEE<2>&X[G3V@NW@-Q=%"9" A E8'RL(07&@7*VNM^9:27>F1"6SUB>]D1Y)U M27]])&NTLA7,8)VG/ W5Z[10!YK>7\>F6&KZ?0=Q)5>A(KH/ VH2ZAX,\Z>?SGCGNH@XN#<#8LKA )2 9!L"X<\ ML,$]:ZJB@#SWPEHFJ7_A'PM&G;0M$T-XKO56AN?"\MW/'',TSAXU@VF%')56 D8 'C.:[ZX\3: M3:ZH-.FGE$^](F9;>1HD=\;4>4+L1CE<*S G=Z"0J$+#:3M!S@9Z4 >;VVL2W":A8V>K/]D>;2Q&]IKLM^P\RZ M,_/(.[)51D'%5=/UB.[TC2?[?UJ6RTC??QM=1 MZI(BF5)L0(;H%&<>5N*Y^_C)R17>7?BO1;(6;37A*7<:S1210O(@C8@!W95( MC0[A\SD#KSP:C\2^)!X<_LUFLY+F.[NO)D,;8:%!&\C28Q\P 0D@*/5 &$ED+%;R_G@FN+=E4R,;-8MLA8F4%F"E"N3M"U/%K!N[G3 M-$DU6X:^.M:A%=V\=TPF6$K=&,-M;@KLI/$EO!J.J03(%MM/L M(KYKA7W;U?81;3W/EQQ3C=N5Y-I( M'R$#"DL2HQSP <'X=OY;?PHL-GJ-S]BAT?2OM#)YUZ6UMBP"93[8 9)"-QVJ&<9W@_< 7 MHI_$^L0BTM#H,*:I/?M9^7->.MN<0M,)$E\HEU*KC[@PV0>G-VW\1-$FI)K- MM'976G0BYF2&?ST:$AB'1MJD_<8$%0XNY+-)VQ=;D>XC&8?F^;..2FW^*O0_"VI0WWA>!!.\DZ0$LLUR)I"FYE1]^ M 71MIVR$ LHR>Y_X M0^:Y34;^ Z7X2L;NUCM[MXXUFV3'5VY&O?:[JX\076E:5I=C<_9;6*XE MEN[]X/\ 6-( %B?./+/)(ZT6/B^RN;.2\N-MK!'807SJQ9I%67?@%0N#G9@ M;68L>PXW &S;:A97I M;NWG)B28>5(&S&^=K<'[IP<'H<&O*/#^D6-SKD%BM M[?HT!UHS"'49A(C"[BVJ6#[E^4JV,C.0QSN)/;2^+]*CU/2FMK>ZFDU2Z-A( MQMID> HCN Z%,J*-&OYKJ."\Q]F1I)'EB>)"BDAG1W 5 MT!'+*2!QSR* /-M1US69]/\ #\\NIPVTL^AV]Q:2SZE-:^;=M]\B.*-OM)'[ MO]V1T? !W''9>,K"'5+[PM:72D+)J+G*'#(PM9R&4]F5@"#V(!I]S\0=(ADL M?*6ZD6XN1!(KVDT<$X(J[+XST*&"UF-S.XNDD>&. M*SFDD81L%?**A8%2<$$ CG/0T BV:VCRW;&.ZB$\;Q022*L1QB1V52(TY'S/@=>>#40\56D3:L M;Q'BCL+U+-3$K3/.S1QN-J(I8G]YC !^Z3ZX .*&L6$&IZ9J5Y?:4+4ZZS2Z MM;R&*TNF-C*NY=SLJD<(<,067J"2!H7M^=2N]=G\,R0SQZE!;V,-S%*%BGN3 MYF]UD4')2+;EAG&S&,K@=5-XIT>#3[6]-Q+)%=$B%8;:660E<[LQJI==N"&R M!M/!P>*?:^)M(O;6.YMKLR0R&'8PB?YO-QY9''(.>O0,E<+A3P%W5L^%];*CRHTBC^)+3K6^\^9X;IF6)8K6620E<[LQJI==N"&R!M/ M!P: ,R\O]-T3QQ<7^MW,-G%-810V=W=,(XE(=S+&'/ 8_NVQG+!1C.PXQ[N\ MT1+?2BUS=:'X7N&NYA.+N2S$DY8&/#*P*HX,SJN0&P..@.]9>.M)ETC2[Z\= MK9M0A$ZI'&\RQ(2%#.ZKA%R1\S;1UYX-:\>N:=-J/]GQSDW8D>,Q>4V0456; M/' PZ'<>#O7!.10!P4YU34-*FN=1O]4MKVU\-Q7A2*X:WVW'[T[W12!N^494 M_+V(.!B'Q!<76D0:M;Q:SJ44;VNEW+W#7+R21R27;)(R9)V@J!\B@+V"X.*] M3JM?6%MJ5K]FNX_,A\Q)-NXK\R.'4Y!SPR@_A0!Y\=0@&G2"+6[E_"O]KI$^ MI'4')2'R-Z*57S&9$4C'/W>C8-WX?:CJ=YK1%W?P23&UU9M:G=+.[D@WNM\ I)1@>-Q[C\ MLBJ6J:HM]X1MY_$.KW-H)_#4.2:]=HH M\J;4=33Q?:6XOK>WE5[%;."34YHVE@*+YFVU6-DF!)E&\D;=H)VA^=QWD/A0QY"",_QG/:44 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 <1X@\-^(-6UKS4GADM$N[:XMR^H30B%8WC=HS B%)[$C= MP!M%6K3PO>0#2 \MN19ZO>7TFUFYCF^T;0O'WAYRY^AP3WZVB@#CM%\/:U8Z MEHL=P=/_ +-T>TDM8I(Y'::<$(JLRE $X3D!CSW[4:-X7U*PUM;BXDM3;1#4 M50I(Q=Q;S?#W4#8:9 /L\[+H\.EW@.I75O& MOEY^8+%CSE.]\HY7H.1DUV.J:3+>:CH5Q"R"/3[MII Y.2I@ECP/4Y=>O;// MKKT4 <,/ UV=2U*"2[C;1+M+6".-)'2:*")Y9&CR.VYU4$$$+GN 38?PM?Z= M]NATDVUUIUU(DTMEJMQ)-]I)0QRH\CB1@N!&P/S%-8L?L M5UI]EI%NUMJ)NTTN.ZD2VA0V[Q%4<1=2S[SB-1DGOEC>G\,ZCK3W4VL/;PF] M,,$UO:7,A$=O$6?:LFU6+.[OHH XS_ (0^[TW46NM'E1Q#.MY ME]=2RL\IC:*5'D;FT8R>FHH XK7?"D]_XJGU1O#WA_68);2&!%U24JT+(TA8K M^YD&#O7T^[4,/@>_MK.6)+NW>1++3XX&8N%,UK,\N&'.(R2B\$D#/' SW=% M'')X-(1ITVGV]T+^YN797P-WDR$1Q#"J2B[@3T*@<^B44 MIII=NFGW?G&*UFDE+#R)8RVYD49)D7"[> "=QS@1:1X6OK#5;>ZEF@*QKJ2M ML9MW^D7*RIV[*#GWZ9ZUUU% ' KX.UJUT.#3K9]/D-SHD.D7SS2/B'RPP\R, M;3YG$K_*VS.%YY-7G\+ZC;75S?63VTMPFJI?VL4TK(CH+5;=E=@IVG&\@@-T M7U..PHH X"\MM0\+)IVI)"+O4'>\-Q!%;7$L0^T2+*VUHHG8;650-RKO&3D= M _P[HMTFH>'QC MQ)_:/FP>3_;)O]NYMWE_8O(QT^]OY],=\\5%:^&]8THVMY9&QGO(9K\&&:9T MC,5S/YH.X*2&7:G&W!Y&>AKL:* /-9/A[J365C&YM;B5M-73[P#4+JVB4!F. MX)#CS5(D8%&*]!@C)KI;/0+RV\7S:Z3;?Z0AM9(P3E8$P8B&VY+[MV03C#]3 ML&>EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HID4T4 M\8DAD21"2 R,",@X/(]P13Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ K&\6Q0S^$-7BN+R:RA>TD62YAC:1XE*G+!5Y./05LT4 >" M:-J?ARQ^'EW#JFF:9<+'JQBLO+N2ME>W#)\KD.=B(JD;LY48S][%6KA+72=0 MT21K[0O$,UGIME;6MK<0-/)=DS,'>V;[N1QAEWD!.0O4^W1Q1PILBC6- 2=J MC R3D_K3Z /(_!/G?\)O:_<_M1?[3&N;/OY^T#R/,Q_L_KRWU MK9SW=K-;*D$+2&.6!G+$ GJ'&/R-:-9^N_\ (O:GG'_'I+U_W#0!H4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5#7?^1?U+_KU MEZ?[AJ_5#7?^1?U+_KUE_P#0#0!?HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "L_7?^1>U/_KTE[9_@-:%4-=_Y%_4O^O67I_N& M@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?KVJKH6@:AJK MP23K9P/,8H_O/M&<"M"JU_!<7.GW$%I=M9W#QE8KA45S$W9MK @X]#0!R.A^ M,-XVO;_:7*1A5VXDP1DG*\8(STJK!\,+^+P_>Z>NMVD#ZC?_:[Y8K% MO(G0#'E;!(K*K8!;#9/3IG.K>> 'O[Y;B;4;>.*=+5=0@M[+8LWV>0O%Y>7/ MECG:0=^0.,=: +&B>.4UC7(;+[$L5K>"Z-C<"?01R;DVC9DG*X+9 YQ MTK7\17MI!HU_!-_;A+:VGVG[#; MB#:8?/D$DFY]QWX/"X"X!. MXG@V>9;VL;32KN^[E$!(!P>2 .#S43MK5W(Z0I;Z?''<+B24>>\T0SNPH("$ M\8)+<9R : $\0ZK+I6FJ;2..74+F5;:SBE;:KRMTW'KM #,<DO;/\ : -"BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHKEO&'B&YTK['9:;/:1:A.QD'VE@%*+CY.3]Z M1RL8[_,S ';0!U-,FFBMX))YY$BAC4N\CL%55 R22>@ K%TW6KO7[2SOM,LQ M!92R'S'OLJ[( .41<]3D?,5(V]",58M="@BEM;F]FDU&^M@_EW5R%W)O^]M" M@*O'' SCC)H ;_;3WJ#^Q[1KQ9; !4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5#7 M?^1?U+_KUEZ?[AJ_6?KO_(O:GG'_ !Z2]?\ <- &A1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%17-U;V5M)I)X%9\GB&S_?K:1W5])"B.5M8&8,'QMVN<(>&!^]TYH U:*RIM M1U4FX6UT.1FC5#$UQ[O/&%O;!K/2QY5 MO;K='%Q"I(N3MV]R,JW)/DI@88Y /1Z*R'UY;>*>>[L;N*TB6-ENHU$\Y\P03QRF-MCA&!V-Z'T/M0!+1110 4444 %%%% ! M1110 4=!DU4U+4[/2;)KN^F\J%2%R%+%F)P%50"6)/ !)JG]DO=4GW7^ZUM M89G"6T4H<74>-H,OR\ _,=@.,$9] -EU2?4A);Z'L8M%NCU)E$ELK;]I7A@ M7888X' (P2,UQDVCZ]=>,-?OM%O)4:&:&VGDGU&-1N6!9!Y:/9S;% G;@-U+ M<Z?I\]\9II6O+:T^S./,E9] MJ%6+JJ[MH&X\**N_V=K.C?/IE[)J5JO6QOY,R ?],YS\V?:3=G^\HH Z&BJ& MF:O:ZJD@A+QSPD+/;3+LEA8] R^_8C((Y!(YJ_0 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !116-XMBAG\(:O%<7DUE"]I(LES#&TCQ*5.6"K MR<>@H UHIHIXQ)#(DB$D!D8$9!P>1[@BGUX'8VS7OP8\4VUG,EC;V4L\DMQI M;GR-0 CR N[.Q?N!@O7!'U\5:;>RQZ-?7$&GV,5KI5[:/)/-NE.Y MH"<*& QRN_&WD+U(![#5#7?^1?U+_KUEZ?[AKS+P3YW_ F]K]S^U%_M,:YL M^_G[0/(\S'^S]S/\.<<5Z+XB>[&C7PB@A>$VLGF.TS*R_*BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **@N;RULE1KJYA@61 MQ&AED"AF/ 49ZD^E9.V?B M6QCN;/Q5-XGT*WO[NX(O[.WO8YI?LLAC6-,DC!B"@D!3_P M",%B#Z?;>'K" M%[66<27UU:EC%((;R.-])@EU%)H7EBGAP(&V MD@#S#QDD8XSZ].:<;;5[Y/\ 2;R*QBDM]KPVBEY(Y">669N",< >6._-:U% M&=!H>GPS?:# )KDQ+$T\Y,CLJXQDGW4'ZC-:-%% !6 ? OA DD^%=#)/4G3X MO_B:WZ* &0PQ6T$<$$210Q*$CC10JHH& !P !VJE=Z-9W;F0*]O.TB2-/:N M8I'*YV[BN-P^8_*V1STK0HH RHY-7LIE2XC34(9;AOWL"B)K>(@%=RLWSX.0 M2N#C'RGFK>G:C9ZM9)>6,ZS0.2 P!&"#@@@\@@@@@\BK54+S2+:[N5O!N@OX MXGBBNXL>9&&&.X*M@G(# C/.* +]%8YFUC3D)G@74K>*W!,D!"7$D@//[LX0 M@CGAATP - M;?1[VW2)K::UC5)]1F,P MX'941AZDLX;W5&[XSJ3^((2+B/3;:XU*YA5"8K M=<*0V",2/A#P0>&)QVH UZS)M75YUM=/0W MF,D-DL-0OY7%Y>_9[9)TDACLBR.RKG*R/GD$D'"A?NXR02*T+>VM[.!8;:". M")22(XD"J,G)X'O0!4L=-:&<7MW-Y^H/"L4LB%ECP#GY(RQ"Y/XG R>*@U2_ MN'N5TG3& OY4#R38!6UB)QYA!X+'!"J>I![*U6-7U,:79"1(C/.Y@E:UU&$$07: M#)4=U8?QH>ZGZC! (;INJR3W#:?J$(MM2C7>4#929,X\R,]USC(/*D@'J"=2 MJ6I:9#J=NJ2,\4L;>9!/$G^X:OU M0UW_ )%_4O\ KUE_] - %^BBB@ HHHH **J:AJ=EI5M]HOKF."+(4%SRS'HJ MCJS'L!DFLG^V-=U ;M*T$10G[L^JSFWW#U$:JS_@X0^WJ =#17F]U:^)-1\8 M7L-ZB7*VUA;2"WL-8NK$#?)< L APS'8 =V. ,'K6OX&OXY+SQ#IIDOHY+6^ M79::A$_>9F)7>7((8CGC@B@#L:*** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJMWJ5E8G;)M;GUA-9M[:=]#U0>19FZ(A@0D[8'/60&1M^3L MQB2'N#D ]%JIJ&J6.DVKW6H7<-M"F,O(P'4X ]R3P!WJDVF:A?(PU#4Y(XY( M%1H+',6Q\@LRR??[$#!'!/?FK=II-A8W$ES;VD:W,J*DMP1NED"@ ;G/S-@# MN30!5FU:\E%RFF:5-/-"4"M=,;>*3=W#D$D#OA3[9I9=.U2\\Y;G5C;Q&=7B M6PB$;B,9^1W?=NSP25"'C'KG6HH HV^CZ?:S231VRF628SM)(2[;SQD%B2.. M !P!P*O444 %%%% !1110 4444 %%%% !1110 4444 %-=$D0I(BNIZJPR#3 MJ* .0_X1;6(M1U:YM]1T1DU&7=(+K1WD?RPH58RPG4%0%'836T8B,XC*;@.%X+,>!@9)).,]ZT:* "F2RQP0O--(L<<:EG=S@* M!R23V%/KGKS_ (J+56TQ3G3+-U:]8=)Y.JP_0<,_U5>*35;S_ (2" M[C9%="FGPN,&*$X)HHH **** "BBB@ HHHH IZEIT.IVP MBE+HZ-YD,T9P\+C.'4^HR?8@D$$$@U-/U.=;O^R]5"1WX4M%(@Q'=(.K)Z$? MQ)R1[C!.O574-.MM3M?L]RK%0P='1BKQL.C*PY!'J* +5%<'-KGB.T\3OH,^ MJ:5;I%;P/%?7&GR2B=I7D50^V6-8W/EX Y#'IC(6NA\.W^HW4NKVFIR6LL^G MWHMQ+;0-"KJ8(I0=K.Y!_>D?>[4 ;=%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 5GZ[_P B]J?_ %Z2]L_P&M"J&N_\B_J7_7K+T_W#0!?HHHH M*RM2U=X+A=/T^$76IR+N$1;"0KTWRM_"N0<=VP<#@D-O]3GDNVTO20CWP ,T MSC=':J>A?GEB.B=3U.!S5O3=-@TNV,4)=W=C)--*K,>YX'L !0! M5T_0H[:Z_M"]E-]J9!!N9!@1@]5B7D1K[#DX^8D\UK55_M"T,UQ!'<1RW-N@ M>6WB<-(H.<94YN1=3F"^G3YA&L84N&#. B*# MN^\03@9P #4TC4Y+SSK2]C6'4K3 N(TSM(.=LB9ZHV#CTP0>5-:=%H]* M_P")IHOVZ2_MUQY4^H33">+^*$>8Y"9ZJ1C#*O;(J73-(6XM[:_TWQ-K7V64 M+(B/*DH9>#M/FHS#T/((Y[T =+163J(\0)=>;ICZ9+;[1_H]RDD;D]_WJEAC M_@''O3WU2XLM)2\U+3YEEW8DAL5:Z*\GD;5#,,8/"YYZ4 :=%9NEZ_I.LM(F MGW\,\L8S)"&Q)'_O(<,OX@5=N+F"SMWN+F:."&,9>25PJJ/4D\"@"6BHK:ZM M[VW2XM9XIX'&4DB<,K#V(X-2T %%%% !1110 4444 %%%% !1110 444=!DT M %%<3I'Q%L;^_P!0@D7S!'B6T2R5KF62$L4W,B E3D!N<#;(A]:Z&2[UB MP('3DBB/3-1N%A?4]6!K=F#-YAC;)(\S.[JS'.M9;> ]">V6V=M6:W4 "%M:O"F!T&TR MXP,#\JZ6B@ HHHH **** "BBB@ HHHH ***.@R: "BL!_$OVYV@\/6IU.0$A MKC?LM4/O+@[N>,(&([XIO_"/7FI?-KVK37"GK:61:V@'UVG>_ON?:?[HH MW M_B;1M,N?LMS?Q_:L9^S1 RS8]?+0%OTKR[[0[_"[^UH+3QC+J(T7[2]__:L\ M<23>3N,FV2=0RAOFPJD$= >E>N:?IEAI-O\ 9].LK>SASGR[>)44GUP!UK*_ MX03P?_T*FA_^"Z'_ .)H /\ A*6AYO\ P]KEFG=S;+< ?A TA_'&*TM,UG3= M9B:33;Z"Z5#AQ$X)0^C#JI]C5ZLS4O#^F:M(DUS;8NHQB.ZA8Q31^RR*0P'M MG![@T :=%<]L\0Z-RC_V[9@_Q- &E1110 45B7'C/PM:7,EM<^)='AGB8I)%)?1*R, M."""V01Z5+>:Y$JV\.F^7?7EW&)+:..0;2AZ2LPSMC_VN<] "2!0 FL7\XEC MTK364:CW#;[FX(P9&] /X5'15[#U.2="@ HHHH **** "BBB M@ HHJC>ZQ8:?9?;+BX'D%M@:-3(6;T 4$D\=!0!>HK,TW6DU2:1(;'48HT7/ MG75JT"MST ?#9[_=JI&_BNYG4O%H^GP!LGYY+IV7TQB,*>O.6Q[T 9OB6UCC MUPW%MJ.M)J%Y:)"]GIL-O+YD43.0S>=&P4 S,.6&P2]N+R2-[V_N/M-P(L[$;8D85<\D!(T M&3C)!.!G -6BBB@ HHHH **** "BBB@ HHHH **** "BBL_7M570M U#57@ MDG6S@>8Q1_>?:,X% &A17G2?$Z2U^'TWB;4-)$LGFR1VT.G3^?'LEO EFU]+]HVM#]I?9&%7;\^#RZC<7MW)IFD,!,AVW5WC*6H(S@=FDP1A>@R"W8-P7AWXI3>.2MG!92 M:1$9'6XO8YA(JQJ@8['94 ..I()48PISE=U+;1[HPVQ\0K+I+1O-::?I)*I+ M$N=S2.A9Y22&SA@&.00QH VI;RV\.)%IFGZ=>WUY*#*(H4+%R3S))*V%!)ZE MFR>P/2K+V%UK&D1PZLSV+-XQA<_*=X7:QQP#C.0>G-.CU*_F:()H=U&LD+2%IY8EV,,X1@K,3QQR+#KS",O?Z='F!ED5+-V(E.<,K&0?*./E*Y.# MR,\ %R_O[72]/GO[Z=(+6W0R2RN>%4=34Z.DL:R1LKHP#*RG((/0@UP7B-K\ M:QIEAJ=]JCV,=N;B>33M&DE1YU8^41M20 JA)7Y1MPB<#[/4 MM--N;S4DF2#RX)S?SDQN#N63;OP7#8.XC/&,XH Z*BN9T.QL]4TN&>;[?'=0 MPO8W,!U*X81N"1(.7^8Y)Q(?F*E2#C%:(\.Z3\W7ISP*P?$?A* MXNI-+_LRVCN+>VR)X;O5KB'>JY,8!"ODASOW8# HF#Q0!F>&O$&M M2L](NTA1XH80[P7*;_.:2%?W@)RB\(2?+S@9&>_L[N"_LXKNUD$D$J[D< C( M_&N0T/PMJ,&NW=U>0)8V<]J(Q'9ZY=3GS<;2Y#(@R4VC<6N,5K7WA2.\% MN4UC6;:2VC*120WK9R<_,V[(<\_Q9' XX% '045RD5OK>C:9-V.R46A;S9.=KAE MEV[>F5 YP>1G@ VZ*R@?$";,KIDO[AMYW21YEYQCAOE/RY[CGK0+G71MWZ78 M/FZ]?EX&0#5ID4T4Z%XI$D4,5)1@1D'!'U!!'X5R7B MGQ/JF@Z*L\]MIEE)07%PQ21>Y:-<1[CZA0: M +%WK&FV+R)C7MO8Q/&@B-M%YDL;<%CN?Y2/O ?)Z'VJAX@\'Q:YHNI637DK37R(ADO"T M\2;<Z7++JVCQPZ?,'1+329(F*;2C1@F MX8 %3CH<$*>PKJZ** "BBB@ HHIDTT5O"\TTB1Q("SN[ *H'RC&X9D *MC:,[00#UJBLRZ77)K.W-G-IUG=$9G$T3W* M*<=%(:,G![G&?04MA::M%#.NH:K%<22*!&T%H(1$>HZGM0!I45AV^A MZG'/%+-XKU68(P+1>1:JC@=CB'=@^S ^F*EU#0FU"[:U3?<3QQ M+@G,CA1QUZUY/%I/AW[9;_VY>:E/IZ3Q[#?:-?P[W+ 1B::7,>-Q7HL8)QV) M!ZZ[M[?Q?<1R66FV9MD&U=7N;5)'*]<6ZL#D?[9^7N _8 O:IXTT33;9Y$O( MKR51_J;617(Z1PZI?F\23+)I]I;R_8\ 9_> M2E<2\?WB%/'RG@UU&D:)I^A6AM]/MDB5CND?&7E;^\S=6/U^@XK0H PI_$*6 MD[VEOHFKSB$^6#!9[8^.REBH(]QQ5N^U*\MK:WDMM$O;R289:..2%##P/OEW M'_CN[I6E10!F6.HW]Q;7$EUHEU:21+E(FFA=IN#PI5\ ]OF('/6O._\ A(M9 M_L23Q UAX@34@[*J?:;8VGFAB!;>4)2>OR9*;\\]<"O5ZH'1-).J_P!JG2[( MZB!C[7]G3SL8Q]_&>G'6@"M?^*-(TN[>WU"YDM-@!,UQ;R)!T!_UI78>O][B MM.WN(+NW2XMIHYH9!N22-@RL/4$<&I:HZAI%GJ=M';SK*B1OOC-O.\+(W(R& M0@CJ: +U4=3T;3M8C1;^U28QG=%)RLD1]4<89#[J0:AL--O=-CG U6YOU*?N M([W9\C#/&]5#$'C[VX^YJO::WJ(N8K75-!NK:21@HGMG%S 3_O##J/=D4>] M$7]E^(-./_$NUF.\A XM]4BW-]!,F"/JRN?>C^T_$\?RR^&K5V_O6^IAD_-X MU/Z5LQW]G-=S6D5W ]S#CS85D!=,C(W+U'!!Y]:L4 >7Z/K6N6EO=:=>07>D MJ-0O)'DMM'O+V4B2YD?*,(1$!\PPWS@C!P,X'5> -'BT?P3HT?V1K>[DL+7,-O OWI)I BCZD\5Q5WJ\6M7][+'>ZE/:6_E?8H='F"^< MK)N,Y<$!EW!DY;;\AR,FNKFT'2+C4QJ5QIMM->@ +/+&'9 /[I/W?PQ3]1T7 M2M8\K^T],LK[R3F/[3;K+L/J-P./PH QO!FL:QK6BQW%_8^3&580W,LB%[@! MV"N43Y1E0K?*V#GCC!JS%IGB&6>.6]\1JBJP8PV%BD:L/[I,AD./<8/IBMT M 8 Z 4M &3J'AG2-5NC<:C:?;"0!Y5Q*\D/'_3(G9^G-:%K:6UC;);6EO% M;V\8PD4*!%4>P' J:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "JU_!<7.GW$%I=M9W#QE8KA45S$W9MK @X]#5FB@#@=+^'+VGA'Q%I$]_ MMUKC2&66VMRD46Y=H*Q[NN.3SU-6]1\ +?:D)UU 16T\=HE]!Y&XS_9G+QE6 MW?)DG# ALCT/-=G10!R.A^!DT;6XKW[<);6T^T_8;<0;3#Y\@DDW/N._!X7 M7 )SFN:^(W@WQ#J/B1_$6E#0YK2+26MIK?4Q(W(,I+J%7&0LA R>YXKU.J&N M_P#(OZESC_19>O\ N&@#D/AOX+U'PO#JG]M6FA":ZNVN86TU"!&&4*T8#(NU M1M& ,]37?444 %%%% !1110 4444 %%%% '/W?\ Q)?$L5^.++5&6WNO1)QQ M$_\ P(?NSZGRQ7055U+3[?5=-N+"Z4F&="C;3AAZ$'L0>0>Q -4O#VH3WNGM M!?%?[2LI#;7@48!< $.!V#J5<#L&QU!H UZ*** "BBB@ K-MM#L=.O+J]T^ M6\]RI\Q$=EB=_P"\4!V[O5@,GN36E10!A6&OS?;(]-UFQ>POY,B-E)DMYR/^ M>\EO-&UF2)I6+R6=\#/ Q[[>0\>?]EMH_NT ; M]%32':HM9!*,\]2N0.AZUE M^+=;U*/3+^TTG1]7GG0+OG@C5 (\@R%&9@2VS=MV@G=B@#K:*\XL9K6;4-+? MP*=/6ZD#'58Q<&>*--AQYI0D&7?MP20Q^;MNQVEA9ZH(KA=6U**Y,R[5%I;F MW$0YS@[V;/(YSVXQ0!>EN8+=HUFFCC:5MD8=P"[>@SU-95]KMS%>26>GZ)J% M]/'@,^T0P+D9_P!8Y&X[AFGG_ ._CDMCV MS6O0!E7=GJFHVEJO]H'2I,9N5M LI)X^57D7&.O.S)]JDTW1+738)8T>YN3- M_K9+RX>=G_[[)P/88'/2M&B@ Z# HHHH **** "BBB@ KG?'4BGP1K-F#FYO M;*>UM81R\TKQL%11U))_(9)X!K4U/5(M-BCS&\]S,VRWMHL;Y6]!G@ =23P! MR:@TW2Y([AM1U)TGU*1=N5_U=NG]R//('3+=6(R< !5 ..U2'Q'XFE@CU'PW MJ=O"NH6KQP&YM3;I$EQ&[O+MF+2,45OEVE1D D;J]&HHH **** "BBB@ HH MHH **** "BBB@#-U+P_H^L%6U'3+2Y=?N221 NA]5;JI]P:2YTJ31V<<4?E+#;JCA !@GRB^#C^]G' M>NGHH R=0\-:7JUT9[^*>XRH4PO=2^3C_KENV9]\9J_96-IIUI':6-K!:VT? MW(8(PB+WX4<#FIZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH *H:[_P B_J7./]%EZ_[AJ_5#7?\ MD7]2_P"O67I_N&@"_1110 4444 %%%% !1110 4444 %<_J__$FUFWUU>+64 M+::AZ!2?W4O_ %F*G_9D)/W!705'<0175M+;W$:R0RH4D1AD,I&"#[$4 24 M5A^'[B6V,VA7DK275@!Y PK%K)UF_M>236Y)D$3- MJ4<3C8"&VA%14 R 3\N20,DX&-RB@#)L/#&BZ5=K?P?HUQ/)-(EZ9)&+,5U&X49)R< /@?A6]10!F:AX>TK58X([^S6Y2!2L M:R,Q&#CJ,_-T'7-2:=HFDZ1;R6^FZ99V<,IS(EO L8M7Z* #H," MBBB@ HHHH **** "BBB@ HHHH **** "J6IZE'IL"$QO-/,_EP6\>-\S]<#/ ML"23P "3P*74M2ATRV$LBO)([;(8(AF29ST51Z\$^@ )) !-5M+TV9)VU+4B MCZE,NW"G*6Z=?+3/;IEN"Q )P H NF:9)!-)J%^ZS:E,NUW7[D*=?+CST4' MJ>K'D]@-2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **9--%;Q-+-(D<:#+.[ #W)I] !6?KO\ R+VI_P#7I+WQ_ :T M*H:[_P B_J7_ %ZR]O\ 8- %^BBB@ HHHH **** "BBB@ HHHH **** ,C7+ M"XF^SZCIZJ=2L26B4G F0_?B)[!@!@]F53VQ5[3K^#5+"&]MF)BE&0&&&4C@ MJP[,""".Q!%6:X?Q#-K&C>*+:/P[]G6._MY[N^CEMFGQY30KYD<:NA+D2C(! MY"\ MU .XHKFO#>LW]]JU[9W=_IU_#'9VUU!N1U(Q MQ72T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5 M/4M2@TRW66;>[.PCAAC&7F<]%4=SP?8 $D@ FHM3U>+3O+A6-[F]FSY%K%R[ M^I/95'&6. ..Y ,>G:7*EP=1U.1)]2==HV9\NW4_P1@]NF6ZL0"< *J@!IVG M3FY_M/4RCW[J51$.4MD/\">I.!N;JQ'8 :M%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ><_&2WMI_"MN;G4(+4 MQW!>*.\B9K:X?RV^20CA>,E23U QDURD]];?;]"U5].TDRQZ78Q6>@ZA!+<7 M#!ICDP.^!N P0P#D;>0O4^W2Q1SQ-%+&LD;##*XR"/<4^@#R/P3YW_";VOW/ M[47^TQKFS[^?M \CS,?[/W,_PYQQ7HOB)[L:-?"*"%X3:R>8[3,K+\ISA0IS M^8K7JAKO_(OZE_UZR]/]PT 7Z*** "BBB@ HHHH **** "BBB@ HHHH *Q]6 MT$ZGJ-I?P:K?:==6L4L*O:"$[DD,98$21N.L2],=ZV** .1M?!,VF:E>:MIW MB"]_M.[""9[F" Q2A"Q =(HX]WWC\P(;ISC(-W^W=5L,KJV@7#*O_+SIK"YC M/_ .) ?8(P]S70T4 <]_PF^@*<274\+=TFLIHV'U5D!'Y4#QOX?;A+R61NRQ MVDSL?H I)KH:* .>_P"$OMY/^/72-=N<],:9+#G\90@H.O:R_P#J?"&I =C/ MUZQ,M[ M9Q/+%/"I*M9SWL>CZYH,MGIWBY&DO7BGBNKN MXN%E7[-,=H5Y64D,JMD?W"0?7J_^$K/_ $+^N_\ @(/_ (J@#H:*Y[_A*S_T M+^N_^ @_^*H'BBX?_4^&-=D_[911\_\ Y%H Z&BN>_MCQ%.<6_A9H?0WU_% M&/Q\KS/ZT"S\57HQ=:K8:=&>JV%L991]))3M_.,T /\ &UZVG>!-?NX[DVTT M>G3M%*'VLLGEMMVGUSC'O7':NFVWM;KPVVNQJ-0LX_[1OM3O&AP]Q&GRPR2? MO@0V#D!2"2&)Q78Q>#]')\R_A?59B"#+J3FXZC!VJWRID$@A5 YIT'@SPK:W M$5Q;^&=&AGBDO;/\!H T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "J]]86>IV+?!5W MXIUG39I-3B73;::.9K=[8&2-D).Z*08(+?*"&STR/0@$NB>.4UC7(;+[$L5K M>"Z-C<"?01R;DVC9DG*X+9 YQTK?UW_ )%_4O\ KUEZ?[AK T3P,FCZ MY'>_;A+:VAN?L-L(-IA^T2"23<^X[\'AZLK>=U& TL2 ML0/Q% %FBL\Z%HYZZ58G_MW3_"C^P='_ .@38?\ @,G^% &A16?_ &#H_P#T M";#_ ,!D_P *3^P-&_Z!-A_X#)_A0!HT5G_V#H__ $";#_P&3_"C^P='_P"@ M38?^ R?X4 6[JX2TM)KF7/EPQM(VT9. ,G%2UG_V#HXZ:38?^ R?X4?V#HYZ MZ38?^ R?X4 :%%9_]@Z/_P! FP_\!D_PH_L'1_\ H$V'_@,G^% &A16=_8&C M?] FP_\ 9/\*7^P='_Z!-A_X#)_A0!H45G_ -@Z/_T";#_P&3_"C^P=''32 M;#_P&3_"@"W:W"7=I#X2ZB:2/.T2/&.G^CI_A0!H45G?V!HW_0)L/_ 9 M/\*7^P='_P"@38?^ R?X4 :%%9_]@Z/_ - FP_\ 9/\*3^P-&_Z!-A_X#)_ MA0!HT5G_ -@Z/_T";#_P&3_"C^P='_Z!-A_X#)_A0!;AN$FEGC3.Z"01OD=] MJMQ^#"I:S_[!T?\ Z!-C_P" Z?X4?V#H_P#T";#_ ,!D_P * -"BL[^P-&_Z M!-A_X#)_A2_V#H__ $";#_P&3_"@#0HK/_L'1_\ H$V'_@,G^%)_8&C?] FP M_P# 9/\ "@#1J);A&NY+89\R.-9&XXPQ8#_T$U4_L'1_^@38?^ R?X4?V#H^ M,?V38_\ @.G^% &A16?_ &#H_P#T";#_ ,!D_P *3^P-&_Z!-A_X#)_A0!HT M5G_V#H__ $";#_P&3_"C^P='_P"@38?^ R?X4 :%%9W]@:-_T";#_P !D_PI M?[!T?_H$V'_@,G^% %M;A&NY+89\R.-9&XXPQ8#_ -!-2UG_ -@Z/C']DV/_ M (#I_A1_8.C_ /0)L/\ P&3_ H T**SO[ T;_H$V'_@,G^%+_8.C_\ 0)L/ M_ 9/\* -"BL_^P='_P"@38?^ R?X4G]@:-_T";#_ ,!D_P * -&HFN$6[CMC MGS)(VD7CC"E0?_0A53^P='_Z!-A_X#)_A1_8.CXQ_9-C_P" Z?X4 :%%9_\ M8.C_ /0)L/\ P&3_ H_L'1_^@38?^ R?X4 :%%9W]@:-_T";#_P&3_"E_L' M1_\ H$V'_@,G^% &A16?_8.C_P#0)L/_ &3_"D_L#1O^@38?^ R?X4 7)KA M(98(WSNGD,:8'?:S<_@IJ6L_^P='_P"@38\]?]'3_"C^P='_ .@38?\ @,G^ M% &A16?_ &#H_P#T";#_ ,!D_P *3^P-&_Z!-A_X#)_A0!HT5G_V#H__ $"; M#_P&3_"C^P='_P"@38?^ R?X4 :%17%PEK$LDF=ID2,8&>68*/U(JG_8&C?] M FP_\!D_PI?[!T?_ *!-CSU_T=/\* -"BL_^P='/72;#_P !D_PH_L'1_P#H M$V'_ (#)_A0!H45G_P!@Z/\ ] FP_P# 9/\ "D_L#1O^@38?^ R?X4 :-%9_ M]@Z/_P! FP_\!D_PH_L'1_\ H$V'_@,G^% %NZN$M+2:YESY<,;2-M&3@#)Q M4M9_]@Z..FDV'_@,G^%:% !1110 4444 %%%% !1110 4444 %%%% !1110 M5PWBV?6[;QQX3,6I"'2)KWR7M8E(>9_*D)+MGE1A<+C&22>@KN:AFM+:YDAD MGMXI7@?S(6D0,8VP1N4GH<$C(]30!YT][<67B+7-0TK4M2O;#3K6Y%\]S*-!>/Q+>WC//_9]W";WSE\X6_RHT.0% M'RF1G.Y\D=FRO7Q>%/#D%V]U#H&E1W+DEIDLXP[$G)R0,GGFK0T?3!JIU4:; M9C42NTW?D+YQ&,8WXSC''6@#SK2;[7Q:^+;'4]6DN=2DU6"SBEMRT:0>:D>1 M$,DJJ!B?4[L:_H_C;Q9)?S3ZJL&G0W%GIUE$Y5 9)%10HR2Q !9L9 MY/917?#3;!9GF6RMA+)*)G<1+N:0#:')QRP'&>N.*D6TMEO'O%MXA=2((WF" M#>R@DA2W4@$GCW- '$_"_5KS4[37EO[N\NKB'591YES!+$ I"_*H<#: <_)U M7C(&>>\J&WL[:T,IMK:&$S2&67RT"[W/5FQU)]34U '/^.=1O-)\#:U?Z>66 M[@M'>-U4,4./O 'CCK^%W6,*6QN(P.,X&? M7 H \KO=0N=)N[G3+/Q!J%[9WDNF,+DWS38MI9BDDHF!'ELYR-J * RG).W M8\/:CK>HK'I]I>NT]G<:F89KF1G5TBD,,*RD'+C+GJ23Y6>M=Q!X=T2UM+FT MM]&T^&VNO^/B&.U14F_WU PWXU9M=.LK%8UM+.WMQ'&(D$42IM035Z**."%(88UCCC4*B(,!0. .PH ?7'_$Z768/ M6IW&C:@MA)# \LTX4F3RU4G$9!&UB<#=V!)'.*["HKFV@O+:2VNH8YX)5*21 M2H&5U/4$'@B@#@->-S=:GH-OI>JZFVN3QV\OD1W+""WMT<-+-*@P&W#*#?NR M< 8)JGXBFDN_#VJ:LGB.\L[J.2ZNK:VBOO*Q!&RQF4("#)@1EE0D(6DPV,Y M'=W7AC0+Z[CN[S0],N+F,*J336D;NH7[H!(R,=O2I+G0=&O8[>.[TFPG2U.Z M!9;9&$1]5!'RG@=* ./.I:NGQ.TN6ZU0_P!BW.E3SP6BH4VA1$2\O.&?+'MA M0..IJA+<^(X]3\"W,NJR1Z??W1>6T!;S)'E267;(V>40;5"]/7[JUZ//I]E= M3+-<6EO+*L;1!Y(@S!&QN7)'0X&1WQ3I+&TF-N9;6!S;-O@+1@^4V",K_=." M1QV- 'GOA?4KI/&;+J7FSG5;B^:REBUI[B...)P C0 ^6G'<$D'(.TG%>DU2 MMM&TNROY[^UTVS@O+C/G7$4"K)+DY.Y@,GGGFKM !7CVD^*-2M+VYU'4FOVN M+N+4_(B6^+Q%H)=JHUN5Q$1\JJR-\Q)WD?;+B\_LNR^U7( GF^ MSIOEP01N;&6P0,9]!0!P.HM/H.L:3<6WB*^OYPYL;B#[9YP,ZVQ*1M#D!02I MD9SE\X'1LC*T'6M4ELQ:)J=[.VJZ/ITS2/JC1],&JG51IMF-1*[3=^0OG$8QC?C.,<=:2VT72K,L;73+* O-]H;RK=5W2 M_P!\X'WN3SUYH \UUG5_$^D:QX[DEU0S26^CI\7%^UZ@WQ(P\N5U5B,')4YP3P<&NJ^Q6@NI+ MH6L/VB5!')+Y8WN@SA2>I R>/IPH MSP* +=5[X79L+@6#0K>&-A TX)0/C@L!R1GTJQ10!Y1IE_)_PKIYM?US5[F[ MAUBY@3[%.T,U_*)71(EVG< 3R%1@ !UV@UJVL5_+;6NE^(-?N+.>TTRVANIX M;SR?.N99,A-_][$07VPMKK1=.G@$K3"*6U1E$C'+-@C M&XDG)ZG-/&@Z,NGR:>NDV LI %>V%LGEL!T!7&"!0!Y?>:CXA7P-ILEKKDJ1 MV>LBTOG)9Y9F%VJ"-)MV6C )&\_,X49 RPK8\<7>O2>'_%U]H^JM81V:B$OR M6"1Q&1S%SA79I A;J I(Y KO1I&FKI\6GC3K06414QVXA7RT*G*D+C P>1Z& MGOI]E+:SVLEI;O;W&[SHFB!23=][<,8.>^>M 'EVMZWJM52GT?3+JXM;BXTVSFGLSFVDD@5F@ MZ?<)&5Z#IZ5=H *\K_MZ^@^(-Q=:E+?)91:S_9T(AOBJ*OV;> ]MM*NAY.G)H \ZOIYH-, MT?6Y/$.H)=K-:S7=FEX288IYBP7R 1O+;Q'\YPJJ2HRN#1T[Q/JMK=+J,MU< MS3W5OJ[W5J\[,B/!.$A5$)(0C(7Y0,[LG->IRZ+I4][;WLVF64EW; +!.]NI M>(#H%8C*CZ4#1=*%S<9;! QGI0!Q4$>O67Q+T? M3+_69)]-?29DC@1F4L4$0:61LY:0LS<]@!CDFKG@*W:>\UK5H[W4'T][I[.R M@N;Z:X4)"Q5I/WK,=S.&Z= H]Z[%K.V>\CO'MH6NHD9(YB@+HIQD!NH!P,CV M%%K9VUC;BWL[:&WA!+".% B@DDDX'&222?7:3> M7J:=XU7Q;XDN46SOHS+Q7$5UI5C/'JD 8(.3Q0!YCJE MSKMGX(\8VFEZ]<1S:7.[O/-*]R\HO)M:U W$ M6D:C]DGM=(BS/,#(@>5LL^W.&=4CR,]WYX)KJ(-$TFUTR33+?2[*'3Y 0]K' M;HL3 ]L11B&&.(,[!%"AG8LQQW)/4^ M]5H])TZ%;-8M/M46RS]E"PJ/(R-IV=,8YGDB#%6W8QSNQU!SS7KUWHFD MZA:M:WNEV5S;M(9FBFMT="Y_B((QNY//7FG/I&F27-K_8EUG^S_+$S!=WV;=Y7D;MACS\_G?>SQMQ\U>D/IEA):):2 M6-L]M&RLD+1*44JZ-S +A)!G MX\/:?976J7-W?RZ]<_,P&6Y]:?!IMA;,K6]E;1,K.ZF.)5(9SESP.K'DGOWH \H_ MM+7[?2_$]IJFMS3:@=YFMKVYMW::0R;2LK#8LA),BKT#MR0.0#P-V72--GBNXI=.M)([P@W M2O"I$Y RXQ\W Y]!4MG96NGVD=I96T-M;1C"0P1A$4=>%' H GKE/B%>ZA M9^&8QIQ=9;F^MK9W24Q$))*JM\XY3.=NX E=V1R*ZNHKFV@O+:2VNH8YX)5* M212H&5U/4$'@B@#S?2=4^W6,.GS:OJ.FPV+ZA]NNY;\2&+8WE "=U&] 9"59 MP2/+YY%9J7EY%J\7AJ75]2:S.LR13RB^D+)']D,L4:W&X2-D@.>1@DJ,@9/J M4.CZ7;6WV:#3;.*#RC!Y4<"JOEDDE, 8VY)XZ/N#'R] M!TQTH L:=+--IEI+< "=X4:0 8 8J,_K5FBB@#AO%L^MVWCCPF8M2$.D37OD MO:Q*0\S^5(27;/*C"X7&,DD]!6:][<67B/7-1TK4M2O;#3K6Y%\]SWBE>!_,A:1 QC;!&Y2>AP2,CU-9T7 MA3PY!=O=0Z!I4=RY):9+.,.Q)R2:]%&CZ8-5.JC3;,:B5VF[\A?.(QC&_&<8XZT\:;8+,\RV5 ML)9)1,[B)=S2 ;0Y..6 XSUQQ0!YK?W'BB/Q!XVMG\00PRKI,3W&O6DXO5MK2YB6WCO;H7,L>Z%&93*&?<,G6>+R9G:)2TD?/R,<#QR:+#3K'2K1;33K*WL[ M922L-O$L: GKPH H LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 454U&\GLK8 M2V^FW6H.6"^3;-$K >O[QT7'XYYZ5E?\)#JG_0F:Y_W^LO\ Y(H Z"BO.%U; MQ-JVLZSY=MXJM(;6Z2".VL_[*Q$/(B%M M(N[CPMK%U-/90RR7$4EFJRLR EP#." 2<@$#KT% '9T5B6VN:C/%-8M MT=@K32RVA5!ZG;.6P/8$^U<[\3=92VM]*T5=;&C3:G.^;TW/D>5'&A>-XYU*]\%>$M4TG[%]KUJ\ALIFN(VDCB9E<2$!64G#(<<\^ MVTE:VTJY00>7N F,Q9HRK,I!0'*[A\QP<@'IE M%>6:+\1]:EM8[K5QI$4-QH,NJQLL)I(H<2736:6ZRCO8 'J=%>3ZM\3=;L+^9[6"RNM.8WT<,J6LB MJLEO$[@;VD!D^X-VV-5&2 Y(-7_^$J\7_:] L_/T,3:MITM^S_8I=L 1$8)C MSLMRQ&[Y>QQQ@@'I-%>8:9\1=7-G:WFJ_P!DQ07NA2ZI$525%@="HVNGZ,\=E_:D\$]P\]O87-Y&RH0$ BC.]2VX9))"X MQELBLW4/B5KEO8ZI[M+AUN_- #$7$>Y(W#<;77GKD Y !Z/17.>/KF>S^'^OW-K/)!<16,KQR MQ.59&"G!!'(-(]5M]+738[+2[F&WDBNXY/,GW(KNPD4X3 88&QLXZC/ M'84 %%%% !11534+N>RMQ+;Z==7[E@OE6S1!@/7]XZ#'XYYZ4 6Z*RIM6O8O MM.SP]J4WDR!$V26P\X'.67=*, 8&=VT\C /.,+Q-XCU^*<:;H.AW3ZB'\X&1 MH-DL"'YB/WORAF*)\V&PS, Q4B@#LJ*P+3Q+-J&F_;[/P_JDT+;#%M>V!E5@ M<6Y=5O(S[*YPQ"LY7CJ!R*QH_%$D M'PJ,UQK+I-J.KS6,-])=$&)&N6&X2$Y 6,,0<\8% 'K=%>;:;J6K^)_A5>6^ MAZD+O6+&=[(W$5R%-R(I!R)1G#218._/5LY'6LLZ@E]9Z'I]O?\ B.U=_$0M MK^SO+V5;BWS$[&'S5(=H^ RG%=&\=QRWEQ<6^CRJ+ M"6ZF,C@RQ*RQF1CN;#OP6)."!G@55T;Q=<:?X!\6P6>L1ZS?: C/!>^?]H\Q M'CWJS/D[MK>8.>R8H ]6HKSCS/\ A'=6\+"PUV]OYKVX6TU&&YOFN!*'A9Q) MM9CY9!7(V!003VQC1N%F\0_$'5-'N[V^MK&PT^"2"*SNY+=G>5GW2%HV!.-@ M !..O!ZT =M17(:IJFKV&K:5X9TBY@DO'LI;F6^U2,R[DCVJ!MC*9=F89.0 M >#FN2?XGZ_?V5U?Z9;Z9;06VA)JS1W44DK,V]U:,,KJ,';D-C\#G@ ]&,]=HZ5:;QMKR:T_ADK MIQU?^TTLTO1!(+?RVA,Q8Q[]VX*"NT/U.21T(!Z-17 -XR\03^&%NK/38Y+V MWU9M.OI8;62Y2-4N*PK7QOJNJV?BBYM;NS6ZL=#,Z7$ M N"@E1Y@W[F4J$;]WW7(/4N * /7**\F'CSQ%8VEI86T(U&]M-)MKR;9IMS. M]XTF2$#1LWE':O+ON#,JP2^?;Q3;'3S$#;'&&7(S@CL: )**** "BB MLS4M4O+&=([?0=1U%67<9+62W55.>A\R5#GZ#'/6@#3HK-AU.[ETR:[?0M0A MFC;"V;O;F63IRI$I3'/=AT/MGD9?%GB6ZO-4N+;2)+"PTO>)EO$@? TX8?B :UE MNIF-IFPN5\]=TF6C_P!'.,X?#K45Y]XSN-2U+3M%UO2EU2[T%H'FNX=)NS;W.UT M!CE3!!?;\WR9Y)'!QQ0MA#XH\5-!#K^LRZ=_PCD$]M<17TUNQ=GD7S66,J"Y M !.5[=* /4**\BU+Q;=:C\/?"5M?:Z-(U'6E+3:@;@6Q58D9B^X$ ;F$8QT. M[%:DOBBY\3>&?!+07-''*[GC*Y!SC.* /2:*XGPS M?>1XVU31;/4IM0TG[##>P--TBMQ<[#&8/-)(P=H_=XY!R!0![;17F[^+=3A\4ZEHUBEN MMU)!I5X M4A9XYBA;++\X(0[.5R3SC=P<@'J%%>37/Q6U:VAO-571Y+K2X9;J(PPZ=?3_-MV1GF0.C M LV5P<;@W()!6@#TJBO-?^$V\1DK8 :5]O'B(Z,UP;>3RBGD^8)!'YF0>G&X MCCJ,Y$]EXXUC4?#GAYHH;&+5M7OYK,R/&[01")I-[[-P8DB/A=W4]>.0#T.B MO(+KX@W\&K1:E=*Q_LRRU2.ZM;>5E@N)H'C4. 2>#GODKDC)QSNS^.-7T.WU MF+68;&ZO++2%U2)[-'BC8-E?+969CPP^]D9!Z#'(!Z%17F;^-O$VFSZLNI#2 M)HM+&GW%Q);02)^XG9A*<&0X* 9'J!G'.!V'A/5[O7M#_M*ZCAC6:XF%N(@> M85D94)R3DD#.1QSTH W**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@#'OO"?AO4[R2\O_ _I5W=28WS3V4*WMXHX8( MD"1QQJ%5% P . .U244 %47TBPDUN+67@W7\4#6TH[&K&C^%='T&\N+O3[>5+FXC2.:66ZEF9U3.T$NQZ9P/; Z M 5LT4 4M.TFQTE;E;&'RA=7#W4WSLVZ5SEFY)QGT'%4X/"FB6UU;W,-EMFMK MJ:\B;S7.V64$2-R>!V K9HH Y:?X<^%;B9I9=-=BSRR!/M!_#TEG!:_8I46%Y'66*[FCF+ M2?ZPM*KAVW?Q;F.<#/05'J/@#PQJL<<5UIG[I+5;,1PSR0H85.51E1@& /(S MG!Y'-=+10!@WG@W0;_4)[ZXLY&GN#$TVVYE5)#$08V*!@I*E1@XSCCH31_PA MF@?VHVHFPS,TS7!C::0P^:R[6D\DMY>\@G+;<\YZUO44 U>RP]Y.VV!\9C7+_*O' &,'Y;\7C6#>9NC9D6XD6*1H_N,\8; M8[+@8+ G@>@K?HH PK3PGIT&@7^C3(9K._FGDGCRR B5BS*"#D=<=?RZ4M]X M0T+4AA:S.L^J:+IU],B[%DNK5)6"YS@%@3C)/'O6G1 M0!!96-IIMI':6-K!:VT>=D,$81%RGB*/2Y9)K-!*Y$3R9W'!;G[QQG. M,\8K>HH Q+CPCH=V-1$UCN_M&9)[G$KC=(@ 5UP?D88'*X/%5V\"^'GM%MC: MW.%N_MHE%].)C/MV[S+OWD[>.6KHZ* ,-?!^A#3TLC9,\"7:WI\R>1WDG4Y# MR.6+2'@?>)X '0"KAT/33J]QJAM5:\N;<6LSEB5DB!)"E<[3U/.,\XK0HH Y M:V^'?ANQUJSUBSM9X;ZS&VWD^U22"./!!C5'9E5,,1A0,9XQ6EJWAK2M;G2X MO(9A.D;0B6VNI;=S&Q!*,T;*67(S@Y%:]% &)>^$-"OK.RM)+#RHK%2EM]EE M>W:)2-K*K1E6"D=1G![TV3P9X?D6Y0Z:BI MMVB@#DO$O@'3=?L+B&(BUGN?LR33$-(&C@?>J;2P'J,CGGO5[_A"M -@UF;. M0JUR+LS&ZE,_G#&)!-N\P-@8R&Z<=.*WZ* ,23PCH="8YG M26.3))<2JP?>"O#VGI>+;:')8+>"2SG>."+R &O9SYD6[<(Y#OS(@/17W #@#'%=( M %4*H & !VI:* "BBB@ HHHH *S+SP]H^H7Z7MWIT$URF,2,O7!RN>S8/3. M<=JTZ* "BBB@##U#P?H.J6^J07NGB:/57C>\#2O^\9 IX/RX"C[N*MPZ%ID M&HWFH1VH%U>0I!.Y=FW1H"%4 G ')Z 9[YK1HH YQ_ OAYK&QLQ9S116,306 M[0WDTW'D+G"$1NH(Y/7U MKI** ,V+P_I4&I6NH0V4<=Q:6OV.W*$A8H<@[50':.@Y S@8Z56_X1+0AI<^ MF_8!]DFN6NV3S7RLS-N+HVF:B_X0/P[Y[RFTN&62Y-V\#WT[0-*6W;C"7\LG=S M]VNDHH P[KPAH5X;IIK$^9=7*7%-$%S]H^Q?O?M_]I;O-?_CXV;-^,X^[QCI[9IA\ M'Z$=&ATG["5M()S*4N7+I(&WJ=S'D$=2.G%;E% &''X.\/Q" +ID1 M$$$MNH=F<,DI!D#@D[RQ )+9).>>34<'@_2=/TJ_L].MD5KRW\AWO'DN@4"E M51M[[C& 3\@8#DXQFN@HH \_M/AM+::+KUI'JEO]JUBW2TDE>UED2.%590 L MD[.6PYP2Y PH P,5VNEZ=!I&DV>FVP/D6D*0QYQG:H &<=^*MT4 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %(S*BEF(50,DD\ 4M5M0 ML8M2T^XLI_\ 53H48@ D9[C((S]10!#+KFD075K:S:K8QW%V ;:)[A \P/0H M")0VW_CXEW7 M&4W-P3@JN"> 5' Q0!TO_"1:&=*.JC6=/_LX-M-W]J3RN:X++'4AX@&E:B-+&JB8P_8)/.Q]C,/F>3 MM\S&XA?NYP,_=YK3CM-3L?A_HMK#%<0W<3V:O%%G=&GFIN4[>RKD'M@'M0!V M%%>=Z98:W9Z698Y=8DN!I=G?,ES<2N9+E&=I8_G)VEP I0 9'%5?$$/B.6Q MTZ;[3JMM'=)/G=!DTR&:*XA2 M:&1)8I%#(Z,"K ]"".HKSB2+7/\ A-ECE;5[F*YS'*@%Q;QQ*80-P96>W*YW M' ,<@;&"W0YEG::[%'X?@MI]9L[>&SM5AC^Q7Y@CN([=YHUFE!,<9>Z/!=/XWLIKJ+66O8OMHNY+ MB.4VJ@NOEB-F_=@%0,"/J!\_S54F37MNK?9SKPO_ +-?_:2QE\K._P#T;R,_ M)NV]/*YZ[_FQ0!Z;5"ZUS2+&S^V7>JV-O:B0Q>?-<(B;P2"NXG&X$$$=<@UF MZ%I\MM)K6GRO?M9>>OV=KFYED?8T*;MLCL6QNW=^"3C%8,$O_",>'((;?0IC M<#4[Y;/9ITLR6:-/*1(5B4L%V$8"XW;@,@$L #LI]9TNUMDN;C4K.&W>+SEE MDG55:/CY@2<%?F7GIR/6GIJ5A)917L=[;/:3%1%.LJE'+$*NULX.20!CJ37' M:?:VMK&UT=.U";3]/M8+>U9[!O/WL^^29864'@^6<*N04.%X J,Z.UUX5M7> MRN9Y(-9BN+9YX665E:\1WF>,@;7(+D_*NT$X"@D4 =O-?V=MYWGW<$7D1>=- MOD"^7'S\[9Z+P>3QP:DEN(8!&99HXQ(X1-[ ;F/0#U)]*XK7M&?6?#OC">YT M^666:.6*T@*,6<11%4^7^+,A=U&#U4CD"CQ3IVOW/B#1[JWLK6ZL+6X@,2FY MD1XWW'>[*(F!&, '/ W?WN #M3/"+A;1 ;FW!RR'Y3L\SGJ%W8[U+#;ZC%X)U:T274EN M(Y+N*VE):6X">8_EE2[!GPN,$MD@#![T =0\T43QI)*B-*VV-68 NV"<#U. M3] :?7E>EV^I3G2Y+NWU>1;/6&\BX+7H#!H'"L8Y1YJ)O"9\PN@+,-VTD5/8 MKK1T>Y,?_"0E3;6@U#[09A-YWF?Z3Y&[YO\ 5Y_U7R]/+RU 'I)GA%PMN98Q M.R%UCW#<5! ) ZX!(Y]Q4E>:2PWGV_3[O38?$,FDPQW*S_:UF^U-$9(RHP7@J:U/$2ZF?$_[C^U_,VVO]G_ &4RBWR)6,_F[?W?W-N?,[?< M^:@#LYYX;6"2>XECAAC4L\DC!54#N2> *DKBULM1@\&^(+E)-5?5)S>>4KSR MLXVR2"(1(3A/EVX*CD8Y/%9K6?B"WBN+FTDUAKRYAU)9 \TCJI68>28T<[$; M9G9@#/?- 'H,=S!--+#%-&\L) E17!*$C(##MD<\U+7DLUM?A-0DT@Z];:9- MJ,1FGNK6]DG:,6^,A0Z7+*) HR&S]4XJ^JZ\K:6=^NRV:06YUARLL4KC/[OR MDRYW#@RA&R5X)+9% 'H\\\-K!)/<2QPPQJ6>21@JJ!W)/ %25AZ[=R7OA'5Y M-):X:Y6&>*+R4=9/-3U.P-2=!DUY=J M5M6\KHU_Y^])/LDP_=F;$H^8IR2%W$;3G<*O7%]?:A=W%U/% MXABT-M07<((+F*W$ZK++;E<1W1(9HR-IW"+., M<[<\$ I?7&L6^GZ7)?RZ['<9=L_G[?EW%2G^LZY.SYLT >IU M'-/#;JK3RQQ*SJBEV"@LQPH&>Y) K"U:RNKSQ1IY62^2VAM)Y<0SR11M,'B M\L/M(#<;_E/!&<@BN+T2/Q.ME(T]UJ\MT9;/[3&]I<1!)?.'F[6DF<,,;MWE M!8MN,<<4 >JT5YWIEAK=GI9ECEUB2<:79WS)0=PY% 'IW M09-,AFBN(4FAD26*10R.C JP/0@CJ*\X>+7/^$W6.5M7N8;G,4R 7%O'$AA M+!E9[=ESN; ,<@;&"1P:FF:3J+Z7IRQ/XAMHX+738A%Y]S%M9IG6YRK8)PO< MYVC:5P #0!ZK3)IHK>%YII$BBC4L[NP"J!U))Z"O*VM_$ZZK:1->:Q#!%*4L M\6US<%L74@/F.)E7'E^5\TX8%>5RS0!Z?U&159M0LEU!-/:\MQ>NAD6V,J^8R#JP7.2/>N.\ M4+=-!8"S_MW[)_9THM?L9N!)]JPGD^=CY^F[_6_+G._G%:%EIEU%XLU;4=MP M+J73+9%:2:0P-+F7< N=G!"]!QN/3<<@'0RZA903^1->6\IXJ6:>&W56GECB5G5%+L%!9CA0,]R2 !7EVGVM])?>;!'XC$SV]A%>S M7:SJWF?:X(&,J MZD9// ;GK0!W0N8#=&U$T9N%02&+>-X4G ;'7&0>:EKR-;?5S%>7&G)X@CNC MI]I'>S7L$[N'$Q,XCY5FPI)Q"P'/[O!JZ-.UNZT55:]UZ016%_+;.@N;1S*& M3R=RF1I&/W]JRL20>1Q0!Z5-U2UYO?17 M]SXGM7N(-;>^34DEB$42#DA]Q_N5/X#GU2RGOXM2&K7$" MI !HS:1X9U/4;<(9K6UDF02*64LJDC(!!(]@ M16I534]/BU72[K3YV=8;F)HG:,X8!A@X/K0!RX\6SZ9I:ZCJUUYT'FR!MFBS MV3[4A>0_+/)G^'[V,=1ZD7K;QI;7FDPWUOIM]*]QVC:%VG;:7)1UD,3 M*%#$MOP-I'WABM/5M%@UA;;SI[F%[=V>.2WD\M@S(R9R.> Y/'?U&161;>!; M*UAG:'4+Y+Z6[^V&_1($E$NTJ3M6,1G*LP.4).[)Y ( $O/'FG:?=:9;WMG> MVTFH,B*MP(XC&S/LVE6<%R&//EAP!@YP03;MO$8CT5=0OX\*VH269:%?E0?: M&B1CD].%R1GKG&.E.X\"6MS,LKZOJNXK;^?F2-C<-#*949V*%OO$_*I5<=D7:S,QW(I/!,YR*DE\(6[6=A#;:CJ%C-:6[6WVFT=%DD1L;PVY6&6*AM MP 8'D$9-,?P7:-K0U%=0U! +H7GV96C\LS>3Y.XDIO.4]6//3% #O^$SL8_" MG_"1W=K=65DPC,(NFB1I@^W81\^U02P'SE<8).!S5)?B+IL^FQWUG87UZABG MFE6U:"3R4A*B0LPDVMC1@]P1Q5<^%;>2!DNM0U"ZD>UN+5YII%+LLQ4L>% 4C: H [4 5- M1\7/'JUI9V-E-) U\MK/>N@,()C9RJX8-N'R\E=O49SQ1I'C:WU&2QB:RO0M MQLB-ZT<<\ MY3=RO8,%SSC/-2:?X0T_38+:&&6Y9;>X2X7>R\LD A&<*.-HR??GVH =HGBB MWURX,,5C>V^Z!;J)[A%"S0L<*Z[6/!P>&PP[@9&.2$!W5'+F1@_* $;5^]G/&"[PCX:U+1[Z:YU"51&MLEI:6ZW?V@0Q* M6(4-Y49P,@#(9N.6/&+EGX0@MKF-Y=3U"ZM89I;B&SF,0BCDYCB@O BB--\"2JLGS[MQW'D+@94$@]=@>& M[-;W[5YMP7%T;K!<$;C!Y&.F2-OJ*ZL4CLY,"2=;FU>Z>)=I)410MEWS@?*V.I&:JVGA"W MM;9;9M4U.>WB>!K>*:52L"PN'1% 49&0 2VYB !NK4U/3I-0BC6'4;VPEC?< MLUHR9Z$$%75E8<]U..",&@#%C\1ZC*WA GRAPHIC 10 gbcvmkcqbvay000002.jpg GRAPHIC begin 644 gbcvmkcqbvay000002.jpg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end GRAPHIC 11 gbcvmkcqbvay000001.jpg GRAPHIC begin 644 gbcvmkcqbvay000001.jpg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end EX-101.SCH 12 arna-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Equity link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - The Company and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Fair Value Disclosures link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Investments, Available-for-Sale link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Sale of Manufacturing Operations link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Collaborations and License Agreements link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Legal Proceedings link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Quarterly Financial Data (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Beacon Discovery, Inc. link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Fair Value Disclosures (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Investments, Available-for-Sale (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Sale of Manufacturing Operations (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Collaborations and License Agreements (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - The Company and Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - The Company and Summary of Significant Accounting Policies - Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - The Company and Summary of Significant Accounting Policies - Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - The Company and Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded From Calculation of Diluted Income (Loss) Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Investments, Available-for-Sale - Schedule of Investments, Available-for-Sale (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Balance Sheet Details - Land, Property and Equipment, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Balance Sheet Details - Accounts Payable and Other Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Sale of Manufacturing Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Sale of Manufacturing Operations - Summary of Discontinued Operations for Consolidated Statements of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Leases - Future Minimum Lease Payments (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Leases - Expected Minimum Rental Payments to be Received under Sublease (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stockholders' Equity - Weighted-Average Assumptions and Estimated Fair Value of Stock Options (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Stockholders' Equity - Share Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Stockholders' Equity - Total Unrecognized Estimated Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Collaborations and License Agreements - Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Collaborations and License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Income Taxes - Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Income Taxes - Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Legal Proceedings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Quarterly Financial Data (Unaudited) (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Beacon Discovery, Inc. - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 13 arna-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 14 arna-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 15 arna-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Voluntary Filers Entity Voluntary Filers Entity Public Float Entity Public Float Document Annual Report Document Annual Report Document Transition Report Document Transition Report Entity Address, Postal Zip Code Entity Address Postal Zip Code Entity Tax Identification Number Entity Tax Identification Number Local Phone Number Local Phone Number City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Shell Company Entity Shell Company Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Carrying value as of the balance sheet date of obligations incurred and payable related to clinical and preclinical study fees due within one year. The sale and leaseback financing obligations due within one year or the normal operating cycle, if longer, accounted for under the financing method. The sale and leaseback financing obligations due after one year from the balance sheet or beyond the normal operating cycle, if longer, accounted for under the financing method. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments, available-for-sale Available For Sale Securities Debt Securities Current Accounts receivable Accounts Receivable Net Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Investments, available-for-sale Available For Sale Securities Debt Securities Noncurrent Land, property and equipment, net Property Plant And Equipment Net Deferred tax assets Deferred Tax Assets Liabilities Net Noncurrent Other non-current assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable and other accrued liabilities Accounts Payable And Other Accrued Liabilities Current Accrued clinical and preclinical study fees Accrued Clinical And Preclinical Study Fees Current portion of lease financing obligations Sale Leaseback Financing Obligations Current Total current liabilities Liabilities Current Lease financing obligations, less current portion Sale Leaseback Financing Obligations Noncurrent Other long-term liabilities Other Liabilities Noncurrent Commitments and contingencies Commitments And Contingencies Stockholders' equity: Stockholders Equity [Abstract] Preferred stock Preferred Stock Value Common stock Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity Stockholders Equity Total liabilities and equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding License agreement costs incurred related to transaction fees. Income (loss) from continuing operations excluding portion attributable to VIE. Income Statement [Abstract] Statement [Table] Statement [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] United therapeutics. United Therapeutics United Therapeutics [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Collaboration and License Revenue License [Member] Collaboration and other revenue. Collaboration and Other Revenue Collaboration And Other Revenue [Member] Royalty Revenue Royalty [Member] Statement [Line Items] Statement [Line Items] Revenues Revenues [Abstract] Total revenues Revenue From Contract With Customer Excluding Assessed Tax Operating costs and expenses Costs And Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Transaction costs License Agreement Costs Incurred Related To Transaction Fees Litigation settlement expense, net Litigation Settlement Expense Total operating costs and expenses Costs And Expenses Income (loss) from operations Operating Income Loss Interest and other income (expense) Nonoperating Income Expense [Abstract] Interest income Investment Income Interest Interest expense Interest Expense Other income Other Nonoperating Income Expense Total interest and other income (expense), net Nonoperating Income Expense Income (loss) from continuing operations before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax (provision) benefit Income Tax Expense Benefit Income (loss) from continuing operations Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest Income (loss) from discontinued operations Discontinued Operation Income Loss From Discontinued Operation Before Income Tax Net income (loss) Profit Loss Less net loss attributable to noncontrolling interest in consolidated variable interest entity Net Income Loss Attributable To Noncontrolling Interest Net income (loss) attributable to stockholders of Arena Net Income Loss Amounts attributable to stockholders of Arena: Income Amounts Attributable To Reporting Entity Disclosures [Abstract] Income (loss) from continuing operations Income Loss From Continuing Operations Excluding Portion Attributable To V I E Income (loss) from discontinued operations Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity Net income (loss) attributable to stockholders of Arena Net income (loss) attributable to stockholders of Arena per share, basic: Earnings Per Share Basic [Abstract] Continuing operations Income Loss From Continuing Operations Per Basic Share Discontinued operations Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share Net income (loss) attributable to stockholders of Arena per share, basic Earnings Per Share Basic Net income (loss) attributable to stockholders of Arena per share, diluted: Earnings Per Share Diluted [Abstract] Continuing operations Income Loss From Continuing Operations Per Diluted Share Discontinued operations Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share Net income (loss) attributable to stockholders of Arena per share, diluted Earnings Per Share Diluted Shares used in calculating net income (loss) attributable to stockholders of Arena per share, basic Weighted Average Number Of Shares Outstanding Basic Shares used in calculating net income (loss) attributable to stockholders of Arena per share, diluted Weighted Average Number Of Diluted Shares Outstanding Comprehensive Income (Loss): Comprehensive Income Net Of Tax [Abstract] Net income (loss) Foreign currency translation adjustment Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Unrealized gain (loss) on available-for-sale investments Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax Comprehensive income (loss) Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest Less comprehensive loss attributable to noncontrolling interest in consolidated variable interest entity Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest Comprehensive income (loss) attributable to stockholders of Arena Comprehensive Income Net Of Tax Stock issued during period, shares, employee stock purchase plan and restricted stock award, net of forfeitures. Stock issued during period, value, employee stock purchase plan and restricted stock award, net of forfeitures. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Total Equity Attributable to Stockholders of Arena Parent [Member] Equity Attributable to Noncontrolling Interest in Consolidated Variable Interest Entity Noncontrolling Interest [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Underwriters Over Allotment Option [Member] At-the-market offering. ATM facility At Market Offering [Member] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] ASU No. 2016-09 Accounting Standards Update201609 [Member] ASC 606 Accounting Standards Update201409 [Member] Beginning Balance Stockholders Equity Including Portion Attributable To Noncontrolling Interest Beginning Balance (in shares) Adoption of ASU No. 2016-09 New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification Issuance of common stock Stock Issued During Period Value New Issues Issuance of common stock (in shares) Stock Issued During Period Shares New Issues Issuance of common stock upon exercise of options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of options (in shares) Stock Issued During Period Shares Stock Options Exercised Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards Stock Issued During Period Value Employee Stock Purchase Plan And Restricted Stock Award Net Of Forfeitures Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards (in shares) Stock Issued During Period Shares Employee Stock Purchase Plan And Restricted Stock Award Net Of Forfeitures Issuance of common stock upon vesting of restricted stock unit awards Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Issuance of common stock upon vesting of restricted stock unit awards (in shares) Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Share-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Unrealized gain (loss) on available-for-sale investments Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Translation gain (loss) Deconsolidation of variable interest entity Noncontrolling Interest Decrease From Deconsolidation Ending Balance Ending Balance (in shares) Non-cash collaboration revenue. Non-cash royalty revenue. Increase (decrease) in accrued litigation settlement. The cash outflow during the period from the payment of sale and leaseback financing obligations. Statement Of Cash Flows [Abstract] Operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] (Income) loss from discontinued operations Income Loss From Discontinued Operations Net Of Tax Depreciation and amortization Depreciation Depletion And Amortization Deferred income taxes Deferred Income Tax Expense Benefit Non-cash collaboration revenue Non Cash Collaboration Revenue Non-cash royalty revenue Non Cash Royalty Revenue Share-based compensation Share Based Compensation Amortization of prepaid financing costs Amortization Of Financing Costs Amortization of original issue discounts, net of premiums, on available- for-sale investments Accretion Amortization Of Discounts And Premiums Investments Loss (gain) on disposal of property and equipment Gain Loss On Sale Of Property Plant Equipment Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Payables and accrued liabilities Increase Decrease In Accounts Payable And Accrued Liabilities Accrued litigation settlement Increase Decrease In Accrued Litigation Settlement Deferred revenues Increase Decrease In Contract With Customer Liability Other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash provided by (used in) operating activities - continuing operations Net Cash Provided By Used In Operating Activities Continuing Operations Net cash used in operating activities - discontinued operations Cash Provided By Used In Operating Activities Discontinued Operations Net cash provided by (used in) operating activities Net Cash Provided By Used In Operating Activities Investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of available-for-sale investments Payments To Acquire Available For Sale Securities Debt Proceeds from sale and maturity of available-for-sale investments Proceeds From Sale And Maturity Of Available For Sale Securities Deconsolidation of variable interest entity Cash Divested From Deconsolidation Purchases of property and equipment Payments To Acquire Property Plant And Equipment Proceeds from sale of property and equipment Proceeds From Sale Of Property Plant And Equipment Other non-current assets Payments For Proceeds From Other Investing Activities Net cash used in investing activities - continuing operations Net Cash Provided By Used In Investing Activities Continuing Operations Net cash provided by (used in) investing activities - discontinued operations Cash Provided By Used In Investing Activities Discontinued Operations Net cash used in investing activities Net Cash Provided By Used In Investing Activities Financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Principal payments on lease financing obligations Repayments Of Sale Lease Back Financing Obligations Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Effect of exchange rate changes on cash Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Net increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of year Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents and restricted cash at end of year Disposition of property and land upon lease expiration. Reduction in lease financing obligation from release of residual value upon lease expiration. Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Net Supplemental disclosure of non-cash investing and financing information: Noncash Investing And Financing Items [Abstract] Disposition of property and land upon lease expiration Disposition Of Property And Land Upon Lease Expiration Reduction in lease financing obligation from release of residual value upon lease expiration Reduction In Lease Financing Obligation From Release Of Residual Value Upon Lease Expiration Accounting Policies [Abstract] The Company and Summary of Significant Accounting Policies Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures Fair Value Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Investments, Available-for-Sale Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Discontinued Operations And Disposal Groups [Abstract] Sale of Manufacturing Operations Disposal Groups Including Discontinued Operations Disclosure [Text Block] Leases [Abstract] Leases Leases Of Lessee Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stockholders' Equity Shareholders Equity And Share Based Payments [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Collaborations and License Agreements Collaborative Arrangement Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Legal Proceedings Legal Matters And Contingencies [Text Block] Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Variable interest entity disclosure. Variable Interest Entity Disclosure [Abstract] Beacon Discovery, Inc. Variable Interest Entity Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Liquidity. Liquidity Liquidity Policy Policy [Text Block] Changes in Accounting Policies - Leases Lessee Leases Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Use of Estimates Use Of Estimates Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Available-for-Sale Investments Marketable Securities Policy Concentrations of Risk Concentration Risk Credit Risk Property and Equipment Property Plant And Equipment Policy [Text Block] Long-lived Assets Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block] Foreign Currency Foreign Currency Transactions And Translations Policy [Text Block] Share-based Compensation Share Based Compensation Option And Incentive Plans Policy Revenue Recognition Revenue Recognition Policy [Text Block] Research and Development Expenses Research And Development Expense Policy Comprehensive Income (Loss) Comprehensive Income Policy Policy [Text Block] Income (Loss) Per Share Earnings Per Share Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Fair Value Measurements Fair Value Measurement Policy Policy [Text Block] Reconciliation of components of cash, cash equivalents and restricted cash. Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash Reconciliation Of Components Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements Schedule Of New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Potentially Dilutive Securities Excluded from Calculation of Diluted Income (Loss) Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of Investments, Available-for-Sale Debt Securities Available For Sale Table [Text Block] Land, Property and Equipment, Net Property Plant And Equipment [Text Block] Accounts Payable and Other Accrued Liabilities Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Summary of Discontinued Operations for Periods Presented in Consolidated Statements of Operations and Assets and Liabilities Classified as Held for Sale Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Text Block] Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for a) sale and leaseback financing obligations and b) operating leases having initial or remaining noncancelable lease terms in excess of one year. Lease Arrangement, Type Lease Arrangement Type [Axis] Lease Arrangement, Type Lease Arrangement Type [Domain] Sublease agreement. Sublease Agreement Sublease Agreement [Member] Future Minimum Lease Payments Schedule Of Future Minimum Payments For Sale Lease Back Financing Obligations And Operating Leases Table Table [Text Block] Expected Minimum Rental Payments to be Received under Sublease Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Weighted-Average Assumptions and Estimated Fair Value of Stock Options Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Share Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Total Unrecognized Estimated Compensation Expense Schedule Of Unrecognized Compensation Cost Nonvested Awards Table [Text Block] Revenue From Contract With Customer [Abstract] Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification Disaggregation Of Revenue Table [Text Block] Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block] Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Components of Net Deferred Tax Assets Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Reconciliation of Unrecognized Tax Benefits Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block] Quarterly Data Schedule Of Quarterly Financial Information Table [Text Block] Schedule of significant accounting policies Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] ASC 842 Accounting Standards Update201602 [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Sales Revenue, Net Sales Revenue Net [Member] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Eisai. Eisai Eisai [Member] Boehringer Ingelheim [Member] Boehringer Ingelheim Boehringer Ingelheim [Member] Outpost medicine. Outpost Medicine Outpost Medicine [Member] Everest. Everest Everest [Member] Axovant. Axovant Axovant [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Building Building [Member] Initial Application Period Cumulative Effect Transition Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition Initial Application Period Cumulative Effect Transition [Domain] Difference between Revenue Guidance in Effect before and after Topic 606 Difference Between Revenue Guidance In Effect Before And After Topic606 [Member] Schedule Of Significant Accounting Policies [Line Items] Schedule Of Significant Accounting Policies [Line Items] Number of business segments Number Of Operating Segments Cash, cash equivalents and available for sale investments. Cash and cash equivalents and available-for-sale investments Cash Cash Equivalents And Available For Sale Investments Operating lease, liability Operating Lease Liability Operating lease, right-of-use asset Operating Lease Right Of Use Asset Operating lease, right-of-use asset Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract] Restricted cash included in other non-current assets Restricted Cash Restricted Cash, Asset, Statement of Financial Position [Extensible List] Restricted Cash Asset Statement Of Financial Position Extensible List Total cash, cash equivalents and restricted cash presented in the consolidated statement of cash flows Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Concentrations of risk percentage Concentration Risk Percentage1 Property and equipment, estimated useful life Property Plant And Equipment Useful Life Accumulated deficit Impairment loss Impairment Of Long Lived Assets To Be Disposed Of New Accounting Pronouncements Or Change In Accounting Principle [Table] New Accounting Pronouncements Or Change In Accounting Principle [Table] Balances without adoption of ASC 606 Calculated Under Revenue Guidance In Effect Before Topic606 [Member] New Accounting Pronouncements Or Change In Accounting Principle [Line Items] New Accounting Pronouncements Or Change In Accounting Principle [Line Items] Loss from operations Loss from continuing operations Total current assets Total assets Total current liabilities Total stockholders' equity Total liabilities and stockholders' equity Number of reportable business segment Number Of Reportable Segments Payment terms on invoiced amounts. Customers billing method, description Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment Payment terms on invoiced amounts Payment Terms On Invoiced Amounts Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Stock options Employee Stock Option [Member] Restricted stock units and restricted stock. RSUs and unvested restricted stock Restricted Stock Units And Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Total antidilutive securities excluded from calculation of diluted net loss per share (shares) Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value Measurements, Recurring Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Prices in Active Markets (Level 1) Fair Value Inputs Level1 [Member] Significant Other Observable Inputs (Level 2) Fair Value Inputs Level2 [Member] Significant Unobservable Inputs (Level 3) Fair Value Inputs Level3 [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Assets: Assets Fair Value Disclosure [Abstract] Money market funds Cash And Cash Equivalents Fair Value Disclosure US government and government agency notes Financial Instruments Owned U S Government And Agency Obligations At Fair Value Corporate debt instruments Financial Instruments Owned Corporate Debt At Fair Value Short term investments maturity period. Long term investments maturity period. Schedule Of Available For Sale Securities [Table] Schedule Of Available For Sale Securities [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Short-term investments, available-for-sale Short Term Investments [Member] Long term investments. Investments, available-for-sale Long Term Investments [Member] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] US government and government agency notes U S Government Agencies Debt Securities [Member] Corporate debt securities Corporate Debt Securities [Member] Schedule Of Available For Sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Maturity in years Short Term Investments Maturity Period Maturity in years Long Term Investments Maturity Period Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Gross Unrealized Gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Gross Unrealized Losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Estimated Fair Value Available For Sale Securities Debt Securities Property Plant And Equipment [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Land Land [Member] Building and capital improvements Building And Building Improvements [Member] Leasehold improvements Leasehold Improvements [Member] Machinery and equipment Machinery And Equipment [Member] Computers and software. Computers and software Computers And Software [Member] Furniture and office equipment Furniture And Fixtures [Member] Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Land, property and equipment, gross Property Plant And Equipment Gross Less accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Land, property and equipment, net Payables And Accruals [Abstract] Accounts payable Accounts Payable Current Accrued compensation Employee Related Liabilities Current Other accrued liabilities Other Accrued Liabilities Current Total accounts payable and other accrued liabilities Number of employees transferred. Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table] Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table] Siegfried Pharma AG and Siegfried AG. Siegfried Siegfried Pharma A G And Siegfried A G [Member] Arena GmbH. Arena Gmb H Arena Gmb H [Member] Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items] Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items] Number of employees transferred Number Of Employees Transferred Sales price of business Disposal Group Including Discontinued Operation Consideration Cash received from sale of business Proceeds From Sales Of Business Affiliate And Productive Assets Disposal group including discontinued operation revenue. Disposal group including discontinued operation sales revenue goods net. Disposal group including discontinued operation other collaboration revenue. Disposal group including discontinued operation toll manufacturing revenue. Disposal group including discontinued operation cost of toll manufacturing. Disposal group including discontinued operation research and development expenses. Disposal group including discontinued operation other income expense net. Disposal group including discontinued operation cost and expense. Revenues Disposal Group Including Discontinued Operation Revenue [Abstract] Net product sales Disposal Group Including Discontinued Operation Sales Revenue Goods Net Other collaboration revenue Disposal Group Including Discontinued Operation Other Collaboration Revenue Toll manufacturing Disposal Group Including Discontinued Operation Toll Manufacturing Revenue Total revenues Disposal Group Including Discontinued Operation Revenue Operating costs and expenses Disposal Group Including Discontinued Operation Cost And Expense [Abstract] Cost of product sales Disposal Group Including Discontinued Operation Costs Of Goods Sold Cost of toll manufacturing Disposal Group Including Discontinued Operation Cost Of Toll Manufacturing Research and development Disposal Group Including Discontinued Operation Research And Development Expenses General and administrative Disposal Group Including Discontinued Operation General And Administrative Expense Other (income) expense, net Disposal Group Including Discontinued Operation Other Income Expense Net Total costs and expenses Disposal Group Including Discontinued Operation Operating Expense Income (loss) from operations of discontinued operations Disposal Group Including Discontinued Operation Operating Income Loss Gain on sale of discontinued operations Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Income (loss) from discontinued operations The financing charge for sale and leaseback transactions. Number of properties in which ownership has transferred under sale leaseback transaction. Sale leaseback transaction, percentage increase in monthly rent. Sale leaseback financing obligations. Residual value of sale and leaseback agreements. Schedule Of Operating Leased Assets [Table] Schedule Of Operating Leased Assets [Table] Properties under sale and leaseback agreements member. Properties under sale and leaseback agreements Properties Under Sale And Leaseback Agreements [Member] Properties under operating leases. Properties under operating lease Properties Under Operating Leases [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] San Diego, California. San Diego, California San Diego California [Member] Massachusetts, Boston. Boston, Massachusetts Massachusetts Boston [Member] Switzerland, Zug. Zug, Switzerland Switzerland Zug [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Number of properties under sale and leaseback agreements Number Of Properties Ownership Transferred Under Sale Leaseback Transaction Percentage of annual increase in monthly lease payments Percentage Increases In Monthly Rental Payment Sale and leaseback transaction, interest expense Sale Leaseback Transactions Income Statement Interest Expense Less amounts representing interest Interest Portion Of Minimum Lease Payments Sale Leaseback Transactions Sale leaseback transaction, description Sale Leaseback Transaction Description Sale and leaseback transaction, total financing obligation Sale Leaseback Financing Obligations Add amounts representing residual value Sale Leaseback Transaction Residual Value Lease expiration, month and year. Additional office space, lease inception date. Operating lease inception date. Operating lease agreement expiration date Lease Expiration Month And Year Weighted average discount rate Operating Lease Weighted Average Discount Rate Percent Operating lease inception date Operating Lease Inception Date Area of office space Land Subject To Ground Leases Additional office space, lease inception date Additional Office Space Lease Inception Date Operating lease, right-of-use asset, statement of financial position [extensible list] Operating lease, right-of-use liabilties Operating Lease Liability Current Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease Liability Current Statement Of Financial Position Extensible List Operating lease liabilities, non current Operating Lease Liability Noncurrent Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List Rent expense Lease And Rental Expense Operating Lease, Weighted Average Remaining Lease Term Operating Lease Weighted Average Remaining Lease Term1 Financing Obligations Finance Lease Liabilities Payments Due [Abstract] 2020 Finance Lease Liability Payments Due Next Twelve Months 2021 Finance Lease Liability Payments Due Year Two 2022 Finance Lease Liability Payments Due Year Three 2023 Finance Lease Liability Payments Due Year Four 2024 Finance Lease Liability Payments Due Year Five Thereafter Finance Lease Liability Payments Due After Year Five Total minimum lease payments Finance Lease Liability Payments Due Less amounts representing interest Lease financing obligations Current portion of lease financing obligations Lease financing obligations, less current portion Operating Leases Operating Lease Liabilities Payments Due [Abstract] 2020 Lessee Operating Lease Liability Payments Due Next Twelve Months 2021 Lessee Operating Lease Liability Payments Due Year Two 2022 Lessee Operating Lease Liability Payments Due Year Three 2023 Lessee Operating Lease Liability Payments Due Year Four 2024 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total minimum lease payments Lessee Operating Lease Liability Payments Due Financing Obligations Minimum Lease Payments Sale Leaseback Transactions [Abstract] 2019 Minimum Lease Payments Sale Leaseback Transactions Within One Year 2020 Minimum Lease Payments Sale Leaseback Transactions Within Two Years 2021 Minimum Lease Payments Sale Leaseback Transactions Within Three Years 2022 Minimum Lease Payments Sale Leaseback Transactions Within Four Years 2023 Minimum Lease Payments Sale Leaseback Transactions Within Five Years Thereafter Minimum Lease Payments Sale Leaseback Transactions Thereafter Total minimum lease payments Minimum Lease Payments Sale Leaseback Transactions Operating Leases Operating Leases Future Minimum Payments Due [Abstract] 2019 Operating Leases Future Minimum Payments Due Current 2020 Operating Leases Future Minimum Payments Due In Two Years 2021 Operating Leases Future Minimum Payments Due In Three Years 2022 Operating Leases Future Minimum Payments Due In Four Years 2023 Operating Leases Future Minimum Payments Due In Five Years Thereafter Operating Leases Future Minimum Payments Due Thereafter Total minimum lease payments Operating Leases Future Minimum Payments Due Sublease expiration period. Sublease expiration period Sublease Expiration Period Rent income from subleases Operating Leases Rent Expense Sublease Rentals1 2020 Operating Leases Future Minimum Payments Receivable Current 2021 Operating Leases Future Minimum Payments Receivable In Two Years 2022 Operating Leases Future Minimum Payments Receivable In Three Years 2023 Operating Leases Future Minimum Payments Receivable In Four Years 2024 Operating Leases Future Minimum Payments Receivable In Five Years Thereafter Operating Leases Future Minimum Payments Receivable Thereafter Total Operating Leases Future Minimum Payments Receivable Stockholders Equity [Line Items] Stockholders' Equity [Table] Stockholders Equity [Table] Stockholders Equity [Table] underwritten public offering. Underwritten Public Offering Underwritten Public Offering [Member] Transaction Type Transaction Type [Axis] Transaction Transaction [Domain] Equity distribution agreement. Equity Distribution Agreement Equity Distribution Agreement [Member] Citigroup Global Markets Inc. Citigroup Global Markets Inc. Citigroup Global Markets Inc [Member] ATM Offering Weighted Average Weighted Average [Member] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Amended long term incentive plan twenty seventeen. Amended Long Term Incentive Plan Twenty Seventeen Amended Long Term Incentive Plan Twenty Seventeen [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Other Than Stock Options And Stock Appreciation Rights [Member] Other Than Stock Options And Stock Appreciation Rights Other Than Stock Options And Stock Appreciation Rights [Member] Equity Compensation Plans [Member] Equity Compensation Plans Equity Compensation Plans [Member] Restricted Stock Units (RSU) Restricted Stock Units R S U [Member] Performance Restricted Stock Units (PRSU) [Member] Performance restricted stock units Performance Restricted Stock Units P R S U [Member] Stock Options and Stock Appreciation Rights (SARs) Stock Appreciation Rights S A R S [Member] Vesting Vesting [Axis] Vesting Vesting [Domain] Tranche One Share Based Compensation Award Tranche One [Member] Tranche Two Share Based Compensation Award Tranche Two [Member] Tranche Three Share Based Compensation Award Tranche Three [Member] Two zero zero nine employee stock purchase plan. 2009 ESPP Two Zero Zero Nine Employee Stock Purchase Plan [Member] 2019 employee stock purchase plan. 2019 ESPP Two Zero One Nine Employee Stock Purchase Plan [Member] Stockholders Equity [Line Items] Stockholders Equity [Line Items] Sale of common stock shares Aggregate gross proceeds from sale of common stock Average market price per share Sale Of Stock Price Per Share Share based compensation arrangement by share based payment award, decrease percentage to available for grant for share issued. Share based compensation arrangement by share based payment award, increase percentage to available for grant for share released. Number of shares authorized Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Reduction in number of shares available for grant for every share issued, percentage Share Based Compensation Arrangement By Share Based Payment Award Decrease Percentage To Available For Grant For Share Issued Increase in number of shares available for grant for every share issued, percentage Share Based Compensation Arrangement By Share Based Payment Award Increase Percentage To Available For Grant For Share Released Common stock shares reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Period of time over which stock options can be exercised, in years Share-based compensation arrangement by share based payment award remaining vesting period. Vesting percentage Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage Vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Remaining vesting period Share Based Compensation Arrangement By Share Based Payment Award Remaining Vesting Period Vesting description Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights Stock options exercisable period Stock Options Exercisable Period Purchase price of common shares as a percentage of fair market value Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Number of stock options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Outstanding at December 31, 2018 Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Exercised Forfeited/cancelled/expired Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Outstanding at December 31, 2019 Vested and expected to vest at December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Vested and exercisable at December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted Average Exercise Price ($ per share) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Outstanding at December 31, 2018 Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Forfeited/cancelled/expired Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Outstanding at December 31, 2019 Vested and expected to vest at December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Vested and exercisable at December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term (in years) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract] Outstanding at December 31, 2019 Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Vested and expected to vest at December 31, 2019 Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Vested and exercisable at December 31, 2019 Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Outstanding at December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Vested and expected to vest at December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Vested and exercisable at December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value Closing price of Company's common stock as reported on the NASDAQ Global Select Market Employee service share based compensation tax impact from exercise of stock options. Common stock closing price ($ per share) Common Stock Closing Price Intrinsic value of stock options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Proceeds from stock option exercises Proceeds From Stock Options Exercised Tax impact from exercise of stock options Employee Service Share Based Compensation Tax Impact From Exercise Of Stock Options Threshold consecutive trading days. Percentage of target number of shares to be issued under share based payment award other than options. Threshold non-consecutive trading days. Common stock closing price percentage. Grant-date fair value of equity instruments other than options granted during period. Price per share market condition vesting threshold. Units granted (shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Threshold consecutive trading days Threshold Consecutive Trading Days Threshold non-consecutive trading days Threshold Non Consecutive Trading Days Common stock closing price, percentage Common Stock Closing Price Percentage Number of shares to be awarded as a percentage of target amounts Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Target Number Of Shares To Be Issued PRSU grant-date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Grant Date Fair Value Compensation expense of requisite service period Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 Price per share market condition vesting threshold Price Per Share Market Condition Vesting Threshold Shares issued to employees upon satisfaction of continuing service requirement Stock Issued During Period Shares Employee Benefit Plan Shares issued Stock Issued During Period Shares Share Based Compensation Maximum Number of Shares Allowed to Purchase per Purchase Period Maximum duration of an ESPP offering period Maximum Percentage of Annual Compensation contributable to ESPP Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate Maximum number of shares allowed to purchase per PURCHASE period Maximum Number Of Shares Allowed To Purchase Per Purchase Period Maximum ESPP offering period Maximum Espp Offering Period ESPP terminated date Share Based Compensation Arrangement By Share Based Payment Award Expiration Date Total common stock issued under employee stock purchase plan (shares) Stock Issued During Period Shares Employee Stock Purchase Plans Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected life (years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Weighted-average estimated fair value per share of stock options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Share based compensation effect on earnings per share basic. Share based compensation effect on earnings per share diluted. Operating Activities Statement Operating Activities Segment [Axis] Operating Activities Segment Operating Activities [Domain] Discontinued operations Segment Discontinued Operations [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and development Research And Development Expense [Member] General and administrative General And Administrative Expense [Member] Share-based compensation expense Allocated Share Based Compensation Expense Impact on net loss per share, basic Share Based Compensation Effect On Earnings Per Share Basic Impact on net loss per share, diluted Share Based Compensation Effect On Earnings Per Share Diluted Unvested stock options PRSUs RSUs Unrecognized Expense (in thousands) Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Remaining Weighted-Average Recognition Period (in years) Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Revenue from contracts with customers including discontinued operations. Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Eisai Incorporation And Eisai Corporation Limited. Eisai Eisai Incorporation And Eisai Corporation Limited [Member] Other Other Customer [Member] Timing of Transfer of Good or Service Timing Of Transfer Of Good Or Service [Axis] Timing of Transfer of Good or Service Timing Of Transfer Of Good Or Service [Domain] Revenue recognized at a point in time Transferred At Point In Time [Member] Revenue recognized over time Transferred Over Time [Member] Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Revenue Revenue From Contracts With Customers Including Discontinued Operations Revenue from continuing operations Revenue reported under discontinued operations Collaborative agreement completion period. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Non us market. Non U.S. Market Non Us Market [Member] Us market. U.S. Market U S Market [Member] Chinese National Medical Products Administration Chinese National Medical Products Administration Chinese National Medical Products Administration [Member] Eisai First Amended Agreement [Member] Eisai First Amended Agreement Eisai First Amended Agreement [Member] Eisai Second Amended Agreement [Member] Eisai Second Amended Agreement Eisai Second Amended Agreement [Member] Eisai agreement. Eisai Agreement Eisai Agreement [Member] Lorcaserin product. Lorcaserin Product Lorcaserin Product [Member] Prior to transaction agreement. Prior to Transaction Agreement Prior To Transaction Agreement [Member] Prior to commercial distribution agreement. Prior to Commercial Distribution Agreement Prior To Commercial Distribution Agreement [Member] Lorcaserin. Lorcaserin Lorcaserin [Member] Ildong. Ildong Ildong [Member] Supply agreement. Supply Agreement Supply Agreement [Member] Product Sales Product [Member] Inventory deliverable. Inventory Deliverable Inventory Deliverable [Member] Manufacturing and supply commitment deliverable. Manufacturing and Supply Commitment Deliverable Manufacturing And Supply Commitment Deliverable [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Beacon Discovery, Inc. Beacon Discovery, Inc. Beacon Discovery Inc [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative arrangement right description Collaborative Arrangement Rights And Obligations Collaborative agreement completion period Collaborative Agreement Completion Period License agreement costs incurred related to transaction fees Collaborative agreement upfront payments. Collaboration agreement estimated transaction cost. Additional amount of cash that may be received upon achievement of milestone under collaborative agreement. Collaborative agreement upfront payments Collaborative Agreement Upfront Payments Additional milestone payments on achievement Additional Payments Receivable On Milestone Achievements Collaboration Agreement Estimated Transaction Price Collaboration Agreement Estimated Transaction Cost Collaboration agreement milestone revenue recognized Payable on milestone achievements. Recognized milestone revenue Collaboration Agreement Milestone Revenue Recognized Paid on Milestone Achievements Payable On Milestone Achievements Recognized revenues Contract With Customer Liability Revenue Recognized Collaborative agreement initiation date. Collaborative agreement initiation date Collaborative Agreement Initiation Date Additional manufacturing support payments received. Additional manufacturing support payments received Additional Manufacturing Support Payments Received Collaborative arrangement royalty percentage on annual net sales. Royalty rate on annual net sales Collaborative Arrangement Royalty Percentage On Annual Net Sales Collaborative agreement estimated future royalty payments. Contract with customer asset increase in resulting from adjustment to future estimated royalty payments. Contract assets. Contract with customer asset decrease in resulting from adjustment to future estimated royalty payments. Reduction in deferred revenue associated with agreement Contract asset associated with agreement Contract With Customer Asset Net Estimated future royalty payments Collaborative Agreement Estimated Future Royalty Payments Increase in contract asset resulting from adjustment to future estimated royalty payments Contract With Customer Asset Increase In Resulting From Adjustment To Future Estimated Royalty Payments Contract Assets Contract Assets Decrease in contract asset resulting from adjustment to future estimated royalty payments Contract With Customer Asset Decrease In Resulting From Adjustment To Future Estimated Royalty Payments Proceeds from repayments of reversal of inventory. Reversal balance of hand on inventory Proceeds From Repayments Of Reversal Of Inventory Revenues Collaborative arrangement consideration agreed to be paid. Collaborative arrangement consideration. Total arrangement consideration under Eisai Agreement Collaborative Arrangement Consideration Agreed To Be Paid Payment received from Eisai Collaborative Arrangement Consideration Recognized revenue of discontinued operations Carrying value of inventory as cost of product sales of discontinued operations Collaborative agreement upfront payments in the form of equity interest. Collaborative agreement upfront payments in the form of equity interest Collaborative Agreement Upfront Payments In Form Of Equity Interest Net income (loss) attributable to domestic. Net income (loss) attributable to foreign. United States Net Income Loss Attributable To Domestic Foreign Net Income Loss Attributable To Foreign Total income (loss) attributable to stockholders of Arena before income taxes Income Loss Attributable To Parent Income tax disclosure. Income tax disclosure. Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income Tax Authority, Name Income Tax Authority Name [Axis] Income Tax Authority, Name Income Tax Authority Name [Domain] Federal Internal Revenue Service I R S [Member] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] California State And Local Jurisdiction [Member] Tax Credit Carryforward Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name Tax Credit Carryforward Name [Domain] Research and Development Tax Credit Research [Member] Orphan drug. Orphan Drug Credit Orphan Drug [Member] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Benefit for income taxes Statutory federal rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Income tax reconciliation change in valuation allowance due to tax reform. Benefit for income taxes at statutory federal rate Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate Change in valuation allowance due to tax reform Income Tax Reconciliation Change In Valuation Allowance Due To Tax Reform Change in federal and foreign valuation allowance Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Permanent differences and other Income Tax Reconciliation Other Adjustments Deferred adjustment related to foreign net operating losses Income Tax Reconciliation Tax Contingencies Foreign Capital loss on foreign subsidiary liquidation Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary Share-based compensation expense Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost Foreign losses at lower effective rates Income Tax Reconciliation Tax Credits Foreign Research and development and Orphan Drug credits Income Tax Reconciliation Tax Credits Research Benefit for income taxes Deferred tax assets arising from lease liabilities. Deferred tax liabilities, right of use assets. Net amount of deferred tax assets before reduction for valuation allowance. Deferred tax assets: Deferred Tax Assets Gross [Abstract] Federal and California NOL carryforwards Deferred Tax Assets Operating Loss Carryforwards Domestic Federal and California research and development credit carryforwards Deferred Tax Assets Tax Credit Carryforwards Research Foreign NOL carryforwards Deferred Tax Assets Operating Loss Carryforwards Foreign Share-based compensation expense Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Depreciation Deferred Tax Assets Property Plant And Equipment Lease liability Deferred Tax Assets Lease Liabilities Other, net Deferred Tax Assets Other Total deferred tax assets Deferred Tax Assets Gross Deferred tax liabilities: Deferred Income Tax Liabilities Right-of-use assets Deferred Tax Liabilities Right Of Use Asset Total deferred tax liabilities Deferred Tax Liabilities Net deferred tax assets Deferred Tax Assets Liabilities Gross Valuation allowance Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Liabilities Net Increase in valuation allowance Valuation Allowance Deferred Tax Asset Change In Amount Net operating loss carryforwards expiration year. Tax credit carryforward expiration year Percentage of operating loss carry forwards limitations on use. NOL carryforwards Operating Loss Carryforwards NOL carryforwards expiration date, year Net Operating Loss Carryforwards Expiration Year Tax credit carryforwards amount Tax Credit Carryforward Amount Tax credit carryforwards expiration year Tax Credit Carryforward Expiration Year Operating loss carryforwards, terms of limitation Operating Loss Carryforwards Limitations On Use Operating loss carryforwards, percentage of limitation Percentage Of Operating Loss Carry Forwards Limitations On Use Net operating loss and research and development tax credit limitation on use threshold percentage of ownership. Period for net operating loss and research and development tax credit limitation on use threshold percentage of ownership. Net operating loss and research and development tax credit limitation on use threshold percentage of ownership Net Operating Loss And Research And Development Tax Credit Limitation On Use Threshold Percentage Of Ownership Period for net operating loss and research and development tax credit limitation on use threshold percentage of ownership Period For Net Operating Loss And Research And Development Tax Credit Limitation On Use Threshold Percentage Of Ownership Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward Gross unrecognized tax benefits at the beginning of the year Unrecognized Tax Benefits Additions from tax positions taken in the current year Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Additions from tax positions taken in prior years Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions Reductions from tax positions taken in prior years Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions Tax settlements Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities Gross unrecognized tax benefits at end of the year Unrecognized tax benefits, that would impact the effective tax rate Unrecognized Tax Benefits That Would Impact Effective Tax Rate Accrued interest or penalties Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Recognize interest and/or penalties expense Unrecognized Tax Benefits Income Tax Penalties And Interest Expense Loss Contingency [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case Litigation Case [Axis] Litigation Case Litigation Case Type [Domain] Litigation amount settlement by insurer. Litigation Amount Settlement By Insurer Litigation Amount Settlement By Insurer [Member] Litigation amount settlement by parent. Litigation Amount Settlement By Parent Litigation Amount Settlement By Parent [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accrued litigation settlement Litigation Reserve Current Litigation settlement expense, net Insurance recovery receivable Loss Contingency Receivable Current Revenues Revenues Operating costs and expenses Net income (loss) Net income (loss) per share, basic Net income (loss) per share, diluted Net income (loss): Net Income Loss Attributable To Reporting Entity [Abstract] Income (loss) from continuing operations Loss from discontinued operations Net income (loss) per share, basic Net income (loss) per share, diluted Continuing operations Income Loss From Continuing Operations Per Basic And Diluted Share Discontinued operations Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share Schedule Of Variable Interest Entities [Table] Schedule Of Variable Interest Entities [Table] Consolidated Entities Consolidated Entities [Axis] Consolidated Entities Consolidated Entities [Domain] Variable Interest Entity, Primary Beneficiary Variable Interest Entity Primary Beneficiary [Member] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Area of space subleased Net loss attributable to noncontrolling interest in consolidated variable interest entity EX-101.PRE 16 arna-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 17 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes

9. Income Taxes

The following table summarizes our income (loss) attributable to stockholders of Arena before provision (benefit) for income taxes by region for the years presented, in thousands:

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

United States

 

$

298,315

 

 

$

(138,522

)

 

$

(62,109

)

Foreign

 

 

209,573

 

 

 

(1,142

)

 

 

(29,298

)

Total income (loss) attributable to stockholders of Arena before income taxes

 

$

507,888

 

 

$

(139,664

)

 

$

(91,407

)

 

For the year ended December 31, 2019, we have recorded an expense for income taxes for the usage of the deferred tax assets that were set up in 2018 related to the taxable gain pursuant to the United Therapeutics transaction. We recorded a benefit for income taxes for the year ended December 31, 2018, due to the estimated taxable gain pursuant to the United Therapeutics transaction. We did not record a benefit for income taxes for the year ended December 31, 2017, because we had a full valuation allowance.

Our effective income tax rate differs from the statutory federal rate of 21% for 2019 and 2018, and 34% for 2017 due to the following, in thousands:

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Benefit for income taxes at statutory federal rate

 

$

106,657

 

 

$

(29,090

)

 

$

(32,140

)

Change in valuation allowance due to tax reform

 

 

—

 

 

 

—

 

 

 

96,333

 

Change in federal and foreign valuation allowance

 

 

34,712

 

 

 

(76,336

)

 

 

(68,604

)

Permanent differences and other

 

 

601

 

 

 

1,963

 

 

 

(782

)

Deferred adjustment related to foreign net operating losses

 

 

15,133

 

 

 

—

 

 

 

—

 

Capital loss on foreign subsidiary liquidation

 

 

(43,685

)

 

 

—

 

 

 

—

 

Share-based compensation expense

 

 

1,624

 

 

 

889

 

 

 

7,071

 

Foreign losses at lower effective rates

 

 

21

 

 

 

257

 

 

 

1,428

 

Research and development and Orphan Drug credits

 

 

(4,730

)

 

 

(7,948

)

 

 

(3,306

)

Benefit for income taxes

 

$

110,333

 

 

$

(110,265

)

 

$

—

 

 

The components of our net deferred tax assets are as follows, in thousands:  

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Federal and California NOL carryforwards

 

$

140,762

 

 

$

210,853

 

Federal and California research and development credit carryforwards

 

 

73,956

 

 

 

69,221

 

Foreign NOL carryforwards

 

 

—

 

 

 

15,131

 

Share-based compensation expense

 

 

11,010

 

 

 

6,124

 

Depreciation

 

 

3,183

 

 

 

2,914

 

Lease liability

 

 

2,359

 

 

 

—

 

Other, net

 

 

354

 

 

 

784

 

Total deferred tax assets

 

 

231,624

 

 

 

305,027

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use assets

 

 

(2,218

)

 

 

—

 

Total deferred tax liabilities

 

 

(2,218

)

 

 

—

 

Net deferred tax assets

 

 

229,406

 

 

 

305,027

 

Valuation allowance

 

 

(229,406

)

 

 

(194,694

)

Net deferred tax assets

 

$

—

 

 

$

110,333

 

 

A valuation allowance is recorded against a portion of our deferred tax assets, as realization of a portion of these assets is not more-likely-than-not. The realization of our deferred tax assets is dependent upon future taxable income. In January 2019, a taxable income generating event, the transaction pursuant to the United Therapeutics Agreement created taxable income, resulting in the realization of a portion of our deferred tax assets. A portion of the valuation allowance in 2018 was released for the anticipated taxable

income generating event. We utilized net operating losses to offset taxable income in 2019. Our ability to generate taxable income is analyzed regularly on a jurisdiction-by-jurisdiction basis. At such time as it is more-likely-than-not that we will generate taxable income in a jurisdiction, we will further reduce or remove the valuation allowance. The valuation allowance increased by $34.7 million from December 31, 2018, to December 31, 2019.

At December 31, 2019, we had federal NOL carryforwards of $539.3 million that will begin to expire in 2029 unless previously utilized. At the same date, we had California NOL carryforwards of $393.9 million, which begin expiring in 2028. Net operating losses generated after December 31, 2017 carry forward indefinitely. At December 31, 2019, we had $151.4 million of net operating losses with no expiration. Net operating losses generated in 2018 are subject to an 80% limitation. At December 31, 2019, we also had federal and California research and development tax credit carryforwards, net of reserves, of $38.7 million and $25.1 million, respectively. At December 31, 2019, we had a Federal Orphan Drug Credit carryforward, net of reserves, of $15.0 million. Federal credit carryforwards will begin to expire after 2026 unless previously utilized. The California research and development credit carries forward indefinitely.

Sections 382 and 383 of the IRC limit the utilization of tax attribute carryforwards that arise prior to certain cumulative changes in a corporation’s ownership. We have completed an IRC Section 382/383 analysis through 2019 and did not identify any ownership changes that limit our utilization of tax attribute carryforwards since 2010. Pursuant to IRC Section 382 and 383, use of our net operating loss and research and development income tax credit carryforwards may be limited in the event of cumulative changes in ownership subsequent to 2019 of more than 50% within a three-year period.

In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

The following table reconciles the beginning and ending amount of unrecognized tax benefits for the years presented, in thousands:  

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Gross unrecognized tax benefits at the beginning of the year

 

$

9,033

 

 

$

7,762

 

 

$

5,906

 

Additions from tax positions taken in the current year

 

 

1,017

 

 

 

1,269

 

 

 

1,133

 

Additions from tax positions taken in prior years

 

 

—

 

 

 

2

 

 

 

723

 

Reductions from tax positions taken in prior years

 

 

(96

)

 

 

—

 

 

 

—

 

Tax settlements

 

 

—

 

 

 

—

 

 

 

—

 

Gross unrecognized tax benefits at end of the year

 

$

9,954

 

 

$

9,033

 

 

$

7,762

 

 

Of our total unrecognized tax benefits at December 31, 2019, $8.6 million will impact our effective tax rate in the event the valuation allowance is removed. We do not anticipate that there will be a substantial change in unrecognized tax benefits within the next 12 months.

Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Because we have incurred net losses since our inception, we did not have any accrued interest or penalties included in our consolidated balance sheets at December 31, 2019, or 2018, and did not recognize any interest and/or penalties in our consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2019, 2018, and 2017.

We are subject to income taxation in the United States at the Federal and state levels. All tax years are subject to examination by US and California tax authorities due to the carryforward of unutilized NOLs and tax credits. We are also subject to foreign income taxes in the countries in which we operate. To our knowledge, we are not currently under examination by any taxing authorities.

 

 

XML 18 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Sale of Manufacturing Operations
 12 Months Ended
Dec. 31, 2019
Discontinued Operations And Disposal Groups [Abstract]  
Sale of Manufacturing Operations

5. Sale of Manufacturing Operations

In order to further focus our efforts and resources on our strategic objectives of developing our pipeline drug candidates, in March 2018, we entered into an Asset Purchase Agreement, or Sale Agreement, with Siegfried Pharma AG and Siegfried AG, (collectively and individually, Siegfried). Under the Sale Agreement, we agreed to sell and assign to Siegfried, and Siegfried agreed to purchase and assume from Arena GmbH, certain drug product finishing facility assets and know-how, including fixtures, equipment, other personal property and real estate assets located in Zofingen, Switzerland and related contracts and certain related liabilities, or collectively, the Manufacturing Operations. We refer to this transaction as the Siegfried Transaction. The Siegfried Transaction was completed on March 31, 2018. In connection with the Siegfried Transaction, all of Arena GmbH’s approximately 50 employees transferred to Siegfried. We have excluded from our continuing operations for all periods presented in this report revenues and expenses associated with the disposed Manufacturing Operations, which are reported as discontinued operations. The total sales price for the Manufacturing Operations was approximately CHF 4 million of which approximately CHF 3 million was received in cash in March 2018 and the remaining portion was received in March 2019.

The following table summarizes the results of discontinued operations for the periods presented in the consolidated statements of operations for the years ended December 31, 2018, and 2017, in thousands:

 

 

Years ended December 31,

 

Revenues

 

2018

 

 

2017

 

Net product sales

 

$

1,129

 

 

$

9,189

 

Other collaboration revenue

 

 

372

 

 

 

6,671

 

Toll manufacturing

 

 

1,006

 

 

 

3,179

 

Total revenues

 

 

2,507

 

 

 

19,039

 

Operating costs and expenses

 

 

 

 

 

 

 

 

Cost of product sales

 

 

1,858

 

 

 

7,472

 

Cost of toll manufacturing

 

 

1,411

 

 

 

4,756

 

Research and development

 

 

—

 

 

 

643

 

General and administrative

 

 

329

 

 

 

1,672

 

Other (income) expense, net

 

 

464

 

 

 

1,374

 

Total costs and expenses

 

 

4,062

 

 

 

15,917

 

Income (loss) from operations of discontinued operations

 

 

(1,555

)

 

 

3,122

 

Gain on sale of discontinued operations

 

 

725

 

 

 

—

 

Income (loss) from discontinued operations

 

$

(830

)

 

$

3,122

 

 
XML 19 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Events
 12 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events

13. Subsequent Events

See Note 12 regarding the collaboration and license agreement with Beacon, which was executed in January 2020.
XML 20 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
The Company and Summary of Significant Accounting Policies - Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]    
Cash and cash equivalents $ 243,274 $ 161,037
Restricted cash included in other non-current assets $ 226 $ 863
Restricted Cash, Asset, Statement of Financial Position [Extensible List] us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent
Total cash, cash equivalents and restricted cash presented in the consolidated statement of cash flows $ 243,500 $ 161,900
XML 21 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investments, Available-for-Sale - Schedule of Investments, Available-for-Sale (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Short-term investments, available-for-sale    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost $ 495,527 $ 284,742
Gross Unrealized Gains 787  
Gross Unrealized Losses (23) (148)
Estimated Fair Value 496,291 284,594
Short-term investments, available-for-sale | US government and government agency notes    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 201,046 139,274
Gross Unrealized Gains 292  
Gross Unrealized Losses (5) (18)
Estimated Fair Value 201,333 139,256
Short-term investments, available-for-sale | Corporate debt securities    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 294,481 145,468
Gross Unrealized Gains 495  
Gross Unrealized Losses (18) (130)
Estimated Fair Value 294,958 145,338
Investments, available-for-sale    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 370,479 82,510
Gross Unrealized Gains 688 6
Gross Unrealized Losses (229) (104)
Estimated Fair Value 370,938 82,412
Investments, available-for-sale | US government and government agency notes    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost 197,157 16,998
Gross Unrealized Gains 85 6
Gross Unrealized Losses (155)  
Estimated Fair Value $ 197,087 $ 17,004
Investments, available-for-sale | US government and government agency notes | Minimum    
Schedule Of Available For Sale Securities [Line Items]    
Maturity in years 1 year 1 year
Investments, available-for-sale | US government and government agency notes | Maximum    
Schedule Of Available For Sale Securities [Line Items]    
Maturity in years 5 years 5 years
Investments, available-for-sale | Corporate debt securities    
Schedule Of Available For Sale Securities [Line Items]    
Amortized Cost $ 173,322 $ 65,512
Gross Unrealized Gains 603  
Gross Unrealized Losses (74) (104)
Estimated Fair Value $ 173,851 $ 65,408
Investments, available-for-sale | Corporate debt securities | Minimum    
Schedule Of Available For Sale Securities [Line Items]    
Maturity in years 1 year 1 year
Investments, available-for-sale | Corporate debt securities | Maximum    
Schedule Of Available For Sale Securities [Line Items]    
Maturity in years 5 years 5 years
XML 22 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 23 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (Unaudited) (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]                      
Revenues $ 3,002 $ 1,350 $ 1,022 $ 801,057 $ 8,648 $ 3,573 $ 3,994 $ 1,755      
Operating costs and expenses 96,875 80,685 69,578 76,547 53,292 39,577 37,160 32,724 $ 323,685 $ 162,753 $ 113,304
Net income (loss) $ (88,311) $ (72,865) $ (61,403) $ 620,134 $ 68,711 $ (34,314) $ (31,833) $ (31,963) $ 397,555 $ (29,399) $ (92,732)
Net income (loss) per share, basic $ (1.76) $ (1.46) $ (1.24) $ 12.53 $ 1.39 $ (0.70) $ (0.65) $ (0.80) $ 7.99 $ (0.63) $ (2.77)
Net income (loss) per share, diluted $ (1.76) $ (1.46) $ (1.24) $ 12.10 $ 1.35 $ (0.70) $ (0.65) $ (0.80) $ 7.69 $ (0.63) $ (2.77)
Net income (loss):                      
Income (loss) from continuing operations         $ 68,711 $ (34,314) $ (31,833) $ (31,133) $ 397,555 $ (28,569) $ (95,854)
Loss from discontinued operations               (830)   (830) 3,122
Net income (loss) $ (88,311) $ (72,865) $ (61,403) $ 620,134 $ 68,711 $ (34,314) $ (31,833) $ (31,963) $ 397,555 $ (29,399) $ (92,732)
Net income (loss) per share, basic                      
Continuing operations         $ 1.39 $ (0.70) $ (0.65) $ (0.78) $ 7.99 $ (0.61) $ (2.87)
Discontinued operations               (0.02)   (0.02) 0.10
Net income (loss) attributable to stockholders of Arena per share, basic $ (1.76) $ (1.46) $ (1.24) $ 12.53 1.39 (0.70) (0.65) (0.80) 7.99 (0.63) (2.77)
Net income (loss) per share, diluted                      
Continuing operations         1.35 (0.70) (0.65) (0.78)      
Discontinued operations               (0.02)      
Net income (loss) attributable to stockholders of Arena per share, diluted $ (1.76) $ (1.46) $ (1.24) $ 12.10 $ 1.35 $ (0.70) $ (0.65) $ (0.80) $ 7.69 $ (0.63) $ (2.77)
XML 24 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
Benefit for income taxes at statutory federal rate $ 106,657,000 $ (29,090,000) $ (32,140,000)
Change in valuation allowance due to tax reform     96,333,000
Change in federal and foreign valuation allowance 34,712,000 (76,336,000) (68,604,000)
Permanent differences and other 601,000 1,963,000 (782,000)
Deferred adjustment related to foreign net operating losses 15,133,000    
Capital loss on foreign subsidiary liquidation (43,685,000)    
Share-based compensation expense 1,624,000 889,000 7,071,000
Foreign losses at lower effective rates 21,000 257,000 1,428,000
Research and development and Orphan Drug credits (4,730,000) (7,948,000) (3,306,000)
Benefit for income taxes $ 110,333,000 $ (110,265,000) $ 0
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Underwriters
ATM facility
Common Stock
Common Stock
Underwriters
Common Stock
ATM facility
Additional Paid-In Capital
Additional Paid-In Capital
Underwriters
Additional Paid-In Capital
ATM facility
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total Equity Attributable to Stockholders of Arena
Total Equity Attributable to Stockholders of Arena
Underwriters
Total Equity Attributable to Stockholders of Arena
ATM facility
Equity Attributable to Noncontrolling Interest in Consolidated Variable Interest Entity
Beginning Balance at Dec. 31, 2016 $ 40,395     $ 2     $ 1,441,737     $ (3,099) $ (1,398,736) $ 39,904     $ 491
Beginning Balance (in shares) at Dec. 31, 2016       24,340,080                      
Adoption of ASU No. 2016-09 | ASU No. 2016-09             44       (44)        
Issuance of common stock   $ 236,388 $ 6,987   $ 2     $ 236,386 $ 6,987       $ 236,388 $ 6,987  
Issuance of common stock (in shares)         14,087,500 489,023                  
Issuance of common stock upon exercise of options 5,404           5,404         5,404      
Issuance of common stock upon exercise of options (in shares)       323,431                      
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards 12           12         12      
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards (in shares)       40,653                      
Share-based compensation expense 7,990           7,973         7,973     17
Unrealized gain (loss) on available-for-sale investments (133)                 (133)   (133)      
Translation gain (loss) 2,016                 2,016   2,016      
Net income (loss) (92,732)                   (91,407) (91,407)     (1,325)
Deconsolidation of variable interest entity 817                           $ 817
Ending Balance at Dec. 31, 2017 207,144     $ 4     1,698,543     (1,216) (1,490,187) 207,144      
Ending Balance (in shares) at Dec. 31, 2017       39,280,687                      
Adoption of ASU No. 2016-09 | ASC 606 20,136                 1,102 19,034 20,136      
Issuance of common stock   $ 383,142     $ 1     $ 383,141         $ 383,142    
Issuance of common stock (in shares)         9,775,000                    
Issuance of common stock upon exercise of options 5,888           5,888         5,888      
Issuance of common stock upon exercise of options (in shares)       317,636                      
Issuance of common stock upon vesting of restricted stock unit awards (166)           (166)         (166)      
Issuance of common stock upon vesting of restricted stock unit awards (in shares)       49,668                      
Share-based compensation expense 19,554           19,554         19,554      
Unrealized gain (loss) on available-for-sale investments (113)                 (113)   (113)      
Translation gain (loss) 72                 72   72      
Net income (loss) (29,399)                   (29,399) (29,399)      
Ending Balance at Dec. 31, 2018 $ 606,258     $ 5     2,106,960     (155) (1,500,552) 606,258      
Ending Balance (in shares) at Dec. 31, 2018 49,422,991     49,422,991                      
Issuance of common stock upon exercise of options $ 15,184           15,184         15,184      
Issuance of common stock upon exercise of options (in shares)       625,757                      
Issuance of common stock upon vesting of restricted stock unit awards (2,037)           (2,037)         (2,037)      
Issuance of common stock upon vesting of restricted stock unit awards (in shares)       122,205                      
Share-based compensation expense 53,047           53,047         53,047      
Unrealized gain (loss) on available-for-sale investments 1,469                 1,469   1,469      
Translation gain (loss) (11)                 (11)   (11)      
Net income (loss) 397,555                   397,555 397,555      
Ending Balance at Dec. 31, 2019 $ 1,071,465     $ 5     $ 2,173,154     $ 1,303 $ (1,102,997) $ 1,071,465      
Ending Balance (in shares) at Dec. 31, 2019 50,170,953     50,170,953                      
XML 26 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2019
Feb. 21, 2020
Jun. 28, 2019
Cover [Abstract]      
Entity Registrant Name ARENA PHARMACEUTICALS, INC.    
Entity Central Index Key 0001080709    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Document Type 10-K    
Document Period End Date Dec. 31, 2019    
Entity File Number 000-31161    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Amendment Flag false    
Trading Symbol ARNA    
Entity Common Stock, Shares Outstanding   50,249,149  
Entity Voluntary Filers No    
Entity Public Float     $ 2.9
Document Annual Report true    
Document Transition Report false    
Entity Address, Postal Zip Code 92121    
Entity Tax Identification Number 23-2908305    
Local Phone Number 453.7200    
City Area Code 858    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 6154 Nancy Ridge Drive    
Entity Address, City or Town San Diego    
Entity Address, State or Province CA    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Shell Company false    
Entity Small Business false    
Entity Emerging Growth Company false    
Documents Incorporated by Reference Certain information required by Part III of this Annual Report on Form 10-K is incorporated by reference from the Registrant’s Definitive Proxy Statement for the Annual Meeting of Stockholders to be held in June 2020, which will be filed with the Securities and Exchange Commission on or before April 29, 2020.    
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investments, Available-for-Sale
 12 Months Ended
Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]  
Investments, Available-for-Sale

3. Investments, Available-for-Sale

Investments, available-for-sale, consisted of the following, in thousands:

 

December 31, 2019

 

Maturity

in years

 

Amortized

Cost

 

 

Gross

Unrealized Gains

 

 

Gross

Unrealized Losses

 

 

Estimated

Fair Value

 

US government and government agency

    notes

 

Less than 1

 

$

201,046

 

 

$

292

 

 

$

(5

)

 

$

201,333

 

Corporate debt securities

 

Less than 1

 

 

294,481

 

 

 

495

 

 

 

(18

)

 

 

294,958

 

Short-term investments, available-for-sale

 

 

 

$

495,527

 

 

$

787

 

 

$

(23

)

 

$

496,291

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

US government and government agency

    notes

 

1 - 5

 

$

197,157

 

 

$

85

 

 

$

(155

)

 

$

197,087

 

Corporate debt securities

 

1 - 5

 

 

173,322

 

 

 

603

 

 

 

(74

)

 

 

173,851

 

Investments, available-for-sale

 

 

 

$

370,479

 

 

$

688

 

 

$

(229

)

 

$

370,938

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2018

 

Maturity

in years

 

Amortized

Cost

 

 

Gross

Unrealized Gains

 

 

Gross

Unrealized Losses

 

 

Estimated

Fair Value

 

US government and government agency

    notes

 

Less than 1

 

$

139,274

 

 

$

—

 

 

$

(18

)

 

$

139,256

 

Corporate debt securities

 

Less than 1

 

 

145,468

 

 

 

—

 

 

 

(130

)

 

 

145,338

 

Short-term investments, available-for-sale

 

 

 

$

284,742

 

 

$

—

 

 

$

(148

)

 

$

284,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

US government and government agency

    notes

 

1 - 5

 

$

16,998

 

 

$

6

 

 

$

—

 

 

$

17,004

 

Corporate debt securities

 

1 - 5

 

 

65,512

 

 

 

—

 

 

 

(104

)

 

 

65,408

 

Investments, available-for-sale

 

 

 

$

82,510

 

 

$

6

 

 

$

(104

)

 

$

82,412

 
XML 28 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Future Minimum Lease Payments (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Financing Obligations    
2020 $ 7,576  
2021 8,461  
2022 8,672  
2023 8,889  
2024 9,111  
Thereafter 22,941  
Total minimum lease payments 65,650  
Less amounts representing interest (21,173) $ (25,960)
Add amounts representing residual value 4,950 4,950
Lease financing obligations 49,427 52,709
Current portion of lease financing obligations (3,814) (3,283)
Lease financing obligations, less current portion 45,613 49,426
Sale and leaseback transaction, total financing obligation 49,427 52,709
Operating Leases    
2020 2,236  
2021 2,497  
2022 2,540  
2023 2,584  
2024 2,280  
Thereafter 4,667  
Total minimum lease payments $ 16,804  
Financing Obligations    
2019   7,391
2020   8,254
2021   8,461
2022   8,672
2023   8,889
Thereafter   32,052
Total minimum lease payments   73,719
Operating Leases    
2019   1,050
2020   1,100
2021   976
2022   1,000
2023   1,025
Thereafter   3,698
Total minimum lease payments   $ 8,849
XML 29 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 30 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity - Weighted-Average Assumptions and Estimated Fair Value of Stock Options (Detail) - Stock options - $ / shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate 2.30% 2.60% 1.90%
Expected volatility 64.00% 63.00% 69.00%
Expected life (years) 4 years 5 months 19 days 4 years 6 months 29 days 4 years 6 months 29 days
Weighted-average estimated fair value per share of stock options granted $ 23.47 $ 20.01 $ 9.17
XML 31 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Stock Option Activity

The following table summarizes our stock option activity under the Prior Plans and the 2017 LTIP, or collectively, our Equity Compensation Plans, for the year ended December 31, 2019, in thousands (except per share data):

 

 

 

Options

 

 

Weighted-

Average

Exercise Price

 

 

Weighted-Average

Remaining

Contractual

Term (in years)

 

 

Aggregate

Intrinsic

Value

 

Outstanding at December 31, 2018

 

 

6,541

 

 

$

28.83

 

 

 

 

 

 

 

 

 

Granted

 

 

3,070

 

 

$

44.53

 

 

 

 

 

 

 

 

 

Exercised

 

 

(626

)

 

$

24.27

 

 

 

 

 

 

 

 

 

Forfeited/cancelled/expired

 

 

(450

)

 

$

38.37

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2019

 

 

8,535

 

 

$

34.31

 

 

 

5.08

 

 

$

104,380

 

Vested and expected to vest at December 31, 2019

 

 

8,535

 

 

$

34.31

 

 

 

5.08

 

 

$

104,380

 

Vested and exercisable at December 31, 2019

 

 

3,194

 

 

$

26.37

 

 

 

4.18

 

 

$

63,866

 
Weighted-Average Assumptions and Estimated Fair Value of Stock Options

The table below sets forth the weighted-average assumptions and estimated fair value of stock options we granted under our Equity Compensation Plans during the years presented:

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Risk-free interest rate

 

 

2.3

%

 

 

2.6

%

 

 

1.9

%

Dividend yield

 

 

—

%

 

 

—

%

 

 

—

%

Expected volatility

 

 

64

%

 

 

63

%

 

 

69

%

Expected life (years)

 

4.47

 

 

4.58

 

 

4.58

 

Weighted-average estimated fair value per share of stock options granted

 

$

23.47

 

 

$

20.01

 

 

$

9.17

 
Share Based Compensation Expense

We recognized share-based compensation expense as follows for the years presented, in thousands, except per share data:

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Research and development

 

$

27,361

 

 

$

8,385

 

 

$

1,945

 

General and administrative

 

 

25,686

 

 

 

11,158

 

 

 

5,925

 

Discontinued operations

 

 

—

 

 

 

11

 

 

 

120

 

Total share-based compensation expense

 

$

53,047

 

 

$

19,554

 

 

$

7,990

 

Impact on net loss per share, basic

 

$

1.07

 

 

$

0.42

 

 

$

0.24

 

Impact on net loss per share, diluted

 

$

1.03

 

 

$

0.42

 

 

$

0.24

 
Total Unrecognized Estimated Compensation Expense

The table below sets forth our total unrecognized estimated compensation expense at December 31, 2019, by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized:

 

 

 

Unrecognized

Expense (in

thousands)

 

 

Remaining

Weighted-Average

Recognition

Period (in years)

 

Unvested stock options

 

$

95,703

 

 

 

2.62

 

PRSUs

 

 

1,750

 

 

 

0.21

 

RSUs

 

 

613

 

 

 

0.57

 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investments, Available-for-Sale (Tables)
 12 Months Ended
Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]  
Schedule of Investments, Available-for-Sale

Investments, available-for-sale, consisted of the following, in thousands:

 

December 31, 2019

 

Maturity

in years

 

Amortized

Cost

 

 

Gross

Unrealized Gains

 

 

Gross

Unrealized Losses

 

 

Estimated

Fair Value

 

US government and government agency

    notes

 

Less than 1

 

$

201,046

 

 

$

292

 

 

$

(5

)

 

$

201,333

 

Corporate debt securities

 

Less than 1

 

 

294,481

 

 

 

495

 

 

 

(18

)

 

 

294,958

 

Short-term investments, available-for-sale

 

 

 

$

495,527

 

 

$

787

 

 

$

(23

)

 

$

496,291

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

US government and government agency

    notes

 

1 - 5

 

$

197,157

 

 

$

85

 

 

$

(155

)

 

$

197,087

 

Corporate debt securities

 

1 - 5

 

 

173,322

 

 

 

603

 

 

 

(74

)

 

 

173,851

 

Investments, available-for-sale

 

 

 

$

370,479

 

 

$

688

 

 

$

(229

)

 

$

370,938

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2018

 

Maturity

in years

 

Amortized

Cost

 

 

Gross

Unrealized Gains

 

 

Gross

Unrealized Losses

 

 

Estimated

Fair Value

 

US government and government agency

    notes

 

Less than 1

 

$

139,274

 

 

$

—

 

 

$

(18

)

 

$

139,256

 

Corporate debt securities

 

Less than 1

 

 

145,468

 

 

 

—

 

 

 

(130

)

 

 

145,338

 

Short-term investments, available-for-sale

 

 

 

$

284,742

 

 

$

—

 

 

$

(148

)

 

$

284,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

US government and government agency

    notes

 

1 - 5

 

$

16,998

 

 

$

6

 

 

$

—

 

 

$

17,004

 

Corporate debt securities

 

1 - 5

 

 

65,512

 

 

 

—

 

 

 

(104

)

 

 

65,408

 

Investments, available-for-sale

 

 

 

$

82,510

 

 

$

6

 

 

$

(104

)

 

$

82,412

 
XML 33 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Expected Minimum Rental Payments to be Received under Sublease (Detail) - Sublease Agreement
$ in Thousands
Dec. 31, 2019
USD ($)
Operating Leased Assets [Line Items]  
2020 $ 1,873
2021 2,477
2022 3,487
2023 3,794
2024 3,896
Thereafter 9,839
Total $ 25,366
XML 34 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity - Share Based Compensation Expense (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation expense $ 53,047 $ 19,554 $ 7,990
Impact on net loss per share, basic $ 1.07 $ 0.42 $ 0.24
Impact on net loss per share, diluted $ 1.03 $ 0.42 $ 0.24
Research and development      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation expense $ 27,361 $ 8,385 $ 1,945
General and administrative      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation expense $ 25,686 11,158 5,925
Discontinued operations      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation expense   $ 11 $ 120
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Tables)
 12 Months Ended
Dec. 31, 2019
Future Minimum Lease Payments

At December 31, 2019, the future lease payments under our existing financing and non-cancellable operating leases were as follows, in thousands:

 

Year ending December 31,

 

Financing

Obligations

 

 

Operating

Leases

 

2020

 

$

7,576

 

 

$

2,236

 

2021

 

 

8,461

 

 

 

2,497

 

2022

 

 

8,672

 

 

 

2,540

 

2023

 

 

8,889

 

 

 

2,584

 

2024

 

 

9,111

 

 

 

2,280

 

Thereafter

 

 

22,941

 

 

 

4,667

 

Total minimum lease payments

 

 

65,650

 

 

$

16,804

 

Less amounts representing interest

 

 

(21,173

)

 

 

 

 

Add amounts representing residual value

 

 

4,950

 

 

 

 

 

Lease financing obligations

 

 

49,427

 

 

 

 

 

Less current portion

 

 

(3,814

)

 

 

 

 

 

 

$

45,613

 

 

 

 

 

Under the prior lease guidance, at December 31, 2018, the future minimum lease payments under our existing financing and operating lease obligations were as follows, in thousands:

 

Year ending December 31,

 

Financing

Obligations

 

 

Operating

Leases

 

2019

 

$

7,391

 

 

$

1,050

 

2020

 

 

8,254

 

 

 

1,100

 

2021

 

 

8,461

 

 

 

976

 

2022

 

 

8,672

 

 

 

1,000

 

2023

 

 

8,889

 

 

 

1,025

 

Thereafter

 

 

32,052

 

 

 

3,698

 

Total minimum lease payments

 

 

73,719

 

 

$

8,849

 

Less amounts representing interest

 

 

(25,960

)

 

 

 

 

Add amounts representing residual value

 

 

4,950

 

 

 

 

 

Lease financing obligations

 

 

52,709

 

 

 

 

 

Less current portion

 

 

(3,283

)

 

 

 

 

 

 

$

49,426

 

 

 

 

 
Sublease Agreement  
Expected Minimum Rental Payments to be Received under Sublease Expected minimum rental payments to be received under the sublease are as follows:

 

Year ending December 31,

 

 

 

 

2020

 

$

1,873

 

2021

 

 

2,477

 

2022

 

 

3,487

 

2023

 

 

3,794

 

2024

 

 

3,896

 

Thereafter

 

 

9,839

 

Total

 

$

25,366

 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Disclosures (Tables)
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables present our valuation hierarchy for our financial assets and liabilities that are measured at fair value on a recurring basis, in thousands:

 

 

 

Fair Value Measurements

 

December 31, 2019

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

147,752

 

 

$

147,752

 

 

$

—

 

 

$

—

 

US government and government agency notes(2)

 

 

398,419

 

 

 

398,419

 

 

 

—

 

 

 

—

 

Corporate debt instruments(2)

 

 

483,788

 

 

 

—

 

 

 

483,788

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements

 

December 31, 2018

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

62,438

 

 

$

62,438

 

 

$

—

 

 

$

—

 

US government and government agency notes(2)

 

 

171,278

 

 

 

171,278

 

 

 

—

 

 

 

—

 

Corporate debt instruments(2)

 

 

240,481

 

 

 

—

 

 

 

240,481

 

 

 

—

 

 

 

 

(1)

Included in cash and cash equivalents in the accompanying consolidated balance sheets.

 

(2)

Included in either cash and cash equivalents or available-for-sale investments in the accompanying consolidated balance sheet.
XML 38 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Beacon Discovery, Inc.
 12 Months Ended
Dec. 31, 2019
Variable Interest Entity Disclosure [Abstract]  
Beacon Discovery, Inc.

12. Beacon Discovery, Inc.

In September 2016, we entered into a series of agreements with Beacon, a privately held drug discovery incubator which focuses on identifying and advancing molecules targeting GPCRs. Beacon was founded in 2016 by several of our former employees.

We entered into an agreement, or License and Collaboration Agreement, with Beacon, pursuant to which we transferred certain equipment to Beacon and granted Beacon a non-exclusive, non-assignable and non-sublicensable license to certain database information relating to compounds, receptors and pharmacology, and transferred certain equipment to Beacon. Beacon will seek to engage global partners to facilitate discovery and development. Beacon has agreed to assign to us any intellectual property relating to our existing research and development programs developed in the course of performing research for us, and grant us a non-exclusive license to any intellectual property developed outside the course of performing work for us that is reasonably necessary or useful for developing or commercializing the products under our research and development programs. We are also entitled to rights of negotiation and rights of first refusal to potentially obtain licenses to compounds discovered and developed by Beacon. In addition, we are entitled to receive (i) a percentage of any revenue received by Beacon on or after the second anniversary of the effective date of

the agreement from any third party pursuant to a third-party license, including upfront payments, milestone payments and royalties; (ii) single-digit royalties on the aggregate net sales of any related products sold by Beacon and its affiliates; and (iii) in the event that Beacon is sold, a percentage of the consideration for such sale transaction.

We entered a services agreement with Beacon, or Master Services Agreement, pursuant to which Beacon performs certain research services for us.

We also entered into a separate services agreement with Beacon, or Beacon Services Agreement, pursuant to which Beacon performed our research obligations under our agreement with Boehringer Ingelheim. In consideration for performing these research obligations, Beacon is entitled to receive the applicable FTE payments that are paid to us by Boehringer Ingelheim for the research services and certain milestone payments.

We also entered into a sublease agreement, or Sublease, with Beacon, pursuant to which we sublease approximately 30,000 square feet of laboratory, office and meeting room space to Beacon until May 2027.

As Beacon’s equity investment at risk in September 2016 was not sufficient to permit Beacon to finance its activities without subordinated financial support, Beacon was considered a variable interest entity in which we held a significant variable interest pursuant to the License and Collaboration Agreement. We do not own any equity interest in Beacon; however, as the agreements described above provided us the controlling financial interest in Beacon until December 2017, we consolidated Beacon’s balances and activity within our consolidated financial statements until December 2017 as we were determined to be the primary beneficiary of Beacon. Pursuant to a contract Beacon entered into with a third party in December 2017, we determined we no longer held the controlling financial interest as of that date and, therefore, deconsolidated Beacon from our consolidated financial statements as we were no longer deemed to be the primary beneficiary. Our consolidated financial statements for the year ended December 31, 2017, include Beacon’s results of operations and cash flows until the December 2017 deconsolidation. Beacon’s net and comprehensive loss of $1.3 million for the year ended December 31, 2017 is presented as net loss attributable to noncontrolling interest in consolidated variable interest entity in our consolidated statement of operations and comprehensive loss as we do not own any equity interest in Beacon.

In January 2020, we entered into a new multi-year strategic Collaboration and License Agreement with Beacon, aimed at building novel medicines across a range of GPCR targets believed to play a role in immune and inflammatory diseases. Under the terms of this agreement Beacon is responsible for early drug discovery activities and we will be responsible for any potential future development and, ultimately, commercialization activities. We are required to pay to Beacon research initiation fees, make quarterly research funding payments for the duration of Beacon’s research activities as well as research, development and regulatory milestone payments depending on the future research and development progress. We are also obligated to pay Beacon tiered royalties on net sales of low single digits levels.
XML 39 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborations and License Agreements
 12 Months Ended
Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Collaborations and License Agreements

8. Collaborations and License Agreements

We have collaborations or license agreements with the following companies: United Therapeutics Corporation, or United Therapeutics, Everest Medicines Limited, Eisai Co., Ltd. and Eisai Inc., or collectively, Eisai, and Boehringer Ingelheim International GmbH, or Boehringer Ingelheim.  

In the following table, revenue is disaggregated by major customers, timing of revenue recognition and revenue classification, in thousands:

 

Year ended December 31,

 

Customers

2019

 

 

2018

 

United Therapeutics

$

800,000

 

 

$

—

 

Everest

 

5,000

 

 

 

2,000

 

Eisai

 

(1,077

)

 

 

8,070

 

Other

 

2,508

 

 

 

10,407

 

    Total

$

806,431

 

 

$

20,477

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

Revenue recognized at a point in time

$

803,580

 

 

$

14,092

 

Revenue recognized over time

 

2,851

 

 

 

6,385

 

    Total

$

806,431

 

 

$

20,477

 

 

 

 

 

 

 

 

 

Classification

 

 

 

 

 

 

 

Revenue from continuing operations

$

806,431

 

 

$

17,970

 

Revenue reported under discontinued operations

 

—

 

 

 

2,507

 

    Total

$

806,431

 

 

$

20,477

 

 

United Therapeutics Corporation

In November 2018, we entered into an exclusive license agreement with United Therapeutics. Under this agreement, we granted United Therapeutics an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize ralinepag in any formulation. This transaction was completed in January 2019. United Therapeutics is responsible for all development, manufacturing and commercialization of the licensed products globally. In connection with this transaction we incurred transaction fees of

approximately $17.0 million, of which $14.6 million was incurred in 2019 and $2.4 million was incurred in 2018, and are presented as transaction costs in the accompanying consolidated statement of operations.

We received an upfront payment of $800.0 million under the agreement in the first quarter of 2019. We are also eligible to receive up to an aggregate of $400.0 million in regulatory milestone payments related to ralinepag, consisting of a payment of $150.0 million upon first marketing approval of an oral formulation of ralinepag in a major non-U.S. market, and a payment of $250.0 million upon U.S. marketing approval of an inhaled formulation of ralinepag to treat pulmonary arterial hypertension, as well as low double-digit, tiered royalties on net sales of ralinepag products, subject to certain adjustments for third party license payments.

The promised goods and services under this agreement are accounted for as a single performance obligation consisting of a research, development and commercialization license. Our performance obligation under this agreement was satisfied upon the closing of the transaction in January 2019, and accordingly, the estimated total transaction price of the agreement of $800.0 million was recognized as revenue at the commencement of this agreement in 2019. The future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained. Under the royalty exception in ASC 606 for licensed intellectual property, we do not include any variable amounts related to sales-based royalties in the transaction price until the later of when the sales occur or the performance obligation is satisfied or partially satisfied.

 

Everest

In December 2017, we and Everest entered into an exclusive agreement, or the Everest Agreement, to conduct joint development for the ralinepag and etrasimod programs. Under the Everest Agreement, we granted Everest an exclusive, royalty-bearing license to develop and commercialize ralinepag (in any formulation) and etrasimod (in oral formulations), in mainland China, Taiwan, Hong Kong, Macau and South Korea, or collectively, the Territories. Everest is generally responsible for development and commercialization of the licensed products in the Territories, and may participate in the portion of our global clinical trials that is conducted in the Territories. In January 2019, we and Everest amended the Everest Agreement by entering into two separate agreements, one for each development program with the terms identical to the original Everest Agreement. Under the agreement with United Therapeutics described above, we assigned all our rights and obligations with respect to the ralinepag program under the Everest Agreement, to United Therapeutics.  

In connection with entering into the Everest Agreement, we received from Everest an upfront payment of $12.0 million in December 2017.

In the fourth quarter of 2018, the Chinese National Medical Products Administration accepted the initial clinical trial applications for etrasimod and the oral formulation of ralinepag. Under the terms of the Everest Agreement, we recognized revenue of $2.0 million from the achievement of these milestones.

In October 2019, Everest announced that the first subject has been dosed in a Phase 3 trial evaluating etrasimod in development for the treatment of UC in Greater China and South Korea. Everest paid us a $5.0 million milestone payment due from this achievement, which we recognized as revenue in the fourth quarter of 2019.

We are also eligible to receive up to an aggregate of $110.0 million in success milestones in case of full commercial success of etrasimod products. We are also eligible to receive tiered royalties on net sales of etrasimod products in the Territories.

The promised goods and services under the Everest Agreement are accounted for as a single performance obligation consisting of a development and commercialization license. The amount of the upfront payment was recognized as revenue in December 2017 as we determined (i) that the license is a deliverable with standalone value to Everest and (ii) the upfront payment represents consideration to be allocated to the delivered license. As of December 31, 2019, all remaining future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained.

For the years ended December 31, 2019, 2018, and 2017, we recognized revenues of $5.0 million, $2.0 million and $12.0 million, respectively from the Everest Agreement.

Eisai

In July 2010, we granted Eisai exclusive commercialization rights for lorcaserin (marketed as BELVIQ/BELVIQ XR) solely in the United States and its territories and possessions. In May 2012, we and Eisai entered into the first amended and restated agreement, which expanded Eisai’s exclusive commercialization rights to include most of North and South America. In November 2013, we and Eisai entered into the second amended and restated agreement, or Second Amended Agreement, which expanded Eisai’s exclusive

commercialization rights for lorcaserin to all countries in the world, except for South Korea, Taiwan, Australia, New Zealand and Israel.

In December 2016, we and Eisai amended and restated the terms of marketing and supply agreement for lorcaserin with Eisai by entering into a Transaction Agreement and a Supply Agreement (collectively, the Eisai Agreement) with Eisai. Under the Transaction Agreement, Eisai acquired an exclusive royalty-bearing license or transfer of intellectual property to global commercialization and manufacturing rights to lorcaserin, including in the territories retained by us under the prior agreement, with control over global development and commercialization decisions. Eisai is responsible for all lorcaserin development expenses in the future. We also assigned to Eisai our rights under the commercial lorcaserin distribution agreements with Ildong Pharmaceutical Co., Ltd., or Ildong, for South Korea; CY Biotech Company Limited, or CYB, for Taiwan; and Teva Pharmaceuticals Ltd.’s Israeli subsidiary, Abic Marketing Limited, or Teva, for Israel.

Under the Supply Agreement, Eisai paid us for finished drug product plus monthly manufacturing support payments through March 2018 totaling CHF 8.7 million.

Until March 31, 2018, when we sold the Manufacturing Operations, including the assignment of the Supply Agreement, to Siegfried (see Note 5), we manufactured lorcaserin at our manufacturing facility in Zofingen, Switzerland. Revenues earned for (i) lorcaserin sold by us to Eisai under the manufacturing and supply commitment within the Supply Agreement and (ii) the manufacturing support payments are classified within discontinued operations as part of the Manufacturing Operations in the consolidated statements of operations (see Note 5). All other revenues earned under the Transaction Agreement, such as royalties, are classified within continuing operations in the consolidated statements of operations.

Royalty payments.

Pursuant to the Transaction Agreement, we are eligible to receive tiered royalty payments from Eisai starting at 9.5% on the global net sales of lorcaserin.

Upfront payments.

Prior to the Transaction Agreement, we received from Eisai total upfront payments of $115.0 million under prior lorcaserin collaboration agreements and $7.5 million from the prior commercial lorcaserin distribution agreements with Ildong and CYB described below, and Teva. Revenues from these upfront payments were previously deferred, as we determined that the exclusive rights did not have standalone value without our ongoing development and regulatory activities. Accordingly, these payments were recognized ratably as revenue over the periods in which we expected the services to be rendered. The Transaction Agreement effectively eliminated our obligation to continue performing the development and regulatory activities required in the original agreement.

In total, prior to the Transaction Agreement, we received a total of $102.1 million in milestone payments from Eisai, and other lorcaserin distributors. These payments were recognized as revenue upon the achievement of the milestones.

Accounting for Eisai Agreement under ASC 606.

Upon implementation of ASC 606 on January 1, 2018, we applied a practical expedient for contract modifications applicable to contracts that were modified before the implementation date. The promised goods and services under the Eisai Agreement were assessed in combination with promised goods and services under our previous agreements with Eisai and commercial lorcaserin distribution agreements with Ildong, CYB, and Teva. The total estimated transaction price of these contracts at the implementation date was $344.4 million, which included previously received upfront payments, milestone payments, proceeds from net products sales, reimbursement of development expenses, reimbursement of patent expenses, manufacturing support payments received and expected to be received under the Supply Agreement, proceeds from the sale of on-hand inventory of bulk lorcaserin and the precursor material, royalty payments received through December 31, 2017, and estimated future royalty payments related to intellectual property sold to Eisai. The future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained due to our assessment of the probability of a significant revenue reversal. The future royalties related to licensed intellectual property were excluded from the estimated total transaction price under the royalty exception in ASC 606. The estimated future royalties that relate to intellectual property sold to Eisai do not qualify for the royalty exception in ASC 606 and were included in the estimated total transaction price.

The estimated total transaction price was allocated between satisfied and unsatisfied performance obligations based on the relative standalone selling prices of the identified performance obligations. The remaining manufacturing and supply obligations under the Supply Agreement was the only unsatisfied performance obligation. As a result of this allocation, on January 1, 2018, we reduced the balance of deferred revenues associated with the Eisai Agreement at the implementation date by $25.5 million, recognized a contract asset of $6.1 million related to future manufacturing support payments under the Supply Agreement and recognized a contract

asset of $4.1 million related to estimated future royalty payments from intellectual property sold to Eisai under the Transaction Agreement. In connection with the sale of the Manufacturing Operations on March 31, 2018, we derecognized the remaining portion of the contract asset associated with the Supply Agreement. During 2018, we adjusted our estimate of future royalty payments from intellectual property sold to Eisai under the Transaction Agreement based on the CVOT study results reported by Eisai and our estimate of the qualifying sales of BELVIQ in the future years and recorded associated royalty revenue and an increase to the contract asset of $3.3 million. As of December 31, 2018, the contract asset balance was $6.0 million. Subsequent to year end, Eisai agreed to voluntarily withdraw BELVIQ products from the U.S. market based on a change in the FDA’s risk-benefit assessment of BELVIQ, and as requested by the FDA. As a result, we revised our estimate of future royalties and recorded a $3.7 million reduction to our contract asset as of December 31, 2019.

Based on the bill-and-hold accounting guidance in ASC 606, effective January 1, 2018, we derecognized $3.6 million of inventory of bulk lorcaserin and the precursor material previously sold to Eisai for which the revenue recognition criteria were met on the implementation date under ASC 606.

For the years ended December 31, 2019, 2018 and 2017, we recorded royalty revenues of $(1.1) million, $6.6 million and $1.7 million, respectively related to the Transaction Agreement. For the year ended December 31, 2018 and 2017, we recognized revenue of $1.5 million and $15.9 million, respectively, related to the Supply Agreement (classified under discontinued operations), all of which was recorded during the first quarter of 2018 and primarily consisting of net product sales and other collaboration revenue.

 

 

Accounting for Eisai Agreement under previous revenue recognition policy.

The total arrangement consideration of $115.6 million primarily consists of (i) the December 28, 2016, balances of deferred revenues from the upfront payments received under the prior Eisai agreements and the distribution agreements with other distributors; (ii) the $10.0 million payment received from Eisai on December 28, 2016; and (iii) the product purchase payments and manufacturing support payments we expect to receive from Eisai for the initial two-year manufacturing and supply commitment period.

All of the deliverables were determined to have standalone value and to meet the criteria to be accounted for as separate units of accounting. Factors considered in the determination included, among other things, for the license, the manufacturing experience and capabilities of Eisai and their sublicense rights, and for the remaining deliverables the fact that they are not proprietary and can be provided by other vendors. The total arrangement consideration was allocated to the units of accounting, consisting of the License Deliverable, the Inventory Deliverable the Manufacturing and Supply Commitment Deliverable, and on the basis of their relative estimated selling prices.

For the year ended December 31, 2017, we recognized $6.4 million as revenue of discontinued operations related to this deliverable and $0.9 million of the carrying value of this inventory as cost of product sales of discontinued operations.

The Manufacturing and Supply Commitment Deliverable was provided over 2017 and 2018 as product was shipped to Eisai until March 31, 2018. For the year ended December 31, 2017, we recognized $9.5 million as revenue of discontinued operations related to this deliverable.

Under the Eisai Agreement, Eisai is solely responsible for all costs and expenses in connection with further development of lorcaserin.

Boehringer Ingelheim International GmbH

In December 2015, we and Boehringer Ingelheim entered into a collaboration and license agreement, or Boehringer Ingelheim Agreement, under which we and Boehringer Ingelheim conduct joint research to identify drug candidates targeting an undisclosed G-protein-coupled receptor, or GPCR, that belongs to the group of orphan central nervous system receptors. Under Boehringer Ingelheim Agreement, we granted Boehringer Ingelheim exclusive rights to our internally discovered, novel compounds and intellectual property for an orphan CNS receptor. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.

In December 2018 and October 2019, we earned a milestone payment of $3.5 million and $1.5 million, respectively upon Boehringer Ingelheim’s initiation of preclinical development of a first and an additional compound.

We are also eligible to receive up to an aggregate of $246.0 million (of which the first $7.0 million is also payable to Beacon – see Note 12) in additional success milestone payments in case of full commercial success of multiple drug products.

The promised goods and services under the Boehringer Ingelheim Agreement are accounted for as a single combined performance obligation consisting of a research license, a development and commercialization license and research services. Our research services performance obligation under the original term of the Boehringer Ingelheim Agreement was completely satisfied as of January 2018, and accordingly the estimated total transaction price of the Boehringer Ingelheim Agreement under the original contractual term was fully recognized as revenue over the period from January 2016 through January 2018. We recognize revenue for the combined performance obligation based on the amount of incurred development expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract. As of December 31, 2019, all future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained.

For the years ended December 31, 2019, 2018, and 2017, we recognized revenues of $1.7 million, $4.4 million and $5.1 million, respectively from the Boehringer Ingelheim Agreement.

Outpost Medicine LLC

In April 2018, we and Outpost Medicine entered into a license agreement, or Outpost Agreement, under which Outpost Medicine has an exclusive right to advance an undisclosed, preclinical compound with potential utility in treating genitourinary disorders.

Under the Outpost Agreement, we received an upfront payment of $3.0 million, of which $1.5 million was in the form of an equity interest in Outpost Medicine. In September 2019, we earned a milestone payment of $0.5 million upon Outpost’s initiation of Phase 1 clinical trials.

The promised goods and services under the Outpost Agreement are accounted for as a single performance obligation consisting of a research, development and commercialization license. Our performance obligation under the Outpost Agreement was fully satisfied at the inception of the Outpost Agreement and, accordingly, the estimated total transaction price of the Outpost Agreement was fully recognized as revenue in the second quarter of 2018. As of December 31, 2019, all future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained.

For the years ended December 31, 2019, 2018 and 2017, we recognized revenues of $0.5 million, $2.8 million and $0.2 million, respectively from the Outpost Agreement. Subsequent to year end, the Outpost Agreement was terminated.

Axovant Sciences GmbH

In 2015, we entered into a development, marketing and supply agreement with Roivant Sciences Ltd., which subsequently assigned the exclusive rights to develop and commercialize nelotanserin to its subsidiary, Axovant. Under this agreement, Axovant had exclusive worldwide rights to develop and commercialize nelotanserin, subject to regulatory approval. We also provided certain services and manufactured and sold nelotanserin to Axovant. We refer to this agreement as the Axovant Agreement.

The promised goods and services under the Axovant Agreement were accounted for as two separate performance obligations: (i) a combined performance obligation consisting of commercialization rights and development and regulatory services and (ii) a manufacturing and supply commitment. We recognized revenue for the combined performance obligation consisting of commercialization rights and development and regulatory services based on the amount of incurred development expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract. In December 2018, Axovant announced negative results of an exploratory Phase 2 clinical study and a discontinuation of further clinical development activities under the nelotanserin program. As a result, we revised our estimate of the total transaction price as of December 31, 2018, based on our assessment that we will not perform any research and development services for Axovant in the future and concluded that all our performance obligations have been satisfied. As of December 31, 2018, all future potential purchase price adjustment payments and milestone payments were excluded from the estimated total transaction price as they were considered constrained.

For the years ended December 31, 2018, and 2017, and we recognized revenues of $2.2 million, and $2.2 million, respectively, from the Axovant Agreement. No revenue was recognized under this agreement for the year ended December 31, 2019. In the fourth quarter of 2019, the Axovant Agreement was terminated.

XML 40 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Balance Sheet Details
 12 Months Ended
Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Details

4. Balance Sheet Details

Land, property and equipment, net consisted of the following, in thousands:

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Land

 

$

4,950

 

 

$

4,950

 

Building and capital improvements

 

 

45,246

 

 

 

45,246

 

Leasehold improvements

 

 

19,277

 

 

 

14,915

 

Machinery and equipment

 

 

169

 

 

 

173

 

Computers and software

 

 

2,749

 

 

 

3,083

 

Furniture and office equipment

 

 

1,531

 

 

 

1,175

 

 

 

 

73,922

 

 

 

69,542

 

Less accumulated depreciation and amortization

 

 

(48,794

)

 

 

(46,428

)

Land, property and equipment, net

 

$

25,128

 

 

$

23,114

 

As of December 31, 2019, majority of our long-lived assets were located in the United States.

Accounts payable and other accrued liabilities consisted of the following, in thousands:  

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Accounts payable

 

$

6,043

 

 

$

6,192

 

Accrued compensation

 

 

14,329

 

 

 

8,622

 

Other accrued liabilities

 

 

5,127

 

 

 

1,367

 

Total accounts payable and other accrued liabilities

 

$

25,499

 

 

$

16,181

 

 
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
The Company and Summary of Significant Accounting Policies - Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Jan. 01, 2018
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                 $ 806,431 $ 17,970 $ 21,337  
Loss from operations                 482,746 (144,783) (91,967)  
Loss from continuing operations         $ 68,711 $ (34,314) $ (31,833) $ (31,133) 397,555 (28,569) (95,854)  
Income (loss) from discontinued operations                   (830) 3,122  
Net income (loss) $ (88,311) $ (72,865) $ (61,403) $ 620,134 68,711 $ (34,314) $ (31,833) $ (31,963) 397,555 (29,399) (92,732)  
Net income (loss) attributable to stockholders of Arena                 397,555 (29,399) (91,407)  
Prepaid expenses and other current assets 18,715       10,008       18,715 10,008    
Total current assets 759,934       460,725       759,934 460,725    
Other non-current assets 18,123       10,319       18,123 10,319    
Total assets 1,174,123       686,903       1,174,123 686,903    
Total current liabilities 44,967       29,918       44,967 29,918    
Accumulated deficit (1,102,997)       (1,500,552)       (1,102,997) (1,500,552)    
Total stockholders' equity 1,071,465       606,258       1,071,465 606,258    
Total liabilities and stockholders' equity $ 1,174,123       686,903       1,174,123 686,903    
ASC 606 | Difference between Revenue Guidance in Effect before and after Topic 606                        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                   (1,742)    
Loss from operations                   (1,742)    
Loss from continuing operations                   (594)    
Income (loss) from discontinued operations                   13,660    
Net income (loss)                   13,066    
Net income (loss) attributable to stockholders of Arena                   13,066    
Prepaid expenses and other current assets         (1,484)         (1,484)    
Total current assets         (1,484)         (1,484)    
Other non-current assets         (4,471)         (4,471)    
Total assets         (5,955)         (5,955)    
Total current liabilities         10         10    
Accumulated deficit         (5,965)         (5,965)   $ (19,000)
Total stockholders' equity         (5,965)         (5,965)    
Total liabilities and stockholders' equity         (5,955)         (5,955)    
ASC 606 | Balances without adoption of ASC 606                        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                   16,228    
Loss from operations                   (146,525)    
Loss from continuing operations                   (29,163)    
Income (loss) from discontinued operations                   12,830    
Net income (loss)                   (16,333)    
Net income (loss) attributable to stockholders of Arena                   (16,333)    
Prepaid expenses and other current assets         8,524         8,524    
Total current assets         459,241         459,241    
Other non-current assets         5,848         5,848    
Total assets         680,948         680,948    
Total current liabilities         29,928         29,928    
Accumulated deficit         (1,506,517)         (1,506,517)    
Total stockholders' equity         600,293         600,293    
Total liabilities and stockholders' equity         $ 680,948         680,948    
Collaboration and Other Revenue                        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                 7,284 11,402 19,632  
Collaboration and Other Revenue | ASC 606 | Difference between Revenue Guidance in Effect before and after Topic 606                        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                   105    
Collaboration and Other Revenue | ASC 606 | Balances without adoption of ASC 606                        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                   11,507    
Royalty Revenue                        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                 $ (853) 6,568 $ 1,705  
Royalty Revenue | ASC 606 | Difference between Revenue Guidance in Effect before and after Topic 606                        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                   (1,847)    
Royalty Revenue | ASC 606 | Balances without adoption of ASC 606                        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]                        
Total revenues                   $ 4,721    
XML 43 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Balance Sheet Details - Land, Property and Equipment, Net (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Land, property and equipment, gross $ 73,922 $ 69,542
Less accumulated depreciation and amortization (48,794) (46,428)
Land, property and equipment, net 25,128 23,114
Land    
Property, Plant and Equipment [Line Items]    
Land, property and equipment, gross 4,950 4,950
Building and capital improvements    
Property, Plant and Equipment [Line Items]    
Land, property and equipment, gross 45,246 45,246
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Land, property and equipment, gross 19,277 14,915
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Land, property and equipment, gross 169 173
Computers and software    
Property, Plant and Equipment [Line Items]    
Land, property and equipment, gross 2,749 3,083
Furniture and office equipment    
Property, Plant and Equipment [Line Items]    
Land, property and equipment, gross $ 1,531 $ 1,175
XML 44 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Legal Proceedings - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Nov. 30, 2017
Loss Contingencies [Line Items]    
Accrued litigation settlement $ 24,000  
Litigation settlement expense, net 11,975  
Insurance recovery receivable $ 12,025  
Litigation Amount Settlement By Insurer    
Loss Contingencies [Line Items]    
Accrued litigation settlement   $ 12,025
Litigation Amount Settlement By Parent    
Loss Contingencies [Line Items]    
Accrued litigation settlement   $ 11,975
XML 45 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Line Items]      
Benefit for income taxes $ 110,333,000 $ (110,265,000) $ 0
Statutory federal rate 21.00% 21.00% 34.00%
Increase in valuation allowance $ 34,700,000    
NOL carryforwards $ 151,400,000    
Operating loss carryforwards, terms of limitation Net operating losses generated in 2018 are subject to an 80% limitation    
Operating loss carryforwards, percentage of limitation 80.00%    
Net operating loss and research and development tax credit limitation on use threshold percentage of ownership 50.00%    
Period for net operating loss and research and development tax credit limitation on use threshold percentage of ownership 3 years    
Unrecognized tax benefits, that would impact the effective tax rate $ 8,600,000    
Accrued interest or penalties 0   $ 0
Recognize interest and/or penalties expense 0 $ 0 $ 0
California      
Income Tax Disclosure [Line Items]      
NOL carryforwards $ 393,900,000    
California | Minimum      
Income Tax Disclosure [Line Items]      
NOL carryforwards expiration date, year 2028    
California | Research and Development Tax Credit      
Income Tax Disclosure [Line Items]      
Tax credit carryforwards amount $ 25,100,000    
Federal      
Income Tax Disclosure [Line Items]      
NOL carryforwards $ 539,300,000    
Federal | Minimum      
Income Tax Disclosure [Line Items]      
NOL carryforwards expiration date, year 2029    
Tax credit carryforwards expiration year 2026    
Federal | Research and Development Tax Credit      
Income Tax Disclosure [Line Items]      
Tax credit carryforwards amount $ 38,700,000    
Federal | Orphan Drug Credit | Minimum      
Income Tax Disclosure [Line Items]      
Tax credit carryforwards amount $ 15,000,000.0    
XML 46 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Disclosures
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Disclosures

2. Fair Value Disclosures

We measure our financial assets and liabilities at fair value, which is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

We use the following three-level valuation hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value our financial assets and liabilities:

 

Level 1

 

-

 

Observable inputs such as unadjusted quoted prices in active markets for identical instruments.

Level 2

 

-

 

Quoted prices for similar instruments in active markets or inputs that are observable for the asset or liability, either directly or indirectly.

Level 3

 

-

 

Significant unobservable inputs based on our assumptions.

The following tables present our valuation hierarchy for our financial assets and liabilities that are measured at fair value on a recurring basis, in thousands:

 

 

 

Fair Value Measurements

 

December 31, 2019

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

147,752

 

 

$

147,752

 

 

$

—

 

 

$

—

 

US government and government agency notes(2)

 

 

398,419

 

 

 

398,419

 

 

 

—

 

 

 

—

 

Corporate debt instruments(2)

 

 

483,788

 

 

 

—

 

 

 

483,788

 

 

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements

 

December 31, 2018

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

(Level 2)

 

 

Significant

Unobservable Inputs

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds(1)

 

$

62,438

 

 

$

62,438

 

 

$

—

 

 

$

—

 

US government and government agency notes(2)

 

 

171,278

 

 

 

171,278

 

 

 

—

 

 

 

—

 

Corporate debt instruments(2)

 

 

240,481

 

 

 

—

 

 

 

240,481

 

 

 

—

 

 

 

 

(1)

Included in cash and cash equivalents in the accompanying consolidated balance sheets.

 

(2)

Included in either cash and cash equivalents or available-for-sale investments in the accompanying consolidated balance sheet.
XML 47 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Revenues      
Total revenues $ 806,431,000 $ 17,970,000 $ 21,337,000
Operating costs and expenses      
Research and development 231,496,000 115,029,000 70,988,000
General and administrative 77,616,000 45,257,000 30,341,000
Transaction costs 14,573,000 2,467,000  
Litigation settlement expense, net     11,975,000
Total operating costs and expenses 323,685,000 162,753,000 113,304,000
Income (loss) from operations 482,746,000 (144,783,000) (91,967,000)
Interest and other income (expense)      
Interest income 26,872,000 8,772,000 492,000
Interest expense (4,791,000) (5,695,000) (6,119,000)
Other income 3,061,000 2,872,000 1,740,000
Total interest and other income (expense), net 25,142,000 5,949,000 (3,887,000)
Income (loss) from continuing operations before income taxes 507,888,000 (138,834,000) (95,854,000)
Income tax (provision) benefit (110,333,000) 110,265,000 0
Income (loss) from continuing operations 397,555,000 (28,569,000) (95,854,000)
Income (loss) from discontinued operations   (830,000) 3,122,000
Net income (loss) 397,555,000 (29,399,000) (92,732,000)
Less net loss attributable to noncontrolling interest in consolidated variable interest entity     1,325,000
Net income (loss) attributable to stockholders of Arena 397,555,000 (29,399,000) (91,407,000)
Amounts attributable to stockholders of Arena:      
Income (loss) from continuing operations 397,555,000 (28,569,000) (94,529,000)
Income (loss) from discontinued operations   (830,000) 3,122,000
Net income (loss) attributable to stockholders of Arena $ 397,555,000 $ (29,399,000) $ (91,407,000)
Net income (loss) attributable to stockholders of Arena per share, basic:      
Continuing operations $ 7.99 $ (0.61) $ (2.87)
Discontinued operations   (0.02) 0.10
Net income (loss) attributable to stockholders of Arena per share, basic 7.99 (0.63) (2.77)
Net income (loss) attributable to stockholders of Arena per share, diluted:      
Continuing operations 7.69 (0.61) (2.87)
Discontinued operations   (0.02) 0.10
Net income (loss) attributable to stockholders of Arena per share, diluted $ 7.69 $ (0.63) $ (2.77)
Shares used in calculating net income (loss) attributable to stockholders of Arena per share, basic 49,779 47,041 32,990
Shares used in calculating net income (loss) attributable to stockholders of Arena per share, diluted 51,698 47,041 32,990
Comprehensive Income (Loss):      
Net income (loss) $ 397,555,000 $ (29,399,000) $ (92,732,000)
Foreign currency translation adjustment (11,000) 72,000 2,016,000
Unrealized gain (loss) on available-for-sale investments 1,469,000 (113,000) (133,000)
Comprehensive income (loss) 399,013,000 (29,440,000) (90,849,000)
Less comprehensive loss attributable to noncontrolling interest in consolidated variable interest entity     1,325,000
Comprehensive income (loss) attributable to stockholders of Arena 399,013,000 (29,440,000) (89,524,000)
Collaboration and Other Revenue      
Revenues      
Total revenues 7,284,000 11,402,000 19,632,000
Royalty Revenue      
Revenues      
Total revenues (853,000) $ 6,568,000 $ 1,705,000
United Therapeutics | Collaboration and License Revenue      
Revenues      
Total revenues $ 800,000,000    
XML 48 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborations and License Agreements - Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation Of Revenue [Line Items]      
Revenue $ 806,431 $ 20,477  
Revenue from continuing operations 806,431 17,970 $ 21,337
Revenue reported under discontinued operations   2,507 $ 19,039
Revenue recognized at a point in time      
Disaggregation Of Revenue [Line Items]      
Revenue 803,580 14,092  
Revenue recognized over time      
Disaggregation Of Revenue [Line Items]      
Revenue 2,851 6,385  
United Therapeutics      
Disaggregation Of Revenue [Line Items]      
Revenue 800,000    
Everest      
Disaggregation Of Revenue [Line Items]      
Revenue 5,000 2,000  
Eisai      
Disaggregation Of Revenue [Line Items]      
Revenue (1,077) 8,070  
Other      
Disaggregation Of Revenue [Line Items]      
Revenue $ 2,508 $ 10,407  
XML 49 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Additional Information (Detail)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2019
USD ($)
ft²
Jun. 30, 2019
USD ($)
ft²
Dec. 31, 2019
USD ($)
Property
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
Jan. 01, 2019
USD ($)
Operating Leased Assets [Line Items]              
Number of properties under sale and leaseback agreements | Property     3        
Sale and leaseback transaction, interest expense     $ 4,800 $ 5,700 $ 6,100    
Less amounts representing interest     $ 21,173 25,960      
Sale leaseback transaction, description     Through the remaining terms of the leases in fiscal year 2027        
Sale and leaseback transaction, total financing obligation     $ 49,427 52,709      
Add amounts representing residual value     4,950 4,950      
Rent expense     1,900 1,200 $ 1,500    
Sublease expiration period         2027-05 2027-05  
Rent income from subleases     $ 3,000 $ 2,500 $ 1,700    
ASC 842              
Operating Leased Assets [Line Items]              
Operating lease, liability             $ 6,300
Operating lease, right-of-use asset             $ 5,900
Weighted average discount rate             7.25%
Properties under sale and leaseback agreements              
Operating Leased Assets [Line Items]              
Percentage of annual increase in monthly lease payments     2.50%        
Properties under operating lease              
Operating Leased Assets [Line Items]              
Operating lease, right-of-use asset     $ 11,800        
Operating lease, right-of-use asset, statement of financial position [extensible list]     us-gaap:OtherAssetsNoncurrent        
Operating lease, right-of-use liabilties     $ 1,300        
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]     us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent        
Operating lease liabilities, non current     $ 11,400        
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]     us-gaap:OtherLiabilitiesNoncurrent        
Operating Lease, Weighted Average Remaining Lease Term     6 years 9 months 18 days        
Properties under operating lease | San Diego, California              
Operating Leased Assets [Line Items]              
Percentage of annual increase in monthly lease payments     2.50%        
Operating lease agreement expiration date     2027-05        
Properties under operating lease | Boston, Massachusetts              
Operating Leased Assets [Line Items]              
Percentage of annual increase in monthly lease payments 2.00%            
Operating lease agreement expiration date 2026-12            
Operating lease, liability $ 5,200            
Operating lease, right-of-use asset $ 5,200            
Weighted average discount rate 7.25%            
Operating lease inception date Sep. 01, 2019            
Area of office space | ft² 12,755            
Properties under operating lease | Zug, Switzerland              
Operating Leased Assets [Line Items]              
Operating lease agreement expiration date   2024-05          
Operating lease, liability   $ 1,400          
Operating lease, right-of-use asset   $ 1,500          
Weighted average discount rate   7.25%          
Area of office space | ft² 4,050 10,500          
Additional office space, lease inception date Jan. 01, 2020 Jun. 01, 2019          
XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 281 483 1 false 103 0 false 9 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) Sheet http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss Consolidated Statements of Operations and Comprehensive Income (Loss) Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Equity Sheet http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity Consolidated Statements of Equity Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Cash Flows Sheet http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - The Company and Summary of Significant Accounting Policies Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies The Company and Summary of Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Fair Value Disclosures Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosures Fair Value Disclosures Notes 8 false false R9.htm 100080 - Disclosure - Investments, Available-for-Sale Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSale Investments, Available-for-Sale Notes 9 false false R10.htm 100090 - Disclosure - Balance Sheet Details Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 10 false false R11.htm 100100 - Disclosure - Sale of Manufacturing Operations Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperations Sale of Manufacturing Operations Notes 11 false false R12.htm 100110 - Disclosure - Leases Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeases Leases Notes 12 false false R13.htm 100120 - Disclosure - Stockholders' Equity Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 100130 - Disclosure - Collaborations and License Agreements Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreements Collaborations and License Agreements Notes 14 false false R15.htm 100140 - Disclosure - Income Taxes Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 15 false false R16.htm 100150 - Disclosure - Legal Proceedings Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedings Legal Proceedings Notes 16 false false R17.htm 100160 - Disclosure - Quarterly Financial Data (Unaudited) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited Quarterly Financial Data (Unaudited) Notes 17 false false R18.htm 100170 - Disclosure - Beacon Discovery, Inc. Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryInc Beacon Discovery, Inc. Notes 18 false false R19.htm 100180 - Disclosure - Subsequent Events Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 100190 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies The Company and Summary of Significant Accounting Policies (Policies) Policies http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables The Company and Summary of Significant Accounting Policies (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies 21 false false R22.htm 100210 - Disclosure - Fair Value Disclosures (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresTables Fair Value Disclosures (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosures 22 false false R23.htm 100220 - Disclosure - Investments, Available-for-Sale (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleTables Investments, Available-for-Sale (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSale 23 false false R24.htm 100230 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetails 24 false false R25.htm 100240 - Disclosure - Sale of Manufacturing Operations (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsTables Sale of Manufacturing Operations (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperations 25 false false R26.htm 100250 - Disclosure - Leases (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeases 26 false false R27.htm 100260 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquity 27 false false R28.htm 100270 - Disclosure - Collaborations and License Agreements (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsTables Collaborations and License Agreements (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreements 28 false false R29.htm 100280 - Disclosure - Income Taxes (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxes 29 false false R30.htm 100290 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables Quarterly Financial Data (Unaudited) (Tables) Tables http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited 30 false false R31.htm 100300 - Disclosure - The Company and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail The Company and Summary of Significant Accounting Policies - Additional Information (Detail) Details 31 false false R32.htm 100310 - Disclosure - The Company and Summary of Significant Accounting Policies - Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail The Company and Summary of Significant Accounting Policies - Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash (Detail) Details 32 false false R33.htm 100320 - Disclosure - The Company and Summary of Significant Accounting Policies - Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail The Company and Summary of Significant Accounting Policies - Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements (Detail) Details 33 false false R34.htm 100330 - Disclosure - The Company and Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded From Calculation of Diluted Income (Loss) Per Share (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail The Company and Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded From Calculation of Diluted Income (Loss) Per Share (Detail) Details 34 false false R35.htm 100340 - Disclosure - Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 35 false false R36.htm 100350 - Disclosure - Investments, Available-for-Sale - Schedule of Investments, Available-for-Sale (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail Investments, Available-for-Sale - Schedule of Investments, Available-for-Sale (Detail) Details 36 false false R37.htm 100360 - Disclosure - Balance Sheet Details - Land, Property and Equipment, Net (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail Balance Sheet Details - Land, Property and Equipment, Net (Detail) Details 37 false false R38.htm 100370 - Disclosure - Balance Sheet Details - Accounts Payable and Other Accrued Liabilities (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail Balance Sheet Details - Accounts Payable and Other Accrued Liabilities (Detail) Details 38 false false R39.htm 100380 - Disclosure - Sale of Manufacturing Operations - Additional Information (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail Sale of Manufacturing Operations - Additional Information (Detail) Details 39 false false R40.htm 100390 - Disclosure - Sale of Manufacturing Operations - Summary of Discontinued Operations for Consolidated Statements of Operations (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail Sale of Manufacturing Operations - Summary of Discontinued Operations for Consolidated Statements of Operations (Detail) Details 40 false false R41.htm 100400 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 41 false false R42.htm 100410 - Disclosure - Leases - Future Minimum Lease Payments (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail Leases - Future Minimum Lease Payments (Detail) Details 42 false false R43.htm 100420 - Disclosure - Leases - Expected Minimum Rental Payments to be Received under Sublease (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail Leases - Expected Minimum Rental Payments to be Received under Sublease (Detail) Details 43 false false R44.htm 100430 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 44 false false R45.htm 100440 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail Stockholders' Equity - Summary of Stock Option Activity (Detail) Details 45 false false R46.htm 100450 - Disclosure - Stockholders' Equity - Weighted-Average Assumptions and Estimated Fair Value of Stock Options (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail Stockholders' Equity - Weighted-Average Assumptions and Estimated Fair Value of Stock Options (Detail) Details 46 false false R47.htm 100460 - Disclosure - Stockholders' Equity - Share Based Compensation Expense (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail Stockholders' Equity - Share Based Compensation Expense (Detail) Details 47 false false R48.htm 100470 - Disclosure - Stockholders' Equity - Total Unrecognized Estimated Compensation Expense (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail Stockholders' Equity - Total Unrecognized Estimated Compensation Expense (Detail) Details 48 false false R49.htm 100480 - Disclosure - Collaborations and License Agreements - Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail Collaborations and License Agreements - Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification (Detail) Details 49 false false R50.htm 100490 - Disclosure - Collaborations and License Agreements - Additional Information (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail Collaborations and License Agreements - Additional Information (Detail) Details 50 false false R51.htm 100500 - Disclosure - Income Taxes - Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionBenefitForIncomeTaxesByRegionDetail Income Taxes - Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region (Detail) Details 51 false false R52.htm 100510 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 52 false false R53.htm 100520 - Disclosure - Income Taxes - Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail Income Taxes - Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes (Detail) Details 53 false false R54.htm 100530 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail Income Taxes - Components of Net Deferred Tax Assets (Detail) Details 54 false false R55.htm 100540 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetail Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) Details 55 false false R56.htm 100550 - Disclosure - Legal Proceedings - Additional Information (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail Legal Proceedings - Additional Information (Detail) Details 56 false false R57.htm 100560 - Disclosure - Quarterly Financial Data (Unaudited) (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail Quarterly Financial Data (Unaudited) (Detail) Details http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables 57 false false R58.htm 100570 - Disclosure - Beacon Discovery, Inc. - Additional Information (Detail) Sheet http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail Beacon Discovery, Inc. - Additional Information (Detail) Details 58 false false All Reports Book All Reports arna-10k_20191231.htm arna-20191231.xsd arna-20191231_cal.xml arna-20191231_def.xml arna-20191231_lab.xml arna-20191231_pre.xml arna-ex211_11.htm arna-ex231_7.htm arna-ex311_15.htm arna-ex312_12.htm arna-ex321_14.htm arna-ex43_819.htm gbcvmkcqbvay000001.jpg gbcvmkcqbvay000002.jpg gbcvmkcqbvay000003.jpg gbcvmkcqbvay000004.jpg http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 51 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity - Summary of Stock Option Activity (Detail) - Stock options
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
$ / shares
shares
Number of stock options  
Outstanding at December 31, 2018 | shares 6,541
Granted | shares 3,070
Exercised | shares (626)
Forfeited/cancelled/expired | shares (450)
Outstanding at December 31, 2019 | shares 8,535
Vested and expected to vest at December 31, 2019 | shares 8,535
Vested and exercisable at December 31, 2019 | shares 3,194
Weighted Average Exercise Price ($ per share)  
Outstanding at December 31, 2018 | $ / shares $ 28.83
Granted | $ / shares 44.53
Exercised | $ / shares 24.27
Forfeited/cancelled/expired | $ / shares 38.37
Outstanding at December 31, 2019 | $ / shares 34.31
Vested and expected to vest at December 31, 2019 | $ / shares 34.31
Vested and exercisable at December 31, 2019 | $ / shares $ 26.37
Weighted-Average Remaining Contractual Term (in years)  
Outstanding at December 31, 2019 5 years 29 days
Vested and expected to vest at December 31, 2019 5 years 29 days
Vested and exercisable at December 31, 2019 4 years 2 months 4 days
Aggregate Intrinsic Value  
Outstanding at December 31, 2019 | $ $ 104,380
Vested and expected to vest at December 31, 2019 | $ 104,380
Vested and exercisable at December 31, 2019 | $ $ 63,866
XML 52 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]  
Land, Property and Equipment, Net

Land, property and equipment, net consisted of the following, in thousands:

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Land

 

$

4,950

 

 

$

4,950

 

Building and capital improvements

 

 

45,246

 

 

 

45,246

 

Leasehold improvements

 

 

19,277

 

 

 

14,915

 

Machinery and equipment

 

 

169

 

 

 

173

 

Computers and software

 

 

2,749

 

 

 

3,083

 

Furniture and office equipment

 

 

1,531

 

 

 

1,175

 

 

 

 

73,922

 

 

 

69,542

 

Less accumulated depreciation and amortization

 

 

(48,794

)

 

 

(46,428

)

Land, property and equipment, net

 

$

25,128

 

 

$

23,114

 
Accounts Payable and Other Accrued Liabilities

Accounts payable and other accrued liabilities consisted of the following, in thousands:  

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Accounts payable

 

$

6,043

 

 

$

6,192

 

Accrued compensation

 

 

14,329

 

 

 

8,622

 

Other accrued liabilities

 

 

5,127

 

 

 

1,367

 

Total accounts payable and other accrued liabilities

 

$

25,499

 

 

$

16,181

 

 
XML 53 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
The Company and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2019
Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with the US generally accepted accounting principles, or GAAP, and reflect all of our activities, including those of our wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. As a result of the sale of our Manufacturing Operations (see Note 5), the operations and cash flows of the Manufacturing Operations are reflected as discontinued operations for the years ended December 31, 2018, and 2017.

The accompanying consolidated financial statements also include the activity of Beacon Discovery, Inc., or Beacon, a variable interest entity in which we had a controlling financial interest until December 2017 at which point we deconsolidated Beacon (see Note 12). The results of operations and comprehensive loss attributable to the noncontrolling interest in Beacon are presented as separate components from the results of operations and comprehensive loss attributable to the stockholders of Arena in the consolidated statements of operations and comprehensive loss.
Liquidity

Liquidity

As of December 31, 2019, we had cash, cash equivalents and available-for-sale investments of approximately $1.1 billion. We believe our cash, cash equivalents and available-for-sale investments will be sufficient to fund our operations for at least the next 12 months from the date these consolidated financial statements are issued.

We will require substantial cash to achieve our objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. We may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. We will need to obtain significant funds under our existing collaborations and license agreements, under new collaboration, licensing or other commercial agreements for one or more of our drug candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions.
Changes in Accounting Policies - Leases

Changes in Accounting Policies - Leases.

Effective January 1, 2019, we adopted Accounting Standard Codification Topic 842, Leases, or ASC 842, issued by the Financial Accounting Standards Board, or FASB. ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard established a right-of-use model that requires a lessee to recognize a right-of-use asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. As a result, we have changed our accounting policy for leases as detailed below.

We implemented ASC 842 using the modified retrospective transition approach by applying the new standard to leases existing at the date of initial application. We used the effective date as our date of initial application. Therefore, we did not update the financial information and did not provide the disclosures required under the new standard for dates and periods before January 1, 2019.

We applied ASC 842 using a package of practical expedients, which permitted us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.

Upon adoption of ASC 842, we recorded an operating lease liability of $6.3 million based on the present value of the remaining minimum rental payments under the terms of our existing operating lease pertaining to one of our leased properties with a corresponding right-of-use asset of $5.9 million. Adoption of this standard did not have a material impact on our consolidated statements of operations or cash flows.

The new standard also provides practical expedients for an entity’s ongoing accounting. We elected the short-term lease recognition exemption for our office equipment leases and short-term office space leases. This means, for those leases that qualify, we do not recognize right-of-use assets or lease liabilities. See Note 6 for disclosures related to our leases.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers, or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. The amendments in ASU No. 2018-18 are applied retrospectively to the date of initial application of ASC 606, which for us was January 1, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12 which modifies ASC 740, Income Taxes to simplify the accounting for income taxes in various areas. The amendments in ASU 2019-12 are effective for us for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. We are currently evaluating the impact of adoption on our consolidated financial statements. 
Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires our management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. The amounts reported could differ under different estimates and assumptions.
Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in our consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows, in thousands:

 

 

 

December 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Cash and cash equivalents

 

$

243,274

 

 

$

161,037

 

Restricted cash included in other non-current assets

 

 

226

 

 

 

863

 

Total cash, cash equivalents and restricted cash presented in the consolidated

      statement of cash flows

 

$

243,500

 

 

$

161,900

 

The restricted cash relates to our property leases. The restriction will lapse when the related leases expire.
Available-for-Sale Investments

Available-for-Sale Investments

We define investments as income-yielding securities that can be readily converted to cash, and classify such investments as available-for-sale. We carry these securities at fair value, and report unrealized gains and losses as a separate component of accumulated other comprehensive income or loss. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in securities judged to be other than temporary are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on available-for-sale securities are included in interest income.
Concentrations of Risk

Concentrations of Risk

Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents and available-for-sale investments. We limit our exposure to credit loss by holding our cash primarily in US dollars or placing our cash and investments in US government, agency or government-sponsored enterprise obligations and in corporate debt instruments that are rated investment grade, in accordance with an investment policy approved by our Board of Directors.

Our customers are typically other biopharmaceutical companies to which we license our intellectual property, or sell research and development services or other services under license or collaboration agreements. For the year ended December 31, 2019, more than 99% of our annual revenues was from United Therapeutics. For the year ended December 31, 2018, Eisai, Boehringer Ingelheim, Outpost Medicine, Axovant and Everest accounted for 36.6%, 24.8%, 15.3%, 12.1% and 11.1%, respectively, of our total revenues. For the year ended December 31, 2017, Everest, Boehringer Ingelheim and Axovant accounted for 56.2%, 23.8%, and 10.5%, respectively, of our total revenues.

We monitor our customers’ financial credit worthiness in order to assess and respond to any changes in their credit profile. During the years ended December 31, 2019, 2018, and 2017, we did not record any write-offs or reserves against accounts receivable.
Property and Equipment

Property and Equipment

Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (generally 3 to 15 years) using the straight-line method. Buildings are stated at cost and depreciated over an estimated useful life of approximately 20 years using the straight-line method. Leasehold improvements are stated at cost and amortized over the shorter of the estimated useful lives of the assets or the lease term using the straight-line method. Capital improvements are stated at cost and amortized over the estimated useful lives of the underlying assets using the straight-line method.
Long-lived Assets

Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted cash flows. If impairment is indicated, we measure the impairment loss by comparing the fair value to the carrying value of the asset.
Foreign Currency

Foreign Currency

The functional currency of our wholly owned subsidiaries in Switzerland, APD GmbH and, until March 31, 2018, Arena Pharmaceuticals GmbH, or Arena GmbH, was the Swiss franc. Accordingly, all assets and liabilities of these subsidiaries are translated to US dollars based on the applicable exchange rate on the balance sheet date. Revenue and expense components are translated to US dollars at weighted-average exchange rates in effect during the period. Gains and losses resulting from foreign currency translation are reported as a separate component of accumulated other comprehensive income or loss in the equity section of our consolidated balance sheets.

Foreign currency transaction gains and losses are primarily the result of remeasuring US dollar-denominated receivables and payables of our foreign subsidiaries. Foreign currency transaction gains and losses recorded by Arena GmbH are included in net income (loss) from discontinued operations.

Share-based Compensation

Share-based Compensation

Our share-based awards are measured at fair value and recognized over the requisite service or performance period. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model, based on the market price of the underlying common stock, expected term, expected stock price volatility and expected risk-free interest rate. Expected volatility is computed using historical volatility for a period equal to the expected term. The expected term of options is determined based on historical experience of similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and post-vesting terminations. The risk-free interest rates are based on the US Treasury yield curve, with a remaining term approximately equal to the expected term used in the option pricing model. We account for the forfeitures in the period they occur. The fair value of each restricted stock unit award is estimated based on the market price of the underlying common stock on the date of the grant. The fair value of restricted stock unit awards that include market-based performance conditions is estimated on the date of grant using a Monte Carlo simulation model, based on the market price of the underlying common stock, expected performance measurement period, expected stock price volatility and expected risk-free interest rate.
Research and Development Expenses

Research and Development Expenses

Research and development expenses, which consist primarily of salaries and other personnel costs, clinical trial costs and preclinical study fees, manufacturing costs for non-commercial products, and the development of earlier-stage programs and technologies, are expensed as incurred when these expenditures have no alternative future uses.

We accrue clinical trial expenses based on work performed. In determining the amount to accrue, we rely on estimates of total costs incurred based on enrollment, the completion of trials and other events. We follow this method because we believe reasonably dependable estimates of the costs applicable to various stages of a clinical trial can be made. However, the actual costs and timing of clinical trials are uncertain, subject to risks and may change depending on a number of factors. Differences between the actual clinical trial costs and the estimated clinical trial costs that we have accrued in any prior period are recognized in the subsequent period in which the actual costs become known. Historically, these differences have not been material; however, material differences could occur in the future. Payments made to reimburse collaborators for our share of their research and development activities are recorded as research and development expenses, and are recognized as the work is performed.
Comprehensive Income (Loss)

Comprehensive Income (Loss)

Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report components of comprehensive income or loss in the period in which they are recognized. For the years ended December 31, 2019, 2018 and 2017, comprehensive income (loss) consisted of net income (loss), foreign currency translation gains and losses, and unrealized gains and losses related to available-for-sale investments.
Income (Loss) Per Share

Income (Loss) Per Share

We calculate basic and diluted income (loss) from continuing operations, income (loss) from discontinued operations and net income (loss) per share using the weighted-average number of shares of common stock outstanding during the period.

Since we report a loss from continuing operations for the years ended December 31, 2018, and 2017, in addition to excluding potentially dilutive out-of-the money securities, we have excluded from our calculation of income (loss) per share all potentially dilutive in-the-money (i) stock options, (ii) restricted stock unit awards, or RSUs, (iii) Performance-Based Restricted Stock Units, or PRSUs, (iv) Total Stockholder Return performance restricted stock unit awards, or TSR PRSUs, and (v) unvested restricted stock in our deferred compensation plan, and our diluted net loss per share is the same as our basic net loss per share. The table below presents the weighted-average number of potentially dilutive securities that were excluded from our calculation of diluted income (loss) per share for the years presented, in thousands.

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Stock options

 

 

3,962

 

 

 

5,835

 

 

 

3,664

 

RSUs and unvested restricted stock

 

 

—

 

 

 

20

 

 

 

3

 

Total

 

 

3,962

 

 

 

5,855

 

 

 

3,667

 

 

Because the market condition for the outstanding PRSUs was not satisfied at December 31, 2019, such securities are excluded from the table above. Because the market condition for the TSR PRSUs was not satisfied at December 31, 2017, such securities are excluded from the table above.
Income Taxes

Income Taxes

We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our deferred tax assets and liabilities are determined using the enacted tax rates expected to be in effect for the years in which those tax assets are expected to be realized.

The realization of our deferred tax assets is dependent upon our ability to generate sufficient future taxable income. We establish a valuation allowance when it is more-likely-than-not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available evidence, both positive and negative.

The impact of an uncertain income tax position is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

 
Fair Value Measurements

We measure our financial assets and liabilities at fair value, which is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

We use the following three-level valuation hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value our financial assets and liabilities:

 

Level 1

 

-

 

Observable inputs such as unadjusted quoted prices in active markets for identical instruments.

Level 2

 

-

 

Quoted prices for similar instruments in active markets or inputs that are observable for the asset or liability, either directly or indirectly.

Level 3

 

-

 

Significant unobservable inputs based on our assumptions.
ASC 606  
Revenue Recognition

Revenue Recognition

Our revenues to date have been generated primarily through collaboration and license agreements. Our collaboration and license agreements frequently contain multiple types of promised goods or services including (i) intellectual property licenses, (ii) product research, development and regulatory services and (iii) product manufacturing. Consideration we receive under these arrangements may include upfront payments, research and development funding, cost reimbursements, milestone payments, payments for product sales and royalty payments.

Effective January 1, 2018, we adopted Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, issued by the Financial Accounting Standards Board, or FASB. As a result, we have changed our accounting policy for revenue recognition as detailed below.

We implemented ASC 606 using the modified retrospective method by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of our accumulated deficit at January 1, 2018. Therefore, the comparative period information has not been adjusted.

We applied ASC 606 using a practical expedient for contracts that were modified before the implementation date, which allowed us to determine an aggregate effect of all modifications that occurred before January 1, 2018, when determining the satisfied and unsatisfied performance obligations, the transaction price, and allocating that transaction price to the performance obligations instead of retrospectively restating the contracts for such contract modifications.  

The cumulative impact to our accumulated deficit balance at January 1, 2018, as a result of the adoption of ASC 606 was a decrease of $19.0 million. The decrease arose primarily from a reduction of deferred revenue balances related to upfront payments received from customers and recognition of contract assets due to a combination of (i) the effects of applying the practical expedient for contract modifications and our conclusions related to satisfied and unsatisfied performance obligations, which resulted in a relatively higher portion of the total transaction price recognized as revenue in periods prior to our adoption of ASC 606, (ii) the effect of the bill-and-hold accounting guidance for inventory in ASC 606 and (iii) the inclusion of estimated future royalty payments related to our intellectual property in the total transaction price to the extent such intellectual property was legally sold to our customer rather than licensed. The cumulative effect adjustment is net of an impairment loss of $13.1 million which was a direct effect of the adoption of ASC 606 on the asset group of the Manufacturing Operations, which was classified as assets of disposal group held for sale since December 2017.

The following table summarizes the impacts of adopting ASC 606 on our consolidated financial statements, in thousands.

 

 

Impact of Changes in Accounting Policies

 

Year ended December 31, 2018

 

As reported

 

 

Adjustments

 

 

Balances without adoption of ASC 606

 

Collaboration and other revenue

 

$

11,402

 

 

$

105

 

 

$

11,507

 

Royalty revenue

 

 

6,568

 

 

 

(1,847

)

 

 

4,721

 

Total revenues

 

 

17,970

 

 

 

(1,742

)

 

 

16,228

 

Loss from operations

 

 

(144,783

)

 

 

(1,742

)

 

 

(146,525

)

Loss from continuing operations

 

 

(28,569

)

 

 

(594

)

 

 

(29,163

)

Income (loss) from discontinued operations

 

 

(830

)

 

 

13,660

 

 

 

12,830

 

Net loss

 

 

(29,399

)

 

 

13,066

 

 

 

(16,333

)

Net loss attributable to stockholders of Arena

 

 

(29,399

)

 

 

13,066

 

 

 

(16,333

)

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2018

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

$

10,008

 

 

$

(1,484

)

 

$

8,524

 

Total current assets

 

 

460,725

 

 

 

(1,484

)

 

 

459,241

 

Other non-current assets

 

 

10,319

 

 

 

(4,471

)

 

 

5,848

 

Total assets

 

 

686,903

 

 

 

(5,955

)

 

 

680,948

 

Total current liabilities

 

 

29,918

 

 

 

10

 

 

 

29,928

 

Accumulated deficit

 

 

(1,500,552

)

 

 

(5,965

)

 

 

(1,506,517

)

Total stockholders' equity

 

 

606,258

 

 

 

(5,965

)

 

 

600,293

 

Total liabilities and stockholders' equity

 

 

686,903

 

 

 

(5,955

)

 

 

680,948

 

 

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that we expect to be entitled to receive in exchange for these services and excludes sales incentives and amounts collected on behalf of third parties. We analyze the nature of these performance obligations in the context of individual collaboration and license agreements in order to assess the distinct performance obligations. We apply the following five steps to recognize revenue:

i) Identify the contract with a customer. We consider the terms and conditions of our collaboration and license agreements to identify contracts within the scope of ASC 606. We consider that we have a contract with a customer when the contract is approved, we can identify each party's rights regarding the goods and services to be transferred, we can identify the payment terms for the goods and services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. We use judgment in determining the customer's ability and intent to pay, which is based upon factors including the customer's historical payment experience or, for new customers, credit and financial information pertaining to the customers.

ii) Identify the performance obligations in the contract. Performance obligations in our collaboration and license agreements are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. Our performance obligations generally consist of intellectual property licenses, research, development and/or regulatory services and manufacturing and supply commitments.

 iii) Determine the transaction price. We determine the transaction price based on the consideration to which we expect to be entitled in exchange for transferring goods and services to the customer. In determining the transaction price, any variable consideration would be considered, to the extent applicable, if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. In accordance with the royalty exception under ASC 606 for licenses of intellectual property, the transaction price excludes future royalty payments to be received from our customers. None of our collaboration and license agreements contain consideration payable to our customer or a significant financing component.

 iv) Allocate the transaction price to performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to that performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price.

 v) Recognize revenue when or as we satisfy a performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised goods or services to a customer. We recognize revenue when we transfer control of the goods or services to our customers for an amount that reflects the consideration that we expect to receive in exchange for those services.

Performance Obligations

The following is a description of principal goods and services from which we generate revenue.

 

Intellectual property licenses

We generate revenue from licensing our intellectual property including know-how and development and commercialization rights. These licenses provide customers with a term-based license to further research, develop and commercialize our internally-discovered drug candidates. The consideration we receive in the form of nonrefundable upfront consideration related to the functional intellectual property licenses is recognized when we transfer such license to the customer unless the license is combined with other goods or services into one performance obligation, in which case the revenue is recognized over a period of time based on our estimated pattern in which we satisfy the combined performance obligation. Our licensing agreements are generally cancelable. Customers have the right to terminate their contracts upon notice. We have the right to terminate the contracts generally only if the customer is in breach of the contract and fails to remedy the breach in accordance with the contractual terms.

 

Intellectual property sales

We generate royalty revenue from sales of our intellectual property. We estimate the future royalty payments and recognize revenue with a corresponding contract asset at a point in time when we transfer the intellectual property to the customer. We periodically reassess our estimate of the future royalty payments and recognize any estimate adjustments as revenue in the current period.

 

Research, development and regulatory services

We generate revenue from research, development and regulatory services we provide to our customers in connection with the licensed intellectual property. The services we provide to our customers primarily include scientific research activities, preparation for and management of clinical trials, and assistance during the regulatory approval application process. Revenue associated with these services is recognized based on our estimate of total consideration to be received for such services and the pattern in which we perform the services. The pattern of performance is generally determined to be the amount of incurred expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.

 

Product manufacturing

In the past, we generated revenue from manufacturing and clinical supply promises to our customers in connection with securing a supply of drug products for development and clinical trial purposes. The drug products were generally manufactured by our contract manufacturing organizations. We used our product manufacturing facility in Zofingen, Switzerland for a portion of the product manufacturing requirements until we sold the Manufacturing Operations on March 31, 2018 (see Note 5). Revenue associated with product manufacturing obligations is recognized at a point in time as control of the related product is transferred to the customer.

Contracts with Multiple Performance Obligations

Most of our collaboration and license agreements with customers contain multiple promised goods or services. Based on the characteristics of the promised goods and services we analyze whether they are separate or combined performance obligations. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price based on our overall pricing and discounting objectives, taking into consideration the type of services, estimates of hourly market rates, and stage of the research, development or clinical trials.

Variable Consideration

Our contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone payments, which are due to us upon achievement of specific development and regulatory milestones and (ii) one-time sales-based payments and sales-based royalties associated with sold or licensed intellectual property.

Due to uncertainty associated with achievement of the development and regulatory milestones, the related milestone payments are excluded from the contract consideration and the corresponding revenue is not recognized until we conclude it is probable that reversal of such milestone revenue will not occur.

Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. We recognize revenue for sales-based royalties under licensed intellectual property and one-time payments at the later of when the sales occur or the performance obligation is satisfied or partially satisfied.

Disaggregation of Revenue

We operate in one reportable business segment. We provide goods and services to our customers in collaboration and license agreements pursuant to various geographical markets.

 

Contract Assets

We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed. Product sales are generally billed as completed. Payment terms on invoiced amounts are typically 30 days. Contract assets include amounts related to our contractual right to consideration for both completed and partially completed performance obligations that have not been invoiced and for which we do not yet have the right to payment. The current portion of contract asset is included in prepaid expenses and other current assets in the consolidated balance sheet. The non-current portion of contract assets is included in other non-current assets in the consolidated balance sheet. We estimate the amount of the contract asset by applying the expected value method to our estimate of future royalty payments we will receive from this customer. Any changes to this estimate are recorded as an adjustment to revenue in the period in which the change in estimate is made.

Cost to Obtain and Fulfill a Contract

We generally do not incur costs to obtain new contracts. Costs to fulfill contracts are expensed as incurred.

Remaining Performance Obligations

The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to our existing collaboration and license agreements as of December 31, 2019 is immaterial.

Under the royalty exception in ASC 606 for licensed intellectual property we do not recognize any revenue for the variable amounts related to sales-based royalties and milestones until the later of when the sales occur or the performance obligation is satisfied or partially satisfied. Accordingly, the revenue related to future sales-based royalties and milestones are excluded from the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied.

Previous Revenue Recognition Policy

Prior to January 1, 2018, we recognized revenue when (i) persuasive evidence of an arrangement existed, (ii) delivery had occurred and title had passed, (iii) the price was fixed or determinable and (iv) collectability was reasonably assured. Any advance payments we received in excess of amounts earned were classified as deferred revenues.

We historically evaluated deliverables in a multiple-element arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered element does not have standalone value without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the inception of the arrangement based on the relative selling price.

To determine the selling price of a separate deliverable, we used the hierarchy as prescribed in Accounting Standards Codification Topic 605-25 based on vendor-specific objective evidence, or VSOE, third-party evidence, or TPE, or best estimate of selling price, or BESP. VSOE was based on the price charged when the element was sold separately and was the price actually charged for that deliverable. TPE was determined based on third-party evidence for a similar deliverable when sold separately. BESP was the estimated selling price at which we would transact a sale if the elements of collaboration and license arrangements were sold on a stand-alone basis to the buyer.

Non-refundable upfront payments received under our collaboration and license agreements for commercialization rights were deferred if such rights were not deemed to have standalone value without ongoing services which may be required under the agreement. If deferred, such amounts were recognized as revenues on a straight-line basis over the period in which we expected to perform the services.

Amounts we received as reimbursement for our research and development expenditures were recognized as revenue as the services are performed.

Under the milestone method, we recognized revenue that was contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone was achieved. A milestone is an event (i) that can be achieved in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due us. A milestone payment is considered substantive when the consideration payable to us for each milestone (a) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (b) relates solely to our past performance and (c) is reasonable relative to all of the other deliverables and payments under the arrangement. In making this assessment, we considered all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables. Other contingent-based payments received were recognized when earned.
XML 54 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborations and License Agreements (Tables)
 12 Months Ended
Dec. 31, 2019
Revenue From Contract With Customer [Abstract]  
Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification

In the following table, revenue is disaggregated by major customers, timing of revenue recognition and revenue classification, in thousands:

 

Year ended December 31,

 

Customers

2019

 

 

2018

 

United Therapeutics

$

800,000

 

 

$

—

 

Everest

 

5,000

 

 

 

2,000

 

Eisai

 

(1,077

)

 

 

8,070

 

Other

 

2,508

 

 

 

10,407

 

    Total

$

806,431

 

 

$

20,477

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

Revenue recognized at a point in time

$

803,580

 

 

$

14,092

 

Revenue recognized over time

 

2,851

 

 

 

6,385

 

    Total

$

806,431

 

 

$

20,477

 

 

 

 

 

 

 

 

 

Classification

 

 

 

 

 

 

 

Revenue from continuing operations

$

806,431

 

 

$

17,970

 

Revenue reported under discontinued operations

 

—

 

 

 

2,507

 

    Total

$

806,431

 

 

$

20,477

 

 
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Sale of Manufacturing Operations - Additional Information (Detail)
SFr in Millions
 1 Months Ended
Mar. 31, 2018
CHF (SFr)
Dec. 31, 2019
employee
Siegfried    
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]    
Number of employees transferred | employee   50
Arena Gmb H    
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]    
Sales price of business SFr 4  
Cash received from sale of business SFr 3  
XML 56 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
The Company and Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
Segment
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jan. 01, 2019
USD ($)
Jan. 01, 2018
USD ($)
Schedule Of Significant Accounting Policies [Line Items]          
Number of business segments | Segment 1        
Cash and cash equivalents and available-for-sale investments $ 1,100,000        
Accumulated deficit $ 1,102,997 $ 1,500,552      
Number of reportable business segment | Segment 1        
Customers billing method, description We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed        
Payment terms on invoiced amounts 30 days        
Building          
Schedule Of Significant Accounting Policies [Line Items]          
Property and equipment, estimated useful life 20 years        
Minimum          
Schedule Of Significant Accounting Policies [Line Items]          
Property and equipment, estimated useful life 3 years        
Maximum          
Schedule Of Significant Accounting Policies [Line Items]          
Property and equipment, estimated useful life 15 years        
Sales Revenue, Net | Eisai          
Schedule Of Significant Accounting Policies [Line Items]          
Concentrations of risk percentage   36.60%      
Sales Revenue, Net | Boehringer Ingelheim          
Schedule Of Significant Accounting Policies [Line Items]          
Concentrations of risk percentage   24.80% 23.80%    
Sales Revenue, Net | Outpost Medicine          
Schedule Of Significant Accounting Policies [Line Items]          
Concentrations of risk percentage   15.30%      
Sales Revenue, Net | Everest          
Schedule Of Significant Accounting Policies [Line Items]          
Concentrations of risk percentage   11.10% 56.20%    
Sales Revenue, Net | Axovant          
Schedule Of Significant Accounting Policies [Line Items]          
Concentrations of risk percentage   12.10% 10.50%    
Sales Revenue, Net | United Therapeutics | Minimum          
Schedule Of Significant Accounting Policies [Line Items]          
Concentrations of risk percentage 99.00%        
ASC 842          
Schedule Of Significant Accounting Policies [Line Items]          
Operating lease, liability       $ 6,300  
Operating lease, right-of-use asset       $ 5,900  
ASC 606          
Schedule Of Significant Accounting Policies [Line Items]          
Impairment loss     $ 13,100    
ASC 606 | Difference between Revenue Guidance in Effect before and after Topic 606          
Schedule Of Significant Accounting Policies [Line Items]          
Accumulated deficit   $ 5,965     $ 19,000
XML 57 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value Measurements, Recurring - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Assets:    
Money market funds $ 147,752 $ 62,438
US government and government agency notes 398,419 171,278
Corporate debt instruments 483,788 240,481
Quoted Prices in Active Markets (Level 1)    
Assets:    
Money market funds 147,752 62,438
US government and government agency notes 398,419 171,278
Significant Other Observable Inputs (Level 2)    
Assets:    
Corporate debt instruments $ 483,788 $ 240,481
XML 58 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Legal Proceedings
 12 Months Ended
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]  
Legal Proceedings

10. Legal Proceedings

Beginning in September 2010, a number of complaints were filed in the US District Court for the Southern District of California, or District Court, against us and certain of our current and former employees and directors on behalf of certain purchasers of our common stock. The complaints were brought as purported stockholder class actions, and, in general, include allegations that we and certain of our current and former employees and directors violated federal securities laws by making materially false and misleading statements regarding our BELVIQ program, thereby artificially inflating the price of our common stock. The plaintiffs sought unspecified monetary damages and other relief. In August 2011, the District Court consolidated the actions and appointed a lead plaintiff and lead counsel. In November 2017, we and the Lead Plaintiff signed a stipulation and agreement of settlement, or Stipulation, to resolve the consolidated class action. Under the terms of the Stipulation, and in exchange for a release of all claims

by class members and a dismissal of the consolidated class action with prejudice, we have agreed that (i) our insurers would pay class members and their attorneys a total of approximately $12.025 million and (ii) Arena would pay class members and their attorneys approximately $11.975 million in either shares of our common stock or cash at our election. On November 30, 2017, the District Court preliminary approved the settlement and the form of notice to potential class members of the proposed settlement and the procedure by which they can become class members. On March 8, 2018, the lead plaintiff filed motions for final approval of the settlement, the plan of allocation and award of attorney fees. On April 12, 2018, the District Court entered its final approval order approving the settlement and the plan of allocation and request for attorneys’ fees and expense. We recognized $11.975 million of net expense for the portion of the settlement that we agreed to pay in either common stock or cash in the consolidated statements of operations for the year ended December 31, 2017, and $24.0 million as a current liability in the consolidated balance sheet as of December 31, 2017 for the gross settlement liability, with a corresponding $12.025 million insurance recovery receivable. In the second quarter of 2018, we and our insurer made settlement payments in cash to the class members and their attorneys to settle our liability under the Stipulation.

We are not currently subject to any material legal proceedings
XML 59 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases

6. Leases

San Diego, California

We have three properties in San Diego, California, under sale and leaseback agreements. The terms of these leases contain a purchase option and stipulate annual increases in monthly lease payments of 2.5%. We account for our sale and leaseback transactions using the financing method. Under the financing method, the book value of the properties and related accumulated depreciation remain on our balance sheet and no sale is recognized. The adoption of ASC 842 did not result in a change to our current accounting policy related to our sale and leaseback agreements. The sales price of the properties is recorded as a financing obligation, and a portion of each lease payment is recorded as interest expense. For the years ended December 31, 2019, 2018, and 2017, we recorded interest expense of $4.8 million, $5.7 million, and $6.1 million respectively, related to these leases. We expect interest expense related to our facilities to total $21.2 million from December 31, 2019, through the remaining terms of the leases in fiscal year 2027. At December 31, 2019, the total financing obligation associated with these sale and leaseback agreements was $49.4 million. The aggregate residual value of the facilities at the end of the lease terms is $5.0 million.

We lease an additional property in San Diego, California under an operating lease, which expires in May 2027, contains a purchase option and stipulates annual increases in monthly lease payments of 2.5%. Upon adoption of ASC 842, we recorded an operating lease liability of $6.3 million based on the present value of the remaining minimum lease payments under the terms of our existing operating lease with a corresponding right-of-use asset of $5.9 million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available at effective date of adoption in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was 7.25%.

Boston, Massachusetts

In the third quarter of 2019, we entered into a new lease agreement for approximately 12,755 square feet of office space in Boston, Massachusetts with the lease inception date of September 1, 2019. This lease is classified as an operating lease and expires in December 2026. The lease stipulates annual increases in monthly lease payments of 2.0%. At the lease inception date, we recorded an

operating lease liability of $5.2 million based on the present value of the remaining minimum lease payments under the terms of this lease with a corresponding right-of-use asset of $5.2 million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available at effective date of adoption in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was also 7.25%.

Zug, Switzerland

In the second quarter of 2019, we entered into a lease in Zug, Switzerland, for approximately 10,500 square feet of office space with the lease inception date of June 1, 2019. This lease expires in May 2024. At the lease inception, we recorded an operating lease liability of $1.4 million based on the present value of the remaining minimum lease payments under the terms of this operating lease with a corresponding right-of-use asset of $1.5 million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available as of the lease inception in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was 7.25%. In the third quarter of 2019, we entered into an addendum to this lease for approximately 4,050 square feet of additional office space in the same location with the same landlord and the lease inception date of January 1, 2020.

As of December 31, 2019, the balance of the right-of-use assets associated with the leases described above was $11.8 million and is included in other non-current assets in the accompanying consolidated balance sheet. As of December 31, 2019, the current portion of the corresponding lease liabilities of $1.3 million is included in accounts payable and other accrued liabilities and the non-current portion of the lease liabilities of $11.4 million is included in other long-term liabilities in the accompanying consolidated balance sheet. The operating lease costs and cash paid for the amounts included in the measurement of lease liabilities are classified as operating activities in the accompanying consolidated cash flow statement. We recognize rent expense on a straight-line basis over the term of each lease. Rent expense of $1.9 million, $1.2 million and $1.5 million was recognized for the years ended December 31, 2019, 2018, and 2017, respectively. The weighted-average remaining lease term for all operating leases as of December 31, 2019 was 6.8 years.

At December 31, 2019, the future lease payments under our existing financing and non-cancellable operating leases were as follows, in thousands:

 

Year ending December 31,

 

Financing

Obligations

 

 

Operating

Leases

 

2020

 

$

7,576

 

 

$

2,236

 

2021

 

 

8,461

 

 

 

2,497

 

2022

 

 

8,672

 

 

 

2,540

 

2023

 

 

8,889

 

 

 

2,584

 

2024

 

 

9,111

 

 

 

2,280

 

Thereafter

 

 

22,941

 

 

 

4,667

 

Total minimum lease payments

 

 

65,650

 

 

$

16,804

 

Less amounts representing interest

 

 

(21,173

)

 

 

 

 

Add amounts representing residual value

 

 

4,950

 

 

 

 

 

Lease financing obligations

 

 

49,427

 

 

 

 

 

Less current portion

 

 

(3,814

)

 

 

 

 

 

 

$

45,613

 

 

 

 

 

Under the prior lease guidance, at December 31, 2018, the future minimum lease payments under our existing financing and operating lease obligations were as follows, in thousands:

 

Year ending December 31,

 

Financing

Obligations

 

 

Operating

Leases

 

2019

 

$

7,391

 

 

$

1,050

 

2020

 

 

8,254

 

 

 

1,100

 

2021

 

 

8,461

 

 

 

976

 

2022

 

 

8,672

 

 

 

1,000

 

2023

 

 

8,889

 

 

 

1,025

 

Thereafter

 

 

32,052

 

 

 

3,698

 

Total minimum lease payments

 

 

73,719

 

 

$

8,849

 

Less amounts representing interest

 

 

(25,960

)

 

 

 

 

Add amounts representing residual value

 

 

4,950

 

 

 

 

 

Lease financing obligations

 

 

52,709

 

 

 

 

 

Less current portion

 

 

(3,283

)

 

 

 

 

 

 

$

49,426

 

 

 

 

 

Subleases

In 2016 and 2017, we entered into agreements to sublease several of our California properties. All our subleases expire in May 2027. The terms of the subleases stipulate annual increases in monthly rental payments. For the years ended December 31, 2019, 2018 and 2017, we recognized rent income from our subleases of $3.0 million, $2.5 million and $1.7 million, respectively

We recognize rent income on a straight-line basis over the term of the subleases. Expected minimum rental payments to be received under the sublease are as follows:

 

Year ending December 31,

 

 

 

 

2020

 

$

1,873

 

2021

 

 

2,477

 

2022

 

 

3,487

 

2023

 

 

3,794

 

2024

 

 

3,896

 

Thereafter

 

 

9,839

 

Total

 

$

25,366

 

 
XML 60 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Operating activities:      
Net income (loss) $ 397,555 $ (29,399) $ (92,732)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
(Income) loss from discontinued operations   830 (3,122)
Depreciation and amortization 3,233 3,759 4,278
Deferred income taxes 110,333 (110,333)  
Non-cash collaboration revenue   (1,500)  
Non-cash royalty revenue 3,744 (3,315)  
Share-based compensation 53,047 19,543 7,855
Litigation settlement expense, net     11,975
Amortization of prepaid financing costs 90 110 136
Amortization of original issue discounts, net of premiums, on available- for-sale investments (5,628) (664)  
Loss (gain) on disposal of property and equipment 112 (791) (379)
Changes in operating assets and liabilities:      
Accounts receivable 3,432 (2,760) 10,787
Prepaid expenses and other assets (8,133) (2,929) 585
Payables and accrued liabilities 12,347 10,871 1,803
Accrued litigation settlement   (11,975)  
Deferred revenues (1,438) (2,061) (4,401)
Other long-term liabilities   (1,265) (577)
Net cash provided by (used in) operating activities - continuing operations 568,694 (131,879) (63,792)
Net cash used in operating activities - discontinued operations   (333) (2,850)
Net cash provided by (used in) operating activities 568,694 (132,212) (66,642)
Investing activities:      
Purchases of available-for-sale investments (1,469,220) (364,539) (112,615)
Proceeds from sale and maturity of available-for-sale investments 976,093 110,564  
Deconsolidation of variable interest entity     (406)
Purchases of property and equipment (4,819) (692) (113)
Proceeds from sale of property and equipment     789
Other non-current assets   (11) (5)
Net cash used in investing activities - continuing operations (497,946) (254,678) (112,350)
Net cash provided by (used in) investing activities - discontinued operations 997 3,405 (40)
Net cash used in investing activities (496,949) (251,273) (112,390)
Financing activities:      
Principal payments on lease financing obligations (3,282) (4,000) (3,518)
Proceeds from issuance of common stock 13,147 389,031 248,805
Net cash provided by financing activities 9,865 385,031 245,287
Effect of exchange rate changes on cash (10) 654 1,870
Net increase in cash, cash equivalents and restricted cash 81,600 2,200 68,125
Cash, cash equivalents and restricted cash at beginning of year 161,900 159,700 91,575
Cash, cash equivalents and restricted cash at end of year 243,500 161,900 159,700
Supplemental disclosure of cash flow information:      
Interest paid $ 4,787 5,696 $ 5,967
Supplemental disclosure of non-cash investing and financing information:      
Disposition of property and land upon lease expiration   3,944  
Reduction in lease financing obligation from release of residual value upon lease expiration   $ 5,039  
XML 61 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 243,274 $ 161,037
Short-term investments, available-for-sale 496,291 284,594
Accounts receivable 1,654 5,086
Prepaid expenses and other current assets 18,715 10,008
Total current assets 759,934 460,725
Investments, available-for-sale 370,938 82,412
Land, property and equipment, net 25,128 23,114
Deferred tax assets   110,333
Other non-current assets 18,123 10,319
Total assets 1,174,123 686,903
Current liabilities:    
Accounts payable and other accrued liabilities 25,499 16,181
Accrued clinical and preclinical study fees 15,654 10,454
Current portion of lease financing obligations 3,814 3,283
Total current liabilities 44,967 29,918
Lease financing obligations, less current portion 45,613 49,426
Other long-term liabilities 12,078 1,301
Commitments and contingencies
Stockholders' equity:    
Preferred stock
Common stock 5 5
Additional paid-in capital 2,173,154 2,106,960
Accumulated other comprehensive income (loss) 1,303 (155)
Accumulated deficit (1,102,997) (1,500,552)
Total stockholders' equity 1,071,465 606,258
Total liabilities and equity $ 1,174,123 $ 686,903
XML 62 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Components of Net Deferred Tax Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets:    
Federal and California NOL carryforwards $ 140,762 $ 210,853
Federal and California research and development credit carryforwards 73,956 69,221
Foreign NOL carryforwards   15,131
Share-based compensation expense 11,010 6,124
Depreciation 3,183 2,914
Lease liability 2,359  
Other, net 354 784
Total deferred tax assets 231,624 305,027
Right-of-use assets (2,218)  
Total deferred tax liabilities (2,218)  
Net deferred tax assets 229,406 305,027
Valuation allowance $ (229,406) (194,694)
Net deferred tax assets   $ 110,333
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborations and License Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended 16 Months Ended
Oct. 31, 2019
USD ($)
Jan. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Apr. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Mar. 31, 2018
CHF (SFr)
Sep. 30, 2019
USD ($)
Dec. 28, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
License agreement costs incurred related to transaction fees               $ 14,573,000 $ 2,467,000        
Recognized revenues               5,000,000.0 2,000,000.0 $ 12,000,000.0      
Reduction in deferred revenue associated with agreement               (1,438,000) (2,061,000) (4,401,000)      
Contract Assets     $ 6,000,000.0       $ 6,000,000.0   6,000,000.0        
Revenues               806,431,000 17,970,000 21,337,000      
Total arrangement consideration under Eisai Agreement               115,600,000          
Payment received from Eisai                         $ 10,000,000.0
Recognized revenue of discontinued operations                 2,507,000 19,039,000      
Carrying value of inventory as cost of product sales of discontinued operations                 1,858,000 7,472,000      
Royalty Revenue                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Decrease in contract asset resulting from adjustment to future estimated royalty payments               3,700,000          
Revenues               (853,000) 6,568,000 1,705,000      
Everest                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaborative agreement upfront payments         $ 12,000,000.0                
Paid on Milestone Achievements               $ 5,000,000.0          
Eisai | Lorcaserin Product                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Royalty rate on annual net sales               9.50%          
Boehringer Ingelheim                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payments on achievement               $ 246,000,000.0          
Recognized milestone revenue $ 1,500,000   3,500,000                    
Revenues               1,700,000 4,400,000 5,100,000      
Boehringer Ingelheim | Beacon Discovery, Inc.                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Paid on Milestone Achievements               7,000,000.0          
Axovant                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Recognized revenues               $ 0 2,200,000 2,200,000      
Chinese National Medical Products Administration | Everest                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Recognized milestone revenue             2,000,000.0            
Maximum | Everest                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payments on achievement         $ 110,000,000.0         110,000,000.0      
Eisai First Amended Agreement                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaborative agreement initiation date               2012-05          
Eisai Second Amended Agreement                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaborative agreement initiation date               2013-11          
Eisai Agreement                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaboration Agreement Estimated Transaction Price               $ 344,400,000          
Additional manufacturing support payments received | SFr                     SFr 8,700,000    
Reduction in deferred revenue associated with agreement               25,500,000          
Contract asset associated with agreement               6,100,000          
Estimated future royalty payments               4,100,000          
Reversal balance of hand on inventory               3,600,000          
Eisai Agreement | Royalty Revenue                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Increase in contract asset resulting from adjustment to future estimated royalty payments     $ 3,300,000       $ 3,300,000   3,300,000        
Revenues               (1,100,000) 6,600,000 1,700,000      
Prior to Transaction Agreement                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaborative agreement upfront payments               115,000,000.0          
Prior to Transaction Agreement | Ildong                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payments on achievement               102,100,000          
Prior to Commercial Distribution Agreement                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaborative agreement upfront payments               $ 7,500,000          
Supply Agreement | Product Sales                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Revenues                 1,500,000 15,900,000      
Inventory Deliverable                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Recognized revenue of discontinued operations                   6,400,000      
Carrying value of inventory as cost of product sales of discontinued operations                   900,000      
Manufacturing and Supply Commitment Deliverable                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Recognized revenue of discontinued operations                   9,500,000      
United Therapeutics                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaborative arrangement right description               In November 2018, we entered into an exclusive license agreement with United Therapeutics. Under this agreement, we granted United Therapeutics an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize ralinepag in any formulation. This transaction was completed in January 2019.          
Collaborative agreement completion period   2019-01                      
License agreement costs incurred related to transaction fees   $ 17,000,000.0           $ 14,600,000 2,400,000        
Collaborative agreement upfront payments           $ 800,000,000.0              
Collaboration Agreement Estimated Transaction Price           800,000,000.0              
United Therapeutics | Maximum                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payments on achievement           400,000,000.0              
United Therapeutics | Non U.S. Market                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payments on achievement           150,000,000.0              
United Therapeutics | U.S. Market                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Additional milestone payments on achievement           $ 250,000,000.0              
Outpost Medicine                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaborative agreement upfront payments       $ 3,000,000.0                  
Paid on Milestone Achievements                       $ 500,000  
Recognized revenues               $ 500,000 $ 2,800,000 $ 200,000      
Collaborative agreement upfront payments in the form of equity interest       $ 1,500,000                  
XML 64 arna-10k_20191231_htm.xml IDEA: XBRL DOCUMENT 0001080709 2019-01-01 2019-12-31 0001080709 2020-02-21 0001080709 2019-06-28 0001080709 2019-12-31 0001080709 2018-12-31 0001080709 arna:UnitedTherapeuticsMember us-gaap:LicenseMember 2019-01-01 2019-12-31 0001080709 arna:CollaborationAndOtherRevenueMember 2019-01-01 2019-12-31 0001080709 arna:CollaborationAndOtherRevenueMember 2018-01-01 2018-12-31 0001080709 arna:CollaborationAndOtherRevenueMember 2017-01-01 2017-12-31 0001080709 us-gaap:RoyaltyMember 2019-01-01 2019-12-31 0001080709 us-gaap:RoyaltyMember 2018-01-01 2018-12-31 0001080709 us-gaap:RoyaltyMember 2017-01-01 2017-12-31 0001080709 2018-01-01 2018-12-31 0001080709 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember 2016-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001080709 us-gaap:RetainedEarningsMember 2016-12-31 0001080709 us-gaap:ParentMember 2016-12-31 0001080709 us-gaap:NoncontrollingInterestMember 2016-12-31 0001080709 2016-12-31 0001080709 us-gaap:AccountingStandardsUpdate201609Member us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001080709 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:ParentMember us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:OverAllotmentOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember arna:AtMarketOfferingMember 2017-01-01 2017-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember arna:AtMarketOfferingMember 2017-01-01 2017-12-31 0001080709 us-gaap:ParentMember arna:AtMarketOfferingMember 2017-01-01 2017-12-31 0001080709 arna:AtMarketOfferingMember 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001080709 us-gaap:ParentMember 2017-01-01 2017-12-31 0001080709 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001080709 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001080709 us-gaap:CommonStockMember 2017-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001080709 us-gaap:RetainedEarningsMember 2017-12-31 0001080709 us-gaap:ParentMember 2017-12-31 0001080709 2017-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:ParentMember 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-12-31 0001080709 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:ParentMember us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:OverAllotmentOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001080709 us-gaap:ParentMember 2018-01-01 2018-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001080709 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001080709 us-gaap:CommonStockMember 2018-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001080709 us-gaap:RetainedEarningsMember 2018-12-31 0001080709 us-gaap:ParentMember 2018-12-31 0001080709 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001080709 us-gaap:ParentMember 2019-01-01 2019-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001080709 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001080709 us-gaap:CommonStockMember 2019-12-31 0001080709 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001080709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001080709 us-gaap:RetainedEarningsMember 2019-12-31 0001080709 us-gaap:ParentMember 2019-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001080709 arna:SubleaseAgreementMember 2019-01-01 2019-12-31 0001080709 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001080709 us-gaap:SalesRevenueNetMember arna:EisaiMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:BoehringerIngelheimMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:BoehringerIngelheimMember 2017-01-01 2017-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:OutpostMedicineMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:EverestMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:EverestMember 2017-01-01 2017-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:AxovantMember 2018-01-01 2018-12-31 0001080709 us-gaap:SalesRevenueNetMember arna:AxovantMember 2017-01-01 2017-12-31 0001080709 srt:MinimumMember us-gaap:SalesRevenueNetMember arna:UnitedTherapeuticsMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember 2019-01-01 2019-12-31 0001080709 srt:MaximumMember 2019-01-01 2019-12-31 0001080709 us-gaap:BuildingMember 2019-01-01 2019-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 0001080709 us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-12-31 0001080709 arna:CollaborationAndOtherRevenueMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001080709 arna:CollaborationAndOtherRevenueMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:RoyaltyMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:RoyaltyMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001080709 us-gaap:AccountingStandardsUpdate201409Member us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001080709 arna:RestrictedStockUnitsAndRestrictedStockMember 2018-01-01 2018-12-31 0001080709 arna:RestrictedStockUnitsAndRestrictedStockMember 2017-01-01 2017-12-31 0001080709 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001080709 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001080709 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001080709 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001080709 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001080709 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001080709 srt:MinimumMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember arna:LongTermInvestmentsMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember us-gaap:CorporateDebtSecuritiesMember arna:LongTermInvestmentsMember 2019-01-01 2019-12-31 0001080709 srt:MaximumMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember arna:LongTermInvestmentsMember 2019-01-01 2019-12-31 0001080709 srt:MaximumMember us-gaap:CorporateDebtSecuritiesMember arna:LongTermInvestmentsMember 2019-01-01 2019-12-31 0001080709 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2019-12-31 0001080709 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2019-12-31 0001080709 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001080709 us-gaap:USGovernmentAgenciesDebtSecuritiesMember arna:LongTermInvestmentsMember 2019-12-31 0001080709 us-gaap:CorporateDebtSecuritiesMember arna:LongTermInvestmentsMember 2019-12-31 0001080709 arna:LongTermInvestmentsMember 2019-12-31 0001080709 srt:MinimumMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember arna:LongTermInvestmentsMember 2018-01-01 2018-12-31 0001080709 srt:MinimumMember us-gaap:CorporateDebtSecuritiesMember arna:LongTermInvestmentsMember 2018-01-01 2018-12-31 0001080709 srt:MaximumMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember arna:LongTermInvestmentsMember 2018-01-01 2018-12-31 0001080709 srt:MaximumMember us-gaap:CorporateDebtSecuritiesMember arna:LongTermInvestmentsMember 2018-01-01 2018-12-31 0001080709 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2018-12-31 0001080709 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2018-12-31 0001080709 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001080709 us-gaap:USGovernmentAgenciesDebtSecuritiesMember arna:LongTermInvestmentsMember 2018-12-31 0001080709 us-gaap:CorporateDebtSecuritiesMember arna:LongTermInvestmentsMember 2018-12-31 0001080709 arna:LongTermInvestmentsMember 2018-12-31 0001080709 us-gaap:LandMember 2019-12-31 0001080709 us-gaap:LandMember 2018-12-31 0001080709 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0001080709 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001080709 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001080709 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001080709 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001080709 us-gaap:MachineryAndEquipmentMember 2018-12-31 0001080709 arna:ComputersAndSoftwareMember 2019-12-31 0001080709 arna:ComputersAndSoftwareMember 2018-12-31 0001080709 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001080709 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001080709 arna:SiegfriedPharmaAGAndSiegfriedAGMember 2019-12-31 0001080709 arna:ArenaGmbHMember 2018-03-31 0001080709 arna:ArenaGmbHMember 2018-03-01 2018-03-31 0001080709 arna:PropertiesUnderSaleAndLeasebackAgreementsMember 2019-01-01 2019-12-31 0001080709 arna:SanDiegoCaliforniaMember arna:PropertiesUnderOperatingLeasesMember 2019-01-01 2019-12-31 0001080709 arna:MassachusettsBostonMember arna:PropertiesUnderOperatingLeasesMember 2019-07-01 2019-09-30 0001080709 arna:MassachusettsBostonMember arna:PropertiesUnderOperatingLeasesMember 2019-09-30 0001080709 arna:SwitzerlandZugMember arna:PropertiesUnderOperatingLeasesMember 2019-06-30 0001080709 arna:SwitzerlandZugMember arna:PropertiesUnderOperatingLeasesMember 2019-09-30 0001080709 arna:SwitzerlandZugMember arna:PropertiesUnderOperatingLeasesMember 2019-04-01 2019-06-30 0001080709 arna:SwitzerlandZugMember arna:PropertiesUnderOperatingLeasesMember 2019-07-01 2019-09-30 0001080709 arna:PropertiesUnderOperatingLeasesMember 2019-12-31 0001080709 2016-01-01 2016-12-31 0001080709 arna:SubleaseAgreementMember 2019-12-31 0001080709 us-gaap:CommonStockMember arna:UnderwrittenPublicOfferingMember 2018-03-01 2018-03-31 0001080709 us-gaap:CommonStockMember arna:UnderwrittenPublicOfferingMember 2017-07-01 2017-07-31 0001080709 us-gaap:CommonStockMember arna:UnderwrittenPublicOfferingMember 2017-04-01 2017-04-30 0001080709 arna:CitigroupGlobalMarketsIncMember us-gaap:CommonStockMember arna:AtMarketOfferingMember arna:EquityDistributionAgreementMember 2017-02-01 2017-04-30 0001080709 arna:CitigroupGlobalMarketsIncMember srt:WeightedAverageMember us-gaap:CommonStockMember arna:AtMarketOfferingMember arna:EquityDistributionAgreementMember 2017-04-30 0001080709 arna:CitigroupGlobalMarketsIncMember arna:AtMarketOfferingMember arna:EquityDistributionAgreementMember 2017-02-01 2017-04-30 0001080709 arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-12-31 0001080709 arna:OtherThanStockOptionsAndStockAppreciationRightsMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-12-31 0001080709 arna:EquityCompensationPlansMember 2019-12-31 0001080709 us-gaap:EmployeeStockOptionMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember arna:PerformanceRestrictedStockUnitsPRSUMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember us-gaap:StockAppreciationRightsSARSMember arna:AmendedLongTermIncentivePlanTwentySeventeenMember 2019-01-01 2019-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2018-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2019-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-01 2019-01-31 0001080709 srt:MaximumMember arna:PerformanceRestrictedStockUnitsPRSUMember 2019-01-01 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-01-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-07-01 2019-09-30 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-01-01 2019-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2018-01-01 2018-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2014-03-01 2014-03-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2018-03-01 2018-03-31 0001080709 arna:TwoZeroZeroNineEmployeeStockPurchasePlanMember 2019-12-31 0001080709 arna:TwoZeroZeroNineEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember arna:TwoZeroZeroNineEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001080709 arna:TwoZeroOneNineEmployeeStockPurchasePlanMember 2019-12-31 0001080709 arna:TwoZeroOneNineEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001080709 srt:MinimumMember arna:TwoZeroOneNineEmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001080709 arna:TwoZeroZeroNineEmployeeStockPurchasePlanMember 2017-01-01 2017-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001080709 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001080709 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001080709 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001080709 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001080709 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001080709 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001080709 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001080709 us-gaap:SegmentDiscontinuedOperationsMember 2018-01-01 2018-12-31 0001080709 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-12-31 0001080709 arna:PerformanceRestrictedStockUnitsPRSUMember 2019-12-31 0001080709 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001080709 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001080709 arna:UnitedTherapeuticsMember 2019-01-01 2019-12-31 0001080709 arna:EverestMember 2019-01-01 2019-12-31 0001080709 arna:EverestMember 2018-01-01 2018-12-31 0001080709 arna:EisaiIncorporationAndEisaiCorporationLimitedMember 2019-01-01 2019-12-31 0001080709 arna:EisaiIncorporationAndEisaiCorporationLimitedMember 2018-01-01 2018-12-31 0001080709 us-gaap:OtherCustomerMember 2019-01-01 2019-12-31 0001080709 us-gaap:OtherCustomerMember 2018-01-01 2018-12-31 0001080709 us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0001080709 us-gaap:TransferredAtPointInTimeMember 2018-01-01 2018-12-31 0001080709 us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0001080709 us-gaap:TransferredOverTimeMember 2018-01-01 2018-12-31 0001080709 arna:UnitedTherapeuticsMember 2019-01-01 2019-12-31 0001080709 arna:UnitedTherapeuticsMember 2019-01-01 2019-01-31 0001080709 arna:UnitedTherapeuticsMember 2018-01-01 2018-12-31 0001080709 arna:UnitedTherapeuticsMember 2019-01-01 2019-03-31 0001080709 srt:MaximumMember arna:UnitedTherapeuticsMember 2019-03-31 0001080709 arna:UnitedTherapeuticsMember arna:NonUsMarketMember 2019-03-31 0001080709 arna:UnitedTherapeuticsMember arna:USMarketMember 2019-03-31 0001080709 arna:EverestMember 2017-12-01 2017-12-31 0001080709 arna:EverestMember srt:MaximumMember 2017-12-31 0001080709 arna:EverestMember arna:ChineseNationalMedicalProductsAdministrationMember 2018-10-01 2018-12-31 0001080709 arna:EverestMember 2019-12-31 0001080709 arna:EisaiFirstAmendedAgreementMember 2019-01-01 2019-12-31 0001080709 arna:EisaiSecondAmendedAgreementMember 2019-01-01 2019-12-31 0001080709 arna:EisaiAgreementMember 2016-12-01 2018-03-31 0001080709 arna:EisaiIncorporationAndEisaiCorporationLimitedMember arna:LorcaserinProductMember 2019-01-01 2019-12-31 0001080709 arna:PriorToTransactionAgreementMember 2019-01-01 2019-12-31 0001080709 arna:PriorToCommercialDistributionAgreementMember 2019-01-01 2019-12-31 0001080709 arna:IldongMember arna:PriorToTransactionAgreementMember 2019-12-31 0001080709 arna:EisaiAgreementMember 2019-01-01 2019-12-31 0001080709 arna:EisaiAgreementMember 2019-12-31 0001080709 us-gaap:RoyaltyMember arna:EisaiAgreementMember 2018-12-31 0001080709 us-gaap:RoyaltyMember 2019-12-31 0001080709 us-gaap:RoyaltyMember arna:EisaiAgreementMember 2019-01-01 2019-12-31 0001080709 us-gaap:RoyaltyMember arna:EisaiAgreementMember 2018-01-01 2018-12-31 0001080709 us-gaap:RoyaltyMember arna:EisaiAgreementMember 2017-01-01 2017-12-31 0001080709 us-gaap:ProductMember arna:SupplyAgreementMember 2018-01-01 2018-12-31 0001080709 us-gaap:ProductMember arna:SupplyAgreementMember 2017-01-01 2017-12-31 0001080709 2016-12-28 0001080709 arna:InventoryDeliverableMember 2017-01-01 2017-12-31 0001080709 arna:ManufacturingAndSupplyCommitmentDeliverableMember 2017-01-01 2017-12-31 0001080709 arna:BoehringerIngelheimMember 2018-12-01 2018-12-31 0001080709 arna:BoehringerIngelheimMember 2019-10-01 2019-10-31 0001080709 arna:BoehringerIngelheimMember 2019-12-31 0001080709 arna:BoehringerIngelheimMember arna:BeaconDiscoveryIncMember 2019-12-31 0001080709 arna:BoehringerIngelheimMember 2019-01-01 2019-12-31 0001080709 arna:BoehringerIngelheimMember 2018-01-01 2018-12-31 0001080709 arna:BoehringerIngelheimMember 2017-01-01 2017-12-31 0001080709 arna:OutpostMedicineMember 2018-04-01 2018-04-30 0001080709 arna:OutpostMedicineMember 2019-09-30 0001080709 arna:OutpostMedicineMember 2019-01-01 2019-12-31 0001080709 arna:OutpostMedicineMember 2018-01-01 2018-12-31 0001080709 arna:OutpostMedicineMember 2017-01-01 2017-12-31 0001080709 arna:AxovantMember 2019-01-01 2019-12-31 0001080709 arna:AxovantMember 2018-01-01 2018-12-31 0001080709 arna:AxovantMember 2017-01-01 2017-12-31 0001080709 us-gaap:InternalRevenueServiceIRSMember 2019-12-31 0001080709 srt:MinimumMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-12-31 0001080709 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001080709 srt:MinimumMember us-gaap:StateAndLocalJurisdictionMember 2019-01-01 2019-12-31 0001080709 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2019-12-31 0001080709 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0001080709 srt:MinimumMember us-gaap:InternalRevenueServiceIRSMember arna:OrphanDrugMember 2019-12-31 0001080709 arna:LitigationAmountSettlementByInsurerMember 2017-11-30 0001080709 arna:LitigationAmountSettlementByParentMember 2017-11-30 0001080709 2019-10-01 2019-12-31 0001080709 2019-07-01 2019-09-30 0001080709 2019-04-01 2019-06-30 0001080709 2019-01-01 2019-03-31 0001080709 2018-10-01 2018-12-31 0001080709 2018-07-01 2018-09-30 0001080709 2018-04-01 2018-06-30 0001080709 2018-01-01 2018-03-31 0001080709 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember arna:SubleaseAgreementMember arna:BeaconDiscoveryIncMember 2019-12-31 0001080709 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember arna:SubleaseAgreementMember arna:BeaconDiscoveryIncMember 2019-08-01 2019-12-31 0001080709 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember arna:BeaconDiscoveryIncMember 2017-01-01 2017-12-31 shares iso4217:USD iso4217:USD shares arna:Segment pure arna:employee iso4217:CHF arna:Property utr:sqft 0001080709 --12-31 Large Accelerated Filer 2019 FY false Through the remaining terms of the leases in fiscal year 2027 us-gaap:OtherAssetsNoncurrent us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent P5D P10D P3Y P3Y 2017-06-30 P3Y P3Y us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent P1Y P1Y P1Y P1Y P5Y P5Y P5Y P5Y P5Y29D P5Y29D P4Y2M4D P4Y5M19D P4Y6M29D P4Y6M29D P2Y7M13D P2M15D P6M25D 10-K true 2019-12-31 false 000-31161 ARENA PHARMACEUTICALS, INC. DE 23-2908305 6154 Nancy Ridge Drive San Diego CA 92121 858 453.7200 Common Stock, par value $0.0001 per share ARNA NASDAQ Yes No Yes Yes false false false 2900000000 50249149 Certain information required by Part III of this Annual Report on Form 10-K is incorporated by reference from the Registrant’s Definitive Proxy Statement for the Annual Meeting of Stockholders to be held in June 2020, which will be filed with the Securities and Exchange Commission on or before April 29, 2020. 243274000 161037000 496291000 284594000 1654000 5086000 18715000 10008000 759934000 460725000 370938000 82412000 25128000 23114000 110333000 18123000 10319000 1174123000 686903000 25499000 16181000 15654000 10454000 3814000 3283000 44967000 29918000 45613000 49426000 12078000 1301000 0.0001 0.0001 7500000 7500000 0 0 0 0 0.0001 0.0001 73500000 73500000 50170953 50170953 49422991 49422991 5000 5000 2173154000 2106960000 1303000 -155000 -1102997000 -1500552000 1071465000 606258000 1174123000 686903000 800000000 7284000 11402000 19632000 -853000 6568000 1705000 806431000 17970000 21337000 231496000 115029000 70988000 77616000 45257000 30341000 14573000 2467000 11975000 323685000 162753000 113304000 482746000 -144783000 -91967000 26872000 8772000 492000 4791000 5695000 6119000 3061000 2872000 1740000 25142000 5949000 -3887000 507888000 -138834000 -95854000 110333000 -110265000 397555000 -28569000 -95854000 -830000 3122000 397555000 -29399000 -92732000 -1325000 397555000 -29399000 -91407000 -397555000 28569000 94529000 -830000 3122000 397555000 -29399000 -91407000 7.99 -0.61 -2.87 -0.02 0.10 7.99 -0.63 -2.77 7.69 -0.61 -2.87 -0.02 0.10 7.69 -0.63 -2.77 49779000 47041000 32990000 51698000 47041000 32990000 397555000 -29399000 -92732000 -11000 72000 2016000 1469000 -113000 -133000 399013000 -29440000 -90849000 -1325000 399013000 -29440000 -89524000 24340080 2000 1441737000 -3099000 -1398736000 39904000 491000 40395000 44000 -44000 14087500 2000 236386000 236388000 236388000 489023 6987000 6987000 6987000 323431 5404000 5404000 5404000 40653 12000 12000 12000 7973000 7973000 17000 7990000 -133000 -133000 -133000 2016000 2016000 2016000 -91407000 -91407000 -1325000 -92732000 817000 817000 39280687 4000 1698543000 -1216000 -1490187000 207144000 207144000 1102000 19034000 20136000 20136000 9775000 1000 383141000 383142000 383142000 317636 5888000 5888000 5888000 49668 -166000 -166000 -166000 19554000 19554000 19554000 -113000 -113000 -113000 72000 72000 72000 -29399000 -29399000 -29399000 49422991 5000 2106960000 -155000 -1500552000 606258000 606258000 625757 15184000 15184000 15184000 122205 -2037000 -2037000 -2037000 53047000 53047000 53047000 1469000 1469000 1469000 -11000 -11000 -11000 397555000 397555000 397555000 50170953 5000 2173154000 1303000 -1102997000 1071465000 1071465000 397555000 -29399000 -92732000 -830000 3122000 3233000 3759000 4278000 110333000 -110333000 1500000 -3744000 3315000 53047000 19543000 7855000 11975000 90000 110000 136000 5628000 664000 -112000 791000 379000 -3432000 2760000 -10787000 8133000 2929000 -585000 12347000 10871000 1803000 -11975000 -1438000 -2061000 -4401000 -1265000 -577000 568694000 -131879000 -63792000 -333000 -2850000 568694000 -132212000 -66642000 1469220000 364539000 112615000 976093000 110564000 406000 4819000 692000 113000 789000 11000 5000 -497946000 -254678000 -112350000 997000 3405000 -40000 -496949000 -251273000 -112390000 3282000 4000000 3518000 13147000 389031000 248805000 9865000 385031000 245287000 -10000 654000 1870000 81600000 2200000 68125000 161900000 159700000 91575000 243500000 161900000 159700000 4787000 5696000 5967000 3944000 5039000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and Summary of Significant Accounting Policies</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Company</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arena Pharmaceuticals, Inc., or Arena, was incorporated on April 14, 1997, and commenced operations in July 1997. We are a biopharmaceutical company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Our proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced investigational clinical programs include: etrasimod, which is being evaluated in a Phase 3 program for ulcerative colitis, a Phase 2b/3 program for Crohn’s disease, and a Phase 2b program in atopic dermatitis. We also plan to evaluate etrasimod in a Phase 2b program for eosinophilic esophagitis, and a Phase 2 program in alopecia areata. Olorinab is being evaluated for a broad range of visceral pain conditions associated with gastrointestinal diseases, currently in a Phase 2b trial for treatment of abdominal pain associated with irritable bowel syndrome. APD418 is being evaluated in a Phase 1 trial for acute heart failure. <span style="Background-color:#FFFFFF;color:#000000;">Additionally, we have collaboration or license agreements with various companies. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate in one business segment. Our primary clinical operations are conducted in San Diego, California and Boston, Massachusetts; and in Zug, Switzerland by Arena Pharmaceuticals Development GmbH, or APD GmbH, our wholly-owned subsidiary.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with the US generally accepted accounting principles, or GAAP, and reflect all of our activities, including those of our wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. <span style="color:#000000;">Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. As a result of the sale of our Manufacturing Operations (see Note 5), the operations and cash flows of the Manufacturing Operations are reflected as discontinued operations for the years ended December 31, 2018, and 2017.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The accompanying consolidated financial statements also include the activity of Beacon Discovery, Inc., or Beacon, a variable interest entity in which we had a controlling financial interest until December 2017 at which point we deconsolidated Beacon (see Note 12). The results of operations and comprehensive loss attributable to the noncontrolling interest in Beacon are presented as separate components from the results of operations and comprehensive loss attributable to the stockholders of Arena in the consolidated statements of operations and comprehensive loss.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, we had cash, cash equivalents and available-for-sale investments of approximately $1.1 billion. We believe our cash, cash equivalents and available-for-sale investments will be sufficient to fund our operations for at least the next 12 months from the date these consolidated financial statements are issued.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require substantial cash to achieve our objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. We may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. We will need to obtain significant funds under our <span style="color:#000000;">existing</span> collaborations and license agreements, under new collaboration, licensing or other commercial agreements for one or more of our drug candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions<span style="color:#000000;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Accounting Policies - Leases.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective<span style="color:#000000;"> January 1, 2019, we adopted </span>Accounting Standard Codification Topic 842, <span style="font-style:italic;">Leases</span>, or ASC 842, <span style="color:#000000;">issued by the </span>Financial<span style="color:#000000;"> Accounting Standards Board, or FASB. </span>ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements<span style="color:#000000;">. </span>The new standard established a right-of-use model that requires a lessee to recognize a right-of-use asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. <span style="color:#000000;">As a result, we have changed our accounting policy for leases as detailed below. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We implemented ASC 842 using the modified retrospective transition approach by applying the new standard to leases existing at the date of initial application. We used the effective date as our date of initial application. Therefore, we did not update the financial information and did not provide the disclosures required under the new standard for dates and periods before January 1, 2019. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We applied ASC 842 using a <span style="color:#000000;">package of practical expedients, which permitted us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us</span>.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption of ASC 842, we recorded an operating lease liability of $6.3 million based on the present value of the remaining minimum rental payments under the terms of our existing operating lease pertaining to one of our leased properties with a corresponding right-of-use asset of $5.9 million. Adoption of this standard did not have a material impact on our consolidated statements of operations or cash flows. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new standard also provides practical expedients for an entity’s ongoing accounting. We elected the short-term lease recognition exemption for our office equipment leases and short-term office space leases. This means, for those leases that qualify, we do not recognize right-of-use assets or lease liabilities. See Note 6 for disclosures related to our leases.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18, <span style="font-style:italic;color:#252525;">Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606</span>. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification Topic 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span>,<span style="font-style:italic;"> </span>or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. The amendments in ASU No. 2018-18 are applied retrospectively to the date of initial application of ASC 606, which for us was January 1, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements. </p> <p id="T222" style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12 which modifies ASC 740, <span style="font-style:italic;">Income Taxes</span> to simplify the accounting for income taxes in various areas. The amendments in ASU 2019-12 are effective for us for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. We are currently evaluating the impact of adoption on our consolidated financial statements. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires our management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. The amounts reported could differ under different estimates and assumptions.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in our consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows, in thousands:</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,037</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other non-current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">863</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash presented in the consolidated</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">      statement of cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,900</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restricted cash relates to our property leases. The restriction will lapse when the related leases expire.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale Investments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We define investments as income-yielding securities that can be readily converted to cash, and classify such investments as available-for-sale. We carry these securities at fair value, and report unrealized gains and losses as a separate component of accumulated other comprehensive income or loss. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in securities judged to be other than temporary are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on <span style="color:#000000;">available</span>-for-sale securities are included in interest income.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents and available-for-sale investments. We limit our exposure to credit loss by holding our cash primarily in US dollars or placing our cash and investments in US government, agency or government-sponsored enterprise obligations and in corporate debt instruments that are rated investment grade, in accordance with an investment policy approved by our Board of Directors.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our customers are typically other biopharmaceutical companies to which we license our intellectual property, or sell research and development services or other services under license or collaboration agreements. For the year ended December 31, 2019, more than 99% of our annual revenues was from United Therapeutics. For the year ended December 31, 2018, Eisai, Boehringer Ingelheim, Outpost Medicine, Axovant and Everest accounted for 36.6%, 24.8%, 15.3%, 12.1% and 11.1%, respectively, of our total revenues. For the year ended December 31, 2017, Everest, Boehringer Ingelheim and Axovant accounted for 56.2%, 23.8%, and 10.5%, respectively, of our total revenues.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We monitor our customers’ financial credit worthiness in order to assess and respond to any changes in their credit profile. During the years ended December 31, 2019, 2018, and 2017, we did not record any write-offs or reserves against accounts receivable<span style="color:#252525;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (generally 3 to 15 years) using the straight-line method. Buildings are stated at cost and depreciated over an estimated useful life of approximately 20 years using the straight-line method. Leasehold improvements are stated at cost and amortized over the shorter of the estimated useful lives of the assets or the lease term using the straight-line method. Capital improvements are stated at cost and amortized over the estimated useful lives of the underlying assets using the straight-line method<span style="color:#000000;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Long-lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted cash flows. If impairment is indicated, we measure the impairment loss by comparing the fair value to the carrying value of the asset.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of our wholly owned subsidiaries in Switzerland, APD GmbH and, until March 31, 2018, Arena Pharmaceuticals GmbH, or Arena GmbH, was the Swiss franc. Accordingly, all assets and liabilities of these subsidiaries are translated to US dollars based on the applicable exchange rate on the balance sheet date. Revenue and expense components are translated to US dollars at weighted-average exchange rates in effect during the period. Gains and losses resulting from foreign currency translation are reported as a separate component of accumulated other comprehensive income or loss in the equity section of our consolidated balance sheets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency transaction gains and losses are primarily the result of remeasuring US dollar-denominated receivables and payables of our foreign subsidi</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aries. Foreign currency transaction gains and losses recorded by Arena GmbH are included in net income (loss) from discontinued operations. </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share-based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share-based awards are measured at fair value and recognized over the requisite service or performance period. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model, based on the market price of the underlying common stock, expected term, expected stock price volatility and expected risk-free interest rate. Expected volatility is computed using historical volatility for a period equal to the expected term. The expected term of options is determined based on historical experience of similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and post-vesting terminations. The risk-free interest rates are based on the US Treasury yield curve, with a remaining term approximately equal to the expected term used in the option pricing model. We account for the forfeitures in the period they occur. The fair value of each restricted stock unit award is estimated based on the market price of the underlying common stock on the date of the grant. The fair value of restricted stock unit awards that include market-based performance conditions is estimated on the date of grant using a Monte Carlo simulation model, based on the market price of the underlying common stock, expected performance measurement period, expected stock price volatility and expected risk-free interest rate.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues to date have been generated primarily through collaboration and license agreements. Our collaboration and license agreements frequently contain multiple types of promised goods or services including (i) intellectual property licenses, (ii) product research, development and regulatory services and (iii) product manufacturing. Consideration we receive under these arrangements may include upfront payments, research and development funding, cost reimbursements, milestone payments, payments for product sales and royalty payments.<span style="color:#000000;"> </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective<span style="color:#000000;"> January 1, 2018, we adopted Accounting Standard Codification 606, </span><span style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</span><span style="color:#000000;">,</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">or ASC 606, issued by the </span>Financial<span style="color:#000000;"> Accounting Standards Board, or FASB. As a result, we have changed our accounting policy for revenue recognition as detailed below. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We implemented ASC 606 using the modified retrospective method by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of our accumulated deficit at January 1, 2018. Therefore, the comparative period information has not been adjusted.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We applied ASC 606 using a practical expedient for contracts that were modified before the implementation date, which allowed us to determine an aggregate effect of all modifications that occurred before January 1, 2018, when determining the satisfied and unsatisfied performance obligations, the transaction price, and allocating that transaction price to the performance obligations instead of retrospectively restating the contracts for such contract modifications.  </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative impact to our accumulated deficit balance at January 1, 2018, as a result of the adoption of ASC 606 was a decrease of $19.0 million. The decrease arose primarily from a reduction of deferred revenue balances related to upfront payments received from customers and recognition of contract assets due to a combination of (i) the effects of applying the practical expedient for contract modifications and our conclusions related to satisfied and unsatisfied performance obligations, which resulted in a relatively higher portion of the total transaction price recognized as revenue in periods prior to our adoption of ASC 606, (ii) the effect of the bill-and-hold accounting guidance for inventory in ASC 606 and (iii) the inclusion of estimated future royalty payments related to our intellectual property in the total transaction price to the extent such intellectual property was legally sold to our customer rather than licensed. The cumulative effect adjustment is net of an impairment loss of $13.1 million which was a direct effect of the adoption of ASC 606 on the asset group of the Manufacturing Operations, which was classified as assets of disposal group held for sale since December 2017.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the impacts of adopting ASC 606 on our consolidated financial statements, in thousands.</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of Changes in Accounting Policies</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances without adoption of ASC 606</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and other revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,568</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,847</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,970</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,742</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144,783</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,742</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,569</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,163</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,660</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,066</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to stockholders of Arena</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,399</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,066</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,008</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,484</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,524</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,725</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,484</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,241</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,319</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,903</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,955</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">680,948</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,918</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,500,552</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,965</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,506,517</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606,258</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,965</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,293</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,903</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,955</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">680,948</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that we expect to be entitled to receive in exchange for these services and excludes sales incentives and amounts <span style="color:#000000;">collected</span> on behalf of third parties. We analyze the nature of these performance obligations in the context of individual collaboration and license agreements in order to assess the distinct performance obligations. We apply the following five steps to recognize revenue:</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">i) Identify the contract with a customer<span style="font-style:normal;">. We consider the terms and conditions of our collaboration and license agreements to identify contracts within the scope of ASC 606. We consider that we have a contract with a customer when the contract is approved, we can identify each party's rights regarding the goods and services to be transferred, we can identify the payment terms for the goods and services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. We use judgment in determining the customer's ability and intent to pay, which is based upon factors including the customer's historical payment experience or, for new customers, credit and financial information pertaining to the customers.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ii) Identify the performance obligations in the contract.<span style="font-style:normal;"> Performance obligations in our collaboration and license agreements are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. Our performance obligations generally consist of intellectual property licenses, research, development and/or regulatory services and manufacturing and supply commitments.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> iii) Determine the transaction price.<span style="font-style:normal;"> We determine the transaction price based on the consideration to which we expect to be entitled in exchange for transferring goods and services to the customer. In determining the transaction price, any variable consideration would be considered, to the extent applicable, if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. In accordance with the royalty exception under ASC 606 for licenses of intellectual property, the transaction price excludes future royalty payments to be received from our customers. None of our collaboration and license agreements contain consideration payable to our customer or a significant financing component.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">iv) Allocate the transaction price to performance obligations in the contract.</span> If the contract contains a single performance obligation, the entire transaction price is allocated to that performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> v) Recognize revenue when or as we satisfy a performance obligation.<span style="font-style:normal;"> Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised goods or services to a customer. We recognize revenue when we transfer control of the goods or services to our customers for an amount that reflects the consideration that we expect to receive in exchange for those services. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Performance Obligations</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a description of principal goods and services from which we generate revenue. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intellectual property licenses </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate revenue from licensing our intellectual property including know-how and development and commercialization rights. These licenses provide customers with a term-based license to further research, develop and commercialize our internally-discovered drug candidates. The consideration we receive in the form of nonrefundable upfront consideration related to the functional intellectual property licenses is recognized when we transfer such license to the customer unless the license is combined with other goods or services into one performance obligation, in which case the revenue is recognized over a period of time based on our estimated pattern in which we satisfy the combined performance obligation.<span style="font-size:13.5pt;"> </span>Our licensing agreements are generally cancelable. Customers have the right to terminate their contracts upon notice. We have the right to terminate the contracts generally only if the customer is in breach of the contract and fails to remedy the breach in accordance with the contractual terms.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intellectual property sales </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate royalty revenue from sales of our intellectual property. We estimate the future royalty payments and recognize revenue with a corresponding contract asset at a point in time when we transfer the intellectual property to the customer. We periodically reassess our estimate of the future royalty payments and recognize any estimate adjustments as revenue in the current period. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research, development and regulatory services</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate revenue from research, development and regulatory services we provide to our customers in connection with the licensed intellectual property. The services we provide to our customers primarily include scientific research activities, preparation for and management of clinical trials, and assistance during the regulatory approval application process. Revenue associated with these services is recognized based on our estimate of total consideration to be received for such services and the pattern in which we perform the services. The pattern of performance is generally determined to be the amount of incurred expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-size:13.5pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Product manufacturing</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, we generated revenue from manufacturing and clinical supply promises to our customers in connection with securing a supply of drug products for development and clinical trial purposes. The drug products were generally manufactured by our contract manufacturing organizations. We used our product manufacturing facility in Zofingen, Switzerland for a portion of the product manufacturing requirements until we sold the Manufacturing Operations on March 31, 2018 (see Note 5). Revenue associated with product manufacturing obligations is recognized at a point in time as control of the related product is transferred to the customer.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contracts with Multiple Performance Obligations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of our collaboration and license agreements with customers contain multiple promised goods or services. Based on the characteristics of the promised goods and services we analyze whether they are separate or combined performance obligations. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price based on our overall pricing and discounting objectives, taking into consideration the type of services, estimates of hourly market rates, and stage of the research, development or clinical trials.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Variable Consideration</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone payments, which are due to us upon achievement of specific development and regulatory milestones and (ii) one-time sales-based payments and sales-based royalties associated with sold or licensed intellectual property.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.2%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to uncertainty associated with achievement of the development <span style="color:#000000;">and</span> regulatory milestones, the related milestone payments are excluded from the contract consideration and the corresponding revenue is not recognized until we conclude it is probable that reversal of such milestone revenue will not occur. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. We recognize revenue for sales-based royalties under licensed intellectual property and one-time payments at the later of when the sales occur or the performance obligation is satisfied or partially satisfied.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disaggregation of Revenue</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate in one reportable business segment. We provide goods and services to our customers in collaboration and license agreements pursuant to various geographical markets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed. Product sales are generally billed as completed. Payment terms on invoiced amounts are typically 30 days. Contract assets include amounts related to our contractual right to consideration for both completed and partially completed performance obligations that have not been invoiced and for which we do not yet have the right to payment. The current portion of contract asset is included in prepaid expenses and other current assets in the consolidated balance sheet. The non-current portion of contract assets is included in other non-current assets in the consolidated balance sheet. We estimate the amount of the contract asset by applying the expected value method to our estimate of future royalty payments we will receive from this customer. Any changes to this estimate are recorded as an adjustment to revenue in the period in which the change in estimate is made.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost to Obtain and Fulfill a Contract</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally do not incur costs to obtain new contracts. Costs to fulfill contracts are expensed as incurred.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Remaining Performance Obligations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to our existing collaboration </span>and license<span style="Background-color:#FFFFFF;"> agreements as of December 31, 2019 is immaterial. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.2%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the royalty exception in ASC 606 for licensed intellectual property we do not recognize any revenue for the variable amounts related to sales-based royalties and milestones until the later of when the sales occur or the performance obligation is satisfied or partially satisfied. Accordingly, the revenue related to future sales-based royalties and milestones are excluded from the <span style="Background-color:#FFFFFF;color:#000000;">estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied</span>.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Previous Revenue Recognition Policy</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Prior to January 1, 2018, we recognized revenue when (i) persuasive evidence of an arrangement existed, (ii) delivery had occurred and title had passed, (iii) the price was fixed or determinable and (iv) collectability was reasonably assured. Any advance payments we received in excess of amounts earned were classified as deferred revenues.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We historically evaluated deliverables in a multiple-element arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered element does not have standalone value without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the inception of the arrangement based on the relative selling price.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine the selling price of a separate deliverable, we used the hierarchy as prescribed in Accounting Standards Codification Topic 605-25 based on vendor-specific objective evidence, or VSOE, third-party evidence, or TPE, or best estimate of selling price, or BESP. VSOE was based on the price charged when the element was sold separately and was the price actually charged for that deliverable. TPE was determined based on third-party evidence for a similar deliverable when sold separately. BESP was the estimated selling price at which we would transact a sale if the elements of collaboration and license arrangements were sold on a stand-alone basis to the buyer.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-refundable upfront payments received under our collaboration and license agreements for commercialization rights were deferred if such rights were not deemed to have standalone value without ongoing services which may be required under the agreement. If deferred, such amounts were recognized as revenues on a straight-line basis over the period in which we expected to perform the services.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts we received as reimbursement for our research and development expenditures were recognized as revenue as the services are performed.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the milestone method, we recognized revenue that was contingen</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t upon the achievement of a substantive milestone in its entirety in the period in which the milestone was achieved. A milestone is an event (i) that can be achieved in whole or in part on either our performance or on the occurrence of a specific outcome r</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">esulting from our performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due us. A milestone payment is considered su</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bstantive when the consideration payable to us for each milestone (a) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (b) relates solely to our past perform</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ance and (c) is reasonable relative to all of the other deliverables and payments under the arrangement. In making this assessment, we considered all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance o</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r deliverables. Other contingent-based payments received were recognized when earned.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses, which consist primarily of salaries and other personnel costs, clinical trial costs and preclinical study fees, manufacturing costs for non-commercial products, and the development of earlier-stage programs and technologies, are expensed as incurred when these expenditures have no alternative future uses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accrue clinical trial expenses based on work performed. In determining the amount to accrue, we rely on estimates of total costs incurred based on enrollment, the completion of trials and other events. We follow this method because we believe reasonably dependable estimates of the costs applicable to various stages of a clinical trial can be made. However, the actual costs and timing of clinical trials are uncertain, subject to risks and may change depending on a number of factors. Differences between the actual clinical trial costs and the estimated clinical trial costs that we have accrued in any prior period are recognized in the subsequent period in which the actual costs become known. Historically, these differences have not been material; however, material differences could occur in the future. Payments made to reimburse collaborators for our share of their research and development activities are recorded as research and development expenses, and are recognized as the work is performed.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss)</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report components of comprehensive income or loss in the period in which they are recognized. For the years ended December 31, 2019, 2018 and 2017, comprehensive income (loss) consisted of net income (loss), foreign currency translation gains and losses, and unrealized gains and losses related to available-for-sale investments.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss) Per Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate basic and diluted income (loss) from continuing operations, income (loss) from discontinued operations and net income (loss) per share using the weighted-average number of shares of common stock outstanding during the period.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we report a loss from continuing operations for the years ended December 31, 2018, and 2017, in addition to excluding potentially dilutive out-of-the money securities, we have excluded from our calculation of income (loss) per share all potentially dilutive in-the-money (i) stock options, (ii) restricted stock unit awards, or RSUs, (iii) Performance-Based Restricted Stock Units, or PRSUs, (iv) Total Stockholder Return performance restricted stock unit awards, or TSR PRSUs, and (v) unvested restricted stock in our deferred compensation plan, and our diluted net loss per share is the same as our basic net loss per share. The table below presents the weighted-average number of potentially dilutive securities that were excluded from our calculation of diluted income (loss) per share for the years presented, in thousands.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,962</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,835</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs and unvested restricted stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,962</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,855</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,667</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the market condition for the outstanding PRSUs was not satisfied at December 31, 2019, such securities are excluded from the table above. Because the market condition for the TSR PRSUs was not satisfied at December 31, 2017, such securities are excluded from the table above.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our deferred tax assets and liabilities are determined using the enacted tax rates expected to be in effect for the years in which those tax assets are expected to be realized.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of our deferred tax assets is dependent upon our ability to generate sufficient future taxable income. We establish a valuation allowance when it is more-likely-than-not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available evidence, both positive and negative.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of an uncertain income tax position is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;"> </p> 1 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with the US generally accepted accounting principles, or GAAP, and reflect all of our activities, including those of our wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. <span style="color:#000000;">Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. As a result of the sale of our Manufacturing Operations (see Note 5), the operations and cash flows of the Manufacturing Operations are reflected as discontinued operations for the years ended December 31, 2018, and 2017.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The accompanying consolidated financial statements also include the activity of Beacon Discovery, Inc., or Beacon, a variable interest entity in which we had a controlling financial interest until December 2017 at which point we deconsolidated Beacon (see Note 12). The results of operations and comprehensive loss attributable to the noncontrolling interest in Beacon are presented as separate components from the results of operations and comprehensive loss attributable to the stockholders of Arena in the consolidated statements of operations and comprehensive loss.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, we had cash, cash equivalents and available-for-sale investments of approximately $1.1 billion. We believe our cash, cash equivalents and available-for-sale investments will be sufficient to fund our operations for at least the next 12 months from the date these consolidated financial statements are issued.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require substantial cash to achieve our objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. We may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. We will need to obtain significant funds under our <span style="color:#000000;">existing</span> collaborations and license agreements, under new collaboration, licensing or other commercial agreements for one or more of our drug candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions<span style="color:#000000;">.</span></p> 1100000000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Accounting Policies - Leases.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective<span style="color:#000000;"> January 1, 2019, we adopted </span>Accounting Standard Codification Topic 842, <span style="font-style:italic;">Leases</span>, or ASC 842, <span style="color:#000000;">issued by the </span>Financial<span style="color:#000000;"> Accounting Standards Board, or FASB. </span>ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements<span style="color:#000000;">. </span>The new standard established a right-of-use model that requires a lessee to recognize a right-of-use asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. <span style="color:#000000;">As a result, we have changed our accounting policy for leases as detailed below. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We implemented ASC 842 using the modified retrospective transition approach by applying the new standard to leases existing at the date of initial application. We used the effective date as our date of initial application. Therefore, we did not update the financial information and did not provide the disclosures required under the new standard for dates and periods before January 1, 2019. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We applied ASC 842 using a <span style="color:#000000;">package of practical expedients, which permitted us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us</span>.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption of ASC 842, we recorded an operating lease liability of $6.3 million based on the present value of the remaining minimum rental payments under the terms of our existing operating lease pertaining to one of our leased properties with a corresponding right-of-use asset of $5.9 million. Adoption of this standard did not have a material impact on our consolidated statements of operations or cash flows. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new standard also provides practical expedients for an entity’s ongoing accounting. We elected the short-term lease recognition exemption for our office equipment leases and short-term office space leases. This means, for those leases that qualify, we do not recognize right-of-use assets or lease liabilities. See Note 6 for disclosures related to our leases.</p> 6300000 5900000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18, <span style="font-style:italic;color:#252525;">Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606</span>. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification Topic 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span>,<span style="font-style:italic;"> </span>or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. The amendments in ASU No. 2018-18 are applied retrospectively to the date of initial application of ASC 606, which for us was January 1, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements. </p> <p id="T222" style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12 which modifies ASC 740, <span style="font-style:italic;">Income Taxes</span> to simplify the accounting for income taxes in various areas. The amendments in ASU 2019-12 are effective for us for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. We are currently evaluating the impact of adoption on our consolidated financial statements. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires our management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. The amounts reported could differ under different estimates and assumptions.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in our consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows, in thousands:</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,037</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other non-current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">863</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash presented in the consolidated</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">      statement of cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,900</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restricted cash relates to our property leases. The restriction will lapse when the related leases expire.</p> The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in our consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows, in thousands: <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,037</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other non-current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">863</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash presented in the consolidated</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">      statement of cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,900</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 243274000 161037000 226000 863000 243500000 161900000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale Investments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We define investments as income-yielding securities that can be readily converted to cash, and classify such investments as available-for-sale. We carry these securities at fair value, and report unrealized gains and losses as a separate component of accumulated other comprehensive income or loss. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in securities judged to be other than temporary are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on <span style="color:#000000;">available</span>-for-sale securities are included in interest income.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents and available-for-sale investments. We limit our exposure to credit loss by holding our cash primarily in US dollars or placing our cash and investments in US government, agency or government-sponsored enterprise obligations and in corporate debt instruments that are rated investment grade, in accordance with an investment policy approved by our Board of Directors.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our customers are typically other biopharmaceutical companies to which we license our intellectual property, or sell research and development services or other services under license or collaboration agreements. For the year ended December 31, 2019, more than 99% of our annual revenues was from United Therapeutics. For the year ended December 31, 2018, Eisai, Boehringer Ingelheim, Outpost Medicine, Axovant and Everest accounted for 36.6%, 24.8%, 15.3%, 12.1% and 11.1%, respectively, of our total revenues. For the year ended December 31, 2017, Everest, Boehringer Ingelheim and Axovant accounted for 56.2%, 23.8%, and 10.5%, respectively, of our total revenues.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We monitor our customers’ financial credit worthiness in order to assess and respond to any changes in their credit profile. During the years ended December 31, 2019, 2018, and 2017, we did not record any write-offs or reserves against accounts receivable<span style="color:#252525;">.</span></p> 0.99 0.366 0.248 0.153 0.121 0.111 0.562 0.238 0.105 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (generally 3 to 15 years) using the straight-line method. Buildings are stated at cost and depreciated over an estimated useful life of approximately 20 years using the straight-line method. Leasehold improvements are stated at cost and amortized over the shorter of the estimated useful lives of the assets or the lease term using the straight-line method. Capital improvements are stated at cost and amortized over the estimated useful lives of the underlying assets using the straight-line method<span style="color:#000000;">.</span></p> P3Y P15Y P20Y <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Long-lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted cash flows. If impairment is indicated, we measure the impairment loss by comparing the fair value to the carrying value of the asset.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of our wholly owned subsidiaries in Switzerland, APD GmbH and, until March 31, 2018, Arena Pharmaceuticals GmbH, or Arena GmbH, was the Swiss franc. Accordingly, all assets and liabilities of these subsidiaries are translated to US dollars based on the applicable exchange rate on the balance sheet date. Revenue and expense components are translated to US dollars at weighted-average exchange rates in effect during the period. Gains and losses resulting from foreign currency translation are reported as a separate component of accumulated other comprehensive income or loss in the equity section of our consolidated balance sheets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency transaction gains and losses are primarily the result of remeasuring US dollar-denominated receivables and payables of our foreign subsidi</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aries. Foreign currency transaction gains and losses recorded by Arena GmbH are included in net income (loss) from discontinued operations. </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share-based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share-based awards are measured at fair value and recognized over the requisite service or performance period. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model, based on the market price of the underlying common stock, expected term, expected stock price volatility and expected risk-free interest rate. Expected volatility is computed using historical volatility for a period equal to the expected term. The expected term of options is determined based on historical experience of similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and post-vesting terminations. The risk-free interest rates are based on the US Treasury yield curve, with a remaining term approximately equal to the expected term used in the option pricing model. We account for the forfeitures in the period they occur. The fair value of each restricted stock unit award is estimated based on the market price of the underlying common stock on the date of the grant. The fair value of restricted stock unit awards that include market-based performance conditions is estimated on the date of grant using a Monte Carlo simulation model, based on the market price of the underlying common stock, expected performance measurement period, expected stock price volatility and expected risk-free interest rate.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues to date have been generated primarily through collaboration and license agreements. Our collaboration and license agreements frequently contain multiple types of promised goods or services including (i) intellectual property licenses, (ii) product research, development and regulatory services and (iii) product manufacturing. Consideration we receive under these arrangements may include upfront payments, research and development funding, cost reimbursements, milestone payments, payments for product sales and royalty payments.<span style="color:#000000;"> </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective<span style="color:#000000;"> January 1, 2018, we adopted Accounting Standard Codification 606, </span><span style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</span><span style="color:#000000;">,</span><span style="font-style:italic;color:#000000;"> </span><span style="color:#000000;">or ASC 606, issued by the </span>Financial<span style="color:#000000;"> Accounting Standards Board, or FASB. As a result, we have changed our accounting policy for revenue recognition as detailed below. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We implemented ASC 606 using the modified retrospective method by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of our accumulated deficit at January 1, 2018. Therefore, the comparative period information has not been adjusted.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We applied ASC 606 using a practical expedient for contracts that were modified before the implementation date, which allowed us to determine an aggregate effect of all modifications that occurred before January 1, 2018, when determining the satisfied and unsatisfied performance obligations, the transaction price, and allocating that transaction price to the performance obligations instead of retrospectively restating the contracts for such contract modifications.  </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative impact to our accumulated deficit balance at January 1, 2018, as a result of the adoption of ASC 606 was a decrease of $19.0 million. The decrease arose primarily from a reduction of deferred revenue balances related to upfront payments received from customers and recognition of contract assets due to a combination of (i) the effects of applying the practical expedient for contract modifications and our conclusions related to satisfied and unsatisfied performance obligations, which resulted in a relatively higher portion of the total transaction price recognized as revenue in periods prior to our adoption of ASC 606, (ii) the effect of the bill-and-hold accounting guidance for inventory in ASC 606 and (iii) the inclusion of estimated future royalty payments related to our intellectual property in the total transaction price to the extent such intellectual property was legally sold to our customer rather than licensed. The cumulative effect adjustment is net of an impairment loss of $13.1 million which was a direct effect of the adoption of ASC 606 on the asset group of the Manufacturing Operations, which was classified as assets of disposal group held for sale since December 2017.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the impacts of adopting ASC 606 on our consolidated financial statements, in thousands.</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of Changes in Accounting Policies</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances without adoption of ASC 606</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and other revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,568</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,847</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,970</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,742</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144,783</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,742</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,569</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,163</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,660</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,066</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to stockholders of Arena</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,399</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,066</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,008</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,484</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,524</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,725</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,484</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,241</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,319</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,903</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,955</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">680,948</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,918</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,500,552</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,965</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,506,517</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606,258</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,965</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,293</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,903</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,955</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">680,948</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that we expect to be entitled to receive in exchange for these services and excludes sales incentives and amounts <span style="color:#000000;">collected</span> on behalf of third parties. We analyze the nature of these performance obligations in the context of individual collaboration and license agreements in order to assess the distinct performance obligations. We apply the following five steps to recognize revenue:</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">i) Identify the contract with a customer<span style="font-style:normal;">. We consider the terms and conditions of our collaboration and license agreements to identify contracts within the scope of ASC 606. We consider that we have a contract with a customer when the contract is approved, we can identify each party's rights regarding the goods and services to be transferred, we can identify the payment terms for the goods and services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. We use judgment in determining the customer's ability and intent to pay, which is based upon factors including the customer's historical payment experience or, for new customers, credit and financial information pertaining to the customers.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ii) Identify the performance obligations in the contract.<span style="font-style:normal;"> Performance obligations in our collaboration and license agreements are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. Our performance obligations generally consist of intellectual property licenses, research, development and/or regulatory services and manufacturing and supply commitments.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> iii) Determine the transaction price.<span style="font-style:normal;"> We determine the transaction price based on the consideration to which we expect to be entitled in exchange for transferring goods and services to the customer. In determining the transaction price, any variable consideration would be considered, to the extent applicable, if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. In accordance with the royalty exception under ASC 606 for licenses of intellectual property, the transaction price excludes future royalty payments to be received from our customers. None of our collaboration and license agreements contain consideration payable to our customer or a significant financing component.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">iv) Allocate the transaction price to performance obligations in the contract.</span> If the contract contains a single performance obligation, the entire transaction price is allocated to that performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> v) Recognize revenue when or as we satisfy a performance obligation.<span style="font-style:normal;"> Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised goods or services to a customer. We recognize revenue when we transfer control of the goods or services to our customers for an amount that reflects the consideration that we expect to receive in exchange for those services. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Performance Obligations</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a description of principal goods and services from which we generate revenue. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intellectual property licenses </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate revenue from licensing our intellectual property including know-how and development and commercialization rights. These licenses provide customers with a term-based license to further research, develop and commercialize our internally-discovered drug candidates. The consideration we receive in the form of nonrefundable upfront consideration related to the functional intellectual property licenses is recognized when we transfer such license to the customer unless the license is combined with other goods or services into one performance obligation, in which case the revenue is recognized over a period of time based on our estimated pattern in which we satisfy the combined performance obligation.<span style="font-size:13.5pt;"> </span>Our licensing agreements are generally cancelable. Customers have the right to terminate their contracts upon notice. We have the right to terminate the contracts generally only if the customer is in breach of the contract and fails to remedy the breach in accordance with the contractual terms.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Intellectual property sales </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate royalty revenue from sales of our intellectual property. We estimate the future royalty payments and recognize revenue with a corresponding contract asset at a point in time when we transfer the intellectual property to the customer. We periodically reassess our estimate of the future royalty payments and recognize any estimate adjustments as revenue in the current period. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research, development and regulatory services</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate revenue from research, development and regulatory services we provide to our customers in connection with the licensed intellectual property. The services we provide to our customers primarily include scientific research activities, preparation for and management of clinical trials, and assistance during the regulatory approval application process. Revenue associated with these services is recognized based on our estimate of total consideration to be received for such services and the pattern in which we perform the services. The pattern of performance is generally determined to be the amount of incurred expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-size:13.5pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Product manufacturing</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, we generated revenue from manufacturing and clinical supply promises to our customers in connection with securing a supply of drug products for development and clinical trial purposes. The drug products were generally manufactured by our contract manufacturing organizations. We used our product manufacturing facility in Zofingen, Switzerland for a portion of the product manufacturing requirements until we sold the Manufacturing Operations on March 31, 2018 (see Note 5). Revenue associated with product manufacturing obligations is recognized at a point in time as control of the related product is transferred to the customer.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contracts with Multiple Performance Obligations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of our collaboration and license agreements with customers contain multiple promised goods or services. Based on the characteristics of the promised goods and services we analyze whether they are separate or combined performance obligations. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price based on our overall pricing and discounting objectives, taking into consideration the type of services, estimates of hourly market rates, and stage of the research, development or clinical trials.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Variable Consideration</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone payments, which are due to us upon achievement of specific development and regulatory milestones and (ii) one-time sales-based payments and sales-based royalties associated with sold or licensed intellectual property.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.2%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to uncertainty associated with achievement of the development <span style="color:#000000;">and</span> regulatory milestones, the related milestone payments are excluded from the contract consideration and the corresponding revenue is not recognized until we conclude it is probable that reversal of such milestone revenue will not occur. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. We recognize revenue for sales-based royalties under licensed intellectual property and one-time payments at the later of when the sales occur or the performance obligation is satisfied or partially satisfied.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disaggregation of Revenue</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate in one reportable business segment. We provide goods and services to our customers in collaboration and license agreements pursuant to various geographical markets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed. Product sales are generally billed as completed. Payment terms on invoiced amounts are typically 30 days. Contract assets include amounts related to our contractual right to consideration for both completed and partially completed performance obligations that have not been invoiced and for which we do not yet have the right to payment. The current portion of contract asset is included in prepaid expenses and other current assets in the consolidated balance sheet. The non-current portion of contract assets is included in other non-current assets in the consolidated balance sheet. We estimate the amount of the contract asset by applying the expected value method to our estimate of future royalty payments we will receive from this customer. Any changes to this estimate are recorded as an adjustment to revenue in the period in which the change in estimate is made.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost to Obtain and Fulfill a Contract</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally do not incur costs to obtain new contracts. Costs to fulfill contracts are expensed as incurred.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Remaining Performance Obligations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to our existing collaboration </span>and license<span style="Background-color:#FFFFFF;"> agreements as of December 31, 2019 is immaterial. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.2%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the royalty exception in ASC 606 for licensed intellectual property we do not recognize any revenue for the variable amounts related to sales-based royalties and milestones until the later of when the sales occur or the performance obligation is satisfied or partially satisfied. Accordingly, the revenue related to future sales-based royalties and milestones are excluded from the <span style="Background-color:#FFFFFF;color:#000000;">estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied</span>.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Previous Revenue Recognition Policy</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Prior to January 1, 2018, we recognized revenue when (i) persuasive evidence of an arrangement existed, (ii) delivery had occurred and title had passed, (iii) the price was fixed or determinable and (iv) collectability was reasonably assured. Any advance payments we received in excess of amounts earned were classified as deferred revenues.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We historically evaluated deliverables in a multiple-element arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered element does not have standalone value without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the inception of the arrangement based on the relative selling price.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine the selling price of a separate deliverable, we used the hierarchy as prescribed in Accounting Standards Codification Topic 605-25 based on vendor-specific objective evidence, or VSOE, third-party evidence, or TPE, or best estimate of selling price, or BESP. VSOE was based on the price charged when the element was sold separately and was the price actually charged for that deliverable. TPE was determined based on third-party evidence for a similar deliverable when sold separately. BESP was the estimated selling price at which we would transact a sale if the elements of collaboration and license arrangements were sold on a stand-alone basis to the buyer.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-refundable upfront payments received under our collaboration and license agreements for commercialization rights were deferred if such rights were not deemed to have standalone value without ongoing services which may be required under the agreement. If deferred, such amounts were recognized as revenues on a straight-line basis over the period in which we expected to perform the services.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts we received as reimbursement for our research and development expenditures were recognized as revenue as the services are performed.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the milestone method, we recognized revenue that was contingen</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t upon the achievement of a substantive milestone in its entirety in the period in which the milestone was achieved. A milestone is an event (i) that can be achieved in whole or in part on either our performance or on the occurrence of a specific outcome r</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">esulting from our performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due us. A milestone payment is considered su</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bstantive when the consideration payable to us for each milestone (a) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (b) relates solely to our past perform</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ance and (c) is reasonable relative to all of the other deliverables and payments under the arrangement. In making this assessment, we considered all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance o</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r deliverables. Other contingent-based payments received were recognized when earned.</span></p> -19000000.0 13100000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the impacts of adopting ASC 606 on our consolidated financial statements, in thousands.</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of Changes in Accounting Policies</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As reported</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances without adoption of ASC 606</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and other revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,568</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,847</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,970</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,742</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,228</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144,783</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,742</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,525</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from continuing operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,569</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,163</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,660</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,066</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to stockholders of Arena</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,399</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,066</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,008</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,484</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,524</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460,725</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,484</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,241</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,319</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,903</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,955</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">680,948</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,918</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,500,552</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,965</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,506,517</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606,258</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,965</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,293</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686,903</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,955</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">680,948</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 11402000 105000 11507000 6568000 -1847000 4721000 17970000 -1742000 16228000 -144783000 -1742000 -146525000 -28569000 -594000 -29163000 -830000 13660000 12830000 -29399000 13066000 -16333000 -29399000 13066000 -16333000 10008000 -1484000 8524000 460725000 -1484000 459241000 10319000 -4471000 5848000 686903000 -5955000 680948000 29918000 10000 29928000 -1500552000 -5965000 -1506517000 606258000 -5965000 600293000 686903000 -5955000 680948000 1 We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed P30D <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses, which consist primarily of salaries and other personnel costs, clinical trial costs and preclinical study fees, manufacturing costs for non-commercial products, and the development of earlier-stage programs and technologies, are expensed as incurred when these expenditures have no alternative future uses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accrue clinical trial expenses based on work performed. In determining the amount to accrue, we rely on estimates of total costs incurred based on enrollment, the completion of trials and other events. We follow this method because we believe reasonably dependable estimates of the costs applicable to various stages of a clinical trial can be made. However, the actual costs and timing of clinical trials are uncertain, subject to risks and may change depending on a number of factors. Differences between the actual clinical trial costs and the estimated clinical trial costs that we have accrued in any prior period are recognized in the subsequent period in which the actual costs become known. Historically, these differences have not been material; however, material differences could occur in the future. Payments made to reimburse collaborators for our share of their research and development activities are recorded as research and development expenses, and are recognized as the work is performed.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss)</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report components of comprehensive income or loss in the period in which they are recognized. For the years ended December 31, 2019, 2018 and 2017, comprehensive income (loss) consisted of net income (loss), foreign currency translation gains and losses, and unrealized gains and losses related to available-for-sale investments.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss) Per Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate basic and diluted income (loss) from continuing operations, income (loss) from discontinued operations and net income (loss) per share using the weighted-average number of shares of common stock outstanding during the period.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we report a loss from continuing operations for the years ended December 31, 2018, and 2017, in addition to excluding potentially dilutive out-of-the money securities, we have excluded from our calculation of income (loss) per share all potentially dilutive in-the-money (i) stock options, (ii) restricted stock unit awards, or RSUs, (iii) Performance-Based Restricted Stock Units, or PRSUs, (iv) Total Stockholder Return performance restricted stock unit awards, or TSR PRSUs, and (v) unvested restricted stock in our deferred compensation plan, and our diluted net loss per share is the same as our basic net loss per share. The table below presents the weighted-average number of potentially dilutive securities that were excluded from our calculation of diluted income (loss) per share for the years presented, in thousands.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,962</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,835</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs and unvested restricted stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,962</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,855</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,667</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the market condition for the outstanding PRSUs was not satisfied at December 31, 2019, such securities are excluded from the table above. Because the market condition for the TSR PRSUs was not satisfied at December 31, 2017, such securities are excluded from the table above.</p> The table below presents the weighted-average number of potentially dilutive securities that were excluded from our calculation of diluted income (loss) per share for the years presented, in thousands. <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,962</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,835</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs and unvested restricted stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,962</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,855</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,667</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 3962000 5835000 3664000 20000 3000 3962000 5855000 3667000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our deferred tax assets and liabilities are determined using the enacted tax rates expected to be in effect for the years in which those tax assets are expected to be realized.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of our deferred tax assets is dependent upon our ability to generate sufficient future taxable income. We establish a valuation allowance when it is more-likely-than-not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available evidence, both positive and negative.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of an uncertain income tax position is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Fair Value Disclosures</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure our financial assets and liabilities at fair value, which is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the following three-level valuation hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value our financial assets and liabilities:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="width:5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="width:1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</p></td> </tr> <tr> <td style="width:5%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="width:1%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:92%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quoted prices for similar instruments in active markets or inputs that are observable for the asset or liability, either directly or indirectly.</p></td> </tr> <tr> <td style="width:5%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="width:1%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:92%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant unobservable inputs based on our assumptions.</p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present our valuation hierarchy for our financial assets and liabilities that are measured at fair value on a recurring basis, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds(1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,752</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,752</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency notes(2)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398,419</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398,419</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt instruments(2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483,788</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483,788</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds(1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,438</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,438</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency notes(2)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,278</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,278</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt instruments(2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.56%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents in the <span style="Background-color:#FFFFFF;color:#000000;">accompanying</span> consolidated balance sheets.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.56%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;color:#000000;">Included in either cash and cash equivalents or available-for-sale investments in the accompanying consolidated balance sheet.</span></p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure our financial assets and liabilities at fair value, which is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the following three-level valuation hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value our financial assets and liabilities:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="width:5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="width:1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</p></td> </tr> <tr> <td style="width:5%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="width:1%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:92%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quoted prices for similar instruments in active markets or inputs that are observable for the asset or liability, either directly or indirectly.</p></td> </tr> <tr> <td style="width:5%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:1%;" valign="top"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="width:1%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:92%;" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant unobservable inputs based on our assumptions.</p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present our valuation hierarchy for our financial assets and liabilities that are measured at fair value on a recurring basis, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds(1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,752</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,752</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency notes(2)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398,419</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398,419</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt instruments(2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483,788</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483,788</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable Inputs</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds(1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,438</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,438</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency notes(2)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,278</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,278</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt instruments(2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.56%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Included in cash and cash equivalents in the <span style="Background-color:#FFFFFF;color:#000000;">accompanying</span> consolidated balance sheets.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.56%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;color:#000000;">Included in either cash and cash equivalents or available-for-sale investments in the accompanying consolidated balance sheet.</span></p></td></tr></table></div> 147752000 147752000 398419000 398419000 483788000 483788000 62438000 62438000 171278000 171278000 240481000 240481000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Investments, Available-for-Sale</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments, available-for-sale, consisted of the following, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201,046</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">294,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">294,958</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495,527</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">787</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496,291</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000552">1 - 5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,157</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(155</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,087</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000553">1 - 5</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,322</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">603</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,851</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,479</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">688</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(229</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,938</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,256</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,338</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,742</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000580">1 - 5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,998</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,004</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000581">1 - 5</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,512</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,408</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,510</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments, available-for-sale, consisted of the following, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201,046</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">294,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">294,958</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495,527</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">787</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496,291</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000552">1 - 5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,157</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(155</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,087</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000553">1 - 5</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,322</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">603</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,851</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,479</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">688</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(229</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,938</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,256</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less than 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,338</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,742</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284,594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government and government agency</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000580">1 - 5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,998</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,004</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000581">1 - 5</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,512</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,408</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments, available-for-sale</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.48%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,510</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 201046000 292000 5000 201333000 294481000 495000 18000 294958000 495527000 787000 23000 496291000 197157000 85000 155000 197087000 173322000 603000 74000 173851000 370479000 688000 229000 370938000 139274000 18000 139256000 145468000 130000 145338000 284742000 148000 284594000 16998000 6000 17004000 65512000 104000 65408000 82510000 6000 104000 82412000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Balance Sheet Details</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land, property and equipment, net consisted of the following, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building and capital improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,246</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,246</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,277</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,915</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,749</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,083</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,531</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,175</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,922</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,542</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,794</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,428</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land, property and equipment, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,128</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,114</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, majority of our long-lived assets were located in the United States.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and other accrued liabilities consisted of the following, in thousands:  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,043</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,329</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,622</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,367</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and other accrued liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,499</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,181</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land, property and equipment, net consisted of the following, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building and capital improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,246</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,246</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,277</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,915</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,749</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,083</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,531</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,175</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,922</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,542</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,794</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,428</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land, property and equipment, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,128</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,114</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 4950000 4950000 45246000 45246000 19277000 14915000 169000 173000 2749000 3083000 1531000 1175000 73922000 69542000 48794000 46428000 25128000 23114000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and other accrued liabilities consisted of the following, in thousands:  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,043</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,329</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,622</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,367</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and other accrued liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,499</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,181</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"> </p> 6043000 6192000 14329000 8622000 5127000 1367000 25499000 16181000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Sale of Manufacturing Operations </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to further focus our efforts and resources on our strategic objectives of developing our pipeline drug candidates, in March 2018, we entered into an Asset Purchase Agreement, or Sale Agreement, with Siegfried Pharma AG and Siegfried AG, (collectively and individually, Siegfried). Under the Sale Agreement, we agreed to sell and assign to Siegfried, and Siegfried agreed to purchase and assume from Arena GmbH, certain drug product finishing facility assets and know-how, including fixtures, equipment, other personal property and real estate assets located in Zofingen, Switzerland and related contracts and certain related liabilities, or collectively, the Manufacturing Operations. We refer to this transaction as the Siegfried Transaction. The Siegfried Transaction was completed on March 31, 2018. In connection with the Siegfried Transaction, all of Arena GmbH’s approximately 50 employees transferred to Siegfried. We have excluded from our continuing operations for all periods presented in this report revenues and expenses associated with the disposed Manufacturing Operations, which are reported as discontinued operations. The total sales price for the Manufacturing Operations was approximately CHF 4 million of which approximately CHF 3 million was received in cash in March 2018 and the remaining portion was received in March 2019.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the results of discontinued operations for the periods presented in the consolidated statements of operations for the years ended December 31, 2018, and 2017, in thousands:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product sales</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,189</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other collaboration revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Toll manufacturing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,006</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,179</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,507</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,039</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,858</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,472</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of toll manufacturing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,411</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,756</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,672</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (income) expense, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,374</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,917</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from operations of discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,555</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of discontinued operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> 50 4000000 3000000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the results of discontinued operations for the periods presented in the consolidated statements of operations for the years ended December 31, 2018, and 2017, in thousands:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product sales</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,189</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other collaboration revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Toll manufacturing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,006</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,179</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,507</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,039</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,858</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,472</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of toll manufacturing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,411</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,756</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,672</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (income) expense, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,374</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,917</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from operations of discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,555</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of discontinued operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">725</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> 1129000 9189000 372000 6671000 1006000 3179000 2507000 19039000 1858000 7472000 1411000 4756000 643000 329000 1672000 -464000 -1374000 4062000 15917000 -1555000 3122000 725000 -830000 3122000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have three properties in San Diego, California, under sale and leaseback agreements. The terms of these leases contain a purchase option and stipulate annual increases in monthly lease payments of 2.5%. We account for our sale and leaseback transactions using the financing method. Under the financing method, the book value of the properties and related accumulated depreciation remain on our balance sheet and no sale is recognized. The adoption of ASC 842 did not result in a change to our current accounting policy related to our sale and leaseback agreements. The sales price of the properties is recorded as a financing obligation, and a portion of each lease payment is recorded as interest expense. For the years ended December 31, 2019, 2018, and 2017, we recorded interest expense of $4.8 million, $5.7 million, and $6.1 million respectively, related to these leases. We expect interest expense related to our facilities to total $21.2 million from December 31, 2019, through the remaining terms of the leases in fiscal year 2027. At December 31, 2019, the total financing obligation associated with these sale and leaseback agreements was $49.4 million. The aggregate residual value of the facilities at the end of the lease terms is $5.0 million.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease an additional property in San Diego, California under an operating lease, which expires in May 2027, contains a purchase option and stipulates annual increases in monthly lease payments of 2.5%. <span style="color:#000000;">Upon adoption of ASC 842, we recorded an operating lease liability of $6.3 million based on the present value of the remaining minimum lease payments under the terms of our existing operating lease with a corresponding right-of-use asset of $5.9 million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available at effective date of adoption in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was 7.25%.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2019, we entered into a new lease agreement for approximately 12,755 square feet of office space in Boston, Massachusetts with the lease inception date of September 1, 2019. This lease is classified as an operating lease and expires in December 2026. The lease stipulates annual increases in monthly lease payments of 2.0%. At the lease inception date, we recorded an </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating lease liability of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million based on the present value of the remaining minimum lease p</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ayments under the terms of this lease with a corresponding right-of-use asset of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available at effective date of adopti</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was also </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.25</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Zug, Switzerland</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2019, we entered into a lease in Zug, Switzerland, for approximately 10,500 square feet of office space with the lease inception date of June 1, 2019. This lease expires in May 2024. At the lease inception, we recorded an operating lease liability of $1.4 million based on the present value of the remaining minimum lease payments under the terms of this operating lease with a corresponding right-of-use asset of $1.5 million. As this lease did not provide an implicit rate, we used our estimated incremental borrowing rate based on the information available as of the lease inception in determining the present value of remaining minimum lease payments. The weighted-average discount rate we used was 7.25%. In the third quarter of 2019, we entered into an addendum to this lease for approximately 4,050 square feet of additional office space in the same location with the same landlord and the lease inception date of January 1, 2020. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, the balance of the right-of-use assets associated with the leases described above was $11.8 million and is included in other non-current assets in the accompanying consolidated balance sheet. As of December 31, 2019, the current portion of the corresponding lease liabilities of $1.3 million is included in accounts payable and other accrued liabilities and the non-current portion of the lease liabilities of $11.4 million is included in other long-term liabilities in the accompanying consolidated balance sheet. The operating lease costs and cash paid for the amounts included in the measurement of lease liabilities are classified as operating activities in the accompanying consolidated cash flow statement. <span style="color:#000000;">We recognize rent expense on a straight-line basis over the term of each lease. Rent expense of $1.9 million, $1.2 million and $1.5 million was recognized for the years ended December 31, 2019, 2018, and 2017, respectively. </span><span style="Background-color:#FFFFFF;color:#212529;">The weighted-average remaining lease term for all operating leases as of December 31, 2019 was </span><span style="color:#000000;">6.8 years</span>.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2019, the future lease payments under our existing financing and non-cancellable operating leases were as follows, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,576</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,461</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,497</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,672</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,540</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,889</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,584</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,111</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,280</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,941</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,667</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,804</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amounts representing interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,173</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add amounts representing residual value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease financing obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,427</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,814</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,613</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the prior lease guidance, at December 31, 2018, the future minimum lease payments under our existing financing and operating lease obligations were as follows, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,391</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,050</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,254</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">976</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,672</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,889</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,052</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,698</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,719</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,849</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amounts representing interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,960</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add amounts representing residual value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease financing obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,709</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,283</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,426</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subleases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016 and 2017, we entered into agreements to sublease several of our California properties. All our subleases expire in May 2027. The terms of the subleases stipulate annual increases in monthly rental payments. For the years ended December 31, 2019, 2018 and 2017, we recognized rent income from our subleases of $3.0 million, $2.5 million and $1.7 million, respectively</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize rent income on a straight-line basis over the term of the subleases. Expected minimum rental payments to be received under the sublease are as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,487</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,794</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,896</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,839</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,366</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> 3 0.025 4800000 5700000 6100000 21200000 49400000 5000000.0 2027-05 0.025 6300000 5900000 0.0725 12755 2019-09-01 2026-12 0.020 5200000 5200000 0.0725 10500 2019-06-01 2024-05 1400000 1500000 0.0725 4050 2020-01-01 11800000 1300000 11400000 1900000 1200000 1500000 P6Y9M18D <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2019, the future lease payments under our existing financing and non-cancellable operating leases were as follows, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,576</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,461</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,497</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,672</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,540</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,889</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,584</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,111</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,280</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,941</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,667</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,804</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amounts representing interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,173</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add amounts representing residual value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease financing obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,427</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,814</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,613</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the prior lease guidance, at December 31, 2018, the future minimum lease payments under our existing financing and operating lease obligations were as follows, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,391</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,050</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,254</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">976</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,672</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,889</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,052</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,698</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,719</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,849</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amounts representing interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,960</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add amounts representing residual value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,950</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease financing obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,709</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,283</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,426</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 7576000 2236000 8461000 2497000 8672000 2540000 8889000 2584000 9111000 2280000 22941000 4667000 65650000 16804000 21173000 4950000 49427000 3814000 45613000 7391000 1050000 8254000 1100000 8461000 976000 8672000 1000000 8889000 1025000 32052000 3698000 73719000 8849000 25960000 4950000 52709000 3283000 49426000 2027-05 2027-05 3000000.0 2500000 1700000 Expected minimum rental payments to be received under the sublease are as follows: <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,487</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,794</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,896</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,839</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,366</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1873000 2477000 3487000 3794000 3896000 9839000 25366000 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Stockholders’ Equity</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In March 2018, we completed the sale of an aggregate of 9,775,000 shares of our common stock under an underwritten public offering. Net proceeds from the offering were approximately $383.1 million after deducting underwriting discounts and commissions and offering expenses payable by us. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="Background-color:#FFFFFF;">In July 2017, we completed the sale of an additional 7,187,500 shares of our common stock under an underwritten public offering. Net proceeds from the offering were $162.0 million after deducting underwriting discounts and commissions, and offering expenses payable by us.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In April 2017, we completed the sale of an aggregate of 6,900,000 shares of our common stock under an underwritten public offering. Net proceeds from the offering were approximately $74.4 million after deducting underwriting discounts and commissions, and offering expenses payable by us. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In January 2017, we entered into an<span style="Background-color:#FFFFFF;"> Equity Distribution Agreement, or ATM, with Citigroup Global Markets, Inc., or the Sales Agent, under which we could sell common stock through our Sales Agent. Sales of the shares under the ATM were made in transactions that are deemed to be “at‑the‑market” </span>equity<span style="Background-color:#FFFFFF;"> offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including on the Nasdaq Stock Market. </span>During the period from February through April 2017, we <span style="Background-color:#FFFFFF;">sold 489,023 shares of </span>our common stock at an average market price of $15.05 per share under the ATM for aggregate net proceeds of approximately $7.0<span style="Background-color:#FFFFFF;"> million </span>after deducting commissions and expenses<span style="Background-color:#FFFFFF;">.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plans</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, our stockholders approved our 2017 Long-Term Incentive Plan, or 2017 LTIP. Upon such approval, our 2013 Long-Term Incentive Plan, or 2013 LTIP, was terminated. Notwithstanding such termination or the previous termination of our 2012 Long-Term Incentive Plan, 2009 Long-Term Incentive Plan, and 2006 Long-Term Incentive Plan, as amended, or, together with the 2013 LTIP, the Prior Plans, all outstanding awards under the Prior Plans continue to be governed under the terms of the Prior Plans. In June 2018, our stockholders approved <span style="color:#000000;">amendment and restatement of our 2017 Long-Term Incentive Plan, to, among other things, increase the number of shares authorized for issuance under the 2017 LTIP. </span>The number of shares of common stock authorized for issuance under the 2017 LTIP may be increased by the number of shares subject to any stock awards under the Prior Plans that are forfeited, expire or otherwise terminate without the issuance of such shares and would otherwise be returned to the share reserve under the Prior Plans but for their termination and as otherwise provided in the 2017 LTIP.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate number of shares of our common stock that initially may be issued pursuant to stock awards granted under the 2017 LTIP is 6,958,560 shares, less 1 share for every share that was subject to an option or stock appreciation right granted under the 2017 Plan and 1.9 shares for every 1 share that share that was subject to an award other than an option or stock appreciation right granted under the 2017 LTIP after March 31, 2018. Shares issued pursuant to the exercise of stock options and stock appreciation rights granted under the 2017 LTIP reduce the available number of shares by 1 share for every share issued while awards other than stock options and stock appreciation rights granted under the 2017 LTIP reduce the available number of shares by 1.9 shares for every share issued.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares under the 2017 LTIP may be granted as incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. <span style="color:#000000;">Performance awards may be based on the achievement of operational, financial, research and development, collaboration and license arrangements and other performance metrics provided under the 2017 LTIP, such as total stockholder return, revenue, research, development and regulatory achievements and strategic and operational initiatives.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A total of 3,024,775 shares of our common stock were reserved for future issuance at December 31, 2019, pursuant to our Equity Compensation Plans.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted under the 2017 LTIP generally vest over four years with 25% of the shares subject to each option vesting on the first anniversary of the grant date and the remainder of the shares vesting monthly over the following three years in equal installments and, to the extent vested, are exercisable for up to seven years from the date of grant. The recipient of a restricted stock award has all rights of a stockholder at the date of grant, subject to certain restrictions on transferability and a risk of forfeiture. Restricted stock unit awards generally vest over one or four years from the date of grant. The minimum performance period under a performance award is 12 months. Neither the exercise price of an option nor the grant price of a stock appreciation right may be less than 100% of the fair market value of the common stock on the date such equity award is granted, except in specified situations. The 2017 LTIP prohibits option and stock appreciation right repricings (other than to reflect stock splits, spin-offs or certain other corporate events) without stockholder approval.<span style="Background-color:#FFFFFF;color:#008000;"> </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our stock option activity under the Prior Plans and the 2017 LTIP, or collectively, our Equity Compensation Plans, for the year ended December 31, 2019, in thousands (except per share data):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,541</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.83</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,070</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.53</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.27</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/cancelled/expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.37</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,535</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000781">5.08</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,380</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,535</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000782">5.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,194</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000783">4.18</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,866</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value in the above table is calculated as the difference between the closing price of our common stock at December 31, 2019, of $45.42 per share and the exercise price of stock options that had strike prices below the closing price. The intrinsic value of all stock options exercised during the years ended December 31, 2019, 2018, and 2017, was $17.2 million, $7.1 million, and $2.8 million, respectively. During the year ended December 31, 2019, cash of $15.2 million was received from stock option exercises. There is no tax impact related to share-based compensation or stock option exercises because we are in a net operating loss position with a full valuation allowance on our deferred tax assets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019,<span style="color:#000000;"> a total of 297,000 target Performance-Based Restricted Stock Units, or PRSUs, were granted to employees in a company-wide grant. The PRSUs vest upon the closing price of our common stock, or the Closing Price, reaching certain price thresholds during the <span style="-sec-ix-hidden:F_000794">three-year</span> performance period beginning January 4, 2019, and ending January 3, 2022, or the Performance Period, and the participant’s subsequent satisfaction of a continuing service requirement of generally 90 calendar days. If, on five consecutive trading days or ten non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60.00, $67.50 or $75.00, and the participant thereafter satisfies a continuing service requirement, then the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the participant’s respective target PRSU amount. The shares may be issued following achievement of each price threshold, and the maximum number of common shares that may be issued pursuant to each PRSU grant equals 200% of the number of PRSUs granted. As these awards contain a market condition, we used a Monte Carlo simulation model to estimate the grant-date fair value, which totaled $18.1 million. The grant-date fair value is recognized as compensation expense over the requisite service period of approximately 1.2 years which was derived from the Monte Carlo simulation; no compensation expense is recognized for service not provided in case of separation from the Company. There is no adjustment of compensation expense recognized for service performed regardless of the number of PRSUs, if any, that ultimately vest. The $60.00 market condition threshold was achieved in the third quarter of 2019. As a result, a total of 140,900 shares were issued to employees upon the satisfaction of the continuing service requirement.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, we granted our executive officers TSR PRSU awards. The TSR PRSUs could be earned and converted into outstanding shares of our common stock based on the total stock return, or TSR, of our common stock relative to the TSR over a <span style="-sec-ix-hidden:F_000808"><span style="-sec-ix-hidden:F_000809">three-year</span></span> performance period beginning March 1 of the year granted of the Nasdaq Biotechnology Index. In March 2018, 32,322 shares were issued to the holders of the remaining TSR PRSUs based on the TSR of our common stock relative to the TSR Nasdaq Biotechnology Index over the three-year performance period.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015, our stockholders approved our 2009 Employee Stock Purchase Plan, as amended, or 2009 ESPP. Under the 2009 ESPP substantially all employees could choose to have up to 15% of their annual compensation withheld to purchase up to 625 shares of our common stock per purchase period, subject to certain limitations. The shares of our common stock could be purchased over an offering period with a maximum duration of 24 months and at a price of not less than 85% of the lesser of the fair market value of the common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of the applicable three-month purchase period. Under applicable accounting guidance, the 2009 ESPP was considered a compensatory plan. In <span style="-sec-ix-hidden:F_000815">June 2017</span>, the 2009 ESPP was terminated.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, our stockholders approved our 2019 Employee Stock Purchase Plan, or 2019 ESPP. Under the 2019 ESPP substantially all employees can elect to have up to 15% of their annual compensation withheld to purchase up to 2,000 shares of our common stock per purchase period, subject to certain limitations. The shares of our common stock can be purchased over an offering period with a maximum duration of 12 months and at a price of not less than 85% of the lesser of the fair market value of the common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of the applicable six-month purchase period. Under applicable accounting guidance, the 2019 ESPP is considered a compensatory plan. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2017, a total of 2,236 shares, respectively, were purchased by our employees under the 2009 ESPP. There were no purchases under the 2019 ESPP in 2019. The amount of compensation expense associated with the 2009 ESPP and 2019 ESPP for the years ended December 31, 2019, 2018, and 2017 was immaterial.  </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share-based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the grant-date fair value of all of our share-based awards in determining our share-based compensation expense. Our share-based awards include stock options, options to purchase stock granted under our employee stock purchase plan, RSUs, and PRSU awards.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below sets forth the weighted-average assumptions and estimated fair value of stock options we granted under our Equity Compensation Plans during the years presented:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000828">4.47</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000829">4.58</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000830">4.58</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average estimated fair value per share of stock options granted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.47</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.01</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.17</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized share-based compensation expense as follows for the years presented, in thousands, except per share data:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,361</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,385</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,945</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,686</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinued operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,047</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,990</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact on net loss per share, basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.07</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.42</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact on net loss per share, diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.03</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.42</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below sets forth our total unrecognized estimated compensation expense at December 31, 2019, by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense (in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognition</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Period (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,703</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000854">2.62</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000855">0.21</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000856">0.57</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 9775000 383100000 7187500 162000000.0 6900000 74400000 489023 15.05 7000000.0 6958560 1.9 1.9 3024775 Stock options granted under the 2017 LTIP generally vest over four years with 25% of the shares subject to each option vesting on the first anniversary of the grant date and the remainder of the shares vesting monthly over the following three years in equal installments P4Y 0.25 P3Y P7Y P1Y P4Y P12M 1 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our stock option activity under the Prior Plans and the 2017 LTIP, or collectively, our Equity Compensation Plans, for the year ended December 31, 2019, in thousands (except per share data):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,541</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.83</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,070</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.53</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.27</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/cancelled/expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.37</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.74%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,535</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000781">5.08</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,380</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,535</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000782">5.08</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,194</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.74%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000783">4.18</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,866</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 6541000 28.83 3070000 44.53 626000 24.27 450000 38.37 8535000 34.31 104380000 8535000 34.31 104380000 3194000 26.37 63866000 45.42 17200000 7100000 2800000 15200000 0 297000 60.00 67.50 75.00 0.50 1 2 2 18100000 P1Y2M12D 60.00 140900 32322 0.15 625 P24M 0.85 0.15 2000 P12M 0.85 2236 0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below sets forth the weighted-average assumptions and estimated fair value of stock options we granted under our Equity Compensation Plans during the years presented:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000828">4.47</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000829">4.58</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000830">4.58</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average estimated fair value per share of stock options granted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.47</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.01</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.17</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.023 0.026 0.019 0.64 0.63 0.69 23.47 20.01 9.17 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized share-based compensation expense as follows for the years presented, in thousands, except per share data:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,361</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,385</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,945</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,686</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinued operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,047</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,990</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact on net loss per share, basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.07</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.42</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact on net loss per share, diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.03</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.42</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 27361000 8385000 1945000 25686000 11158000 5925000 11000 120000 53047000 19554000 7990000 1.07 0.42 0.24 1.03 0.42 0.24 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below sets forth our total unrecognized estimated compensation expense at December 31, 2019, by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense (in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognition</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Period (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,703</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000854">2.62</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000855">0.21</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000856">0.57</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 95703000 1750000 613000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Collaborations and License Agreements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have collaborations or license agreements with the following companies: United Therapeutics Corporation, or United Therapeutics, Everest Medicines Limited, Eisai Co., Ltd. and Eisai Inc., or collectively, Eisai, and Boehringer Ingelheim International GmbH, or Boehringer Ingelheim.  </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the following table, revenue is disaggregated by major customers, timing of revenue recognition and revenue classification, in thousands:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Customers</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-top:solid 0.75pt #000000;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Therapeutics</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Everest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eisai</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,077</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,508</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,407</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,431</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Timing of revenue recognition</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-top:solid 0.75pt #000000;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized at a point in time</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803,580</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,092</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized over time</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,851</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,385</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,431</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-top:solid 0.75pt #000000;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from continuing operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,431</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,970</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue reported under discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,507</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,431</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">United Therapeutics Corporation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, we entered into an exclusive license agreement with United Therapeutics. Under this agreement, we granted United Therapeutics an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize ralinepag in any formulation. This transaction was completed in January 2019. United Therapeutics is responsible for all development, manufacturing and commercialization of the licensed products globally. In connection with this transaction we incurred transaction fees of </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.0</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, of which $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million was incurred in 2019 and $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million was incurred in 2018, and are presented as transaction costs in the accompanying consolidated statement of operations.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received an upfront payment<span style="color:#000000;"> of $800.0 million under the agreement in the first quarter of 2019. </span>We are also eligible to receive up <span style="color:#000000;">to an aggregate of $400.0 million in regulatory milestone payments related to ralinepag, consisting of a payment of $150.0 million upon first marketing approval of an oral formulation of ralinepag in a major non-U.S. market, and a payment of $250.0 million upon U.S. marketing approval of an inhaled formulation of ralinepag to treat pulmonary arterial hypertension, as well as low double-digit, tiered royalties on net sales of ralinepag products, subject to certain adjustments for third party license payments.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised goods and services under this<span style="color:#000000;"> </span>agreement are accounted for as a single performance obligation consisting of a research, development and commercialization license. Our performance obligation under this<span style="color:#000000;"> a</span>greement was satisfied upon the closing of the transaction in January 2019, and accordingly, the estimated total transaction price of the agreement of $800.0 million was recognized as revenue at the commencement of this agreement in 2019. The future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained. Under the royalty exception in ASC 606 for licensed intellectual property, we do not include any variable amounts related to sales-based royalties in the transaction price until the later of when the sales occur or the performance obligation is satisfied or partially satisfied. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Everest</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we and Everest entered into an exclusive agreement, or the Everest Agreement, to conduct joint <span style="color:#000000;">development</span> for the ralinepag and etrasimod programs. Under the Everest Agreement, we granted Everest an exclusive, royalty-bearing license to develop and commercialize ralinepag (in any formulation) and etrasimod (in oral formulations), in mainland China, Taiwan, Hong Kong, Macau and South Korea, or collectively, the Territories. Everest is generally responsible for development and commercialization of the licensed products in the Territories, and may participate in the portion of our global clinical trials that is conducted in the Territories. In January 2019, we and Everest amended the Everest Agreement by entering into two separate agreements, one for each development program with the terms identical to the original Everest Agreement. Under the agreement with United Therapeutics described above, we assigned all our rights and obligations with respect to the ralinepag program under the Everest Agreement, to United Therapeutics.  </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with entering into the Everest Agreement, we received from <span style="color:#000000;">Everest an upfront payment of $12.0 million in December 2017. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2018, the Chinese National Medical Products Administration accepted the initial clinical trial applications for etrasimod and the oral formulation of ralinepag. Under the terms of the Everest Agreement, we recognized revenue of $2.0 million from the achievement of these milestones. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, Everest announced that the first subject has been dosed in a Phase 3 trial evaluating etrasimod in development for the treatment of UC in Greater China and South Korea. Everest paid us a $5.0 million milestone payment due from this achievement, which we recognized as revenue in the fourth quarter of 2019. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also eligible to receive up to an aggregate of $110.0 million in success milestones in case of full commercial success of etrasimod products. We are also eligible to receive tiered royalties on net sales of <span style="color:#000000;">etrasimod products in the Territories</span>.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised goods and services under the Everest Agreement are accounted for as a single performance obligation consisting of a development and commercialization license. The amount of the upfront payment was recognized as revenue in December 2017 as we determined (i) that the license is a deliverable with standalone value to Everest and (ii) the upfront payment represents consideration to be allocated to the delivered license. As of December 31, 2019, all remaining future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2019, 2018, and 2017, we recognized revenues of $5.0 million, $2.0 million and $12.0 million, respectively from the <span style="color:#000000;">Everest Agreement</span>.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eisai</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2010, we granted Eisai exclusive commercialization rights for lorcaserin (marketed as BELVIQ/BELVIQ XR) solely in the United States and its territories and possessions. In May 2012, we and Eisai entered into the first amended and restated agreement, which expanded Eisai’s exclusive commercialization rights to include most of North and South America. In November 2013, we and Eisai entered into the second amended and restated agreement, or Second Amended Agreement, which expanded Eisai’s exclusive </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization rights for lorcaserin to all countries in the world, except for South Korea, Taiwan, Australia, New Zealand and Israel. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, we and Eisai amended and restated the terms of marketing and supply agreement for lorcaserin with Eisai by entering into a Transaction Agreement and a Supply Agreement (collectively, the Eisai Agreement) with Eisai. Under the Transaction Agreement, Eisai acquired an exclusive royalty-bearing license or transfer of intellectual property to global commercialization and manufacturing rights to lorcaserin, including in the territories retained by us under the prior agreement, with control over global development and commercialization decisions. Eisai is responsible for all lorcaserin development expenses in the future. We also assigned to Eisai our rights under the commercial lorcaserin distribution agreements with Ildong Pharmaceutical Co., Ltd., or Ildong, for South Korea; CY Biotech Company Limited, or CYB, for Taiwan; and Teva Pharmaceuticals Ltd.’s Israeli subsidiary, Abic Marketing Limited, or Teva, for Israel. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Supply Agreement, Eisai paid <span style="color:#000000;">us for finished drug product plus monthly manufacturing support payments through March 2018 totaling </span>CHF 8.7 million.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until March 31, 2018, when we sold the Manufacturing Operations, including the assignment of the Supply Agreement, to Siegfried (see Note 5), we manufactured lorcaserin at our manufacturing facility in Zofingen, Switzerland. Revenues earned for (i) lorcaserin sold by us to Eisai under the manufacturing and supply commitment within the Supply Agreement and (ii) the manufacturing support payments are classified within discontinued operations as part of the Manufacturing Operations in the consolidated statements of operations (see Note 5). All other revenues earned under the Transaction Agreement, such as royalties, are classified within continuing operations in the consolidated statements of operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalty payments.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Transaction Agreement, we are eligible to receive tiered royalty payments from Eisai starting at 9.5% on the global net sales of lorcaserin.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Upfront payments.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Transaction Agreement, we received from Eisai total upfront payments of $115.0 million under prior lorcaserin collaboration agreements <span style="color:#000000;">and $7.5 million from the prior commercial lorcaserin distribution agreements with Ildong and CYB described below, and Teva</span>. Revenues from these upfront payments were previously deferred, as we determined that the exclusive rights did not have standalone value without our ongoing development and regulatory activities. Accordingly, these payments were recognized ratably as revenue over the periods in which we expected the services to be rendered. The Transaction Agreement effectively eliminated our obligation to continue performing the development and regulatory activities required in the original agreement<span style="color:#000000;">.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In total, <span style="color:#000000;">prior to the Transaction Agreement, we received a total of $102.1 million in milestone payments from Eisai, and other </span>lorcaserin distributors<span style="color:#000000;">. These payments were recognized as revenue upon the achievement of the milestones.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.2%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Accounting for Eisai Agreement under ASC 606.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon implementation of ASC 606 on January 1, 2018, we applied a practical expedient for contract modifications applicable to contracts that were modified before the implementation date. The promised goods and services under the Eisai Agreement were assessed in combination with promised goods and services under our previous agreements with Eisai and commercial lorcaserin distribution agreements with Ildong, CYB, and Teva. The total estimated transaction price of these contracts at the implementation date was $344.4 million, which included previously received upfront payments, milestone payments, proceeds from net products sales, reimbursement of development expenses, reimbursement of patent expenses, manufacturing support payments received and expected to be received under the Supply Agreement, proceeds from the sale of on-hand inventory of bulk lorcaserin and the precursor material, royalty payments received through December 31, 2017, and estimated future royalty payments related to intellectual property sold to Eisai. The future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained due to our assessment of the probability of a significant revenue reversal. The future royalties related to licensed intellectual property were excluded from the estimated total transaction price under the royalty exception in ASC 606. The estimated future royalties that relate to intellectual property sold to Eisai do not qualify for the royalty exception in ASC 606 and were included in the estimated total transaction price.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated total transaction price was allocated between satisfied and unsatisfied performance obligations based on the relative standalone selling prices of the identified performance obligations. The remaining manufacturing and supply obligations under the Supply Agreement was the only unsatisfied performance obligation. As a result of this allocation, on January 1, 2018, we reduced the balance of deferred revenues associated with the Eisai Agreement at the implementation date by $25.5 million, recognized a contract asset of $6.1 million related to future manufacturing support payments under the Supply Agreement and recognized a contract </p> <p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">asset of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million related to estimated futu</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re royalty payments from intellectual property sold to Eisai under the Transaction Agreement. In connection with the sale of the Manufacturing Operations on March 31, 2018, we derecognized the remaining portion of the contract asset associated with the Sup</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ply Agreement. During 2018, we adjusted our estimate of future royalty payments from intellectual property sold to Eisai under the Transaction Agreement based on the CVOT study results reported by Eisai and our estimate of the qualifying sales of BELVIQ in</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the future years and recorded associated royalty revenue and an increase to the contract asset of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. As of December 31, 2018, the contract asset balance was $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to year end, Eisai agreed to voluntarily withdraw BELVIQ</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products from the U.S. market based on a change in the FDA’s risk-benefit assessment of BELVIQ, and as requested by the FDA. As a result, we revised our estimate of future royalties and recorded a $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million reduction to our contract asset as of Decem</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ber 31, 2019</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the bill-and-hold accounting guidance in ASC 606, effective January 1, 2018, we derecognized $3.6 million of inventory of bulk lorcaserin and the precursor material previously sold to Eisai for which the revenue recognition criteria were met on the implementation date under ASC 606.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2019, 2018 and 2017, we recorded royalty revenues of $(1.1) million, $6.6 million and $1.7 million, respectively related to the Transaction Agreement. For the year ended December 31, 2018 and 2017, we recognized revenue of $1.5 million and $15.9 million, respectively, related to the Supply Agreement (classified under discontinued operations), all of which was recorded during the first quarter of 2018 and primarily consisting of net product sales and other collaboration revenue.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.2%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Accounting for Eisai Agreement under previous revenue recognition policy.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total arrangement consideration of $115.6 million primarily consists of (i) the December 28, 2016, balances of deferred revenues from the upfront payments received under the prior Eisai agreements and the distribution agreements with other distributors; (ii) the $10.0 million payment received from Eisai on December 28, 2016; and (iii) the product purchase payments and manufacturing support payments we expect to receive from Eisai for the initial two-year manufacturing and supply commitment period.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the deliverables were determined to have standalone value and to meet the criteria to be accounted for as separate units of accounting. Factors considered in the determination included, among other things, for the license, the manufacturing experience and capabilities of Eisai and their sublicense rights, and for the remaining deliverables the fact that they are not proprietary and can be provided by other vendors. The total arrangement consideration was allocated to the units of accounting, consisting of <span style="color:#000000;">the License Deliverable</span>, <span style="color:#000000;">the Inventory Deliverable</span> <span style="color:#000000;">the Manufacturing and Supply Commitment Deliverable,</span> and on the basis of their relative estimated selling prices.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2017, we recognized $6.4 million as revenue of discontinued operations related to this deliverable and $0.9 million of the carrying value of this inventory as <span style="color:#000000;">cost</span> of product sales of discontinued operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Manufacturing and Supply Commitment Deliverable<span style="color:#000000;"> was provided over 2017 and 2018 as product was shipped to Eisai until March 31, 2018</span>. For the year ended December 31, 2017, we recognized $9.5 million as revenue of discontinued operations related to this deliverable.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Eisai Agreement, Eisai is solely responsible for all costs and expenses in connection with further development of lorcaserin.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Boehringer Ingelheim International GmbH</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, we and Boehringer Ingelheim entered into a collaboration and license agreement, or Boehringer Ingelheim Agreement, under which we and Boehringer Ingelheim conduct joint research to identify drug candidates targeting an undisclosed G-protein-coupled receptor, or GPCR, that belongs to the group of orphan central nervous system receptors. Under Boehringer Ingelheim Agreement, we granted Boehringer Ingelheim exclusive rights to our internally discovered, novel compounds and intellectual property for an orphan CNS receptor. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018 and October 2019, we earned a milestone payment of $3.5 million and $1.5 million, respectively upon <span style="color:#000000;">Boehringer Ingelheim’s initiation of preclinical development of a first and an additional compound</span>.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also eligible to receive up to an aggregate of $246.0 million (of which the first $7.0 million is also payable to Beacon – see Note 12) in additional success milestone payments in case of full commercial success of multiple drug products.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised goods and services under the Boehringer Ingelheim Agreement are accounted for as a singl</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e combined performance obligation consisting of a research license, a development and commercialization license and research services. Our research services performance obligation under the original term of the Boehringer Ingelheim Agreement was completely</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> satisfied as of January 2018, and accordingly the estimated total transaction price of the Boehringer Ingelheim Agreement under the original contractual term was fully recognized as revenue over the period from January 2016 through January 2018. We recogn</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ize revenue for the combined performance obligation based on the amount of incurred development expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.</span><span style="color:#000000;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, all future po</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tential milestone payments were excluded from the estimated total transaction price as they are considered constrained.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2019, 2018, and 2017, we recognized revenues of $1.7 million, $4.4 million and $5.1 million, respectively from the <span style="color:#000000;">Boehringer Ingelheim Agreement</span>.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Outpost Medicine LLC</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we and Outpost Medicine entered into a license agreement, or Outpost Agreement, under which Outpost Medicine has an exclusive right to advance an undisclosed, preclinical compound with potential utility in treating genitourinary disorders.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Outpost Agreement, we received an upfront payment of $3.0 million, of which $1.5 million was in the form of an equity interest in Outpost Medicine. <span style="color:#000000;">In September 2019, we earned a milestone payment of $0.5 million upon </span>Outpost’s initiation of Phase 1 clinical trials<span style="color:#000000;">.</span> </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised goods and services under the Outpost Agreement are accounted for as a single performance obligation consisting of a research, development and commercialization license. Our performance obligation under the Outpost Agreement was fully satisfied at the inception of the Outpost Agreement and, accordingly, the estimated total transaction price of the Outpost Agreement was fully recognized as revenue in the second quarter of 2018. As of December 31, 2019, all future potential milestone payments were excluded from the estimated total transaction price as they are considered constrained.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2019, 2018 and 2017, we recognized revenues of $0.5 million, $2.8 million and $0.2 million, respectively from the <span style="color:#000000;">Outpost Agreement. Subsequent to year end, the Outpost Agreement was terminated.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Axovant Sciences GmbH</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015, we entered into a development, marketing and supply agreement with Roivant Sciences Ltd., which subsequently assigned the exclusive rights to develop and commercialize nelotanserin to its subsidiary, Axovant. Under this agreement, Axovant had exclusive worldwide rights to develop and commercialize nelotanserin, subject to regulatory approval. We also provided certain services and manufactured and sold nelotanserin to Axovant. We refer to this agreement as the Axovant Agreement.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised goods and services under the Axovant Agreement were accounted for as two separate performance obligations: (i) a combined performance obligation consisting of commercialization rights and development and regulatory services and (ii) a manufacturing and supply commitment. We recognized revenue for the combined performance obligation consisting of commercialization rights and development and regulatory services based on the amount of incurred development expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract. In December 2018, Axovant announced negative results of an exploratory Phase 2 clinical study and a discontinuation of further clinical development activities under the nelotanserin program. As a result, we revised our estimate of the total transaction price as of December 31, 2018, based on our assessment that we will not perform any research and development services for Axovant in the future and concluded that all our performance obligations have been satisfied. As of December 31, 2018, all future potential purchase price adjustment payments and milestone payments were excluded from the estimated total transaction price as they were considered constrained.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2018, and 2017, and we recognized revenues of $2.2 million, and $2.2 million, respectively, from <span style="color:#000000;">the Axovant Agreement</span>. No revenue was recognized under this agreement for the year ended December 31, 2019. In the fourth quarter of 2019, the Axovant Agreement was terminated. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the following table, revenue is disaggregated by major customers, timing of revenue recognition and revenue classification, in thousands:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Customers</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-top:solid 0.75pt #000000;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Therapeutics</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Everest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eisai</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,077</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,070</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,508</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,407</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,431</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Timing of revenue recognition</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-top:solid 0.75pt #000000;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized at a point in time</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803,580</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,092</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized over time</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,851</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,385</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,431</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.54%; border-top:solid 0.75pt #000000;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from continuing operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,431</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,970</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue reported under discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,507</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806,431</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 800000000 5000000 2000000 -1077000 8070000 2508000 10407000 806431000 20477000 803580000 14092000 2851000 6385000 806431000 20477000 806431000 17970000 2507000 806431000 20477000 In November 2018, we entered into an exclusive license agreement with United Therapeutics. Under this agreement, we granted United Therapeutics an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize ralinepag in any formulation. This transaction was completed in January 2019. 2019-01 17000000.0 14600000 2400000 800000000.0 400000000.0 150000000.0 250000000.0 800000000.0 12000000.0 2000000.0 5000000.0 110000000.0 5000000.0 2000000.0 12000000.0 2012-05 2013-11 8700000 0.095 115000000.0 7500000 102100000 344400000 25500000 6100000 4100000 3300000 6000000.0 3700000 3600000 -1100000 6600000 1700000 1500000 15900000 115600000 10000000.0 6400000 900000 9500000 3500000 1500000 246000000.0 7000000.0 1700000 4400000 5100000 3000000.0 1500000 500000 500000 2800000 200000 2200000 2200000 0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our income (loss) attributable to stockholders of Arena before provision (benefit) for income taxes by region for the years presented, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298,315</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(138,522</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,109</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,573</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,142</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,298</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income (loss) attributable to stockholders of Arena before income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507,888</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,407</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, we have recorded an expense for income taxes for the usage of the deferred tax assets that were set up in 2018 related to the taxable gain pursuant to the United Therapeutics transaction. We recorded a benefit for income taxes for the year ended December 31, 2018, due to the estimated taxable gain pursuant to the United Therapeutics transaction. We did not record a benefit for income taxes for the year ended December 31, 2017, because we had a full valuation allowance.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our effective income tax rate differs from the statutory federal rate of 21% for 2019 and 2018, and 34% for 2017 due to the following, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit for income taxes at statutory federal rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,657</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,090</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,140</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance due to tax reform</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in federal and foreign valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,712</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,336</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences and other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">601</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,963</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(782</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred adjustment related to foreign net operating losses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,133</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital loss on foreign subsidiary liquidation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,685</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,624</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">889</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,071</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign losses at lower effective rates</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development and Orphan Drug credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,730</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,948</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,306</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit for income taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of our net deferred tax assets are as follows, in thousands:  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and California NOL carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,762</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,853</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and California research and development credit carryforwards</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,956</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,221</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign NOL carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,131</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,010</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,124</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,183</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,914</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,359</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">784</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,624</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305,027</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,218</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,218</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,406</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305,027</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(229,406</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(194,694</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance is recorded against a portion of our deferred tax assets, as realization of a portion of these assets is not more-likely-than-not. The realization of our deferred tax assets is dependent upon future taxable income. In January 2019, a taxable income generating event, the transaction pursuant to the United Therapeutics Agreement created taxable income, resulting in the realization of a portion of our deferred tax assets. A portion of the valuation allowance in 2018 was released for the anticipated taxable </p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income generating event. We utilized net operating losses to offset taxable income in 2019.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Our ability to generate taxable income is analyzed regularly on a jurisdiction-by-jurisdiction basis. At such time as it is more-likely-than-not</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that we will generate taxable income in a jurisdiction, we will further reduce or remove the valuation allowance. The valuation allowance increased by $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million from December 31, 2018, to December 31, 2019.</span><span style="color:#7030A0;"> </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2019, we had federal NOL carryforwards of $539.3 million that will begin to expire in 2029 unless previously utilized. At the same date, we had California NOL carryforwards of $393.9 million, which begin expiring in 2028. Net operating losses generated after December 31, 2017 carry forward indefinitely. At December 31, 2019, we had $151.4 million of net operating losses with no expiration. Net operating losses generated in 2018 are subject to an 80% limitation. At December 31, 2019, we also had federal and California research and development tax credit carryforwards, net of reserves, of $38.7 million and $25.1 million, respectively. At December 31, 2019, we had a Federal Orphan Drug Credit carryforward, net of reserves, of $15.0 million. Federal credit carryforwards will begin to expire after 2026 unless previously utilized. The California research and development credit carries forward indefinitely.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sections 382 and 383 of the IRC limit the utilization of tax attribute carryforwards that arise prior to certain cumulative changes in a corporation’s ownership. We have completed an IRC Section 382/383 analysis through 2019 and did not identify any ownership changes that limit our utilization of tax attribute carryforwards since 2010. Pursuant to IRC Section 382 and 383, use of our net operating loss and research and development income tax credit carryforwards may be limited in the event of cumulative changes in ownership subsequent to 2019 of more than 50% within a <span style="-sec-ix-hidden:F_001005">three-year</span> period.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles the beginning and ending amount of unrecognized tax benefits for the years presented, in thousands:  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrecognized tax benefits at the beginning of the year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,033</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,906</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions from tax positions taken in the current year</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,269</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,133</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions from tax positions taken in prior years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions from tax positions taken in prior years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax settlements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrecognized tax benefits at end of the year</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,954</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,033</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of our total unrecognized tax benefits at December 31, 2019, $8.6 million will impact our effective tax rate in the event the valuation allowance is removed. We do not anticipate that there will be a substantial change in unrecognized tax benefits within the next 12 months.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Because we have incurred net losses since our inception, we did not have any accrued interest or penalties included in our consolidated balance sheets at December 31, 2019, or 2018, and did not recognize any interest and/or penalties in our consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2019, 2018, and 2017.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to income taxation in the United States at the Federal and state levels. All tax years are subject to examination by US and California tax authorities due to the carryforward of unutilized NOLs and tax credits. We are also subject to foreign income taxes in the countries in which we operate. To our knowledge, we are not currently under examination by any taxing authorities.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our income (loss) attributable to stockholders of Arena before provision (benefit) for income taxes by region for the years presented, in thousands:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298,315</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(138,522</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,109</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,573</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,142</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,298</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total income (loss) attributable to stockholders of Arena before income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507,888</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,407</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> 298315000 -138522000 -62109000 209573000 -1142000 -29298000 507888000 -139664000 -91407000 0 Our effective income tax rate differs from the statutory federal rate of 21% for 2019 and 2018, and 34% for 2017 due to the following, in thousands: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit for income taxes at statutory federal rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,657</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,090</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,140</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance due to tax reform</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in federal and foreign valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,712</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,336</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences and other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">601</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,963</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(782</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred adjustment related to foreign net operating losses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,133</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital loss on foreign subsidiary liquidation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,685</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,624</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">889</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,071</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign losses at lower effective rates</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development and Orphan Drug credits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,730</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,948</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,306</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit for income taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 0.21 0.21 0.34 106657000 -29090000 -32140000 96333000 34712000 -76336000 -68604000 601000 1963000 -782000 15133000 43685000 1624000 889000 7071000 21000 257000 1428000 4730000 7948000 3306000 110333000 -110265000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of our net deferred tax assets are as follows, in thousands:  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and California NOL carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,762</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,853</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and California research and development credit carryforwards</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,956</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,221</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign NOL carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,131</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,010</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,124</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,183</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,914</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,359</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">784</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">231,624</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305,027</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,218</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,218</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,406</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305,027</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(229,406</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(194,694</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 140762000 210853000 73956000 69221000 15131000 11010000 6124000 3183000 2914000 2359000 354000 784000 231624000 305027000 2218000 2218000 229406000 305027000 229406000 194694000 110333000 34700000 539300000 2029 393900000 2028 151400000 Net operating losses generated in 2018 are subject to an 80% limitation 0.80 38700000 25100000 15000000.0 2026 0.50 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles the beginning and ending amount of unrecognized tax benefits for the years presented, in thousands:  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrecognized tax benefits at the beginning of the year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,033</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,906</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions from tax positions taken in the current year</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,017</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,269</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,133</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions from tax positions taken in prior years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions from tax positions taken in prior years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax settlements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrecognized tax benefits at end of the year</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,954</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,033</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 9033000 7762000 5906000 1017000 1269000 1133000 2000 723000 96000 9954000 9033000 7762000 8600000 0 0 0 0 0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Legal Proceedings</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in September 2010, a number of complaints were filed in the US District Court for the Southern District of California, or District Court, against us and certain of our current and former employees and directors on behalf of certain purchasers of our common stock. The complaints were brought as purported stockholder class actions, and, in general, include allegations that we and certain of our current and former employees and directors violated federal securities laws by making materially false and misleading statements regarding our BELVIQ program, thereby artificially inflating the price of our common stock. The plaintiffs sought unspecified monetary damages and other relief. In August 2011, the District Court consolidated the actions and appointed a lead plaintiff and lead counsel. In November 2017, we and the Lead Plaintiff signed a stipulation and agreement of settlement, or Stipulation, to resolve the consolidated class action. Under the terms of the Stipulation, and in exchange for a release of all claims </p> <p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by class members and a dism</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issal of the consolidated class action with prejudice, we have agreed that (i) our insurers would pay class members and their attorneys a total of approximately $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.025</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and (ii) Arena would pay class members and their attorneys approximately $</span>11.975<span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in either shares of our common stock or cash at our election. On November 30, 2017, the District Court preliminary approved the settlement and the form of notice to potential class members of the proposed settlement and the procedure by which</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> they can become class members. On March 8, 2018, the lead plaintiff filed motions for final approval of the settlement, the plan of allocation and award of attorney fees. On April 12, 2018, the District Court entered its final approval order approving the</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> settlement and the plan of allocation and request for attorneys’ fees and expense. We recognized $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.975</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of net expense for the portion of the settlement that we agreed to pay in either common stock or cash in the consolidated statements of oper</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ations for the year ended December 31, 2017, and $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.0</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million as a current liability in the consolidated balance sheet as of December 31, 2017 for the gross settlement liability, with a corresponding $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.025</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million insurance recovery receivable. In t</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he second quarter of 2018, we and our insurer made settlement payments in cash to the class members and their attorneys to settle our liability under the Stipulation.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently subject to any material legal proceedings</p> 12025000.000 11975000 11975000 24000000.0 12025000.000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Quarterly Financial Data (Unaudited)</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present selected quarterly financial data for the years presented, in thousands, except per share data:  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,002</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,350</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801,057</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,875</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,685</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,578</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,547</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88,311</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,865</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,403</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620,134</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share, basic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.76</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.46</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.24</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.53</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share, diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.76</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter<span style="font-family:Calibri;"> </span>ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,648</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,573</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,994</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,755</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,292</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,577</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,160</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,724</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from continuing operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,711</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,833</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,133</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,711</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,833</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,963</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share, basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuing operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinued operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.02</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share, diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuing operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinued operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.02</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present selected quarterly financial data for the years presented, in thousands, except per share data:  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,002</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,350</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801,057</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,875</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,685</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,578</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,547</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88,311</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,865</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,403</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620,134</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share, basic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.76</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.46</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.24</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.53</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share, diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.76</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter<span style="font-family:Calibri;"> </span>ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,648</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,573</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,994</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,755</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,292</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,577</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,160</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,724</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from continuing operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,711</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,833</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,133</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from discontinued operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(830</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,711</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,833</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,963</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share, basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuing operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinued operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.02</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) per share, diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuing operations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.78</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discontinued operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.02</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.46%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> 3002000 1350000 1022000 801057000 96875000 80685000 69578000 76547000 -88311000 -72865000 -61403000 620134000 -1.76 -1.46 -1.24 12.53 -1.76 -1.46 -1.24 12.10 8648000 3573000 3994000 1755000 53292000 39577000 37160000 32724000 68711000 -34314000 -31833000 -31133000 -830000 68711000 -34314000 -31833000 -31963000 1.39 -0.70 -0.65 -0.78 -0.02 1.39 -0.70 -0.65 -0.80 1.35 -0.70 -0.65 -0.78 -0.02 1.35 -0.70 -0.65 -0.80 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Beacon Discovery, Inc.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="color:#000000;">September 2016, we entered into a </span>series of agreements with Beacon, a privately held drug discovery incubator which focuses on identifying and advancing molecules targeting GPCRs. Beacon was founded in 2016 by several of our former employees.<span style="color:#000000;"> </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into an agreement, or License and Collaboration Agreement, with Beacon, pursuant to which we transferred certain equipment to Beacon and granted Beacon a non-exclusive, non-assignable and non-sublicensable license to certain database information relating to compounds, receptors and pharmacology, and transferred certain equipment to Beacon. Beacon will seek to engage global partners to facilitate discovery and development. Beacon has agreed to assign to us any intellectual property relating to our existing research and development programs developed in the course of performing research for us, and grant us a non-exclusive license to any intellectual property developed outside the course of performing work for us that is reasonably necessary or useful for developing or commercializing the products under our research and development programs. We are also entitled to rights of negotiation and rights of first refusal to potentially obtain licenses to compounds discovered and developed by Beacon. In addition, we are entitled to receive (i) a percentage of any revenue received by Beacon on or after the second anniversary of the effective date of </p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the agreement from any third party pursuant to a third-party license, including upfront payments, milestone payments and royalties; (ii) single-digit royalties on the aggregate net sales of any related products sold by Beacon and its affiliates; a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd (iii) in the event that Beacon is sold, a percentage of the consideration for such sale transaction.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered a services agreement with Beacon, or Master Services Agreement, pursuant to which Beacon performs certain research services for us.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also entered into a separate services agreement with Beacon, or Beacon Services Agreement, pursuant to which Beacon performed our research obligations under our agreement with Boehringer Ingelheim. In consideration for performing these research obligations, Beacon is entitled to receive the applicable FTE payments that are paid to us by Boehringer Ingelheim for the research services and certain milestone payments.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also entered into a sublease agreement, or Sublease, with Beacon, pursuant to which we sublease approximately 30,000 square feet of laboratory, office and meeting room space to Beacon until May 2027.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As Beacon’s equity investment at risk in September 2016 was not sufficient to permit Beacon to finance its activities without subordinated financial support, Beacon was considered a variable interest entity in which we held a significant variable interest pursuant to the License and Collaboration Agreement. We do not own any equity interest in Beacon; however, as the agreements described above provided us the controlling financial interest in Beacon until December 2017, we consolidated Beacon’s balances and activity within our consolidated financial statements until December 2017 as we were determined to be the primary beneficiary of Beacon. Pursuant to a contract Beacon entered into with a third party in December 2017, we determined we no longer held the controlling financial interest as of that date and, therefore, deconsolidated Beacon from our consolidated financial statements as we were no longer deemed to be the primary beneficiary. Our consolidated financial statements for the year ended December 31, 2017, include Beacon’s results of operations and cash flows until the December 2017 deconsolidation. Beacon’s net and comprehensive loss of $1.3 million for the year ended December 31, 2017 is presented as net loss <span style="color:#000000;">attributable to noncontrolling interest in consolidated variable interest entity in our consolidated statement of operations and comprehensive loss as we do not own any equity interest in Beacon.</span> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, we entered into a new multi-year strategic Collaboration and License Agreement with Beacon, aimed at building novel medicines across a range of GPCR targets believed to play a role in immune and inflammatory diseases. Under the terms of this agreement Beacon is responsible for early drug discovery activities and we will be responsible for any potential future development and, ultimately, commercialization activities. We are required to pay to Beacon research initiation fees, make quarterly research funding payments for the duration of Beacon’s research activities as well as research, development and regulatory milestone payments depending on the future research and development progress. We are also obligated to pay Beacon tiered royalties on net sales of low single digits levels.</p> 30000 2027-05 1300000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. Subsequent Events</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 12 regarding the collaboration and license agreement with Beacon, which was executed in January 2020<span style="color:#000000;">.</span></p> XML 65 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Beacon Discovery, Inc. - Additional Information (Detail)
$ in Thousands
 5 Months Ended 12 Months Ended
Dec. 31, 2019
ft²
Dec. 31, 2017
USD ($)
Dec. 31, 2016
Variable Interest Entity [Line Items]      
Sublease expiration period   2027-05 2027-05
Net loss attributable to noncontrolling interest in consolidated variable interest entity   $ (1,325)  
Beacon Discovery, Inc. | Variable Interest Entity, Primary Beneficiary      
Variable Interest Entity [Line Items]      
Net loss attributable to noncontrolling interest in consolidated variable interest entity   $ 1,300  
Beacon Discovery, Inc. | Variable Interest Entity, Primary Beneficiary | Sublease Agreement      
Variable Interest Entity [Line Items]      
Area of space subleased | ft² 30,000    
Sublease expiration period 2027-05    
XML 66 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Data

The following tables present selected quarterly financial data for the years presented, in thousands, except per share data:  

 

2019

 

Quarter ended

December 31

 

 

Quarter ended

September 30

 

 

Quarter ended

June 30

 

 

Quarter ended

March 31

 

Revenues

 

$

3,002

 

 

$

1,350

 

 

$

1,022

 

 

$

801,057

 

Operating costs and expenses

 

 

96,875

 

 

 

80,685

 

 

 

69,578

 

 

 

76,547

 

Net income (loss)

 

 

(88,311

)

 

 

(72,865

)

 

 

(61,403

)

 

 

620,134

 

Net income (loss) per share, basic

 

 

(1.76

)

 

 

(1.46

)

 

 

(1.24

)

 

 

12.53

 

Net income (loss) per share, diluted

 

 

(1.76

)

 

 

(1.46

)

 

 

(1.24

)

 

 

12.10

 

 

 

2018

 

Quarter ended

December 31

 

 

Quarter ended

September 30

 

 

Quarter ended

June 30

 

 

Quarter ended

March 31

 

Revenues

 

$

8,648

 

 

$

3,573

 

 

$

3,994

 

 

$

1,755

 

Operating costs and expenses

 

 

53,292

 

 

 

39,577

 

 

 

37,160

 

 

 

32,724

 

Income (loss) from continuing operations

 

 

68,711

 

 

 

(34,314

)

 

 

(31,833

)

 

 

(31,133

)

Loss from discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(830

)

Net income (loss)

 

 

68,711

 

 

 

(34,314

)

 

 

(31,833

)

 

 

(31,963

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share, basic

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.39

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.78

)

Discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(0.02

)

 

 

$

1.39

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.80

)

Net income (loss) per share, diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.35

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.78

)

Discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(0.02

)

 

 

$

1.35

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.80

)
XML 67 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
The Company and Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded From Calculation of Diluted Income (Loss) Per Share (Detail) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities excluded from calculation of diluted net loss per share (shares) 3,962 5,855 3,667
Stock options      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities excluded from calculation of diluted net loss per share (shares) 3,962 5,835 3,664
RSUs and unvested restricted stock      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total antidilutive securities excluded from calculation of diluted net loss per share (shares)   20 3
XML 68 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Balance Sheet Details - Accounts Payable and Other Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Payables And Accruals [Abstract]    
Accounts payable $ 6,043 $ 6,192
Accrued compensation 14,329 8,622
Other accrued liabilities 5,127 1,367
Total accounts payable and other accrued liabilities $ 25,499 $ 16,181
XML 69 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Data (Unaudited)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data (Unaudited)

11. Quarterly Financial Data (Unaudited)

The following tables present selected quarterly financial data for the years presented, in thousands, except per share data:  

 

2019

 

Quarter ended

December 31

 

 

Quarter ended

September 30

 

 

Quarter ended

June 30

 

 

Quarter ended

March 31

 

Revenues

 

$

3,002

 

 

$

1,350

 

 

$

1,022

 

 

$

801,057

 

Operating costs and expenses

 

 

96,875

 

 

 

80,685

 

 

 

69,578

 

 

 

76,547

 

Net income (loss)

 

 

(88,311

)

 

 

(72,865

)

 

 

(61,403

)

 

 

620,134

 

Net income (loss) per share, basic

 

 

(1.76

)

 

 

(1.46

)

 

 

(1.24

)

 

 

12.53

 

Net income (loss) per share, diluted

 

 

(1.76

)

 

 

(1.46

)

 

 

(1.24

)

 

 

12.10

 

 

 

2018

 

Quarter ended

December 31

 

 

Quarter ended

September 30

 

 

Quarter ended

June 30

 

 

Quarter ended

March 31

 

Revenues

 

$

8,648

 

 

$

3,573

 

 

$

3,994

 

 

$

1,755

 

Operating costs and expenses

 

 

53,292

 

 

 

39,577

 

 

 

37,160

 

 

 

32,724

 

Income (loss) from continuing operations

 

 

68,711

 

 

 

(34,314

)

 

 

(31,833

)

 

 

(31,133

)

Loss from discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(830

)

Net income (loss)

 

 

68,711

 

 

 

(34,314

)

 

 

(31,833

)

 

 

(31,963

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share, basic

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.39

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.78

)

Discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(0.02

)

 

 

$

1.39

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.80

)

Net income (loss) per share, diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

1.35

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.78

)

Discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(0.02

)

 

 

$

1.35

 

 

$

(0.70

)

 

$

(0.65

)

 

$

(0.80

)
XML 70 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity
 12 Months Ended
Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stockholders' Equity

7. Stockholders’ Equity

In March 2018, we completed the sale of an aggregate of 9,775,000 shares of our common stock under an underwritten public offering. Net proceeds from the offering were approximately $383.1 million after deducting underwriting discounts and commissions and offering expenses payable by us. 

In July 2017, we completed the sale of an additional 7,187,500 shares of our common stock under an underwritten public offering. Net proceeds from the offering were $162.0 million after deducting underwriting discounts and commissions, and offering expenses payable by us.

In April 2017, we completed the sale of an aggregate of 6,900,000 shares of our common stock under an underwritten public offering. Net proceeds from the offering were approximately $74.4 million after deducting underwriting discounts and commissions, and offering expenses payable by us. 

In January 2017, we entered into an Equity Distribution Agreement, or ATM, with Citigroup Global Markets, Inc., or the Sales Agent, under which we could sell common stock through our Sales Agent. Sales of the shares under the ATM were made in transactions that are deemed to be “at‑the‑market” equity offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including on the Nasdaq Stock Market. During the period from February through April 2017, we sold 489,023 shares of our common stock at an average market price of $15.05 per share under the ATM for aggregate net proceeds of approximately $7.0 million after deducting commissions and expenses.

Equity Compensation Plans

In June 2017, our stockholders approved our 2017 Long-Term Incentive Plan, or 2017 LTIP. Upon such approval, our 2013 Long-Term Incentive Plan, or 2013 LTIP, was terminated. Notwithstanding such termination or the previous termination of our 2012 Long-Term Incentive Plan, 2009 Long-Term Incentive Plan, and 2006 Long-Term Incentive Plan, as amended, or, together with the 2013 LTIP, the Prior Plans, all outstanding awards under the Prior Plans continue to be governed under the terms of the Prior Plans. In June 2018, our stockholders approved amendment and restatement of our 2017 Long-Term Incentive Plan, to, among other things, increase the number of shares authorized for issuance under the 2017 LTIP. The number of shares of common stock authorized for issuance under the 2017 LTIP may be increased by the number of shares subject to any stock awards under the Prior Plans that are forfeited, expire or otherwise terminate without the issuance of such shares and would otherwise be returned to the share reserve under the Prior Plans but for their termination and as otherwise provided in the 2017 LTIP.

The aggregate number of shares of our common stock that initially may be issued pursuant to stock awards granted under the 2017 LTIP is 6,958,560 shares, less 1 share for every share that was subject to an option or stock appreciation right granted under the 2017 Plan and 1.9 shares for every 1 share that share that was subject to an award other than an option or stock appreciation right granted under the 2017 LTIP after March 31, 2018. Shares issued pursuant to the exercise of stock options and stock appreciation rights granted under the 2017 LTIP reduce the available number of shares by 1 share for every share issued while awards other than stock options and stock appreciation rights granted under the 2017 LTIP reduce the available number of shares by 1.9 shares for every share issued.

Shares under the 2017 LTIP may be granted as incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Performance awards may be based on the achievement of operational, financial, research and development, collaboration and license arrangements and other performance metrics provided under the 2017 LTIP, such as total stockholder return, revenue, research, development and regulatory achievements and strategic and operational initiatives.

A total of 3,024,775 shares of our common stock were reserved for future issuance at December 31, 2019, pursuant to our Equity Compensation Plans.

Stock options granted under the 2017 LTIP generally vest over four years with 25% of the shares subject to each option vesting on the first anniversary of the grant date and the remainder of the shares vesting monthly over the following three years in equal installments and, to the extent vested, are exercisable for up to seven years from the date of grant. The recipient of a restricted stock award has all rights of a stockholder at the date of grant, subject to certain restrictions on transferability and a risk of forfeiture. Restricted stock unit awards generally vest over one or four years from the date of grant. The minimum performance period under a performance award is 12 months. Neither the exercise price of an option nor the grant price of a stock appreciation right may be less than 100% of the fair market value of the common stock on the date such equity award is granted, except in specified situations. The 2017 LTIP prohibits option and stock appreciation right repricings (other than to reflect stock splits, spin-offs or certain other corporate events) without stockholder approval.

The following table summarizes our stock option activity under the Prior Plans and the 2017 LTIP, or collectively, our Equity Compensation Plans, for the year ended December 31, 2019, in thousands (except per share data):

 

 

 

Options

 

 

Weighted-

Average

Exercise Price

 

 

Weighted-Average

Remaining

Contractual

Term (in years)

 

 

Aggregate

Intrinsic

Value

 

Outstanding at December 31, 2018

 

 

6,541

 

 

$

28.83

 

 

 

 

 

 

 

 

 

Granted

 

 

3,070

 

 

$

44.53

 

 

 

 

 

 

 

 

 

Exercised

 

 

(626

)

 

$

24.27

 

 

 

 

 

 

 

 

 

Forfeited/cancelled/expired

 

 

(450

)

 

$

38.37

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2019

 

 

8,535

 

 

$

34.31

 

 

 

5.08

 

 

$

104,380

 

Vested and expected to vest at December 31, 2019

 

 

8,535

 

 

$

34.31

 

 

 

5.08

 

 

$

104,380

 

Vested and exercisable at December 31, 2019

 

 

3,194

 

 

$

26.37

 

 

 

4.18

 

 

$

63,866

 

 

The aggregate intrinsic value in the above table is calculated as the difference between the closing price of our common stock at December 31, 2019, of $45.42 per share and the exercise price of stock options that had strike prices below the closing price. The intrinsic value of all stock options exercised during the years ended December 31, 2019, 2018, and 2017, was $17.2 million, $7.1 million, and $2.8 million, respectively. During the year ended December 31, 2019, cash of $15.2 million was received from stock option exercises. There is no tax impact related to share-based compensation or stock option exercises because we are in a net operating loss position with a full valuation allowance on our deferred tax assets.

In January 2019, a total of 297,000 target Performance-Based Restricted Stock Units, or PRSUs, were granted to employees in a company-wide grant. The PRSUs vest upon the closing price of our common stock, or the Closing Price, reaching certain price thresholds during the three-year performance period beginning January 4, 2019, and ending January 3, 2022, or the Performance Period, and the participant’s subsequent satisfaction of a continuing service requirement of generally 90 calendar days. If, on five consecutive trading days or ten non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60.00, $67.50 or $75.00, and the participant thereafter satisfies a continuing service requirement, then the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the participant’s respective target PRSU amount. The shares may be issued following achievement of each price threshold, and the maximum number of common shares that may be issued pursuant to each PRSU grant equals 200% of the number of PRSUs granted. As these awards contain a market condition, we used a Monte Carlo simulation model to estimate the grant-date fair value, which totaled $18.1 million. The grant-date fair value is recognized as compensation expense over the requisite service period of approximately 1.2 years which was derived from the Monte Carlo simulation; no compensation expense is recognized for service not provided in case of separation from the Company. There is no adjustment of compensation expense recognized for service performed regardless of the number of PRSUs, if any, that ultimately vest. The $60.00 market condition threshold was achieved in the third quarter of 2019. As a result, a total of 140,900 shares were issued to employees upon the satisfaction of the continuing service requirement.

In March 2015, we granted our executive officers TSR PRSU awards. The TSR PRSUs could be earned and converted into outstanding shares of our common stock based on the total stock return, or TSR, of our common stock relative to the TSR over a three-year performance period beginning March 1 of the year granted of the Nasdaq Biotechnology Index. In March 2018, 32,322 shares were issued to the holders of the remaining TSR PRSUs based on the TSR of our common stock relative to the TSR Nasdaq Biotechnology Index over the three-year performance period.

Employee Stock Purchase Plan

In June 2015, our stockholders approved our 2009 Employee Stock Purchase Plan, as amended, or 2009 ESPP. Under the 2009 ESPP substantially all employees could choose to have up to 15% of their annual compensation withheld to purchase up to 625 shares of our common stock per purchase period, subject to certain limitations. The shares of our common stock could be purchased over an offering period with a maximum duration of 24 months and at a price of not less than 85% of the lesser of the fair market value of the common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of the applicable three-month purchase period. Under applicable accounting guidance, the 2009 ESPP was considered a compensatory plan. In June 2017, the 2009 ESPP was terminated.

In June 2019, our stockholders approved our 2019 Employee Stock Purchase Plan, or 2019 ESPP. Under the 2019 ESPP substantially all employees can elect to have up to 15% of their annual compensation withheld to purchase up to 2,000 shares of our common stock per purchase period, subject to certain limitations. The shares of our common stock can be purchased over an offering period with a maximum duration of 12 months and at a price of not less than 85% of the lesser of the fair market value of the common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of the applicable six-month purchase period. Under applicable accounting guidance, the 2019 ESPP is considered a compensatory plan.

During the years ended December 31, 2017, a total of 2,236 shares, respectively, were purchased by our employees under the 2009 ESPP. There were no purchases under the 2019 ESPP in 2019. The amount of compensation expense associated with the 2009 ESPP and 2019 ESPP for the years ended December 31, 2019, 2018, and 2017 was immaterial.  

Share-based Compensation

We estimate the grant-date fair value of all of our share-based awards in determining our share-based compensation expense. Our share-based awards include stock options, options to purchase stock granted under our employee stock purchase plan, RSUs, and PRSU awards.

 

The table below sets forth the weighted-average assumptions and estimated fair value of stock options we granted under our Equity Compensation Plans during the years presented:

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Risk-free interest rate

 

 

2.3

%

 

 

2.6

%

 

 

1.9

%

Dividend yield

 

 

—

%

 

 

—

%

 

 

—

%

Expected volatility

 

 

64

%

 

 

63

%

 

 

69

%

Expected life (years)

 

4.47

 

 

4.58

 

 

4.58

 

Weighted-average estimated fair value per share of stock options granted

 

$

23.47

 

 

$

20.01

 

 

$

9.17

 

 

 

We recognized share-based compensation expense as follows for the years presented, in thousands, except per share data:

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Research and development

 

$

27,361

 

 

$

8,385

 

 

$

1,945

 

General and administrative

 

 

25,686

 

 

 

11,158

 

 

 

5,925

 

Discontinued operations

 

 

—

 

 

 

11

 

 

 

120

 

Total share-based compensation expense

 

$

53,047

 

 

$

19,554

 

 

$

7,990

 

Impact on net loss per share, basic

 

$

1.07

 

 

$

0.42

 

 

$

0.24

 

Impact on net loss per share, diluted

 

$

1.03

 

 

$

0.42

 

 

$

0.24

 

The table below sets forth our total unrecognized estimated compensation expense at December 31, 2019, by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized:

 

 

 

Unrecognized

Expense (in

thousands)

 

 

Remaining

Weighted-Average

Recognition

Period (in years)

 

Unvested stock options

 

$

95,703

 

 

 

2.62

 

PRSUs

 

 

1,750

 

 

 

0.21

 

RSUs

 

 

613

 

 

 

0.57

 

 
XML 71 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
The Company and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
The Company and Summary of Significant Accounting Policies

1. The Company and Summary of Significant Accounting Policies

The Company

Arena Pharmaceuticals, Inc., or Arena, was incorporated on April 14, 1997, and commenced operations in July 1997. We are a biopharmaceutical company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Our proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility.

Our most advanced investigational clinical programs include: etrasimod, which is being evaluated in a Phase 3 program for ulcerative colitis, a Phase 2b/3 program for Crohn’s disease, and a Phase 2b program in atopic dermatitis. We also plan to evaluate etrasimod in a Phase 2b program for eosinophilic esophagitis, and a Phase 2 program in alopecia areata. Olorinab is being evaluated for a broad range of visceral pain conditions associated with gastrointestinal diseases, currently in a Phase 2b trial for treatment of abdominal pain associated with irritable bowel syndrome. APD418 is being evaluated in a Phase 1 trial for acute heart failure. Additionally, we have collaboration or license agreements with various companies.

We operate in one business segment. Our primary clinical operations are conducted in San Diego, California and Boston, Massachusetts; and in Zug, Switzerland by Arena Pharmaceuticals Development GmbH, or APD GmbH, our wholly-owned subsidiary.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with the US generally accepted accounting principles, or GAAP, and reflect all of our activities, including those of our wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. As a result of the sale of our Manufacturing Operations (see Note 5), the operations and cash flows of the Manufacturing Operations are reflected as discontinued operations for the years ended December 31, 2018, and 2017.

The accompanying consolidated financial statements also include the activity of Beacon Discovery, Inc., or Beacon, a variable interest entity in which we had a controlling financial interest until December 2017 at which point we deconsolidated Beacon (see Note 12). The results of operations and comprehensive loss attributable to the noncontrolling interest in Beacon are presented as separate components from the results of operations and comprehensive loss attributable to the stockholders of Arena in the consolidated statements of operations and comprehensive loss.

Liquidity

As of December 31, 2019, we had cash, cash equivalents and available-for-sale investments of approximately $1.1 billion. We believe our cash, cash equivalents and available-for-sale investments will be sufficient to fund our operations for at least the next 12 months from the date these consolidated financial statements are issued.

We will require substantial cash to achieve our objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. We may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. We will need to obtain significant funds under our existing collaborations and license agreements, under new collaboration, licensing or other commercial agreements for one or more of our drug candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions.

Changes in Accounting Policies - Leases.

Effective January 1, 2019, we adopted Accounting Standard Codification Topic 842, Leases, or ASC 842, issued by the Financial Accounting Standards Board, or FASB. ASC 842 requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. The new standard established a right-of-use model that requires a lessee to recognize a right-of-use asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. As a result, we have changed our accounting policy for leases as detailed below.

We implemented ASC 842 using the modified retrospective transition approach by applying the new standard to leases existing at the date of initial application. We used the effective date as our date of initial application. Therefore, we did not update the financial information and did not provide the disclosures required under the new standard for dates and periods before January 1, 2019.

We applied ASC 842 using a package of practical expedients, which permitted us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us.

Upon adoption of ASC 842, we recorded an operating lease liability of $6.3 million based on the present value of the remaining minimum rental payments under the terms of our existing operating lease pertaining to one of our leased properties with a corresponding right-of-use asset of $5.9 million. Adoption of this standard did not have a material impact on our consolidated statements of operations or cash flows.

The new standard also provides practical expedients for an entity’s ongoing accounting. We elected the short-term lease recognition exemption for our office equipment leases and short-term office space leases. This means, for those leases that qualify, we do not recognize right-of-use assets or lease liabilities. See Note 6 for disclosures related to our leases.

Recent Accounting Pronouncements

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers, or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. The amendments in ASU No. 2018-18 are applied retrospectively to the date of initial application of ASC 606, which for us was January 1, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12 which modifies ASC 740, Income Taxes to simplify the accounting for income taxes in various areas. The amendments in ASU 2019-12 are effective for us for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. We are currently evaluating the impact of adoption on our consolidated financial statements. 

Use of Estimates

The preparation of financial statements in conformity with GAAP requires our management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. The amounts reported could differ under different estimates and assumptions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in our consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows, in thousands:

 

 

 

December 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Cash and cash equivalents

 

$

243,274

 

 

$

161,037

 

Restricted cash included in other non-current assets

 

 

226

 

 

 

863

 

Total cash, cash equivalents and restricted cash presented in the consolidated

      statement of cash flows

 

$

243,500

 

 

$

161,900

 

The restricted cash relates to our property leases. The restriction will lapse when the related leases expire.

Available-for-Sale Investments

We define investments as income-yielding securities that can be readily converted to cash, and classify such investments as available-for-sale. We carry these securities at fair value, and report unrealized gains and losses as a separate component of accumulated other comprehensive income or loss. The cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. Realized gains and losses and declines in securities judged to be other than temporary are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on available-for-sale securities are included in interest income.

Concentrations of Risk

Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents and available-for-sale investments. We limit our exposure to credit loss by holding our cash primarily in US dollars or placing our cash and investments in US government, agency or government-sponsored enterprise obligations and in corporate debt instruments that are rated investment grade, in accordance with an investment policy approved by our Board of Directors.

Our customers are typically other biopharmaceutical companies to which we license our intellectual property, or sell research and development services or other services under license or collaboration agreements. For the year ended December 31, 2019, more than 99% of our annual revenues was from United Therapeutics. For the year ended December 31, 2018, Eisai, Boehringer Ingelheim, Outpost Medicine, Axovant and Everest accounted for 36.6%, 24.8%, 15.3%, 12.1% and 11.1%, respectively, of our total revenues. For the year ended December 31, 2017, Everest, Boehringer Ingelheim and Axovant accounted for 56.2%, 23.8%, and 10.5%, respectively, of our total revenues.

We monitor our customers’ financial credit worthiness in order to assess and respond to any changes in their credit profile. During the years ended December 31, 2019, 2018, and 2017, we did not record any write-offs or reserves against accounts receivable.

Property and Equipment

Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (generally 3 to 15 years) using the straight-line method. Buildings are stated at cost and depreciated over an estimated useful life of approximately 20 years using the straight-line method. Leasehold improvements are stated at cost and amortized over the shorter of the estimated useful lives of the assets or the lease term using the straight-line method. Capital improvements are stated at cost and amortized over the estimated useful lives of the underlying assets using the straight-line method.

Long-lived Assets

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted cash flows. If impairment is indicated, we measure the impairment loss by comparing the fair value to the carrying value of the asset.

Foreign Currency

The functional currency of our wholly owned subsidiaries in Switzerland, APD GmbH and, until March 31, 2018, Arena Pharmaceuticals GmbH, or Arena GmbH, was the Swiss franc. Accordingly, all assets and liabilities of these subsidiaries are translated to US dollars based on the applicable exchange rate on the balance sheet date. Revenue and expense components are translated to US dollars at weighted-average exchange rates in effect during the period. Gains and losses resulting from foreign currency translation are reported as a separate component of accumulated other comprehensive income or loss in the equity section of our consolidated balance sheets.

Foreign currency transaction gains and losses are primarily the result of remeasuring US dollar-denominated receivables and payables of our foreign subsidiaries. Foreign currency transaction gains and losses recorded by Arena GmbH are included in net income (loss) from discontinued operations.

Share-based Compensation

Our share-based awards are measured at fair value and recognized over the requisite service or performance period. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model, based on the market price of the underlying common stock, expected term, expected stock price volatility and expected risk-free interest rate. Expected volatility is computed using historical volatility for a period equal to the expected term. The expected term of options is determined based on historical experience of similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and post-vesting terminations. The risk-free interest rates are based on the US Treasury yield curve, with a remaining term approximately equal to the expected term used in the option pricing model. We account for the forfeitures in the period they occur. The fair value of each restricted stock unit award is estimated based on the market price of the underlying common stock on the date of the grant. The fair value of restricted stock unit awards that include market-based performance conditions is estimated on the date of grant using a Monte Carlo simulation model, based on the market price of the underlying common stock, expected performance measurement period, expected stock price volatility and expected risk-free interest rate.

Revenue Recognition

Our revenues to date have been generated primarily through collaboration and license agreements. Our collaboration and license agreements frequently contain multiple types of promised goods or services including (i) intellectual property licenses, (ii) product research, development and regulatory services and (iii) product manufacturing. Consideration we receive under these arrangements may include upfront payments, research and development funding, cost reimbursements, milestone payments, payments for product sales and royalty payments.

Effective January 1, 2018, we adopted Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, issued by the Financial Accounting Standards Board, or FASB. As a result, we have changed our accounting policy for revenue recognition as detailed below.

We implemented ASC 606 using the modified retrospective method by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of our accumulated deficit at January 1, 2018. Therefore, the comparative period information has not been adjusted.

We applied ASC 606 using a practical expedient for contracts that were modified before the implementation date, which allowed us to determine an aggregate effect of all modifications that occurred before January 1, 2018, when determining the satisfied and unsatisfied performance obligations, the transaction price, and allocating that transaction price to the performance obligations instead of retrospectively restating the contracts for such contract modifications.  

The cumulative impact to our accumulated deficit balance at January 1, 2018, as a result of the adoption of ASC 606 was a decrease of $19.0 million. The decrease arose primarily from a reduction of deferred revenue balances related to upfront payments received from customers and recognition of contract assets due to a combination of (i) the effects of applying the practical expedient for contract modifications and our conclusions related to satisfied and unsatisfied performance obligations, which resulted in a relatively higher portion of the total transaction price recognized as revenue in periods prior to our adoption of ASC 606, (ii) the effect of the bill-and-hold accounting guidance for inventory in ASC 606 and (iii) the inclusion of estimated future royalty payments related to our intellectual property in the total transaction price to the extent such intellectual property was legally sold to our customer rather than licensed. The cumulative effect adjustment is net of an impairment loss of $13.1 million which was a direct effect of the adoption of ASC 606 on the asset group of the Manufacturing Operations, which was classified as assets of disposal group held for sale since December 2017.

The following table summarizes the impacts of adopting ASC 606 on our consolidated financial statements, in thousands.

 

 

Impact of Changes in Accounting Policies

 

Year ended December 31, 2018

 

As reported

 

 

Adjustments

 

 

Balances without adoption of ASC 606

 

Collaboration and other revenue

 

$

11,402

 

 

$

105

 

 

$

11,507

 

Royalty revenue

 

 

6,568

 

 

 

(1,847

)

 

 

4,721

 

Total revenues

 

 

17,970

 

 

 

(1,742

)

 

 

16,228

 

Loss from operations

 

 

(144,783

)

 

 

(1,742

)

 

 

(146,525

)

Loss from continuing operations

 

 

(28,569

)

 

 

(594

)

 

 

(29,163

)

Income (loss) from discontinued operations

 

 

(830

)

 

 

13,660

 

 

 

12,830

 

Net loss

 

 

(29,399

)

 

 

13,066

 

 

 

(16,333

)

Net loss attributable to stockholders of Arena

 

 

(29,399

)

 

 

13,066

 

 

 

(16,333

)

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2018

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

$

10,008

 

 

$

(1,484

)

 

$

8,524

 

Total current assets

 

 

460,725

 

 

 

(1,484

)

 

 

459,241

 

Other non-current assets

 

 

10,319

 

 

 

(4,471

)

 

 

5,848

 

Total assets

 

 

686,903

 

 

 

(5,955

)

 

 

680,948

 

Total current liabilities

 

 

29,918

 

 

 

10

 

 

 

29,928

 

Accumulated deficit

 

 

(1,500,552

)

 

 

(5,965

)

 

 

(1,506,517

)

Total stockholders' equity

 

 

606,258

 

 

 

(5,965

)

 

 

600,293

 

Total liabilities and stockholders' equity

 

 

686,903

 

 

 

(5,955

)

 

 

680,948

 

 

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that we expect to be entitled to receive in exchange for these services and excludes sales incentives and amounts collected on behalf of third parties. We analyze the nature of these performance obligations in the context of individual collaboration and license agreements in order to assess the distinct performance obligations. We apply the following five steps to recognize revenue:

i) Identify the contract with a customer. We consider the terms and conditions of our collaboration and license agreements to identify contracts within the scope of ASC 606. We consider that we have a contract with a customer when the contract is approved, we can identify each party's rights regarding the goods and services to be transferred, we can identify the payment terms for the goods and services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. We use judgment in determining the customer's ability and intent to pay, which is based upon factors including the customer's historical payment experience or, for new customers, credit and financial information pertaining to the customers.

ii) Identify the performance obligations in the contract. Performance obligations in our collaboration and license agreements are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. Our performance obligations generally consist of intellectual property licenses, research, development and/or regulatory services and manufacturing and supply commitments.

 iii) Determine the transaction price. We determine the transaction price based on the consideration to which we expect to be entitled in exchange for transferring goods and services to the customer. In determining the transaction price, any variable consideration would be considered, to the extent applicable, if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. In accordance with the royalty exception under ASC 606 for licenses of intellectual property, the transaction price excludes future royalty payments to be received from our customers. None of our collaboration and license agreements contain consideration payable to our customer or a significant financing component.

 iv) Allocate the transaction price to performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to that performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price.

 v) Recognize revenue when or as we satisfy a performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised goods or services to a customer. We recognize revenue when we transfer control of the goods or services to our customers for an amount that reflects the consideration that we expect to receive in exchange for those services.

Performance Obligations

The following is a description of principal goods and services from which we generate revenue.

 

Intellectual property licenses

We generate revenue from licensing our intellectual property including know-how and development and commercialization rights. These licenses provide customers with a term-based license to further research, develop and commercialize our internally-discovered drug candidates. The consideration we receive in the form of nonrefundable upfront consideration related to the functional intellectual property licenses is recognized when we transfer such license to the customer unless the license is combined with other goods or services into one performance obligation, in which case the revenue is recognized over a period of time based on our estimated pattern in which we satisfy the combined performance obligation. Our licensing agreements are generally cancelable. Customers have the right to terminate their contracts upon notice. We have the right to terminate the contracts generally only if the customer is in breach of the contract and fails to remedy the breach in accordance with the contractual terms.

 

Intellectual property sales

We generate royalty revenue from sales of our intellectual property. We estimate the future royalty payments and recognize revenue with a corresponding contract asset at a point in time when we transfer the intellectual property to the customer. We periodically reassess our estimate of the future royalty payments and recognize any estimate adjustments as revenue in the current period.

 

Research, development and regulatory services

We generate revenue from research, development and regulatory services we provide to our customers in connection with the licensed intellectual property. The services we provide to our customers primarily include scientific research activities, preparation for and management of clinical trials, and assistance during the regulatory approval application process. Revenue associated with these services is recognized based on our estimate of total consideration to be received for such services and the pattern in which we perform the services. The pattern of performance is generally determined to be the amount of incurred expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.

 

Product manufacturing

In the past, we generated revenue from manufacturing and clinical supply promises to our customers in connection with securing a supply of drug products for development and clinical trial purposes. The drug products were generally manufactured by our contract manufacturing organizations. We used our product manufacturing facility in Zofingen, Switzerland for a portion of the product manufacturing requirements until we sold the Manufacturing Operations on March 31, 2018 (see Note 5). Revenue associated with product manufacturing obligations is recognized at a point in time as control of the related product is transferred to the customer.

Contracts with Multiple Performance Obligations

Most of our collaboration and license agreements with customers contain multiple promised goods or services. Based on the characteristics of the promised goods and services we analyze whether they are separate or combined performance obligations. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price based on our overall pricing and discounting objectives, taking into consideration the type of services, estimates of hourly market rates, and stage of the research, development or clinical trials.

Variable Consideration

Our contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone payments, which are due to us upon achievement of specific development and regulatory milestones and (ii) one-time sales-based payments and sales-based royalties associated with sold or licensed intellectual property.

Due to uncertainty associated with achievement of the development and regulatory milestones, the related milestone payments are excluded from the contract consideration and the corresponding revenue is not recognized until we conclude it is probable that reversal of such milestone revenue will not occur.

Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. We recognize revenue for sales-based royalties under licensed intellectual property and one-time payments at the later of when the sales occur or the performance obligation is satisfied or partially satisfied.

Disaggregation of Revenue

We operate in one reportable business segment. We provide goods and services to our customers in collaboration and license agreements pursuant to various geographical markets.

 

Contract Assets

We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed. Product sales are generally billed as completed. Payment terms on invoiced amounts are typically 30 days. Contract assets include amounts related to our contractual right to consideration for both completed and partially completed performance obligations that have not been invoiced and for which we do not yet have the right to payment. The current portion of contract asset is included in prepaid expenses and other current assets in the consolidated balance sheet. The non-current portion of contract assets is included in other non-current assets in the consolidated balance sheet. We estimate the amount of the contract asset by applying the expected value method to our estimate of future royalty payments we will receive from this customer. Any changes to this estimate are recorded as an adjustment to revenue in the period in which the change in estimate is made.

Cost to Obtain and Fulfill a Contract

We generally do not incur costs to obtain new contracts. Costs to fulfill contracts are expensed as incurred.

Remaining Performance Obligations

The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to our existing collaboration and license agreements as of December 31, 2019 is immaterial.

Under the royalty exception in ASC 606 for licensed intellectual property we do not recognize any revenue for the variable amounts related to sales-based royalties and milestones until the later of when the sales occur or the performance obligation is satisfied or partially satisfied. Accordingly, the revenue related to future sales-based royalties and milestones are excluded from the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied.

Previous Revenue Recognition Policy

Prior to January 1, 2018, we recognized revenue when (i) persuasive evidence of an arrangement existed, (ii) delivery had occurred and title had passed, (iii) the price was fixed or determinable and (iv) collectability was reasonably assured. Any advance payments we received in excess of amounts earned were classified as deferred revenues.

We historically evaluated deliverables in a multiple-element arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered element does not have standalone value without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the inception of the arrangement based on the relative selling price.

To determine the selling price of a separate deliverable, we used the hierarchy as prescribed in Accounting Standards Codification Topic 605-25 based on vendor-specific objective evidence, or VSOE, third-party evidence, or TPE, or best estimate of selling price, or BESP. VSOE was based on the price charged when the element was sold separately and was the price actually charged for that deliverable. TPE was determined based on third-party evidence for a similar deliverable when sold separately. BESP was the estimated selling price at which we would transact a sale if the elements of collaboration and license arrangements were sold on a stand-alone basis to the buyer.

Non-refundable upfront payments received under our collaboration and license agreements for commercialization rights were deferred if such rights were not deemed to have standalone value without ongoing services which may be required under the agreement. If deferred, such amounts were recognized as revenues on a straight-line basis over the period in which we expected to perform the services.

Amounts we received as reimbursement for our research and development expenditures were recognized as revenue as the services are performed.

Under the milestone method, we recognized revenue that was contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone was achieved. A milestone is an event (i) that can be achieved in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due us. A milestone payment is considered substantive when the consideration payable to us for each milestone (a) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (b) relates solely to our past performance and (c) is reasonable relative to all of the other deliverables and payments under the arrangement. In making this assessment, we considered all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables. Other contingent-based payments received were recognized when earned.

Research and Development Expenses

Research and development expenses, which consist primarily of salaries and other personnel costs, clinical trial costs and preclinical study fees, manufacturing costs for non-commercial products, and the development of earlier-stage programs and technologies, are expensed as incurred when these expenditures have no alternative future uses.

We accrue clinical trial expenses based on work performed. In determining the amount to accrue, we rely on estimates of total costs incurred based on enrollment, the completion of trials and other events. We follow this method because we believe reasonably dependable estimates of the costs applicable to various stages of a clinical trial can be made. However, the actual costs and timing of clinical trials are uncertain, subject to risks and may change depending on a number of factors. Differences between the actual clinical trial costs and the estimated clinical trial costs that we have accrued in any prior period are recognized in the subsequent period in which the actual costs become known. Historically, these differences have not been material; however, material differences could occur in the future. Payments made to reimburse collaborators for our share of their research and development activities are recorded as research and development expenses, and are recognized as the work is performed.

Comprehensive Income (Loss)

Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report components of comprehensive income or loss in the period in which they are recognized. For the years ended December 31, 2019, 2018 and 2017, comprehensive income (loss) consisted of net income (loss), foreign currency translation gains and losses, and unrealized gains and losses related to available-for-sale investments.

Income (Loss) Per Share

We calculate basic and diluted income (loss) from continuing operations, income (loss) from discontinued operations and net income (loss) per share using the weighted-average number of shares of common stock outstanding during the period.

Since we report a loss from continuing operations for the years ended December 31, 2018, and 2017, in addition to excluding potentially dilutive out-of-the money securities, we have excluded from our calculation of income (loss) per share all potentially dilutive in-the-money (i) stock options, (ii) restricted stock unit awards, or RSUs, (iii) Performance-Based Restricted Stock Units, or PRSUs, (iv) Total Stockholder Return performance restricted stock unit awards, or TSR PRSUs, and (v) unvested restricted stock in our deferred compensation plan, and our diluted net loss per share is the same as our basic net loss per share. The table below presents the weighted-average number of potentially dilutive securities that were excluded from our calculation of diluted income (loss) per share for the years presented, in thousands.

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Stock options

 

 

3,962

 

 

 

5,835

 

 

 

3,664

 

RSUs and unvested restricted stock

 

 

—

 

 

 

20

 

 

 

3

 

Total

 

 

3,962

 

 

 

5,855

 

 

 

3,667

 

 

Because the market condition for the outstanding PRSUs was not satisfied at December 31, 2019, such securities are excluded from the table above. Because the market condition for the TSR PRSUs was not satisfied at December 31, 2017, such securities are excluded from the table above.

Income Taxes

We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our deferred tax assets and liabilities are determined using the enacted tax rates expected to be in effect for the years in which those tax assets are expected to be realized.

The realization of our deferred tax assets is dependent upon our ability to generate sufficient future taxable income. We establish a valuation allowance when it is more-likely-than-not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available evidence, both positive and negative.

The impact of an uncertain income tax position is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

 
XML 72 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Statement Of Financial Position [Abstract]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 7,500,000 7,500,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 73,500,000 73,500,000
Common stock, shares issued 50,170,953 49,422,991
Common stock, shares outstanding 50,170,953 49,422,991
ZIP 73 0001564590-20-007399-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-007399-xbrl.zip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end XML 74 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Gross unrecognized tax benefits at the beginning of the year $ 9,033 $ 7,762 $ 5,906
Additions from tax positions taken in the current year 1,017 1,269 1,133
Additions from tax positions taken in prior years   2 723
Reductions from tax positions taken in prior years (96)    
Gross unrecognized tax benefits at end of the year $ 9,954 $ 9,033 $ 7,762

XML 75 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]      
United States $ 298,315 $ (138,522) $ (62,109)
Foreign 209,573 (1,142) (29,298)
Total income (loss) attributable to stockholders of Arena before income taxes $ 507,888 $ (139,664) $ (91,407)
XML 76 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Sale of Manufacturing Operations - Summary of Discontinued Operations for Consolidated Statements of Operations (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Revenues      
Net product sales   $ 1,129 $ 9,189
Other collaboration revenue   372 6,671
Toll manufacturing   1,006 3,179
Total revenues   2,507 19,039
Operating costs and expenses      
Cost of product sales   1,858 7,472
Cost of toll manufacturing   1,411 4,756
Research and development     643
General and administrative   329 1,672
Other (income) expense, net   464 1,374
Total costs and expenses   4,062 15,917
Income (loss) from operations of discontinued operations   (1,555) 3,122
Gain on sale of discontinued operations   725  
Income (loss) from discontinued operations $ (830) $ (830) $ 3,122
XML 77 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2019
Mar. 31, 2018
Jul. 31, 2017
Apr. 30, 2017
Mar. 31, 2014
Sep. 30, 2019
Apr. 30, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Stockholders Equity [Line Items]                    
Aggregate gross proceeds from sale of common stock               $ 13,147,000 $ 389,031,000 $ 248,805,000
Common stock closing price ($ per share)               $ 45.42    
Intrinsic value of stock options exercised               $ 17,200,000 $ 7,100,000 $ 2,800,000
Proceeds from stock option exercises               15,200,000    
Tax impact from exercise of stock options               $ 0    
Equity Compensation Plans                    
Stockholders Equity [Line Items]                    
Common stock shares reserved for future issuance               3,024,775    
Performance restricted stock units                    
Stockholders Equity [Line Items]                    
Vesting period 3 years       3 years       3 years  
Units granted (shares) 297,000                  
Threshold consecutive trading days 5 days                  
Threshold non-consecutive trading days 10 days                  
PRSU grant-date fair value $ 18,100,000                  
Compensation expense of requisite service period 1 year 2 months 12 days                  
Price per share market condition vesting threshold           $ 60.00        
Shares issued to employees upon satisfaction of continuing service requirement               140,900    
Shares issued   32,322                
Performance restricted stock units | Tranche One                    
Stockholders Equity [Line Items]                    
Common stock closing price ($ per share) $ 60.00                  
Common stock closing price, percentage 50.00%                  
Performance restricted stock units | Tranche Two                    
Stockholders Equity [Line Items]                    
Common stock closing price ($ per share) $ 67.50                  
Common stock closing price, percentage 100.00%                  
Performance restricted stock units | Tranche Three                    
Stockholders Equity [Line Items]                    
Common stock closing price ($ per share) $ 75.00                  
Common stock closing price, percentage 200.00%                  
Amended Long Term Incentive Plan Twenty Seventeen                    
Stockholders Equity [Line Items]                    
Number of shares authorized               6,958,560    
Stock options exercisable period               7 years    
Amended Long Term Incentive Plan Twenty Seventeen | Other Than Stock Options And Stock Appreciation Rights                    
Stockholders Equity [Line Items]                    
Reduction in number of shares available for grant for every share issued, percentage               190.00%    
Increase in number of shares available for grant for every share issued, percentage               190.00%    
Amended Long Term Incentive Plan Twenty Seventeen | Stock options                    
Stockholders Equity [Line Items]                    
Vesting percentage               25.00%    
Vesting period               4 years    
Remaining vesting period               3 years    
Vesting description               Stock options granted under the 2017 LTIP generally vest over four years with 25% of the shares subject to each option vesting on the first anniversary of the grant date and the remainder of the shares vesting monthly over the following three years in equal installments    
2009 ESPP                    
Stockholders Equity [Line Items]                    
Maximum Percentage of Annual Compensation contributable to ESPP               15.00%    
Maximum number of shares allowed to purchase per PURCHASE period               625    
Maximum ESPP offering period               24 months    
ESPP terminated date               Jun. 30, 2017    
Total common stock issued under employee stock purchase plan (shares)                   2,236
2019 ESPP                    
Stockholders Equity [Line Items]                    
Maximum Percentage of Annual Compensation contributable to ESPP               15.00%    
Maximum number of shares allowed to purchase per PURCHASE period               2,000    
Maximum ESPP offering period               12 months    
Total common stock issued under employee stock purchase plan (shares)               0    
Minimum | Amended Long Term Incentive Plan Twenty Seventeen | Restricted Stock Units (RSU)                    
Stockholders Equity [Line Items]                    
Vesting period               1 year    
Minimum | Amended Long Term Incentive Plan Twenty Seventeen | Performance restricted stock units                    
Stockholders Equity [Line Items]                    
Vesting period               12 months    
Minimum | Amended Long Term Incentive Plan Twenty Seventeen | Stock Options and Stock Appreciation Rights (SARs)                    
Stockholders Equity [Line Items]                    
Purchase price of common shares as a percentage of fair market value               100.00%    
Minimum | 2009 ESPP                    
Stockholders Equity [Line Items]                    
Purchase price of common shares as a percentage of fair market value               85.00%    
Minimum | 2019 ESPP                    
Stockholders Equity [Line Items]                    
Purchase price of common shares as a percentage of fair market value               85.00%    
Maximum | Performance restricted stock units                    
Stockholders Equity [Line Items]                    
Number of shares to be awarded as a percentage of target amounts 200.00%                  
Maximum | Amended Long Term Incentive Plan Twenty Seventeen | Restricted Stock Units (RSU)                    
Stockholders Equity [Line Items]                    
Vesting period               4 years    
Underwritten Public Offering | Common Stock                    
Stockholders Equity [Line Items]                    
Sale of common stock shares   9,775,000 7,187,500 6,900,000            
Aggregate gross proceeds from sale of common stock   $ 383,100,000 $ 162,000,000.0 $ 74,400,000            
ATM Offering | Equity Distribution Agreement | Citigroup Global Markets Inc.                    
Stockholders Equity [Line Items]                    
Aggregate gross proceeds from sale of common stock             $ 7,000,000.0      
ATM Offering | Common Stock                    
Stockholders Equity [Line Items]                    
Sale of common stock shares                   489,023
ATM Offering | Common Stock | Equity Distribution Agreement | Citigroup Global Markets Inc.                    
Stockholders Equity [Line Items]                    
Sale of common stock shares             489,023      
ATM Offering | Common Stock | Equity Distribution Agreement | Citigroup Global Markets Inc. | Weighted Average                    
Stockholders Equity [Line Items]                    
Average market price per share       $ 15.05     $ 15.05      
XML 78 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity - Total Unrecognized Estimated Compensation Expense (Detail)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
Unvested stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized Expense (in thousands) $ 95,703
Remaining Weighted-Average Recognition Period (in years) 2 years 7 months 13 days
PRSUs  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized Expense (in thousands) $ 1,750
Remaining Weighted-Average Recognition Period (in years) 2 months 15 days
RSUs  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized Expense (in thousands) $ 613
Remaining Weighted-Average Recognition Period (in years) 6 months 25 days
JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "arna-10k_20191231.htm": { "axisCustom": 0, "axisStandard": 33, "contextCount": 281, "dts": { "calculationLink": { "local": [ "arna-20191231_cal.xml" ] }, "definitionLink": { "local": [ "arna-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "arna-10k_20191231.htm" ] }, "labelLink": { "local": [ "arna-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "arna-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "arna-20191231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 673, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 23, "http://www.arenapharm.com/20191231": 11, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 40 }, "keyCustom": 81, "keyStandard": 402, "memberCustom": 46, "memberStandard": 47, "nsprefix": "arna", "nsuri": "http://www.arenapharm.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Balance Sheet Details", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Sale of Manufacturing Operations", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperations", "shortName": "Sale of Manufacturing Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Leases", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Stockholders' Equity", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Collaborations and License Agreements", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreements", "shortName": "Collaborations and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Income Taxes", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Legal Proceedings", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedings", "shortName": "Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Quarterly Financial Data (Unaudited)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited", "shortName": "Quarterly Financial Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Beacon Discovery, Inc.", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryInc", "shortName": "Beacon Discovery, Inc.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Subsequent Events", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "The Company and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "arna:ReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "The Company and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "arna:ReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Fair Value Disclosures (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresTables", "shortName": "Fair Value Disclosures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Investments, Available-for-Sale (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleTables", "shortName": "Investments, Available-for-Sale (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Balance Sheet Details (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Sale of Manufacturing Operations (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsTables", "shortName": "Sale of Manufacturing Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "arna:ScheduleOfFutureMinimumPaymentsForSaleLeaseBackFinancingObligationsAndOperatingLeasesTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Leases (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "arna:ScheduleOfFutureMinimumPaymentsForSaleLeaseBackFinancingObligationsAndOperatingLeasesTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Collaborations and License Agreements (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsTables", "shortName": "Collaborations and License Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Income Taxes (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables", "shortName": "Quarterly Financial Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_arnaSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - The Company and Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "The Company and Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_arnaSegment", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - The Company and Summary of Significant Accounting Policies - Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail", "shortName": "The Company and Summary of Significant Accounting Policies - Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - The Company and Summary of Significant Accounting Policies - Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "shortName": "The Company and Summary of Significant Accounting Policies - Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101_20181231", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - The Company and Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded From Calculation of Diluted Income (Loss) Per Share (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail", "shortName": "The Company and Summary of Significant Accounting Policies - Potentially Dilutive Securities Excluded From Calculation of Diluted Income (Loss) Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail", "shortName": "Fair Value Disclosures - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Investments, Available-for-Sale - Schedule of Investments, Available-for-Sale (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail", "shortName": "Investments, Available-for-Sale - Schedule of Investments, Available-for-Sale (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Balance Sheet Details - Land, Property and Equipment, Net (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail", "shortName": "Balance Sheet Details - Land, Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Balance Sheet Details - Accounts Payable and Other Accrued Liabilities (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail", "shortName": "Balance Sheet Details - Accounts Payable and Other Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_srtCounterpartyNameAxis_arnaSiegfriedPharmaAGAndSiegfriedAGMember_20191231", "decimals": "0", "first": true, "lang": null, "name": "arna:NumberOfEmployeesTransferred", "reportCount": 1, "unique": true, "unitRef": "U_arnaemployee", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Sale of Manufacturing Operations - Additional Information (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail", "shortName": "Sale of Manufacturing Operations - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_srtCounterpartyNameAxis_arnaSiegfriedPharmaAGAndSiegfriedAGMember_20191231", "decimals": "0", "first": true, "lang": null, "name": "arna:NumberOfEmployeesTransferred", "reportCount": 1, "unique": true, "unitRef": "U_arnaemployee", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20180101_20181231", "decimals": "-3", "first": true, "lang": null, "name": "arna:DisposalGroupIncludingDiscontinuedOperationSalesRevenueGoodsNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Sale of Manufacturing Operations - Summary of Discontinued Operations for Consolidated Statements of Operations (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail", "shortName": "Sale of Manufacturing Operations - Summary of Discontinued Operations for Consolidated Statements of Operations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20180101_20181231", "decimals": "-3", "first": true, "lang": null, "name": "arna:DisposalGroupIncludingDiscontinuedOperationSalesRevenueGoodsNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "INF", "first": true, "lang": null, "name": "arna:NumberOfPropertiesOwnershipTransferredUnderSaleLeasebackTransaction", "reportCount": 1, "unique": true, "unitRef": "U_arnaProperty", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Leases - Additional Information (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "INF", "first": true, "lang": null, "name": "arna:NumberOfPropertiesOwnershipTransferredUnderSaleLeasebackTransaction", "reportCount": 1, "unique": true, "unitRef": "U_arnaProperty", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "arna:ScheduleOfFutureMinimumPaymentsForSaleLeaseBackFinancingObligationsAndOperatingLeasesTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Leases - Future Minimum Lease Payments (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail", "shortName": "Leases - Future Minimum Lease Payments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "arna:ScheduleOfFutureMinimumPaymentsForSaleLeaseBackFinancingObligationsAndOperatingLeasesTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapLeaseArrangementTypeAxis_arnaSubleaseAgreementMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Leases - Expected Minimum Rental Payments to be Received under Sublease (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail", "shortName": "Leases - Expected Minimum Rental Payments to be Received under Sublease (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapLeaseArrangementTypeAxis_arnaSubleaseAgreementMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "2", "lang": null, "name": "arna:CommonStockClosingPrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Stockholders' Equity - Weighted-Average Assumptions and Estimated Fair Value of Stock Options (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail", "shortName": "Stockholders' Equity - Weighted-Average Assumptions and Estimated Fair Value of Stock Options (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Stockholders' Equity - Share Based Compensation Expense (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail", "shortName": "Stockholders' Equity - Share Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Stockholders' Equity - Total Unrecognized Estimated Compensation Expense (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail", "shortName": "Stockholders' Equity - Total Unrecognized Estimated Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "arna:RevenueFromContractsWithCustomersIncludingDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Collaborations and License Agreements - Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail", "shortName": "Collaborations and License Agreements - Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "arna:RevenueFromContractsWithCustomersIncludingDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20161231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Equity", "role": "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity", "shortName": "Consolidated Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20161231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "arna:LicenseAgreementCostsIncurredRelatedToTransactionFees", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Collaborations and License Agreements - Additional Information (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "shortName": "Collaborations and License Agreements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "arna:NetIncomeLossAttributableToDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Income Taxes - Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionBenefitForIncomeTaxesByRegionDetail", "shortName": "Income Taxes - Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "arna:NetIncomeLossAttributableToDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "INF", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Income Taxes - Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail", "shortName": "Income Taxes - Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail", "shortName": "Income Taxes - Components of Net Deferred Tax Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetail", "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20161231", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20171231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LitigationReserveCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Legal Proceedings - Additional Information (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail", "shortName": "Legal Proceedings - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20171231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LitigationReserveCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191001_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Quarterly Financial Data (Unaudited) (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "shortName": "Quarterly Financial Data (Unaudited) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20191001_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "arna:SubleaseExpirationPeriod", "p", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20170101_20171231", "decimals": null, "first": true, "lang": "en-US", "name": "arna:SubleaseExpirationPeriod", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Beacon Discovery, Inc. - Additional Information (Detail)", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "shortName": "Beacon Discovery, Inc. - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_deiLegalEntityAxis_arnaBeaconDiscoveryIncMember_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_20170101_20171231", "decimals": "-5", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - The Company and Summary of Significant Accounting Policies", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies", "shortName": "The Company and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Fair Value Disclosures", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosures", "shortName": "Fair Value Disclosures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Investments, Available-for-Sale", "role": "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSale", "shortName": "Investments, Available-for-Sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "arna-10k_20191231.htm", "contextRef": "C_0001080709_20190101_20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 103, "tag": { "arna_AccruedClinicalAndPreclinicalStudyFees": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable related to clinical and preclinical study fees due within one year.", "label": "Accrued Clinical And Preclinical Study Fees", "terseLabel": "Accrued clinical and preclinical study fees" } } }, "localname": "AccruedClinicalAndPreclinicalStudyFees", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "arna_AdditionalManufacturingSupportPaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Additional manufacturing support payments received.", "label": "Additional Manufacturing Support Payments Received", "terseLabel": "Additional manufacturing support payments received" } } }, "localname": "AdditionalManufacturingSupportPaymentsReceived", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_AdditionalOfficeSpaceLeaseInceptionDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Additional office space, lease inception date.", "label": "Additional Office Space Lease Inception Date", "terseLabel": "Additional office space, lease inception date" } } }, "localname": "AdditionalOfficeSpaceLeaseInceptionDate", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "arna_AdditionalPaymentsReceivableOnMilestoneAchievements": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Additional amount of cash that may be received upon achievement of milestone under collaborative agreement.", "label": "Additional Payments Receivable On Milestone Achievements", "terseLabel": "Additional milestone payments on achievement" } } }, "localname": "AdditionalPaymentsReceivableOnMilestoneAchievements", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_AmendedLongTermIncentivePlanTwentySeventeenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended long term incentive plan twenty seventeen.", "label": "Amended Long Term Incentive Plan Twenty Seventeen [Member]", "terseLabel": "Amended Long Term Incentive Plan Twenty Seventeen" } } }, "localname": "AmendedLongTermIncentivePlanTwentySeventeenMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_ArenaGmbHMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arena GmbH.", "label": "Arena Gmb H [Member]", "terseLabel": "Arena Gmb H" } } }, "localname": "ArenaGmbHMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_AtMarketOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At-the-market offering.", "label": "At Market Offering [Member]", "terseLabel": "ATM Offering", "verboseLabel": "ATM facility" } } }, "localname": "AtMarketOfferingMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "arna_AxovantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Axovant.", "label": "Axovant [Member]", "terseLabel": "Axovant" } } }, "localname": "AxovantMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_BeaconDiscoveryIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Beacon Discovery, Inc.", "label": "Beacon Discovery Inc [Member]", "terseLabel": "Beacon Discovery, Inc." } } }, "localname": "BeaconDiscoveryIncMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_BoehringerIngelheimMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boehringer Ingelheim [Member]", "label": "Boehringer Ingelheim [Member]", "terseLabel": "Boehringer Ingelheim" } } }, "localname": "BoehringerIngelheimMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_CashCashEquivalentsAndAvailableForSaleInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash, cash equivalents and available for sale investments.", "label": "Cash Cash Equivalents And Available For Sale Investments", "terseLabel": "Cash and cash equivalents and available-for-sale investments" } } }, "localname": "CashCashEquivalentsAndAvailableForSaleInvestments", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_ChineseNationalMedicalProductsAdministrationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Chinese National Medical Products Administration", "label": "Chinese National Medical Products Administration [Member]", "terseLabel": "Chinese National Medical Products Administration" } } }, "localname": "ChineseNationalMedicalProductsAdministrationMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_CitigroupGlobalMarketsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Citigroup Global Markets Inc.", "label": "Citigroup Global Markets Inc [Member]", "terseLabel": "Citigroup Global Markets Inc." } } }, "localname": "CitigroupGlobalMarketsIncMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_CollaborationAgreementEstimatedTransactionCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaboration agreement estimated transaction cost.", "label": "Collaboration Agreement Estimated Transaction Cost", "terseLabel": "Collaboration Agreement Estimated Transaction Price" } } }, "localname": "CollaborationAgreementEstimatedTransactionCost", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_CollaborationAgreementMilestoneRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration agreement milestone revenue recognized", "label": "Collaboration Agreement Milestone Revenue Recognized", "terseLabel": "Recognized milestone revenue" } } }, "localname": "CollaborationAgreementMilestoneRevenueRecognized", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_CollaborationAndOtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration and other revenue.", "label": "Collaboration And Other Revenue [Member]", "terseLabel": "Collaboration and Other Revenue" } } }, "localname": "CollaborationAndOtherRevenueMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "arna_CollaborativeAgreementCompletionPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative agreement completion period.", "label": "Collaborative Agreement Completion Period", "terseLabel": "Collaborative agreement completion period" } } }, "localname": "CollaborativeAgreementCompletionPeriod", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "arna_CollaborativeAgreementEstimatedFutureRoyaltyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative agreement estimated future royalty payments.", "label": "Collaborative Agreement Estimated Future Royalty Payments", "terseLabel": "Estimated future royalty payments" } } }, "localname": "CollaborativeAgreementEstimatedFutureRoyaltyPayments", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_CollaborativeAgreementInitiationDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative agreement initiation date.", "label": "Collaborative Agreement Initiation Date", "terseLabel": "Collaborative agreement initiation date" } } }, "localname": "CollaborativeAgreementInitiationDate", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "arna_CollaborativeAgreementUpfrontPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative agreement upfront payments.", "label": "Collaborative Agreement Upfront Payments", "terseLabel": "Collaborative agreement upfront payments" } } }, "localname": "CollaborativeAgreementUpfrontPayments", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_CollaborativeAgreementUpfrontPaymentsInFormOfEquityInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative agreement upfront payments in the form of equity interest.", "label": "Collaborative Agreement Upfront Payments In Form Of Equity Interest", "terseLabel": "Collaborative agreement upfront payments in the form of equity interest" } } }, "localname": "CollaborativeAgreementUpfrontPaymentsInFormOfEquityInterest", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_CollaborativeArrangementConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement consideration.", "label": "Collaborative Arrangement Consideration", "terseLabel": "Payment received from Eisai" } } }, "localname": "CollaborativeArrangementConsideration", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_CollaborativeArrangementConsiderationAgreedToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement consideration agreed to be paid.", "label": "Collaborative Arrangement Consideration Agreed To Be Paid", "terseLabel": "Total arrangement consideration under Eisai Agreement" } } }, "localname": "CollaborativeArrangementConsiderationAgreedToBePaid", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_CollaborativeArrangementRoyaltyPercentageOnAnnualNetSales": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement royalty percentage on annual net sales.", "label": "Collaborative Arrangement Royalty Percentage On Annual Net Sales", "terseLabel": "Royalty rate on annual net sales" } } }, "localname": "CollaborativeArrangementRoyaltyPercentageOnAnnualNetSales", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "arna_CommonStockClosingPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing price of Company's common stock as reported on the NASDAQ Global Select Market", "label": "Common Stock Closing Price", "terseLabel": "Common stock closing price ($ per share)" } } }, "localname": "CommonStockClosingPrice", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "arna_CommonStockClosingPricePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock closing price percentage.", "label": "Common Stock Closing Price Percentage", "terseLabel": "Common stock closing price, percentage" } } }, "localname": "CommonStockClosingPricePercentage", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "arna_ComputersAndSoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Computers and software.", "label": "Computers And Software [Member]", "terseLabel": "Computers and software" } } }, "localname": "ComputersAndSoftwareMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "arna_ContractAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract assets.", "label": "Contract Assets", "terseLabel": "Contract Assets" } } }, "localname": "ContractAssets", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_ContractWithCustomerAssetDecreaseInResultingFromAdjustmentToFutureEstimatedRoyaltyPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contract with customer asset decrease in resulting from adjustment to future estimated royalty payments.", "label": "Contract With Customer Asset Decrease In Resulting From Adjustment To Future Estimated Royalty Payments", "terseLabel": "Decrease in contract asset resulting from adjustment to future estimated royalty payments" } } }, "localname": "ContractWithCustomerAssetDecreaseInResultingFromAdjustmentToFutureEstimatedRoyaltyPayments", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_ContractWithCustomerAssetIncreaseInResultingFromAdjustmentToFutureEstimatedRoyaltyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract with customer asset increase in resulting from adjustment to future estimated royalty payments.", "label": "Contract With Customer Asset Increase In Resulting From Adjustment To Future Estimated Royalty Payments", "terseLabel": "Increase in contract asset resulting from adjustment to future estimated royalty payments" } } }, "localname": "ContractWithCustomerAssetIncreaseInResultingFromAdjustmentToFutureEstimatedRoyaltyPayments", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred tax assets arising from lease liabilities.", "label": "Deferred Tax Assets Lease Liabilities", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DeferredTaxAssetsLiabilitiesGross": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Net amount of deferred tax assets before reduction for valuation allowance.", "label": "Deferred Tax Assets Liabilities Gross", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesGross", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10050.0, "parentTag": "arna_DeferredTaxAssetsLiabilitiesGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred tax liabilities, right of use assets.", "label": "Deferred Tax Liabilities Right Of Use Asset", "negatedLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DisposalGroupIncludingDiscontinuedOperationCostAndExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation cost and expense.", "label": "Disposal Group Including Discontinued Operation Cost And Expense [Abstract]", "terseLabel": "Operating costs and expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostAndExpenseAbstract", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "stringItemType" }, "arna_DisposalGroupIncludingDiscontinuedOperationCostOfTollManufacturing": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10060.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation cost of toll manufacturing.", "label": "Disposal Group Including Discontinued Operation Cost Of Toll Manufacturing", "terseLabel": "Cost of toll manufacturing" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostOfTollManufacturing", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DisposalGroupIncludingDiscontinuedOperationOtherCollaborationRevenue": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10110.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation other collaboration revenue.", "label": "Disposal Group Including Discontinued Operation Other Collaboration Revenue", "terseLabel": "Other collaboration revenue" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCollaborationRevenue", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10090.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation other income expense net.", "label": "Disposal Group Including Discontinued Operation Other Income Expense Net", "negatedLabel": "Other (income) expense, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10070.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation research and development expenses.", "label": "Disposal Group Including Discontinued Operation Research And Development Expenses", "terseLabel": "Research and development" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DisposalGroupIncludingDiscontinuedOperationRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation revenue.", "label": "Disposal Group Including Discontinued Operation Revenue [Abstract]", "terseLabel": "Revenues" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenueAbstract", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "stringItemType" }, "arna_DisposalGroupIncludingDiscontinuedOperationSalesRevenueGoodsNet": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10100.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation sales revenue goods net.", "label": "Disposal Group Including Discontinued Operation Sales Revenue Goods Net", "terseLabel": "Net product sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationSalesRevenueGoodsNet", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DisposalGroupIncludingDiscontinuedOperationTollManufacturingRevenue": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10120.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation toll manufacturing revenue.", "label": "Disposal Group Including Discontinued Operation Toll Manufacturing Revenue", "terseLabel": "Toll manufacturing" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationTollManufacturingRevenue", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "arna_DispositionOfPropertyAndLandUponLeaseExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposition of property and land upon lease expiration.", "label": "Disposition Of Property And Land Upon Lease Expiration", "terseLabel": "Disposition of property and land upon lease expiration" } } }, "localname": "DispositionOfPropertyAndLandUponLeaseExpiration", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "arna_EisaiAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eisai agreement.", "label": "Eisai Agreement [Member]", "terseLabel": "Eisai Agreement" } } }, "localname": "EisaiAgreementMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_EisaiFirstAmendedAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eisai First Amended Agreement [Member]", "label": "Eisai First Amended Agreement [Member]", "terseLabel": "Eisai First Amended Agreement" } } }, "localname": "EisaiFirstAmendedAgreementMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_EisaiIncorporationAndEisaiCorporationLimitedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eisai Incorporation And Eisai Corporation Limited.", "label": "Eisai Incorporation And Eisai Corporation Limited [Member]", "terseLabel": "Eisai" } } }, "localname": "EisaiIncorporationAndEisaiCorporationLimitedMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "domainItemType" }, "arna_EisaiMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eisai.", "label": "Eisai [Member]", "terseLabel": "Eisai" } } }, "localname": "EisaiMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_EisaiSecondAmendedAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eisai Second Amended Agreement [Member]", "label": "Eisai Second Amended Agreement [Member]", "terseLabel": "Eisai Second Amended Agreement" } } }, "localname": "EisaiSecondAmendedAgreementMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_EmployeeServiceShareBasedCompensationTaxImpactFromExerciseOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Employee service share based compensation tax impact from exercise of stock options.", "label": "Employee Service Share Based Compensation Tax Impact From Exercise Of Stock Options", "terseLabel": "Tax impact from exercise of stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxImpactFromExerciseOfStockOptions", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_EquityCompensationPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Compensation Plans [Member]", "label": "Equity Compensation Plans [Member]", "terseLabel": "Equity Compensation Plans" } } }, "localname": "EquityCompensationPlansMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_EquityDistributionAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity distribution agreement.", "label": "Equity Distribution Agreement [Member]", "terseLabel": "Equity Distribution Agreement" } } }, "localname": "EquityDistributionAgreementMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_EverestMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Everest.", "label": "Everest [Member]", "terseLabel": "Everest" } } }, "localname": "EverestMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_IldongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ildong.", "label": "Ildong [Member]", "terseLabel": "Ildong" } } }, "localname": "IldongMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_IncomeLossFromContinuingOperationsExcludingPortionAttributableToVIE": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10110.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income (loss) from continuing operations excluding portion attributable to VIE.", "label": "Income Loss From Continuing Operations Excluding Portion Attributable To V I E", "negatedLabel": "Income (loss) from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsExcludingPortionAttributableToVIE", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "arna_IncomeTaxDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income tax disclosure.", "label": "Income Tax Disclosure [Line Items]", "terseLabel": "Income Tax Disclosure [Line Items]" } } }, "localname": "IncomeTaxDisclosureLineItems", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "arna_IncomeTaxDisclosureTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income tax disclosure.", "label": "Income Tax Disclosure [Table]", "terseLabel": "Income Tax Disclosure [Table]" } } }, "localname": "IncomeTaxDisclosureTable", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "arna_IncomeTaxReconciliationChangeInValuationAllowanceDueToTaxReform": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10020.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Income tax reconciliation change in valuation allowance due to tax reform.", "label": "Income Tax Reconciliation Change In Valuation Allowance Due To Tax Reform", "terseLabel": "Change in valuation allowance due to tax reform" } } }, "localname": "IncomeTaxReconciliationChangeInValuationAllowanceDueToTaxReform", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "arna_IncreaseDecreaseInAccruedLitigationSettlement": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10310.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in accrued litigation settlement.", "label": "Increase Decrease In Accrued Litigation Settlement", "terseLabel": "Accrued litigation settlement" } } }, "localname": "IncreaseDecreaseInAccruedLitigationSettlement", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "arna_InventoryDeliverableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventory deliverable.", "label": "Inventory Deliverable [Member]", "terseLabel": "Inventory Deliverable" } } }, "localname": "InventoryDeliverableMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_LeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease expiration, month and year.", "label": "Lease Expiration Month And Year", "terseLabel": "Operating lease agreement expiration date" } } }, "localname": "LeaseExpirationMonthAndYear", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "arna_LicenseAgreementCostsIncurredRelatedToTransactionFees": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10270.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "License agreement costs incurred related to transaction fees.", "label": "License Agreement Costs Incurred Related To Transaction Fees", "terseLabel": "Transaction costs", "verboseLabel": "License agreement costs incurred related to transaction fees" } } }, "localname": "LicenseAgreementCostsIncurredRelatedToTransactionFees", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "arna_LiquidityPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liquidity.", "label": "Liquidity Policy Policy [Text Block]", "terseLabel": "Liquidity" } } }, "localname": "LiquidityPolicyPolicyTextBlock", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "arna_LitigationAmountSettlementByInsurerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Litigation amount settlement by insurer.", "label": "Litigation Amount Settlement By Insurer [Member]", "terseLabel": "Litigation Amount Settlement By Insurer" } } }, "localname": "LitigationAmountSettlementByInsurerMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_LitigationAmountSettlementByParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Litigation amount settlement by parent.", "label": "Litigation Amount Settlement By Parent [Member]", "terseLabel": "Litigation Amount Settlement By Parent" } } }, "localname": "LitigationAmountSettlementByParentMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_LongTermInvestmentsMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long term investments maturity period.", "label": "Long Term Investments Maturity Period", "terseLabel": "Maturity in years" } } }, "localname": "LongTermInvestmentsMaturityPeriod", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "durationItemType" }, "arna_LongTermInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long term investments.", "label": "Long Term Investments [Member]", "terseLabel": "Investments, available-for-sale" } } }, "localname": "LongTermInvestmentsMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "domainItemType" }, "arna_LorcaserinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lorcaserin.", "label": "Lorcaserin [Member]", "terseLabel": "Lorcaserin" } } }, "localname": "LorcaserinMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_LorcaserinProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lorcaserin product.", "label": "Lorcaserin Product [Member]", "terseLabel": "Lorcaserin Product" } } }, "localname": "LorcaserinProductMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_ManufacturingAndSupplyCommitmentDeliverableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Manufacturing and supply commitment deliverable.", "label": "Manufacturing And Supply Commitment Deliverable [Member]", "terseLabel": "Manufacturing and Supply Commitment Deliverable" } } }, "localname": "ManufacturingAndSupplyCommitmentDeliverableMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_MassachusettsBostonMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Massachusetts, Boston.", "label": "Massachusetts Boston [Member]", "terseLabel": "Boston, Massachusetts" } } }, "localname": "MassachusettsBostonMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_MaximumEsppOfferingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum duration of an ESPP offering period", "label": "Maximum Espp Offering Period", "terseLabel": "Maximum ESPP offering period" } } }, "localname": "MaximumEsppOfferingPeriod", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "arna_MaximumNumberOfSharesAllowedToPurchasePerPurchasePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum Number of Shares Allowed to Purchase per Purchase Period", "label": "Maximum Number Of Shares Allowed To Purchase Per Purchase Period", "terseLabel": "Maximum number of shares allowed to purchase per PURCHASE period" } } }, "localname": "MaximumNumberOfSharesAllowedToPurchasePerPurchasePeriod", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "arna_NetIncomeLossAttributableToDomestic": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionBenefitForIncomeTaxesByRegionDetail": { "order": 10010.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net income (loss) attributable to domestic.", "label": "Net Income Loss Attributable To Domestic", "terseLabel": "United States" } } }, "localname": "NetIncomeLossAttributableToDomestic", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionBenefitForIncomeTaxesByRegionDetail" ], "xbrltype": "monetaryItemType" }, "arna_NetIncomeLossAttributableToForeign": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionBenefitForIncomeTaxesByRegionDetail": { "order": 10020.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net income (loss) attributable to foreign.", "label": "Net Income Loss Attributable To Foreign", "terseLabel": "Foreign" } } }, "localname": "NetIncomeLossAttributableToForeign", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionBenefitForIncomeTaxesByRegionDetail" ], "xbrltype": "monetaryItemType" }, "arna_NetOperatingLossAndResearchAndDevelopmentTaxCreditLimitationOnUseThresholdPercentageOfOwnership": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net operating loss and research and development tax credit limitation on use threshold percentage of ownership.", "label": "Net Operating Loss And Research And Development Tax Credit Limitation On Use Threshold Percentage Of Ownership", "terseLabel": "Net operating loss and research and development tax credit limitation on use threshold percentage of ownership" } } }, "localname": "NetOperatingLossAndResearchAndDevelopmentTaxCreditLimitationOnUseThresholdPercentageOfOwnership", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "arna_NetOperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net operating loss carryforwards expiration year.", "label": "Net Operating Loss Carryforwards Expiration Year", "terseLabel": "NOL carryforwards expiration date, year" } } }, "localname": "NetOperatingLossCarryforwardsExpirationYear", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "arna_NonCashCollaborationRevenue": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Non-cash collaboration revenue.", "label": "Non Cash Collaboration Revenue", "negatedLabel": "Non-cash collaboration revenue" } } }, "localname": "NonCashCollaborationRevenue", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "arna_NonCashRoyaltyRevenue": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Non-cash royalty revenue.", "label": "Non Cash Royalty Revenue", "negatedLabel": "Non-cash royalty revenue" } } }, "localname": "NonCashRoyaltyRevenue", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "arna_NonUsMarketMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non us market.", "label": "Non Us Market [Member]", "terseLabel": "Non U.S. Market" } } }, "localname": "NonUsMarketMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_NumberOfEmployeesTransferred": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of employees transferred.", "label": "Number Of Employees Transferred", "terseLabel": "Number of employees transferred" } } }, "localname": "NumberOfEmployeesTransferred", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "arna_NumberOfPropertiesOwnershipTransferredUnderSaleLeasebackTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of properties in which ownership has transferred under sale leaseback transaction.", "label": "Number Of Properties Ownership Transferred Under Sale Leaseback Transaction", "terseLabel": "Number of properties under sale and leaseback agreements" } } }, "localname": "NumberOfPropertiesOwnershipTransferredUnderSaleLeasebackTransaction", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "decimalItemType" }, "arna_OperatingLeaseInceptionDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease inception date.", "label": "Operating Lease Inception Date", "terseLabel": "Operating lease inception date" } } }, "localname": "OperatingLeaseInceptionDate", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "arna_OrphanDrugMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Orphan drug.", "label": "Orphan Drug [Member]", "terseLabel": "Orphan Drug Credit" } } }, "localname": "OrphanDrugMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_OtherThanStockOptionsAndStockAppreciationRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Than Stock Options And Stock Appreciation Rights [Member]", "label": "Other Than Stock Options And Stock Appreciation Rights [Member]", "terseLabel": "Other Than Stock Options And Stock Appreciation Rights" } } }, "localname": "OtherThanStockOptionsAndStockAppreciationRightsMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_OutpostMedicineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outpost medicine.", "label": "Outpost Medicine [Member]", "terseLabel": "Outpost Medicine" } } }, "localname": "OutpostMedicineMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_PayableOnMilestoneAchievements": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Payable on milestone achievements.", "label": "Payable On Milestone Achievements", "terseLabel": "Paid on Milestone Achievements" } } }, "localname": "PayableOnMilestoneAchievements", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_PaymentTermsOnInvoicedAmounts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Payment terms on invoiced amounts.", "label": "Payment Terms On Invoiced Amounts", "terseLabel": "Payment terms on invoiced amounts" } } }, "localname": "PaymentTermsOnInvoicedAmounts", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "arna_PercentageIncreasesInMonthlyRentalPayment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale leaseback transaction, percentage increase in monthly rent.", "label": "Percentage Increases In Monthly Rental Payment", "terseLabel": "Percentage of annual increase in monthly lease payments" } } }, "localname": "PercentageIncreasesInMonthlyRentalPayment", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "arna_PercentageOfOperatingLossCarryForwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of operating loss carry forwards limitations on use.", "label": "Percentage Of Operating Loss Carry Forwards Limitations On Use", "terseLabel": "Operating loss carryforwards, percentage of limitation" } } }, "localname": "PercentageOfOperatingLossCarryForwardsLimitationsOnUse", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "arna_PerformanceRestrictedStockUnitsPRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Restricted Stock Units (PRSU) [Member]", "label": "Performance Restricted Stock Units P R S U [Member]", "terseLabel": "Performance restricted stock units", "verboseLabel": "PRSUs" } } }, "localname": "PerformanceRestrictedStockUnitsPRSUMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "arna_PeriodForNetOperatingLossAndResearchAndDevelopmentTaxCreditLimitationOnUseThresholdPercentageOfOwnership": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period for net operating loss and research and development tax credit limitation on use threshold percentage of ownership.", "label": "Period For Net Operating Loss And Research And Development Tax Credit Limitation On Use Threshold Percentage Of Ownership", "terseLabel": "Period for net operating loss and research and development tax credit limitation on use threshold percentage of ownership" } } }, "localname": "PeriodForNetOperatingLossAndResearchAndDevelopmentTaxCreditLimitationOnUseThresholdPercentageOfOwnership", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "arna_PricePerShareMarketConditionVestingThreshold": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price per share market condition vesting threshold.", "label": "Price Per Share Market Condition Vesting Threshold", "terseLabel": "Price per share market condition vesting threshold" } } }, "localname": "PricePerShareMarketConditionVestingThreshold", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "arna_PriorToCommercialDistributionAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prior to commercial distribution agreement.", "label": "Prior To Commercial Distribution Agreement [Member]", "terseLabel": "Prior to Commercial Distribution Agreement" } } }, "localname": "PriorToCommercialDistributionAgreementMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_PriorToTransactionAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prior to transaction agreement.", "label": "Prior To Transaction Agreement [Member]", "terseLabel": "Prior to Transaction Agreement" } } }, "localname": "PriorToTransactionAgreementMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_ProceedsFromRepaymentsOfReversalOfInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from repayments of reversal of inventory.", "label": "Proceeds From Repayments Of Reversal Of Inventory", "terseLabel": "Reversal balance of hand on inventory" } } }, "localname": "ProceedsFromRepaymentsOfReversalOfInventory", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_PropertiesUnderOperatingLeasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Properties under operating leases.", "label": "Properties Under Operating Leases [Member]", "terseLabel": "Properties under operating lease" } } }, "localname": "PropertiesUnderOperatingLeasesMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_PropertiesUnderSaleAndLeasebackAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Properties under sale and leaseback agreements member.", "label": "Properties Under Sale And Leaseback Agreements [Member]", "terseLabel": "Properties under sale and leaseback agreements" } } }, "localname": "PropertiesUnderSaleAndLeasebackAgreementsMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_ReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of components of cash, cash equivalents and restricted cash.", "label": "Reconciliation Of Components Of Cash Cash Equivalents And Restricted Cash Table [Text Block]", "terseLabel": "Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "arna_ReductionInLeaseFinancingObligationFromReleaseOfResidualValueUponLeaseExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reduction in lease financing obligation from release of residual value upon lease expiration.", "label": "Reduction In Lease Financing Obligation From Release Of Residual Value Upon Lease Expiration", "terseLabel": "Reduction in lease financing obligation from release of residual value upon lease expiration" } } }, "localname": "ReductionInLeaseFinancingObligationFromReleaseOfResidualValueUponLeaseExpiration", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "arna_RepaymentsOfSaleLeaseBackFinancingObligations": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the payment of sale and leaseback financing obligations.", "label": "Repayments Of Sale Lease Back Financing Obligations", "negatedLabel": "Principal payments on lease financing obligations" } } }, "localname": "RepaymentsOfSaleLeaseBackFinancingObligations", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "arna_RestrictedStockUnitsAndRestrictedStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted stock units and restricted stock.", "label": "Restricted Stock Units And Restricted Stock [Member]", "terseLabel": "RSUs and unvested restricted stock" } } }, "localname": "RestrictedStockUnitsAndRestrictedStockMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail" ], "xbrltype": "domainItemType" }, "arna_RevenueFromContractsWithCustomersIncludingDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from contracts with customers including discontinued operations.", "label": "Revenue From Contracts With Customers Including Discontinued Operations", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractsWithCustomersIncludingDiscontinuedOperations", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "monetaryItemType" }, "arna_SaleLeasebackFinancingObligations": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10070.0, "parentTag": "arna_SaleLeasebackFinancingObligationsNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sale leaseback financing obligations.", "label": "Sale Leaseback Financing Obligations", "terseLabel": "Sale and leaseback transaction, total financing obligation", "totalLabel": "Lease financing obligations" } } }, "localname": "SaleLeasebackFinancingObligations", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "arna_SaleLeasebackFinancingObligationsCurrent": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10080.0, "parentTag": "arna_SaleLeasebackFinancingObligationsNoncurrent", "weight": 1.0 }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sale and leaseback financing obligations due within one year or the normal operating cycle, if longer, accounted for under the financing method.", "label": "Sale Leaseback Financing Obligations Current", "negatedLabel": "Current portion of lease financing obligations", "terseLabel": "Current portion of lease financing obligations" } } }, "localname": "SaleLeasebackFinancingObligationsCurrent", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "arna_SaleLeasebackFinancingObligationsNoncurrent": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sale and leaseback financing obligations due after one year from the balance sheet or beyond the normal operating cycle, if longer, accounted for under the financing method.", "label": "Sale Leaseback Financing Obligations Noncurrent", "terseLabel": "Lease financing obligations, less current portion", "totalLabel": "Lease financing obligations, less current portion" } } }, "localname": "SaleLeasebackFinancingObligationsNoncurrent", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "arna_SaleLeasebackTransactionResidualValue": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10110.0, "parentTag": "arna_SaleLeasebackFinancingObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Residual value of sale and leaseback agreements.", "label": "Sale Leaseback Transaction Residual Value", "terseLabel": "Add amounts representing residual value" } } }, "localname": "SaleLeasebackTransactionResidualValue", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "arna_SaleLeasebackTransactionsIncomeStatementInterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The financing charge for sale and leaseback transactions.", "label": "Sale Leaseback Transactions Income Statement Interest Expense", "terseLabel": "Sale and leaseback transaction, interest expense" } } }, "localname": "SaleLeasebackTransactionsIncomeStatementInterestExpense", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_SanDiegoCaliforniaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "San Diego, California.", "label": "San Diego California [Member]", "terseLabel": "San Diego, California" } } }, "localname": "SanDiegoCaliforniaMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_ScheduleOfFutureMinimumPaymentsForSaleLeaseBackFinancingObligationsAndOperatingLeasesTableTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for a) sale and leaseback financing obligations and b) operating leases having initial or remaining noncancelable lease terms in excess of one year.", "label": "Schedule Of Future Minimum Payments For Sale Lease Back Financing Obligations And Operating Leases Table Table [Text Block]", "terseLabel": "Future Minimum Lease Payments" } } }, "localname": "ScheduleOfFutureMinimumPaymentsForSaleLeaseBackFinancingObligationsAndOperatingLeasesTableTableTextBlock", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "arna_ScheduleOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of significant accounting policies", "label": "Schedule Of Significant Accounting Policies [Line Items]", "terseLabel": "Schedule Of Significant Accounting Policies [Line Items]" } } }, "localname": "ScheduleOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "arna_ScheduleOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Significant Accounting Policies [Table]", "label": "Schedule Of Significant Accounting Policies [Table]", "terseLabel": "Schedule Of Significant Accounting Policies [Table]" } } }, "localname": "ScheduleOfSignificantAccountingPoliciesTable", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "arna_ShareBasedCompensationArrangementByShareBasedPaymentAwardDecreasePercentageToAvailableForGrantForShareIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award, decrease percentage to available for grant for share issued.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Decrease Percentage To Available For Grant For Share Issued", "terseLabel": "Reduction in number of shares available for grant for every share issued, percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDecreasePercentageToAvailableForGrantForShareIssued", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "arna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Grant-date fair value of equity instruments other than options granted during period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Grant Date Fair Value", "terseLabel": "PRSU grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateGrantDateFairValue", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "arna_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreasePercentageToAvailableForGrantForShareReleased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award, increase percentage to available for grant for share released.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Percentage To Available For Grant For Share Released", "terseLabel": "Increase in number of shares available for grant for every share issued, percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreasePercentageToAvailableForGrantForShareReleased", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "arna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "arna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of target number of shares to be issued under share based payment award other than options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Target Number Of Shares To Be Issued", "terseLabel": "Number of shares to be awarded as a percentage of target amounts" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfTargetNumberOfSharesToBeIssued", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "arna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingVestingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based compensation arrangement by share based payment award remaining vesting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Remaining Vesting Period", "terseLabel": "Remaining vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingVestingPeriod", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "arna_ShareBasedCompensationEffectOnEarningsPerShareBasic": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation effect on earnings per share basic.", "label": "Share Based Compensation Effect On Earnings Per Share Basic", "terseLabel": "Impact on net loss per share, basic" } } }, "localname": "ShareBasedCompensationEffectOnEarningsPerShareBasic", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "perShareItemType" }, "arna_ShareBasedCompensationEffectOnEarningsPerShareDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation effect on earnings per share diluted.", "label": "Share Based Compensation Effect On Earnings Per Share Diluted", "terseLabel": "Impact on net loss per share, diluted" } } }, "localname": "ShareBasedCompensationEffectOnEarningsPerShareDiluted", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "perShareItemType" }, "arna_ShortTermInvestmentsMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short term investments maturity period.", "label": "Short Term Investments Maturity Period", "terseLabel": "Maturity in years" } } }, "localname": "ShortTermInvestmentsMaturityPeriod", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "durationItemType" }, "arna_SiegfriedPharmaAGAndSiegfriedAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Siegfried Pharma AG and Siegfried AG.", "label": "Siegfried Pharma A G And Siegfried A G [Member]", "terseLabel": "Siegfried" } } }, "localname": "SiegfriedPharmaAGAndSiegfriedAGMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlanAndRestrictedStockAwardNetOfForfeitures": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period, shares, employee stock purchase plan and restricted stock award, net of forfeitures.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plan And Restricted Stock Award Net Of Forfeitures", "terseLabel": "Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlanAndRestrictedStockAwardNetOfForfeitures", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "arna_StockIssuedDuringPeriodValueEmployeeStockPurchasePlanAndRestrictedStockAwardNetOfForfeitures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period, value, employee stock purchase plan and restricted stock award, net of forfeitures.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan And Restricted Stock Award Net Of Forfeitures", "terseLabel": "Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock unit awards" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlanAndRestrictedStockAwardNetOfForfeitures", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "arna_StockOptionsExercisablePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time over which stock options can be exercised, in years", "label": "Stock Options Exercisable Period", "terseLabel": "Stock options exercisable period" } } }, "localname": "StockOptionsExercisablePeriod", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "arna_StockholdersEquityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stockholders Equity [Line Items]", "label": "Stockholders Equity [Line Items]", "terseLabel": "Stockholders Equity [Line Items]" } } }, "localname": "StockholdersEquityLineItems", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "arna_StockholdersEquityTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stockholders' Equity [Table]", "label": "Stockholders Equity [Table]", "terseLabel": "Stockholders Equity [Table]" } } }, "localname": "StockholdersEquityTable", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "arna_SubleaseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sublease agreement.", "label": "Sublease Agreement [Member]", "terseLabel": "Sublease Agreement" } } }, "localname": "SubleaseAgreementMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "domainItemType" }, "arna_SubleaseExpirationPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sublease expiration period.", "label": "Sublease Expiration Period", "terseLabel": "Sublease expiration period" } } }, "localname": "SubleaseExpirationPeriod", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "arna_SupplyAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supply agreement.", "label": "Supply Agreement [Member]", "terseLabel": "Supply Agreement" } } }, "localname": "SupplyAgreementMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_SwitzerlandZugMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Switzerland, Zug.", "label": "Switzerland Zug [Member]", "terseLabel": "Zug, Switzerland" } } }, "localname": "SwitzerlandZugMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_TaxCreditCarryforwardExpirationYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax credit carryforward expiration year", "label": "Tax Credit Carryforward Expiration Year", "terseLabel": "Tax credit carryforwards expiration year" } } }, "localname": "TaxCreditCarryforwardExpirationYear", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "arna_ThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold consecutive trading days.", "label": "Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days" } } }, "localname": "ThresholdConsecutiveTradingDays", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "arna_ThresholdNonConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold non-consecutive trading days.", "label": "Threshold Non Consecutive Trading Days", "terseLabel": "Threshold non-consecutive trading days" } } }, "localname": "ThresholdNonConsecutiveTradingDays", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "arna_TwoZeroOneNineEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 employee stock purchase plan.", "label": "Two Zero One Nine Employee Stock Purchase Plan [Member]", "terseLabel": "2019 ESPP" } } }, "localname": "TwoZeroOneNineEmployeeStockPurchasePlanMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_TwoZeroZeroNineEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two zero zero nine employee stock purchase plan.", "label": "Two Zero Zero Nine Employee Stock Purchase Plan [Member]", "terseLabel": "2009 ESPP" } } }, "localname": "TwoZeroZeroNineEmployeeStockPurchasePlanMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_USMarketMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Us market.", "label": "U S Market [Member]", "terseLabel": "U.S. Market" } } }, "localname": "USMarketMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "underwritten public offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten Public Offering" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "arna_UnitedTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "United therapeutics.", "label": "United Therapeutics [Member]", "terseLabel": "United Therapeutics" } } }, "localname": "UnitedTherapeuticsMember", "nsuri": "http://www.arenapharm.com/20191231", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "arna_VariableInterestEntityDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Variable interest entity disclosure.", "label": "Variable Interest Entity Disclosure [Abstract]" } } }, "localname": "VariableInterestEntityDisclosureAbstract", "nsuri": "http://www.arenapharm.com/20191231", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r450" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r448" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r447" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r449" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r60", "r116" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case Type [Domain]", "terseLabel": "Litigation Case" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r161", "r215", "r221", "r432" ], "lang": { "en-US": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r159", "r215", "r219", "r426", "r430" ], "lang": { "en-US": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r160", "r215", "r220", "r431", "r442", "r444" ], "lang": { "en-US": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update201409 [Member]", "terseLabel": "ASC 606" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update201602 [Member]", "terseLabel": "ASC 842" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201609Member": { "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.", "label": "Accounting Standards Update201609 [Member]", "terseLabel": "ASU No. 2016-09" } } }, "localname": "AccountingStandardsUpdate201609Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable And Other Accrued Liabilities Current", "terseLabel": "Accounts payable and other accrued liabilities", "totalLabel": "Total accounts payable and other accrued liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail": { "order": 10010.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r26", "r39", "r162", "r163", "r216" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r106" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization of original issue discounts, net of premiums, on available- for-sale investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r50", "r191" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r66", "r67", "r68" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r65", "r68", "r69", "r328" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r40" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r229", "r231", "r275", "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r231", "r259", "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r84", "r105", "r353" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization Of Financing Costs", "terseLabel": "Amortization of prepaid financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Total antidilutive securities excluded from calculation of diluted net loss per share (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r156", "r397", "r414" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r27", "r28", "r59" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "terseLabel": "Total current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r170" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r171" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r168", "r184" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r165", "r169", "r184" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r167", "r184" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available For Sale Securities Debt Securities Current", "terseLabel": "Short-term investments, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r167", "r184" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Available For Sale Securities Debt Securities Noncurrent", "terseLabel": "Investments, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r232", "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building And Building Improvements [Member]", "terseLabel": "Building and capital improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.", "label": "Calculated Under Revenue Guidance In Effect Before Topic606 [Member]", "terseLabel": "Balances without adoption of ASC 606" } } }, "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r25", "r47", "r107" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r32", "r108", "r111" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r101", "r107", "r110" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash presented in the consolidated statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r101", "r107", "r110" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r101", "r349" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDivestedFromDeconsolidation": { "auth_ref": [ "r97" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.", "label": "Cash Divested From Deconsolidation", "negatedLabel": "Deconsolidation of variable interest entity" } } }, "localname": "CashDivestedFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r18", "r101" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided By Used In Investing Activities Discontinued Operations", "terseLabel": "Net cash provided by (used in) investing activities - discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r18", "r101" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided By Used In Operating Activities Discontinued Operations", "terseLabel": "Net cash used in operating activities - discontinued operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r315", "r316", "r318" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborations and License Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementRightsAndObligations": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Description of rights and obligations under the collaborative arrangements.", "label": "Collaborative Arrangement Rights And Obligations", "terseLabel": "Collaborative arrangement right description" } } }, "localname": "CollaborativeArrangementRightsAndObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r56", "r197", "r401", "r419" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r38", "r208" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r38" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r71", "r73", "r74" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive income (loss) attributable to stockholders of Arena" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income Net Of Tax [Abstract]", "terseLabel": "Comprehensive Income (Loss):" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r71", "r73", "r322", "r323", "r336" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest", "negatedLabel": "Less comprehensive loss attributable to noncontrolling interest in consolidated variable interest entity", "verboseLabel": "Net loss attributable to noncontrolling interest in consolidated variable interest entity" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r71", "r73", "r321", "r336" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r144", "r145", "r346", "r347" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r144", "r145", "r346", "r347", "r436" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r144", "r145", "r346", "r347", "r436" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r141", "r412" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentrations of Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r144", "r145", "r346", "r347" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentrations of risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r144", "r145", "r346", "r347" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r212", "r213", "r216" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract With Customer Asset Net", "terseLabel": "Contract asset associated with agreement" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r217" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "verboseLabel": "Recognized revenues" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Description of effect, from relationship that timing of satisfaction of performance obligation has on timing of payment, on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and on obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment", "terseLabel": "Customers billing method, description" } } }, "localname": "ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r225", "r228", "r434" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r85" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10240.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs And Expenses", "terseLabel": "Operating costs and expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs And Expenses [Abstract]", "terseLabel": "Operating costs and expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Table [Text Block]", "terseLabel": "Schedule of Investments, Available-for-Sale" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r115", "r308", "r311" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense Benefit", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r35", "r36", "r299", "r398", "r413" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10040.0, "parentTag": "arna_DeferredTaxAssetsLiabilitiesGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Income Tax Liabilities", "negatedLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r300" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10030.0, "parentTag": "arna_DeferredTaxAssetsLiabilitiesGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r302" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": { "auth_ref": [ "r285", "r286", "r302" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Assets Liabilities Net Noncurrent", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r279", "r306", "r307" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards Domestic", "terseLabel": "Federal and California NOL carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r279", "r306", "r307" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards Foreign", "terseLabel": "Foreign NOL carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r280", "r306", "r307" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10130.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Other, net" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets Property Plant And Equipment", "terseLabel": "Depreciation" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r304", "r306", "r307" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research", "terseLabel": "Federal and California research and development credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r279", "r306", "r307" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Share-based compensation expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r301" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r286", "r302" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail": { "order": 10060.0, "parentTag": "arna_DeferredTaxAssetsLiabilitiesGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities", "negatedLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r105", "r154" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference Between Revenue Guidance In Effect Before And After Topic606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Summary of Revenue Disaggregated by Major Customers, Timing of Revenue Recognition and Revenue Classification" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "auth_ref": [ "r5", "r7", "r9", "r20" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10020.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax", "terseLabel": "Gain on sale of discontinued operations" } } }, "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r5", "r6", "r7", "r8", "r9", "r16", "r80", "r421" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10150.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation Income Loss From Discontinued Operation Before Income Tax", "terseLabel": "Income (loss) from discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail": { "order": 10420.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation, when the per share amount is the same.", "label": "Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share", "terseLabel": "Discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10090.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share", "terseLabel": "Discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10070.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share", "terseLabel": "Discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations And Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group Including Discontinued Operation Consideration", "terseLabel": "Sales price of business" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r17" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10050.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group Including Discontinued Operation Costs Of Goods Sold", "terseLabel": "Cost of product sales", "verboseLabel": "Carrying value of inventory as cost of product sales of discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r17" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10080.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group Including Discontinued Operation General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r17" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10040.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group Including Discontinued Operation Operating Expense", "totalLabel": "Total costs and expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r17" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10010.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group Including Discontinued Operation Operating Income Loss", "totalLabel": "Income (loss) from operations of discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r17" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": 10030.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group Including Discontinued Operation Revenue", "terseLabel": "Revenue reported under discontinued operations", "totalLabel": "Total revenues", "verboseLabel": "Recognized revenue of discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r24", "r196" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups Including Discontinued Operations Disclosure [Text Block]", "terseLabel": "Sale of Manufacturing Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r82", "r121", "r126", "r127", "r128", "r129", "r133", "r406", "r423" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Net income (loss) per share, basic", "totalLabel": "Net income (loss) attributable to stockholders of Arena per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share Basic [Abstract]", "terseLabel": "Net income (loss) attributable to stockholders of Arena per share, basic:", "verboseLabel": "Net income (loss) per share, basic" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r82", "r121", "r126", "r127", "r128", "r129", "r133", "r406", "r423" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Net income (loss) per share, diluted", "totalLabel": "Net income (loss) attributable to stockholders of Arena per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share Diluted [Abstract]", "terseLabel": "Net income (loss) attributable to stockholders of Arena per share, diluted:", "verboseLabel": "Net income (loss) per share, diluted" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r111", "r130", "r131", "r132" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r349" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r287", "r288", "r310" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Statutory federal rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail": { "order": 10020.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized Expense (in thousands)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Remaining Weighted-Average Recognition Period (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Unvested stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r338", "r339", "r340", "r344" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r225", "r226", "r228", "r339", "r376" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r338", "r339", "r341", "r342", "r345" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosures" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r225", "r226", "r228", "r339", "r377" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Quoted Prices in Active Markets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r225", "r226", "r228", "r339", "r378" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r225", "r226", "r228", "r339", "r379" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r343", "r345" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease Liabilities Payments Due [Abstract]", "terseLabel": "Financing Obligations" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10260.0, "parentTag": "arna_SaleLeasebackFinancingObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10340.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10290.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10330.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10320.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10310.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10300.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease Liability Payments Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r185", "r186", "r187", "r188" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsOwnedCorporateDebtAtFairValue": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of firm holdings in corporate fixed income securities. Includes pledged and unpledged holdings.", "label": "Financial Instruments Owned Corporate Debt At Fair Value", "terseLabel": "Corporate debt instruments" } } }, "localname": "FinancialInstrumentsOwnedCorporateDebtAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The fair value as of the balance sheet date of firm holdings in debt obligations issued by the US government including short-term Treasury bills, medium-term Treasury notes, and long-term Treasury bonds, as well as debt issued by agencies. Includes both pledged (to counterparties as collateral for financing transactions) and unpledged holdings.", "label": "Financial Instruments Owned U S Government And Agency Obligations At Fair Value", "terseLabel": "US government and government agency notes" } } }, "localname": "FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r111", "r348", "r351" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions And Translations Policy [Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and office equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r105" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain Loss On Sale Of Property Plant Equipment", "negatedLabel": "Loss (gain) on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10260.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r83" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r105", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment Of Long Lived Assets To Be Disposed Of", "terseLabel": "Impairment loss" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]", "terseLabel": "Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Amounts Attributable To Reporting Entity Disclosures [Abstract]", "terseLabel": "Amounts attributable to stockholders of Arena:" } } }, "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r86" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionBenefitForIncomeTaxesByRegionDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income Loss Attributable To Parent", "totalLabel": "Total income (loss) attributable to stockholders of Arena before income taxes" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionBenefitForIncomeTaxesByRegionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r79", "r121", "r393", "r403", "r424" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10160.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Income (loss) from continuing operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r321" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail": { "order": 10430.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10140.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest", "terseLabel": "Loss from continuing operations", "totalLabel": "Income (loss) from continuing operations", "verboseLabel": "Income (loss) from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail": { "order": 10410.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income Loss From Continuing Operations Per Basic And Diluted Share", "terseLabel": "Continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r76", "r82", "r126", "r127", "r128", "r402", "r404", "r406", "r420" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10080.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income Loss From Continuing Operations Per Basic Share", "terseLabel": "Continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r76", "r82", "r126", "r127", "r128", "r129", "r406", "r420", "r423" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10060.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income Loss From Continuing Operations Per Diluted Share", "terseLabel": "Continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r5", "r6", "r7", "r8", "r9", "r20", "r82", "r421" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail": { "order": 10440.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income Loss From Discontinued Operations Net Of Tax", "negatedLabel": "(Income) loss from discontinued operations", "terseLabel": "Loss from discontinued operations", "totalLabel": "Income (loss) from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsSummaryOfDiscontinuedOperationsForConsolidatedStatementsOfOperationsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r5", "r6", "r7", "r8", "r9", "r16", "r20", "r321" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity", "totalLabel": "Income (loss) from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r10", "r11", "r12", "r13", "r14", "r15", "r19", "r21", "r22", "r23", "r194", "r195" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]", "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority Name [Domain]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r115", "r155", "r312" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10170.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax (provision) benefit", "terseLabel": "Benefit for income taxes", "totalLabel": "Benefit for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r75", "r111", "r283", "r284", "r297", "r298", "r303", "r313", "r443" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r282", "r287", "r288" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10030.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in federal and foreign valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10060.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.", "label": "Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary", "negatedLabel": "Capital loss on foreign subsidiary liquidation" } } }, "localname": "IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r114", "r287", "r288" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10010.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate", "terseLabel": "Benefit for income taxes at statutory federal rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10070.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost", "terseLabel": "Share-based compensation expense" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r287" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10040.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Income Tax Reconciliation Other Adjustments", "terseLabel": "Permanent differences and other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingenciesForeign": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10050.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in foreign income tax contingency.", "label": "Income Tax Reconciliation Tax Contingencies Foreign", "terseLabel": "Deferred adjustment related to foreign net operating losses" } } }, "localname": "IncomeTaxReconciliationTaxContingenciesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10080.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Income Tax Reconciliation Tax Credits Foreign", "terseLabel": "Foreign losses at lower effective rates" } } }, "localname": "IncomeTaxReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail": { "order": 10090.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Income Tax Reconciliation Tax Credits Research", "negatedTerseLabel": "Research and development and Orphan Drug credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfProvisionBenefitForIncomeTaxesAtStatutoryFederalRateToProvisionBenefitForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r104" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10300.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Payables and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r104" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r104" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10320.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Deferred revenues", "verboseLabel": "Reduction in deferred revenue associated with agreement" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10330.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase Decrease In Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r104" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10290.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r77", "r153", "r352", "r353", "r407" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10210.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r99", "r102", "r109" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions": { "auth_ref": [ "r359" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10100.0, "parentTag": "arna_SaleLeasebackFinancingObligations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount necessary to reduce minimum lease payments to present value for sale-leaseback transactions accounted for using the deposit method or as a financing.", "label": "Interest Portion Of Minimum Lease Payments Sale Leaseback Transactions", "negatedLabel": "Less amounts representing interest", "terseLabel": "Less amounts representing interest" } } }, "localname": "InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service I R S [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r88", "r152" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10200.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r437", "r438", "r439", "r440" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r437", "r438", "r439", "r440" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r178", "r395", "r411", "r441" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Investments, Available-for-Sale" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSale" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LandSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of land subject to a ground lease.", "label": "Land Subject To Ground Leases", "terseLabel": "Area of office space", "verboseLabel": "Area of space subleased" } } }, "localname": "LandSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Lease And Rental Expense", "terseLabel": "Rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement Type [Axis]", "terseLabel": "Lease Arrangement, Type" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement Type [Domain]", "terseLabel": "Lease Arrangement, Type" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases Of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters And Contingencies [Text Block]", "terseLabel": "Legal Proceedings" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Changes in Accounting Policies - Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10230.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10180.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10220.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10210.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10200.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r370" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10190.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r44", "r399", "r417" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "terseLabel": "Total liabilities and stockholders' equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "terseLabel": "Total current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "Collaboration and License Revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r56", "r197", "r204" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Litigation Reserve Current", "terseLabel": "Accrued litigation settlement" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10280.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement Expense", "terseLabel": "Litigation settlement expense, net", "verboseLabel": "Litigation settlement expense, net" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r206", "r207" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Loss Contingency [Abstract]" } } }, "localname": "LossContingencyAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LossContingencyReceivableCurrent": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.", "label": "Loss Contingency Receivable Current", "terseLabel": "Insurance recovery receivable" } } }, "localname": "LossContingencyReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Available-for-Sale Investments" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactions": { "auth_ref": [ "r361" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10090.0, "parentTag": "arna_SaleLeasebackFinancingObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing.", "label": "Minimum Lease Payments Sale Leaseback Transactions", "totalLabel": "Total minimum lease payments" } } }, "localname": "MinimumLeasePaymentsSaleLeasebackTransactions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum Lease Payments Sale Leaseback Transactions [Abstract]", "terseLabel": "Financing Obligations" } } }, "localname": "MinimumLeasePaymentsSaleLeasebackTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactionsThereafter": { "auth_ref": [ "r361" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10170.0, "parentTag": "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactions", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Minimum Lease Payments Sale Leaseback Transactions Thereafter", "terseLabel": "Thereafter" } } }, "localname": "MinimumLeasePaymentsSaleLeasebackTransactionsThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactionsWithinFiveYears": { "auth_ref": [ "r361" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10160.0, "parentTag": "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactions", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Minimum Lease Payments Sale Leaseback Transactions Within Five Years", "terseLabel": "2023" } } }, "localname": "MinimumLeasePaymentsSaleLeasebackTransactionsWithinFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactionsWithinFourYears": { "auth_ref": [ "r361" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10150.0, "parentTag": "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactions", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Minimum Lease Payments Sale Leaseback Transactions Within Four Years", "terseLabel": "2022" } } }, "localname": "MinimumLeasePaymentsSaleLeasebackTransactionsWithinFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactionsWithinOneYear": { "auth_ref": [ "r361" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10120.0, "parentTag": "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactions", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Minimum Lease Payments Sale Leaseback Transactions Within One Year", "terseLabel": "2019" } } }, "localname": "MinimumLeasePaymentsSaleLeasebackTransactionsWithinOneYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactionsWithinThreeYears": { "auth_ref": [ "r361" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10140.0, "parentTag": "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactions", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Minimum Lease Payments Sale Leaseback Transactions Within Three Years", "terseLabel": "2021" } } }, "localname": "MinimumLeasePaymentsSaleLeasebackTransactionsWithinThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactionsWithinTwoYears": { "auth_ref": [ "r361" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10130.0, "parentTag": "us-gaap_MinimumLeasePaymentsSaleLeasebackTransactions", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Minimum Lease Payments Sale Leaseback Transactions Within Two Years", "terseLabel": "2020" } } }, "localname": "MinimumLeasePaymentsSaleLeasebackTransactionsWithinTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r101" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities Continuing Operations", "totalLabel": "Net cash used in investing activities - continuing operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r101", "r103", "r106" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r101", "r103", "r106" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities Continuing Operations", "totalLabel": "Net cash provided by (used in) operating activities - continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r70", "r72", "r81", "r106", "r131", "r405", "r422" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10100.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net income (loss) attributable to stockholders of Arena", "totalLabel": "Net income (loss) attributable to stockholders of Arena" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r70", "r72", "r325", "r335" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10130.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income Loss Attributable To Noncontrolling Interest", "negatedLabel": "Less net loss attributable to noncontrolling interest in consolidated variable interest entity" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToReportingEntityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income Loss Attributable To Reporting Entity [Abstract]", "terseLabel": "Net income (loss):" } } }, "localname": "NetIncomeLossAttributableToReportingEntityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.", "label": "New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification", "terseLabel": "Adoption of ASU No. 2016-09" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements Or Change In Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r120", "r122" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements Or Change In Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing information:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "auth_ref": [ "r210", "r327" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.", "label": "Noncontrolling Interest Decrease From Deconsolidation", "terseLabel": "Deconsolidation of variable interest entity" } } }, "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Equity Attributable to Noncontrolling Interest in Consolidated Variable Interest Entity" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10190.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total interest and other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Interest and other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of business segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable business segment" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10180.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "terseLabel": "Loss from operations", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities Payments Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "terseLabel": "Operating lease, liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease, right-of-use liabilties" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities, non current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease, right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List", "terseLabel": "Operating lease, right-of-use asset", "verboseLabel": "Operating lease, right-of-use asset, statement of financial position [extensible list]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r369", "r371" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r368", "r371" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r355", "r356" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Leases Future Minimum Payments Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r355", "r356" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due Current", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r355", "r356" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10050.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r355", "r356" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10040.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r355", "r356" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10030.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r355", "r356" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r355", "r356" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail": { "order": 10060.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable": { "auth_ref": [ "r358" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future minimum rental payments in aggregate as of the balance sheet date under operating leases.", "label": "Operating Leases Future Minimum Payments Receivable", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent": { "auth_ref": [ "r358" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within one year of the balance sheet date under an operating lease.", "label": "Operating Leases Future Minimum Payments Receivable Current", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears": { "auth_ref": [ "r358" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail": { "order": 10050.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the fifth year from the balance sheet date under an operating lease.", "label": "Operating Leases Future Minimum Payments Receivable In Five Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears": { "auth_ref": [ "r358" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail": { "order": 10040.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the fourth year from the balance sheet date under an operating lease.", "label": "Operating Leases Future Minimum Payments Receivable In Four Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears": { "auth_ref": [ "r358" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail": { "order": 10030.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the third year from the balance sheet date under an operating lease.", "label": "Operating Leases Future Minimum Payments Receivable In Three Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears": { "auth_ref": [ "r358" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future rental payments receivable within the second year from the balance sheet date under an operating lease.", "label": "Operating Leases Future Minimum Payments Receivable In Two Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableThereafter": { "auth_ref": [ "r358" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail": { "order": 10060.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Future minimum lease payments receivable under operating leases for periods greater than five years following the balance sheet date.", "label": "Operating Leases Future Minimum Payments Receivable Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": { "auth_ref": [ "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.", "label": "Operating Leases Rent Expense Sublease Rentals1", "terseLabel": "Rent income from subleases" } } }, "localname": "OperatingLeasesRentExpenseSubleaseRentals1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "NOL carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating Loss Carryforwards Limitations On Use", "terseLabel": "Operating loss carryforwards, terms of limitation" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r119", "r123", "r149", "r337" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block]", "terseLabel": "The Company and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r29", "r30", "r31", "r53" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail": { "order": 10030.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsAccountsPayableAndOtherAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r63", "r64", "r66" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10050.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r63", "r64", "r66" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r62", "r350" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10040.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Translation gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCustomerMember": { "auth_ref": [ "r425", "r427", "r428", "r429", "r433", "r435" ], "lang": { "en-US": { "role": { "documentation": "Customer classified as other.", "label": "Other Customer [Member]", "terseLabel": "Other" } } }, "localname": "OtherCustomerMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10220.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Underwriters" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Equity Attributable to Stockholders of Arena" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r94", "r97", "r118" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments For Proceeds From Other Investing Activities", "negatedLabel": "Other non-current assets" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r91", "r95", "r166" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments To Acquire Available For Sale Securities Debt", "negatedLabel": "Purchases of available-for-sale investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r96" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r232", "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r37" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r27", "r45", "r46" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r98" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "positiveTerseLabel": "Aggregate gross proceeds from sale of common stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r91", "r92", "r166" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds From Sale And Maturity Of Available For Sale Securities", "terseLabel": "Proceeds from sale and maturity of available-for-sale investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r93" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds From Sale Of Property Plant And Equipment", "terseLabel": "Proceeds from sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds From Sales Of Business Affiliate And Productive Assets", "terseLabel": "Cash received from sale of business" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r98", "r262" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r70", "r72", "r100", "r156", "r158", "r321", "r324", "r326", "r335", "r336" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10120.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r50", "r192" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r49", "r190" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Land, property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r33", "r34", "r192", "r418" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Land, property and equipment, net", "totalLabel": "Land, property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r48", "r111", "r192" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r33", "r192" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Land, Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r33", "r190" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Property and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r227", "r372", "r373", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r278", "r446" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10250.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r111", "r278" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research [Member]", "terseLabel": "Research and Development Tax Credit" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r110", "r396", "r415" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "verboseLabel": "Restricted cash included in other non-current assets" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage.", "label": "Restricted Cash Asset Statement Of Financial Position Extensible List", "terseLabel": "Restricted Cash, Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "RestrictedCashAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesReconciliationOfComponentsOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units (RSU)", "verboseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r41", "r209", "r416" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r214", "r215" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10230.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "positiveLabel": "Revenue from continuing operations", "terseLabel": "Total revenues", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r112", "r113" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r78", "r150", "r151", "r157" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty Revenue" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "us-gaap_SaleLeasebackTransactionDescription": { "auth_ref": [ "r354", "r360" ], "lang": { "en-US": { "role": { "documentation": "A description of the significant provisions of the transaction involving the sale of property to another party and the lease of the property back to the seller.", "label": "Sale Leaseback Transaction Description", "terseLabel": "Sale leaseback transaction, description" } } }, "localname": "SaleLeasebackTransactionDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale Of Stock Price Per Share", "terseLabel": "Average market price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Sales Revenue, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]", "terseLabel": "Accounts Payable and Other Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomeLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Potentially Dilutive Securities Excluded from Calculation of Diluted Income (Loss) Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r408", "r409" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule Of Available For Sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Components of Net Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r0", "r10", "r11", "r12", "r13", "r14", "r15", "r19", "r21", "r22", "r23", "r194", "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Text Block]", "terseLabel": "Summary of Discontinued Operations for Periods Presented in Consolidated Statements of Operations and Assets and Liabilities Classified as Held for Sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSaleOfManufacturingOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r231", "r258", "r274" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Share Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r338", "r339" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureFairValueDisclosuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]", "terseLabel": "Expected Minimum Rental Payments to be Received under Sublease" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]", "terseLabel": "Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r120", "r122", "r134", "r135", "r137" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule Of New Accounting Pronouncements And Changes In Accounting Principles [Text Block]", "terseLabel": "Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule Of Operating Leased Assets [Table]", "terseLabel": "Schedule Of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesExpectedMinimumRentalPaymentsToBeReceivedUnderSubleaseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r50", "r192" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetailsLandPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Schedule Of Quarterly Financial Information Table [Text Block]", "terseLabel": "Quarterly Data" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r232", "r261" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r238", "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Weighted-Average Assumptions and Estimated Fair Value of Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.", "label": "Schedule Of Unrecognized Compensation Cost Nonvested Awards Table [Text Block]", "terseLabel": "Total Unrecognized Estimated Compensation Expense" } } }, "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r296", "r309" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule Of Variable Interest Entities [Table]", "terseLabel": "Schedule Of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDiscontinuedOperationsMember": { "auth_ref": [ "r1", "r2", "r3", "r4" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Segment Discontinued Operations [Member]", "terseLabel": "Discontinued operations" } } }, "localname": "SegmentDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Segment Operating Activities [Domain]", "terseLabel": "Operating Activities" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r104" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1", "terseLabel": "Compensation expense of requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights", "terseLabel": "Vesting description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "verboseLabel": "Units granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Date the equity-based award expires, in CCYY-MM-DD format.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Expiration Date", "terseLabel": "ESPP terminated date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate", "terseLabel": "Maximum Percentage of Annual Compensation contributable to ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Vested and exercisable at December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period", "negatedLabel": "Forfeited/cancelled/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price", "terseLabel": "Forfeited/cancelled/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average estimated fair value per share of stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Outstanding at December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r240", "r261" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Outstanding at December 31, 2019", "periodStartLabel": "Outstanding at December 31, 2018" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Number of stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Outstanding at December 31, 2019", "periodStartLabel": "Outstanding at December 31, 2018" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted Average Exercise Price ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value", "terseLabel": "Vested and exercisable at December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price", "terseLabel": "Vested and exercisable at December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest at December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Vested and expected to vest at December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r230", "r236" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityTotalUnrecognizedEstimatedCompensationExpenseDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche One [Member]", "terseLabel": "Tranche One" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Three [Member]", "terseLabel": "Tranche Three" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Two [Member]", "terseLabel": "Tranche Two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r111", "r232", "r237" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Share-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r253", "r273" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityWeightedAverageAssumptionsAndEstimatedFairValueOfStockOptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Vested and exercisable at December 31, 2019" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Outstanding at December 31, 2019" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Vested and expected to vest at December 31, 2019" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Purchase price of common shares as a percentage of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r211", "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders Equity And Share Based Payments [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r440" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short Term Investments [Member]", "terseLabel": "Short-term investments, available-for-sale" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "California" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r58", "r208" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Statement Operating Activities Segment [Axis]", "terseLabel": "Operating Activities" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesTables", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights S A R S [Member]", "terseLabel": "Stock Options and Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period Shares Employee Benefit Plan", "terseLabel": "Shares issued to employees upon satisfaction of continuing service requirement" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r37", "r38", "r208", "r209" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "verboseLabel": "Total common stock issued under employee stock purchase plan (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r37", "r38", "r208", "r209" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock (in shares)", "verboseLabel": "Sale of common stock shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r37", "r38", "r208", "r209" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures", "verboseLabel": "Issuance of common stock upon vesting of restricted stock unit awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r37", "r38", "r208", "r209" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period Shares Share Based Compensation", "terseLabel": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r37", "r38", "r208", "r209", "r243" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised", "terseLabel": "Issuance of common stock upon exercise of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r37", "r38", "r208", "r209" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r208", "r209" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures", "terseLabel": "Issuance of common stock upon vesting of restricted stock unit awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r58", "r208", "r209" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r38", "r42", "r43", "r164" ], "calculation": { "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "terseLabel": "Total stockholders' equity", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r319", "r320", "r334" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Tax credit carryforwards amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing Of Transfer Of Good Or Service [Axis]", "terseLabel": "Timing of Transfer of Good or Service" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing Of Transfer Of Good Or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred At Point In Time [Member]", "terseLabel": "Revenue recognized at a point in time" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred Over Time [Member]", "terseLabel": "Revenue recognized over time" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsSummaryOfRevenueDisaggregatedByMajorCustomersTimingOfRevenueRecognitionAndRevenueClassificationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type Of Adoption [Member]", "terseLabel": "Type of Adoption" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactsOfAdoptingASC606OnConsolidatedStatementsOfFinancialStatementsDetail", "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesTables", "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureCollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r225", "r400" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "US government and government agency notes" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureInvestmentsAvailableForSaleScheduleOfInvestmentsAvailableForSaleDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r281", "r291" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Gross unrecognized tax benefits at end of the year", "periodStartLabel": "Gross unrecognized tax benefits at the beginning of the year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r292" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions", "negatedTerseLabel": "Reductions from tax positions taken in prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued", "terseLabel": "Accrued interest or penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense", "terseLabel": "Recognize interest and/or penalties expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Additions from tax positions taken in the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions", "terseLabel": "Additions from tax positions taken in prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities", "terseLabel": "Tax settlements" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r295" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits, that would impact the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r139", "r140", "r142", "r143", "r146", "r147", "r148" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r282" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "Beacon Discovery, Inc." } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureBeaconDiscoveryIncAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r125", "r129" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Shares used in calculating net income (loss) attributable to stockholders of Arena per share, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r124", "r129" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Shares used in calculating net income (loss) attributable to stockholders of Arena per share, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.arenapharm.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130550-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164451&loc=d3e36991-112694" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77913982&loc=d3e50796-112755" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77914019&loc=d3e50824-112756" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35711157&loc=d3e42546-110969" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r411": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419109&loc=SL117422543-158416" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419472&loc=d3e14931-158439" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419472&loc=SL117782755-158439" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "7B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419472&loc=SL117782768-158439" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "9C", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884803&loc=SL65671395-207642" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=SL117422267-158473" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r441": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r447": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r448": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r449": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r451": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r452": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r453": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" } }, "version": "2.1" } XML 80 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Summary of Income (Loss) Before Provision (Benefit) for Income Taxes by Region

The following table summarizes our income (loss) attributable to stockholders of Arena before provision (benefit) for income taxes by region for the years presented, in thousands:

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

United States

 

$

298,315

 

 

$

(138,522

)

 

$

(62,109

)

Foreign

 

 

209,573

 

 

 

(1,142

)

 

 

(29,298

)

Total income (loss) attributable to stockholders of Arena before income taxes

 

$

507,888

 

 

$

(139,664

)

 

$

(91,407

)
Reconciliation of Provision (Benefit) for Income Taxes at Statutory Federal Rate to Provision (Benefit) for Income Taxes Our effective income tax rate differs from the statutory federal rate of 21% for 2019 and 2018, and 34% for 2017 due to the following, in thousands:

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Benefit for income taxes at statutory federal rate

 

$

106,657

 

 

$

(29,090

)

 

$

(32,140

)

Change in valuation allowance due to tax reform

 

 

—

 

 

 

—

 

 

 

96,333

 

Change in federal and foreign valuation allowance

 

 

34,712

 

 

 

(76,336

)

 

 

(68,604

)

Permanent differences and other

 

 

601

 

 

 

1,963

 

 

 

(782

)

Deferred adjustment related to foreign net operating losses

 

 

15,133

 

 

 

—

 

 

 

—

 

Capital loss on foreign subsidiary liquidation

 

 

(43,685

)

 

 

—

 

 

 

—

 

Share-based compensation expense

 

 

1,624

 

 

 

889

 

 

 

7,071

 

Foreign losses at lower effective rates

 

 

21

 

 

 

257

 

 

 

1,428

 

Research and development and Orphan Drug credits

 

 

(4,730

)

 

 

(7,948

)

 

 

(3,306

)

Benefit for income taxes

 

$

110,333

 

 

$

(110,265

)

 

$

—

 

 
Components of Net Deferred Tax Assets

The components of our net deferred tax assets are as follows, in thousands:  

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Federal and California NOL carryforwards

 

$

140,762

 

 

$

210,853

 

Federal and California research and development credit carryforwards

 

 

73,956

 

 

 

69,221

 

Foreign NOL carryforwards

 

 

—

 

 

 

15,131

 

Share-based compensation expense

 

 

11,010

 

 

 

6,124

 

Depreciation

 

 

3,183

 

 

 

2,914

 

Lease liability

 

 

2,359

 

 

 

—

 

Other, net

 

 

354

 

 

 

784

 

Total deferred tax assets

 

 

231,624

 

 

 

305,027

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use assets

 

 

(2,218

)

 

 

—

 

Total deferred tax liabilities

 

 

(2,218

)

 

 

—

 

Net deferred tax assets

 

 

229,406

 

 

 

305,027

 

Valuation allowance

 

 

(229,406

)

 

 

(194,694

)

Net deferred tax assets

 

$

—

 

 

$

110,333

 
Reconciliation of Unrecognized Tax Benefits

The following table reconciles the beginning and ending amount of unrecognized tax benefits for the years presented, in thousands:  

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Gross unrecognized tax benefits at the beginning of the year

 

$

9,033

 

 

$

7,762

 

 

$

5,906

 

Additions from tax positions taken in the current year

 

 

1,017

 

 

 

1,269

 

 

 

1,133

 

Additions from tax positions taken in prior years

 

 

—

 

 

 

2

 

 

 

723

 

Reductions from tax positions taken in prior years

 

 

(96

)

 

 

—

 

 

 

—

 

Tax settlements

 

 

—

 

 

 

—

 

 

 

—

 

Gross unrecognized tax benefits at end of the year

 

$

9,954

 

 

$

9,033

 

 

$

7,762

 
EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 82 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Sale of Manufacturing Operations (Tables)
 12 Months Ended
Dec. 31, 2019
Discontinued Operations And Disposal Groups [Abstract]  
Summary of Discontinued Operations for Periods Presented in Consolidated Statements of Operations and Assets and Liabilities Classified as Held for Sale

The following table summarizes the results of discontinued operations for the periods presented in the consolidated statements of operations for the years ended December 31, 2018, and 2017, in thousands:

 

 

Years ended December 31,

 

Revenues

 

2018

 

 

2017

 

Net product sales

 

$

1,129

 

 

$

9,189

 

Other collaboration revenue

 

 

372

 

 

 

6,671

 

Toll manufacturing

 

 

1,006

 

 

 

3,179

 

Total revenues

 

 

2,507

 

 

 

19,039

 

Operating costs and expenses

 

 

 

 

 

 

 

 

Cost of product sales

 

 

1,858

 

 

 

7,472

 

Cost of toll manufacturing

 

 

1,411

 

 

 

4,756

 

Research and development

 

 

—

 

 

 

643

 

General and administrative

 

 

329

 

 

 

1,672

 

Other (income) expense, net

 

 

464

 

 

 

1,374

 

Total costs and expenses

 

 

4,062

 

 

 

15,917

 

Income (loss) from operations of discontinued operations

 

 

(1,555

)

 

 

3,122

 

Gain on sale of discontinued operations

 

 

725

 

 

 

—

 

Income (loss) from discontinued operations

 

$

(830

)

 

$

3,122

 

 

XML 83 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
The Company and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2019
Reconciliation of Components of Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in our consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows, in thousands:

 

 

 

December 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Cash and cash equivalents

 

$

243,274

 

 

$

161,037

 

Restricted cash included in other non-current assets

 

 

226

 

 

 

863

 

Total cash, cash equivalents and restricted cash presented in the consolidated

      statement of cash flows

 

$

243,500

 

 

$

161,900

 
Potentially Dilutive Securities Excluded from Calculation of Diluted Income (Loss) Per Share The table below presents the weighted-average number of potentially dilutive securities that were excluded from our calculation of diluted income (loss) per share for the years presented, in thousands.

 

 

 

Years ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Stock options

 

 

3,962

 

 

 

5,835

 

 

 

3,664

 

RSUs and unvested restricted stock

 

 

—

 

 

 

20

 

 

 

3

 

Total

 

 

3,962

 

 

 

5,855

 

 

 

3,667

 
ASC 606  
Summary of Impacts of Adopting ASC 606 on Consolidated Statements of Financial Statements

The following table summarizes the impacts of adopting ASC 606 on our consolidated financial statements, in thousands.

 

 

Impact of Changes in Accounting Policies

 

Year ended December 31, 2018

 

As reported

 

 

Adjustments

 

 

Balances without adoption of ASC 606

 

Collaboration and other revenue

 

$

11,402

 

 

$

105

 

 

$

11,507

 

Royalty revenue

 

 

6,568

 

 

 

(1,847

)

 

 

4,721

 

Total revenues

 

 

17,970

 

 

 

(1,742

)

 

 

16,228

 

Loss from operations

 

 

(144,783

)

 

 

(1,742

)

 

 

(146,525

)

Loss from continuing operations

 

 

(28,569

)

 

 

(594

)

 

 

(29,163

)

Income (loss) from discontinued operations

 

 

(830

)

 

 

13,660

 

 

 

12,830

 

Net loss

 

 

(29,399

)

 

 

13,066

 

 

 

(16,333

)

Net loss attributable to stockholders of Arena

 

 

(29,399

)

 

 

13,066

 

 

 

(16,333

)

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2018

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

$

10,008

 

 

$

(1,484

)

 

$

8,524

 

Total current assets

 

 

460,725

 

 

 

(1,484

)

 

 

459,241

 

Other non-current assets

 

 

10,319

 

 

 

(4,471

)

 

 

5,848

 

Total assets

 

 

686,903

 

 

 

(5,955

)

 

 

680,948

 

Total current liabilities

 

 

29,918

 

 

 

10

 

 

 

29,928

 

Accumulated deficit

 

 

(1,500,552

)

 

 

(5,965

)

 

 

(1,506,517

)

Total stockholders' equity

 

 

606,258

 

 

 

(5,965

)

 

 

600,293

 

Total liabilities and stockholders' equity

 

 

686,903

 

 

 

(5,955

)

 

 

680,948